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Summary 
Huntington’s disease is an autosomal dominant neurological disease caused by an 
elongated CAG repeat in exon 1 of the huntingtin gene. There is currently no cure 
and treatments are limited. The genetic mutation causes selective cell death of the 
medium spiny neurons which reside in the striatum of the basal ganglia. Current 
disease models don’t necessarily recapitulate all aspects of the human disease and 
so alternatives are needed. The advent of induced pluripotent stem cells (iPSC), 
has allowed for HD patient specific pluripotent stem cells to be derived, hence 
differentiation of these cells in vitro could provide a disease model for drug testing 
and investigation of disease pathology. Current protocols for differentiation of 
pluripotent stem cells into medium spiny neurons (MSNs) are often inconsistent and 
lead to low yields of MSNs. Directing differentiation through forced expression of 
transcription factors has been used to differentiate neurons from fibroblasts and 
pluripotent stem cells, often with increased efficiency. Utilising transcription factors 
vital in post-mitotic MSN development, this study has aimed to produce MSNs in 
vitro, by transfection of transcription factors or combinations thereof in a 
multicistronic plasmid into ventral forebrain neural progenitors. 
This study has involved the cloning and expression of 5 different transcription 
factors important in MSN development in iPSC-derived neural progenitors. Two of 
these transcription factors; NOLZ1 (ZNF503) and ISL1 were further investigated for 
their ability to differentiate neural progentiroes into MSNs. This study showed that 
transfection of ISL1 enabled differentiation of neurons to produce a higher 
proportion of cells resembling MSNs, characterised by co-expression of the MSN 
markers DARPP32 and CTIP2 and expressing FOXP1. The combination of NOLZ1 
and ISL1 in transfection improved functional maturation of neurons, becoming 
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increasingly spontaneously active and increased excitability, as well as responding 
to GABA and NMDA, with dopamine D1 agonist enhancement of NMDA currents. 
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1. Introduction 
1.1 Stem cells  
Stem cells are undifferentiated cells which can divide indefinitely giving rise to 
daughter cells. These daughter cells can remain as stem cells or differentiate into 
any number of cell types as a result of signalling cues. Stem cells are found in most 
areas of the human body and help to maintain the population of cells in that area. 
These are termed adult stem cells and are multipotent, meaning they can 
differentiate, on cue, into several cell types which would reside in that area. For 
example, bone marrow mesenchymal stem cells can form cells of different 
connective tissues and bone. Pluripotent stem cells can differentiate into any cell of 
the developing embryo, excluding the extra-embryonic tissue, such as the placenta. 
The pluripotent stem cells are isolated from the inner cell mass of the developing 
embryo (Figure 1.1) and are termed embryonic stem cells (ESCs).  
ESCs were first isolated from the mouse embryo (mESCs) by Evans & Kaufman 
(1981). They delayed embryonic development by performing an ovariectomy on 
mice which were 2.5 days post fertilisation and injected the mice with progesterone 
(Evans & Kaufman 1981). This caused the embryos to hatch from the zona 
pellucida, but not implant into the endometrium (Evans & Kaufman 1981). The 
embryos were then harvested 4-6 days later and cultured in vitro in droplets of 
media (Evans & Kaufman 1981). The blastocyst attached to the tissue culture 
plastic and the trophectoderm (which would form the extraembryonic tissue) grew 
out from the blastocyst attachment and differentiated (Evans & Kaufman 1981). The 
inner cell mass (ICM), remained as an egg-like structure as part of the blastocyst, 
this was removed and trypsinized (Evans & Kaufman 1981). The individual cells 
were grown on mitomycin-inactivated STO mouse embryonic fibroblasts, and then 
stem cell colonies formed. It took 17 years for human embryonic stem cells to be 
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successfully isolated and cultured, most likely due to the problems with obtaining 
human embryos, the ICM was isolated, following a previously utilised protocol to 
isolate rhesus monkey ESCs (Thomson et al., 1998b), by immunosurgery with 
rabbit antiserum to BeWO cells (a cell line isolated from a malignant gestational 
choriocarcinoma of the fetal placenta), grown on inactivated mouse embryonic 
fibroblasts (MEFis) (Thomson et al., 1998a). The human ESCs were found to 
express pluripotent cell surface markers and could still differentiate into cells of all 3 
germ layers of the embryo after being cultured in a pluripotent state for several 
months (Thomson et al., 1998a). 
 
Figure 1.1: Derivation of embryonic stem cells and induced pluripotent stem cells. 
Embryonic stem cells are harvested from the inner cell mass of the fertilised embryo when 
the embryo has progressed through development to the blastocyst. Induced pluripotent stem 
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cells are derived from adult or embryonic fibroblasts and transduced with viruses containing 
the 4 pluripotent transcription factors OCT4, KLF4 SOX2 and c-MYC. Both sets of 
pluripotent stem cells can be cultured to form cells of all 3 germ layers of the developing 
embryo. 
 
Induced pluripotent stem cells (iPSCs) have been derived from human and mouse 
fibroblasts. They were first derived from mouse embryonic and adult fibroblasts by 
retroviral transduction of 4 pluripotent transcription factors, Oct3/4, Sox2, Klf4 and c-
Myc (Takahashi & Yamanaka 2006). Mouse iPSCs were found to behave as 
pluripotent stem cells by forming colonies, expressing mouse ESC markers, 
enabled the formation of chimaeras when injected into a blastocyst and formed 
teratomas containing cells of all 3 germ layers when subcutaneously injected into 
the mouse (Takahashi & Yamanaka 2006). The derivation of human iPSCs 
occurred not long after, using the same transcription factors in 4 retroviruses, 
colonies were observed 25 days post induction with efficiency of induction of 0.02% 
and 3-6 integration sites of each of the viruses in to the genome (Takahashi et al., 
2007). The integration of the viruses into the genome was shown to cause 
tumorigenic properties, mostly though the action of c-Myc, with 20% of offspring 
from chimeras forming tumours (Okita et al., 2007). One study showed that the 
random integration of viruses into the genome can cause pluripotent reprogramming 
without the use of transcription factors (Kane et al., 2010). However, this was at a 
much lower efficiency of 0.000004% (Kane et al., 2010) in comparison to the 0.02% 
by Takahashi et al., (2007). 
As a result of viral integration into the genome causing problems of tumorigenicity 
and random integration of viral DNA causing the dedifferentiation of cells, other 
methods have been sought to induce pluripotency. LoxP enzyme sites were 
introduced to the 5’ and 3’ ends of the coding region of the pluripotent transcription 
factors used for reprogramming, the cells were co-transduced with a doxycycline 
inducible Cre recombinase in order to excise the pluripotent transcription factors 
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that integrated into the genome on completion of pluripotent induction (Soldner et 
al., 2009). This was also done by Kaji et al., (2009), but instead of having 4 vectors 
one for each of the transcription factors, they utilised the 2A peptide linkers between 
the 4 genes in a non-viral vector which limited the number of integration sites. They 
also combined this vector with the use of piggyBac transposon integration to 
produce iPSCs, which allowed the removal of the integrated DNA and left no foreign 
DNA in the chromosome, (Kaji et al., 2009, Woltjen et al., 2009). Adenoviruses have 
also been used to induce pluripotency. However, there was still integration into the 
chromosomes (Okita et al., 2008). The recombinant proteins of the 4 pluripotent 
transcription factors that possessed a poly-arginine tag in order to enhance cell 
uptake have proved successful in inducing pluripotency when supplemented in the 
culture media at 8 µg/ml (Zhou et al., 2009). This was carried out in combination 
with valproic acid (VPA) treatment, a histone deacetylase inhibitor (HDACi), which 
has been shown to improve rate of pluripotency induction (Zhou et al., 2009). 
In order to reduce the number of transcription factors involved in inducing 
pluripotency, several studies have been performed to reduce the number or totally 
eliminate the use of transcription factors. When brain derived neural stem cells were 
treated with the 4 transcription factors (Oct4, Sox2, c-Myc and Klf4) to induce 
pluropotency, dual inhibition of glycogen synthase kinase 3 (GSK3), and mitogen 
activated protein kinase (MAPK) alongside treatment with the cytokine leukemia 
inhibitory factor (LIF), improved aspects of pluripotency (Silva et al., 2008). These 
included Oct4 and Nanog stabilisation, X chromosome reactivation, transgene 
silencing and somatic and germline chimeraism (Silva et al., 2008). It was found that 
c-Myc and Sox2 were not needed to induce pluripotency of these cells (Silva et al., 
2008). The requirement for Oct3/4 in induction was superfluous when replaced with 
the transcription factor GATA3 along with KLF4, c-MYC and SOX2 (Montserrat et 
al., 2013). iPSCs were produced albeit at a lower efficiency at 0.001%, possibly due 
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to the decreased up-regulation of endogenous OCT4 and NANOG expression as 
compared to using the original 4 transcription factors (Montserrat et al., 2013). The 
use of small molecules to induce pluripotency has also been explored. CHIR99021 
(a GSK3 inhibitor) and tranylcypromine (an inhibitor of lysine-specific demethylase 
1) have been used to induce human primary keratinocytes into iPSCs with the use 
of only OCT4 and KLF4 transcription factors (Li et al., 2009). TGF-β inhibition was 
found to replace the need for Sox2 and c-Myc expression, by inducing Nanog 
expression (Maherali et al., 2009, Ichida et al., 2009). Building on the protocols by Li 
et al (2009), Maherali et al., (2009) and Ichida et al., (2009), only OCT4 forced 
expression was required with the addition of VPA and 616452 (a TGF-β inhibitor), to 
induce pluripotency, with an efficiency of 0.002-0.03% (Li et al., 2011). To remove 
the need for any transcription factor for pluripotency induction, the removal of OCT4 
expression was investigated by using an Oct4 promoter driven GFP expressing 
MEF cell line with Sox2/c-Myc/Klf4 transduction and subsequent screening of 
thousands of small molecules, which induced GFP expression (Hou et al., 2013). 
Forskolin (an adenylate cyclase activator) was found to be sufficient and therefore 
was used in combination with the 4 molecules from Li et al., (2011), to induce 
pluripotency (Hou et al., 2013). Further enhancement of induction of pluripotency 
was carried out by addition of DZNep (a global histone demethylation inhibitor 
(Miranda et al., 2009)) at 16 days post treatment (Hou et al., 2013). DZNep reduced 
methylation of DNA and H3K9 at the Oct4 promoter (Hou et al., 2013). The addition 
of the retinoic acid receptor ligand, TTNPB further enhanced efficiency of induction 
to pluripotency of MEFs to be comparable with transcription factor induced 
pluripotency at up to 0.2% (Hou et al., 2013).  
Human ESC and human iPSC have been derived, which carry the HTT mutation, 
these can be utilised in disease modelling (Section 1.2.2.3) 
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1.2 Huntington’s Disease 
1.2.1 Huntington’s Disease 
Huntington’s disease (HD) is a neurodegenerative disorder which arises from a 
genetic mutation, mapped to chromosome 4 in humans (Gusella et al., 1983). The 
gene affected is the huntingtin gene; the mutation consists of an elongated CAG 
repeat (over 36 repeats) in exon 1, encoding a polyglutamine stretch of amino acids 
at the N-terminus of the protein (The Huntington’s Disease Collaborative Research 
Group 1993). This expanded CAG repeat leads initially to extensive but selective 
cell death of medium spiny neurones (MSN) in the striatum of the ventral forebrain, 
more specifically the enkephalin+ MSNs which synapse with the external globus 
pallidus (Albin et al., 1992, Richfield et al., 1995). There is a significant decrease in 
volume of the caudate nucleus (57%) and putamen (64%) as seen in post mortem 
(de la Monte 1988). Further to striatal degeneration, the volume of the substantia 
nigra decreases by about 40% (Oyanagi et al. 1989), the cerebral cortex by 21-29% 
volume (de la Monte et al., 1988) and a 35% neuronal loss in the CA1 region of the 
hippocampus (Spargo et al., 1993).  
Patients with HD experience a decline in cognitive function, incoordination and 
uncontrolled movement of limbs, deterioration of speech, and depression being 
another common symptom (Walker 2007) with ~7-10% of the HD population 
resorting to suicide (Baliko et al., 2004, Di Maio et al., 1993). Finally, death occurs 
around 20 years from diagnosis (Folstein 1989) usually resulting from complications 
of falls, dysphagia or aspiration (Walker 2007). There is presently no cure, and 
current treatments are limited to medications and therapies to reduce symptoms, 
such as antidepressants, muscle relaxants and anticonvulsants (Ross & Tabrizi 
2011). Clinical trials of neural transplantation into the striatum of HD patients to 
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replace those cells lost in the disease have met with varied levels of success 
(reviewed by Dunnett & Rosser 2007).  
1.2.2 Huntington’s Disease Modelling 
1.2.2.1 Animal models of HD – excitotoxic models 
A wide variety of Huntington’s disease models have been generated (reviewed by 
Pouladi et al., 2013), from different species to different methods of generation. 
Before the genetic causation of HD was discovered, the use of excitotoxic lesion of 
the striatum was utilised to try and recapitulate motor phenotypes of the disease, 
which involved injection of glutamate receptor agonists such as ibotenic or kainic 
acid, causing selective loss of the GABAergic MSNs (McGeer & McGeer 1976, 
Schwarcz et al., 1984, Coyle & Schwarcz., 1976). However, this method of lesion 
creation also caused loss of the striatal interneurons and as a result the NMDA 
receptor agonist, quinolinic acid, was used due to its more specific effects (Beal et 
al., 1986, Schwarcz et al., 1983, Beal et al., 1991, Ferrante et al., 1993). These 
models result in rapid degeneration of the neurons in the striatum and therefore do 
not recapitulate the disease process. 
1.2.2.2 Animal models of HD – genetic models 
Once the genetic mutation was discovered, genetic models were made in mice, 
rats, sheep, mini-pigs and monkeys, as well as disease models of Caenorhabditis 
elegans and Drosophila melanogaster have also been created. These models either 
used full length Htt gene or truncated N-terminal fragment models, with expanded 
CAG repeats. Expression of the N-terminal fragment of the human HTT gene, with 
150 CAG repeats, in sensory neurons of C. elegans caused aggregation of HTT 
protein, neuronal dysfunction and neurodegeneration of the sensory neurons (Faber 
et al., 1999), in contrast to expression of a 128 CAG repeat in mechanosensory 
neurons of C. elegans, there was no neuronal degeneration, but they were 
1. Introduction 
 
 
- 9 - 
insensitive to touch and there was nuclear accumulation of HTT aggregates (Parker 
et al., 2001). Studies in D. melanogaster have focussed on expression of the N-
terminal fragment of mutant HTT in the compound eye of the Drosophila, all show 
neuronal degeneration of the rhabdomeres of the eye (Jackson et al., 1998, Steffan 
et al., 2001, Steffan et al., 2004, Lee et al., 2004, Kaltenbach et al., 2007), pan-
neuronal expression of human mutant HTT also led to deficits in climbing behaviour 
and reduced survival of adults (Steffan et al., 2001, Steffan et al., 2004, Lee et al., 
2004, Kaltenbach et al., 2007). Interacting proteins of mutant HTT have been 
identified, which have enhanced or reduced the phenotype of degeneration of 
rhabdomeres when overexpressed or knocked down (Kaltenbach et al., 2007). A 
full-length mutant HTT Drosophila model has also been created and shows similar 
deterioration of climbing behaviour when expressed pan-neuronally, there was also 
a Ca2+-dependent increase in neurotransmitter release efficiency, loss of synaptic 
transmission, but an absence of nuclear accumulation of HTT protein aggregates 
(Romero et al., 2008). 
Many mouse disease models have been created (reviewed by Pouladi et al., 2013), 
which recapitulate many aspects of the disease phenotype. One of the first models 
was the R6/1 and R6/2 mouse models, an N-terminal fragment human HTT with 
116 and 144 CAG repeats respectively, although in the R6/2 mouse, the length of 
the CAG repeats showed instability, with an increase in the number of repeats 
(Mangiarini et al., 1996). This mouse model recapitulated the chorea observed in 
HD patients, and in the R6/2 mouse, the brains are smaller compared to wild-type 
littermate controls, with a decreased striatal size, but no neuronal loss (Mangiarini et 
al., 1996). HTT protein aggregates are also observed in the R6/2 mouse (Safren et 
al., 2014). Full length human HTT knock-in models have also been generated, with 
140 CAG repeats which replicated increased locomotor activity during early disease 
progression, before progressing to a hypoactivity phenotype at later stages of the 
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disease, HTT nuclear aggregates are formed in the striatum, and layers II, III and 
deep layer V of the cerebral cortex and changes in gait are also observed (Menalled 
et al., 2003).  
Transgenic mouse models of HD have also been created; one example is the 
YAC128 mouse, which was created by homologous recombination with yeast 
artificial chromosome to express the full length human HTT containing 128 CAG 
repeats, using human regulatory elements (Slow et al., 2003). The mice showed 
hyperactivity phenotypes originally, then progressing to motor deficits and 
hypokinesis with a decrease in performance on the rotarod test (Slow et al., 2003). 
HTT protein inclusions were observed at 18 months, as well as cortical and striatal 
atrophy, with an 8% decrease in number of MSNs, judged by DARPP32 expression 
(Slow et al., 2003). Rat models of HD have also been created by BAC transgenesis, 
expressing the full-length human protein, with 97 CAG/CAA repeats to increase 
stability of the CAG expansion (Yu-Taegar et al., 2012). These rats showed motor 
deficits (measured by rotarod, hindlimb clasping on tail-suspension, and shorter 
steps with increased stride width) and increased HTT aggregates (Yu-Taegar et al., 
2012). Rhesus macaque monkey models have also been created, with 84 CAG 
repeats, which showed evidence of HTT nuclear inclusions, dystonia, chorea and 
difficulty swallowing (Yang et al., 2008).  
1.2.2.3 Cellular models of HD 
The use of animal models has been extremely helpful in discovering certain aspects 
of HD, however, many disease correcting effects of drugs from animal studies do 
not necessarily cross over in to human clinical trials with the same level of success 
(Kaye & Finkbeiner 2013), with the human brain size and organisation being fairly 
different in comparison to rodent models, the studies of which, form the bulk of the 
information and rationale for disease modifying drugs. Human tissue is hard to 
obtain to evaluate effects of disease and test out possible drug treatments. 
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Recently, human cell models have been created, either derived from embryos 
(ESCs), or through the formation of iPSC. iPSC and ESC models have been derived 
from monkey (Chan et al., 2010, Laowtammathron et al., 2010) and the R6/2 mouse 
(Castiglioni et al., 2012) as well as a rat neuroprogenitor cell model (Dong et al., 
2011). Here, I focus on the human cell models of HD. Derivation of hESC from 
preimplantation genetic diagnosis in vitro fertilisation embryos has provided cell 
models with 37 and 51 CAG repeats, which showed partial and full penetrance of 
the phenotype, but there has also been evidence of instability of the CAG repeat 
length, neurons and astrocytes have been created from this cell source (Niclis et al., 
2009). Further characterisation of these cell lines showed that dysregulated genes 
in HD remained comparable to the controls in these HD cells when differentiated 
into βIII-tubulin (a neuronal marker)/GABAergic neurons, but there were elevated 
glutamate-evoked responses observed by a larger [Ca2+]I (Niclis et al., 2013). 
MAP2+ (a mature neuronal marker) neurons have also been made from hESCs with 
various CAG repeat lengths in the HTT gene (Bradley et al., 2011). Other HD hESC, 
with 40-51 CAG repeats, have been differentiated to MAP2+ neurons for the 
purpose of analysing gene expression changes, with 3 genes being either up-
regulated (coiled-coil helix coiled-coil helix domain containing 2, CHCHD2, tripartite 
motif containing 4, TRIM4) or down-regulated (protein kinase inhibitor β, PKIB) in 
the HD hESC in comparison to the control cells (Feyeux et al., 2012). These genes 
have a role in mitochondrial function (CHCHD2), and protein kinase A (PKA) 
dependent regulation (Feyeux et al., 2012). Transfection of hESC has also been 
used to deliver HTT exon 1 fragments with expanded CAG repeats (Lu & Palacino 
2013). These have been differentiated into Tuj1+/MAP2+ neurons, (Tuj1, another 
neuronal marker), which showed insoluble mutant HTT protein aggregates and 
neurodegeneration, which was proportional to the levels of soluble monomeric 
mutant HTT (Lu & Palacino 2013). Basal culture of these neurons without growth 
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factors also led to neurodegeneration (Lu & Palacino 2013). Rhes, a HTT toxicity 
modifier, rescued the neurodegeneration observed; siRNA knock-down also 
decreased the amount of soluble monomeric HTT (Lu & Palacino 2013).  
Park and colleagues (2008) were the first to report the derivation of a human HD 
iPSC line, which possessed the HTT gene with 72 CAG repeats and was 
subsequently differentiated into nestin+/PAX6+/SOX1+/OCT4- neural stem cells and 
further differentiated into DARPP32+ neurons (~10%, Zhang et al., 2010). The 
derived neural stem cells showed increased caspase 3/7 activity on growth factor 
withdrawal, an important feature of HD pathology (Zhang et al., 2010). Further work 
on this cell line has highlighted the appearance of EM48+ HTT aggregates in 
neurons which were 27% DARPP32+ and 38% GABA+, however they only appeared 
after proteasome inhibitor treatment of the iPSC or after engraftment into a P2 
mouse brain, and observed at 33 and 40 week post-transplant (Jeon et al., 2012). 
These neural precursors have provided behavioural recovery when implanted into 
the 12 month YAC128 mouse and GABAergic neurons are formed, and no HTT 
aggregates are observed at 12 weeks post transplantation (Jeon et al., 2014). The 
HD72 iPS cell line has also showed disparity in protein expression compared to H9 
control hESC line in the pluripotent state (Chae et al., 2012). Proteins involved in 
oxidative stress and programmed cell death, as well as cytoskeletal associated 
proteins (Chae et al., 2012). They also observed that cell death was increased in 
the HD iPSCs; neurite outgrowth was stunted in the HD iPSCs when differentiated 
into MAP2+ neurons, as well as a decreased efficiency of differentiation in the HD 
iPSCs compared to control (Chae et al., 2012). MicroRNAs (miRNAs) have been 
used to improve the phenotype of HD iPSC and also a HD transgenic mouse model, 
miR-196a decreased the number of mutant HTT aggregates in iPSC and in the 
transgenic mouse model (Cheng et al., 2013). TNFα (tumour necrosis factor α) 
dominant negative inhibitor (XPro1595) has suppressed the inflammatory response 
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of an astrocyte enriched culture derived from HD iPSC, and it also protects against 
cytokine induced toxicity of neurons derived from the same iPSC (Hsiao et al., 2014 
The HD iPSC consortium recently published data using iPSC derived from HD 
patients, which showed gene expression changes between several HD iPS cell lines 
with varying lengths of CAG repeats and also showed decreased levels of cell 
adhesion in HD neuroprogenitor cells (HD iPSC consortium 2012). There was also a 
decrease in spontaneous and induced action potentials in HD neurons, an 
increased cell death in response to BDNF withdrawal in HD neurons and a change 
in Ca2+ dyshomeostasis in HD cells (HD iPSC consortium 2012). Another protocol, 
which formed neurons from HD iPSCs, one with 50 CAG repeats, the other with 109 
CAG repeats, differentiated to neurons and were engrafted into the normal adult 
mouse brain and were characterised as phenotypically normal (Juopperi et al., 
2012). However, when astrocytes were derived from these cells, cytoplasmic 
vacuoles were observed that appeared empty, which were more pronounced in the 
cell line with 109 CAG repeats (Juopperi et al., 2012). An increased number of 
lysosomes has also been observed in HD iPS cells (Camnasio et al., 2012) 
A disease modifying approach has been attempted in the HD72 iPS cells derived by 
Park and colleagues, utilising homologous recombination of full length HTT with 21 
CAG repeats, the cells were able to be differentiated into striatal neurons, and the 
cell death phenotype, increased caspase activity and BDNF levels were able to be 
rescued by the homologous recombination (An et al., 2012).  
These data show that cell models of HD, reproduce aspects of the disease 
phenotype, can be differentiated into striatal neurons and can have the disease 
phenotype corrected by genetic manipulation. The range of cell lines available is 
increasing and therefore will allow for more models to be produced, with varying 
disease severity dependent on CAG repeat length. The protocols currently in use 
tend to make non-specified neurons, which do not allow characterisation of the 
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disease phenotype, as not all cells are affected to such an extent as the MSNs by 
HD. Provided a more reproducible differentiation protocol can be established to 
create the MSNs of the striatum, then dysfunction of the disease at the cellular level 
could be further investigated. 
1.3 The Striatum 
The striatum is one of the nuclei of the basal ganglia (Figure 1.2). The striatum is a 
collection of the caudate nucleus, putamen and nucleus accumbens. The striatum is 
made up of several populations of neurons, the majority being the MSNs 
constituting around 90% of the total population, the rest consisting of various 
populations of: interneurons, large acetylcholine+ neurons possessing long 
dendrites lacking branches (Bolam et al., 1984); several types of somatostatin+ 
medium aspiny neurons with cell bodies <20 µm in diameter, invaginated oval nuclei 
and long branched dendrites of up to 120 µm in length, receiving few inputs (Difiglia 
& Aronin 1982, Vincent & Johansson 1983), and; parvalbumin+ neurons (Gerfen et 
al., 1985). MSNs possess a cell body with a diameter of around 20-25 µm, have 
many branched dendrites that are densely populated with spines. The spines start 
to appear on dendrites ~20 µm from the soma and populate the dendrites all the 
way to the dendritic tip (Kemp and Powell 1971, Wilson and Groves 1980). The 
dendritic arbours spread between 150-250 µm in diameter and can synapse with 
many neighbouring neurons (Gerfen 1992). The axons form from a large dendritic 
trunk or through the cell soma tapering, the axon travels up to 1 mm to reach the 
globus pallidus (Wilson & Groves 1980).  
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Figure 1.2: The basal ganglia in situ. The striatum (only caudate nucleus and putamen 
shown here) is located under the cerebral cortex and is anterior to the thalamus and 
substantia nigra. Adapted from Bradbury & Vehrencamp (2011) 
 
The striatum receives inputs from the cortex and thalamus. More specifically, 
cortical input is predominantly from layer V of the cerebral cortex with secondary 
input from layers II, III and VI (Ferino et al., 1987, Jones et al., 1977, Royce 1982, 
Wilson 1987). The striatum also receives dopaminergic input from the midbrain 
(Bouyer et al., 1984). The input to the striatum from the midbrain predominantly 
synapses with the striatonigral neurons, with 59% of the tyrosine hydroxylase+ 
synaptic boutons, from the midbrain, synapsing on to the dendritic spines, and 35% 
on to the dendritic shafts of the striatonigral neurons (Freund et al., 1984). Midbrain 
input modulates the striatal response from cortical and thalamic input (Gerfen 1992).  
There are 3 types of synapses that form onto MSNs, those which contain round 
regular vesicles and synapse with spiny regions of dendrites (axo-spinous) (Hattori 
et al., 1970), some containing small vesicles of various shape and synapse with the 
cell body and dendrites, and synaptic boutons which contain large irregular shaped 
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vesicles which synapse with spines, dendrites and the soma (Wilson & Groves 
1980).  
Between 80 and 84% of rat MSNs are GAD+ (glutamic acid decarboxylase), staining 
with medium intensity, 3-5% of striatal neurons, smaller than MSNs with large 
invaginated nuclei stain intensely for GAD (Kita & Kitai 1988), therefore they are 
GABAergic and inhibitory on their targets of the globus pallidus, entopeduncular 
nucleus (Fonnum et al., 1978) and substantia nigra (Chevalier et al., 1985, Deniau 
& Chevalier 1985). 
1.3.1 Types of Medium Spiny Neuron 
There are two main efferent pathways from the striatum: striatonigral and 
striatopallidal, the striatonigral pathway has been demonstrated by applying 
glutamate to the striatum directly and recording the decrease in the substantia nigral 
neuronal firing (Chevalier et al., 1985, Deniau & Chevalier 1985). These pathways 
show differential expression of dopamine D1α receptor or dopamine D2 receptor 
(Figure 1.3), dopamine D3 receptor is expressed in the striosomal patches of the 
nucleus accumbens and ventral putamen (Murray et al., 1994). The D1 receptor is 
localised to striatonigral neurons and the D2 receptor is expressed by striatopallidal 
neurons and this pattern of expression can be altered in a rat model of Parkinson’s 
disease, where the nigrostriatal pathway is destroyed by excitotoxic treatment with 
6-hydroxy dopamine (6-OHDA) (Gerfen et al., 1990). Here, the striatopallidal 
neurons increase the amount of D2 receptor mRNA and also enkephalin mRNA 
(another marker of striatopallidal neurons), this effect can be reversed using the D2 
receptor agonist quinpirole (Gerfen et al., 1990). Excitotoxic treatment of the 
nigrostriatal pathway with 6-OHDA produces the opposite effect in the striatonigral 
neurons with a decrease of D1 receptor mRNA and substance P mRNA (another 
marker of striatonigral neurons), which is reversed when treated with the dopamine 
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D1 receptor agonist, SKF-38393, and this also increases the amount of dynorphin 
mRNA (a third marker specific to striatonigral neurons) (Gerfen et al., 1990).  
 
Figure 1.3: Schematic showing the types of medium spiny neuron in the striatum and 
their differential expression patterns. The top panel shows a striatonigral neuron which 
specifically expresses substance P and the dopamine D1α receptor subtype. The expression 
of the dopamine receptor is localised to the dendrites of these neurons. Bottom panel shows 
the striatopallidal neuron, which expresses enkephalin, adenosine 2A receptor and the 
dopamine type 2 receptor subtype. The expression of the dopamine receptor in these 
neurons is localised to the spines of the neurons. Figure drawn using information in section 
1.2.1 
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This dichotomy of the two pathways was confirmed by an electron microscope study 
of dopamine D1 and D2 receptor immunostaining in the rat striatum, where 53% of 
the medium spiny neurons stained for D1 receptor and 48% of the neurons were D2 
receptor+, the main localisation of D1 receptor was on the dendrites with less in the 
spines and the D2 receptor was more localised to the spines than dendrites, also 
being observed in synaptic terminals whereas D1 receptor was not (Hersch et al., 
1995). There was no co-localisation observed when performing dual staining for 
both receptors (Hersch et al., 1995). There has been some evidence of the 
dopamine D1 and D2 receptor mRNA not necessarily co-localising with substance P 
and enkephalin mRNA exclusively as 4% of both substance P+ and enkephalin+ 
neurons co-express either D2 receptors or D1 receptors, respectively. However D1 
and D2 receptors did not co-localise (LeMoine & Bloch 1995). This was in contrast 
to what others have observed, using an in vitro fluorescent ligand to bind each of 
the receptor subtypes, D1 and D2 receptors co-localised on striatonigral neurons 
(Larson & Ariano 1994). In situ hybridisation studies in rat have shown a 26-27% co-
localisation of D1 and D2 receptors in striatal neurons (Lester et al., 1993). Adora2a 
(adenosine A2 receptor) co-localises with the striatopallidal neurons that are 
dopamine D2 receptor+ and seldom seen in the D1+ neurons of the striatonigral 
pathway (Schiffman & Vanderhaegen 1993). Physiologically there was also a 
difference in the pathways. D1+ cells have a more hyperpolarised resting membrane 
potential and the cell capacitance is larger in D1+ neurons, reflected by an increased 
complexity when analysed using Sholl analysis (Gertler et al., 2008).  
BAC transgenic mice, expressing GFP controlled either by dopamine receptor D1 
promoter (Drd1α EGFP BAC mice) or the dopamine receptor D2 promoter (Drd2 
EGFP BAC mice) have shown that GFP expression is localised to the medium spiny 
neurons. Retrograde labelling has demonstrated that all D1 receptor containing cells 
were synapsing in the substantia nigra, with less than 1% of D2 receptor cells 
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synapsing in the substantia nigra, D1 receptor cells would also project terminals to 
the lateral part of globus pallidus (Matamales et al., 2009). Another study utilising 
the Drd1α EGFP and DRD2 EGFP BAC transgenic mice profiled gene expression of 
the two separate populations by FACS sorting for the GFP+ cells and subsequent 
identification of differential gene expression between the two populations (Lobo et 
al., 2006). The striatonigral cells showed 8 genes were significantly up-regulated 
including Ebf1 (early B cell factor 1, a transcription factor expressed in the 
developing striatum), Zfp521 (a zinc finger protein which is an interacting partner of 
Ebf1), Slc35d3 (solute carrier 35d3) and in the striatopallidal cells there were 23 
genes specifically and significantly up-regulated including Adora2a (Lobo et al., 
2006). They also showed that only the striatopallidal neurons expressed 
proenkephalin (Lobo et al., 2006). They also used a Chrm4:EGFP BAC transgenic 
mouse, which uses the promoter of μ opioid receptor 1 and is localised to the 
striatonigral neurons (Lobo et al., 2006). They crossed this with an Ebf1-/- knockout 
mouse and showed there was a decrease in the number of striatonigral cells 
postnatally and determined it was a problem of synapse formation and not the 
inability of the cells to differentiate (Lobo et al., 2006). 
1.3.2 Compartmentalisation of the Striatum 
The striatum is also divided into two compartments, the striosomal patch and matrix 
compartments. The patches show an increased expression of μ opiate receptor 
(Herkenham & Pert 1981), and a diminished expression of acetylcholinesterase 
(Graybiel & Ragsdale 1978). The striatonigral and striatopallidal neurons arise from 
both areas as judged by substance P, dynorphin and enkephalin positivity and they 
are fairly evenly distributed ~45-60% of the neurons are positive for each of the 
markers of striatonigral and striatopallidal neurons in the patch and matrix 
compartments (Gerfen & Young 1988). A biocytin labelling study of neurons in the 
matrix compartment showed 3 types of neurons: striatopallidal cells which had the 
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most dense arborisations in the globus pallidus compared to the other types: a 
second type synapsing in the entopeduncular nucleus and substantia nigra pars 
reticulata with an axon collateral to the globus pallidus, and; a third type which 
synapsed with the substantia nigra with an axon collateral to the globus pallidus 
(Kawaguchi et al., 1990). Retrograde labelling of striatopallidal neurons in the non-
human primate by horse radish peroxidase-wheat germ agglutinin and fluorescent 
dyes showed that striatopallidal neurons originate in the caudate and putamen with 
the majority arising from the matrix compartment (Giménez-Amaya & Graybiel 
1990). Also a level of organisation was maintained from origin to target, efferent 
neurons leaving the rostral pole of the caudate and putamen synapse in the rostral 
portion of the globus pallidus and the same organisation was conserved along the 
dorsal/ventral axis (Giménez-Amaya & Graybiel 1990). The nucleus accumbens and 
olfactory tubercle were not labelled in the study and when the two different dyes 
were used in the external and internal segments of the globus pallidus, there was 
intermingling of neurons in the striatum (Giménez-Amaya & Graybiel 1990). 
Anterograde axonal tracing of neurons from midbrain to striatum has shown that 
neurons go to both the patch and matrix compartments and three types of neurons 
have been identified type A possess a large plexus of dendrites, with thin fibres and 
small varicosities; type B also have a large plexus of dendrites with thicker fibres 
and slightly larger varicosities, and; type C neurons are the minority of cells with 
larger fibres possessing larger varicosities (Gerfen et al., 1987a). Cells arising in the 
ventral tegmental area are dopaminergic type A neurons, which synapse in the 
dorsal MOR1- matrix compartment of the striatum, cells of the dorsal tier of 
substantia nigra pars compacta are also dopaminergic type A cells and synapse in 
the MOR1- matrix, the ventral tier of substantia nigra afferents are dopaminergic 
type B neurons and synapse with the MOR1+ patches, remaining cells from the 
substantia nigra are non-dopaminergic type C neurons which synapse in the matrix 
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(Gerfen et al., 1987a). The dopamine afferents that synapse in the patch 
compartment arrive first in the striatum during development as 6-hydroxy-dopamine 
injections into the new-born rat striatum leads to selective death of these cells which 
innervate the striosomal patch compartment, whereas the matrix-innervating 
dopaminergic cells are spared and survive (Gerfen et al., 1987b). 
1.4 Development of the Striatum. 
The central nervous system forms from the ectoderm layer of the three germ layers 
after gastrulation of the embryo. The ectoderm undergoes a process of neural 
induction to form neuroectoderm and then neurulation to form the neural tube. The 
neural tube lies dorsal to the notochord and prechordal plate, important ventral 
midline organising centres, in the embryo. Molecular patterning and folding of the 
neural tube gives rise to the prosencephalon, which lies most anteriorly and is 
subdivided into the most anterior telencephalon and diencephalon. Posterior to 
these structures is the mesencephalon and rhombencephalon. Here, I will focus on 
the development of the telencephalon, the anterior portion of neural tube that gives 
rise to the forebrain. 
1.4.1 The Telencephalon 
The telencephalon is divided into two main sections (Figure 1.4), the dorsally 
located pallium and the more ventrally located subpallium (Campbell 2003, Evans et 
al., 2012). The pallium forms the neocortex and the subpallium forms the striatum, 
globus pallidus and the origin of the olfactory bulb (Evans et al., 2012). The 
subpallium is divided into three substructures; the lateral ganglionic eminence 
(LGE), the medial ganglionic eminence (MGE), the caudal ganglionic eminence 
(CGE) and the septum. The LGE is the source of the MSNs, which locate ventrally 
and anteriorly populate the caudate and putamen of the striatum, nucleus 
accumbens and olfactory tubercle (Deacon et al., 1994, Evans et al., 2012, 
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Wichterle et al., 2001). In general, the cells from the caudal LGE, give rise to the 
MSNs of the nucleus accumbens and those of the dorsal anterior LGE; the olfactory 
bulb granule layer (Wichterle et al., 2001). The ganglionic eminences form as a 
result of cells being produced and migrating ventrally throughout the following zones 
during differentiation. Cells are produced from the ventricular zone (VZ), which lies 
on the border of the lateral ventricles, spanning the two ganglionic eminences 
(GEs), the second proliferative region the subventricular zone (SVZ) is more ventral 
to this and spans the VZ, the final region is non-proliferative and is where neural 
differentiation mostly occurs, the mantle zone (MZ), which spans the SVZ (Evans et 
al., 2012). 
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Figure 1.4: Molecule signalling and morphogen gradients in the developing 
telencephalon. A ventro-dorsal gradient of signalling molecules SHH and FGF8, and a 
dorso-ventral gradient of WNT, BMP and GLI3 is established in development and plays an 
important role of patterning development of the dorsal and ventral forebrain. The pallium will 
give rise to the cerebral cortex and the subpallium the striatum and globus pallidus. The LGE 
and MGE, which make up the subpallium, are indicated and the molecular interactions which 
take place between the regions of LGE and pallium are indicated on the diagram. VZ = 
ventricular zone, SVZ = subventricular zone, MZ = mantle zone (Adapted from Evans et al., 
2012).  
 
Unlike the rest of the CNS, the forebrain is not influenced by signals from the 
notochord, as it is not present and the prechordal plate adopts this role (Shimamura 
& Rubenstein 1997). The notochord and prechordal plate lie ventral to the 
developing neural tube and are involved in the patterning of the ventral neural tube. 
This was shown by the removal of the prechordal plate and the subsequent loss of 
Nkx2.1 gene expression (a marker of the ventral telencephalon) in the MGE of the 
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developing telencephalon and ectopic expression of Nkx2.1 laterally when the 
prechordal plate was transplanted to the lateral telencephalon (Shimamura & 
Rubenstein 1997). The anterior neural ridge (ANR) is also a source of patterning 
signals in the telencephalon and resides at the junction between the anterior neural 
plate and anterior non-neural ectoderm (Shimamura & Rubenstein 1997). The 
interactions between the following signalling pathways are an important factor for 
designing a differentiation protocol in order to derive ventral forebrain neural 
precursors. This is beyond the scope of this study and has been optimised by Joy et 
al., (unpublished data). 
1.4.2 FGF8 signalling 
The identity of the signalling molecule that originates from the ANR is FGF8, as 
identified by removing the ANR and replacing it with an FGF8 soaked heparin bead 
(Shimamura & Rubenstein 1997). Removing the ANR led to a loss of expression of 
Foxg1 (Shimamura & Rubenstein 1997), a forebrain marker important for patterning 
the telencephalon (Section 1.4.6 The role of FoxG1), and this loss of expression has 
also been observed in the Fgf8-/- mouse knockout, in addition to a decrease in cell 
proliferation and up-regulation of apoptosis (Storm et al., 2006). Fgf8-/- knockout 
mice developed abnormally with a reduction in size of the telencephalon possessing 
only one ganglionic eminence and also showing aberrant expression of genes in the 
telencephalon (Storm et al., 2006). There was rostral and caudal expansion of Otx2 
and Wnt8b expression domains, Bmp4 expression was absent from the rostro-
dorsal midline at E9.5, and reduced expression of Nkx2.1 and Shh in the ventral 
telencephalon concomitantly with ventral expansion of Pax6 expression, a dorsal 
marker (Storm et al., 2006). In the zebrafish, ace (zebrafish Fgf8 homologue) was 
required for the development of midline structures in the telencephalon and also for 
the differentiation of the basal telencephalon with the reduction of nkx2.1b 
(zebrafish Nkx2.1 homologue), lim1 and lim6 expression observed in the ace-/- 
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mutant (Shanmugalingam et al., 2000). In the Fgfr triple mutant mouse, targeted 
deletion of Fgfr1, Fgfr2 and Fgfr3 led to a total loss of FGF signalling in the 
forebrain, the telencephalon failed to develop with loss of expression at E12.5 of 
Foxg1, dorsal telencephalic marker Emx1 and ventral markers; Dlx2, Nkx2.1 and 
Gli1 and Shh expression were downregulated implying that FGF signalling regulates 
Shh expression (Paek et al., 2009). The role of FGF signalling in the anterior neural 
plate seems to be in promoting survival and proliferation of the Foxg1+ cells (Paek 
et al., 2009). FGF15 was also observed to play a role in telencephalic development 
but its expression was repressed by FGF8 in the telencephalon and FGF15 is 
responsible for cortical maturation (Borello et al., 2008).  
 
1.4.3 Sonic hedgehog signalling 
Sonic hedgehog (SHH) acts as a morphogen and its signalling pathway is shown in 
Figure 1.5. The importance of SHH signalling in the development of the CNS and its 
expression from the notochord was established by Echelard et al., (1993). In the 
forebrain, the prechordal mesoderm was implicated (Shawlot & Behringer 1995) as 
the organiser of the ventral forebrain and the cyclops mutant zebrafish has 
demonstrated the role of the prechordal mesoderm as a continuation of the 
notochord (Hatta et al., 1994). The expression of SHH was adopted by the 
prechordal mesoderm (Shimamura et al., 1995) and this leads to the induction of 
Nkx2.1 specifically in the forebrain, the expression of Nkx2.1 was first observed at 
the 3 somite stage in the medial prosencephalic neural plate (Shimamura & 
Rubenstein 1997). Nkx2.1 expression later is a marker of the MGE. Shh expression 
was identified as being limited to the MGE in development and co-expressed with 
Nkx2.1 in the rat telencephalon from E11.5 onwards (Kohtz et al., 1998). SHH was 
required for the development of the LGE, but in lower concentrations than needed 
for the MGE, as observed in rat telencephalic explants, where there was a 
1. Introduction 
 
 
- 26 - 
generation of Dlx+/Isl1+/Ikaros+ ventral-like cells (Kohtz et al., 1998). When these 
explants were cultured in the absence of SHH, there is the generation of dorsal 
progenitors as SHH represses the dorsal markers Emx1 and Tbr1 (Kohtz et al., 
1998). Shh or activated Smo viral injections into the forebrain induced Nkx2.1 
expression medially or Dlx2 and Gsx2 more laterally (Rallu et al., 2002). Retroviral 
injections of Shh into mouse amniotic cavity (E8.5) or telencephalic ventricles (E9.0) 
led to an enlarged single telencephalic ventricle (Gaiano et al., 1999). Nkx2.1 and 
Crbp1 (cellular retinol binding protein 1) were expressed in Shh infected and 
adjacent cells whilst dorsal midline structures were lost and aberrant Dlx2 
expression was observed in the dorsal telencephalon (Gaiano et al., 1999). In the 
chick lateral neural plate explants, exogenous Shh was shown to induce Nkx2.1 and 
Isl1 (Ericson et al., 1995). In the Shh-/- mouse, the notochord was degenerated and 
the ventral forebrain was lost resulting in a single vesicle present in the midline in 
the forebrain that is Emx1+ (Chiang et al., 1996). Also, in the Shh-/- mutant there was 
a lack of maintenance of Fgf8 expression post developmental stage E9.0 (Chiang et 
al., 1996), there was no Nkx2.1 expression but Dlx2 and Gsx2 expression persists 
at the ventral midline, implying that SHH is not necessary for their expression (Rallu 
et al., 2002). SHH also induced endogenous dopamine neurons with the help of 
FGF8 signalling in the developing telencephalon (Ye et al., 1998).   
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Figure 1.5: Schematic of the SHH signalling pathway. SHH, when present, binds to the 
molecule Patched (Ptc) and binds to the cell receptor Smoothened (SMO). This leads to 
downstream activation of the GLI family of transcription factors and target genes of SHH are 
expressed. When SHH is not present, Ptc binds SMO and inhibits the GLI complex of 
transcription factors therefore inhibiting the expression of SHH target genes. (Adapted from 
Evans et al., 2012) 
 
As demonstrated in Figure 1.5 SHH acts by signalling via the GLI family of zinc 
finger transcription factors, by binding the receptor Smoothened (Evans et al., 
2012). The Foxg1Cre Smofl/fl mouse showed a loss of ventral telencephalon 
patterning, with a lack of Nkx2.1, Gsx2, Ascl1 and Dlx2 mRNA, plus Pax6 and Ngn2 
expression was evident throughout the dorsal and ventral telencephalon and the 
other dorsal marker Emx2 displayed a ventral expansion in expression, also the 
GEs failed to form and the other dorsal marker Ngn2 was present throughout the VZ 
(Fuccillo et al., 2004). GLI3 was shown to repress Shh expression and vice versa 
(Rallu et al., 2002). The extratoes mouse mutant, Gli3-/-, demonstrated that Gli3 
expression is complementary to that of Shh, as the pallium is completely lost and 
the basal ganglia occupy a dorsal position in the telencephalon with the dorsal 
markers Emx1/2 were undetected (Theil et al., 1999). In the same mutant, the 
ventrally expressed Isl1 and Dlx2 expanded their expression into the dorsal 
telencephalon (Tole et al., 2000). In the extratoes mouse, that carries a naturally 
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occurring mutation in Gli3, there was also a failure of the telencephalic roof to 
invaginate and the dorsally located choroid plexus and cortical hem fail to form, 
which led to disruption in Wnt and BMP signalling (Tole et al., 2000, Grove et al., 
1998, Theil et al., 1999). The double knockout mouse for Shh-/-;Gli3-/- had a larger 
telencephalon than the Shh-/- mouse, the ventral markers Dlx2, Gsx2 and Ascl1 
were almost restored to wild type levels, Pax6 was not co-expressed with Gsx2 and 
there were low levels of Nkx2.1 ventromedially and a small MGE-like structure 
formed (Rallu et al., 2002). Another GLI family member, Gli1 usually expressed at 
the border between MGE and LGE was lost in the Shh-/- mutant and Shh-/-; Gli3-/- 
mutant and Ptch1 (Ptc), usually expressed in the MGE, was also lost in the Shh-/- 
mutant but its expression was slightly retained in the Shh-/-; Gli3-/- double mutant 
(Rallu et al., 2002). 
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1.4.4 Retinoic acid signalling 
 
Figure 1.6: Retinol processing and the retinoic acid signalling pathway. Retinol is 
carried in serum by retinol binding protein (RBP4), which is secreted from the liver. Retinol 
enters the cell (top) via STRA6 receptor and inside the cell, either binds to cellular retinol 
binding protein (CRBP) and this facilitates the conversion of retinol to retinyl ester for 
storage, or in retinoic acid generating tissue, retinol becomes oxidised by alcohol/retinol 
dehydrogenase (ADH/RDH) to retinaldehyde. Retinaldehyde is then oxidised by 
retinaldehyde dehydrogenase (RALDH) to retinoic acid (RA). RA is then released to 
surrounding cells and when taken up by cells (left) that express cytochrome P450 (CYP26), 
RA is oxidised and therefore degraded. Some RA target cells (right) express cellular retinoic 
acid binding protein (CRABP), which facilitates RA uptake, and transports it to the nucleus 
where RA binds to retinoic acid receptor (RAR). The ternary complex of RA-RAR-RXR and 
retinoic acid response element (RARE) regulate transcription of RA targets. 
 
The various stages involved in producing retinoic acid (RA) and how RA then acts 
on cells can be seen in Figure 1.6. MEIS2 is a marker of striatal progenitors in the 
intermediate telencephalon in the mouse and chick embryo and was required during 
striatal development (Toresson et al., 2000b, Marklund et al., 2004). In chick 
intermediate telencephalon explants harvested at progressively later stages of 
development, MEIS2 expression was upregulated, therefore was induced later in 
vivo (Marklund et al., 2004). RA was required for the specification of MEIS2+ cells in 
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the chick and RALDH3, an enzyme required for the formation of RA (Figure 1.6), 
was expressed at HH (Hamburger-Hamilton) stage 14 in the ventral and 
intermediate telencephalon in the chick (Marklund et al., 2004) and at E8.75 in the 
mouse frontonasal surface ectoderm and later at E12.5 in the LGE (Molotkova et 
al., 2007). In the Raldh2-/-;Raldh3-/- mouse, there was no requirement of RA for the 
expression of Meis2, which was in disagreement with what was observed in the 
chick development (Molotkova et al., 2007). However, Meis2 expression was up-
regulated in P19 EC cells by the addition of RA and the LGE was shown to be a 
source of retinoids possibly via the radial glia which can provide migrating striatal 
cells with retinoids and aid striatal differentiation (Toresson et al., 1999).  
Citral inhibited the synthesis of RA and when a citral-soaked bead was inserted into 
the HH stage 10 rostral margin of the forebrain in the chick, the whole telencephalon 
failed to form (Schneider et al., 2001). Using a retinoic acid receptor (RAR) 
antagonist soaked bead led to a loss of fgf8 and shh expression in the forebrain 
only 12 hours post implantation and at 72 hours, there was a decrease in foxg1, 
nkx2.1 and dlx2 (Schneider et al., 2001). However, in the Raldh2-/-;Raldh3-/- mouse, 
there was no effect on FGF8 and SHH signalling in the forebrain (Molotkova et al., 
2007). 
In Raldh3-/- mutant mouse embryos, there was no loss of RA activity in the early 
forebrain but there was an absence of dopamine receptor D2 in the nucleus 
accumbens and depletion in RARβ in the striatum at E18.5 (Molotkova et al., 2007). 
There was also a decrease in the amount of GAD67+/TUJ1+ neurons produced in 
vitro from E14.5 Raldh3-/- mouse mutant embryos (Chiatzi et al., 2011). The ectopic 
expression of RARβ1 in cortical explant culture was shown to selectively up-
regulate expression of DARPP32 (Liao & Liu 2005), and in the RARβ-/- mouse there 
was a depletion of DARPP32, tyrosine phosphatase (Liao et al., 2005), dynorphin, 
MOR1 and tyrosine hydroxylase (Evans et al., 2012). 
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Figure 1.7: The canonical WNT signalling pathway. In the absence of WNT, its receptor 
Frizzled and co-receptor LRP5/6 are not bound and Dickkopf (DKK) binds LRP5/6, this 
allows glycogen synthase kinase 3β (GSK3β) to phosphorylate β-catenin which results in the 
degradation of β-catenin. When WNT is present, it binds the receptors Frizzled and LRP5/6 
and Dishevelled (Dsh) is activated to repress GSK3β, therefore preventing β-catenin 
phosphorylation, stabilising it and allowing β-catenin to translocate to the nucleus and induce 
transcription via the TCF/LEF family of transcription factors. (Adapted from Evans et al., 
2012) 
 
1.4.5 WNT and BMP signalling 
WNT signalling is important for the patterning of the dorsal telencephalon, the 
canonical WNT pathway can be seen in Figure 1.7. A frizzled related WNT 
antagonist ,TLC, is secreted from the anterior boundary of the neural plate in the 
zebrafish and promotes telencephalic gene expression in a concentration-
dependent manner, and disruption of this gene leads to abnormal telencephalic 
development, a likely target of TLC is Wnt8b as it controls regional identity in the 
anterior neural plate (Houart et al., 2002). The expression of tlc was reduced in 
embryos lacking BMP signalling and in the Bmp knockout, implantation of tlc 
expressing cells led to restoration of emx1 and fgf8 expression (Houart et al., 2002). 
In explants of HH stage 8 chick dorsal neural fold combined with dorsal epidermal 
ectoderm, the dorsal telencephalic marker emx1 was induced in culture (Gunhaga 
et al., 2003). Several wnt genes were candidates for controlling dorsal 
telencephalon development; wnt1 and wnt4 were expressed in dorsal epidermal 
ectoderm at HH stage 8 and wnt8b in the dorsal telencephalon at HH stage 10 chick 
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embryos (Gunhaga et al., 2003). Wnt3a blocked the differentiation of ventral 
telencephalic cells by inhibiting nkx2.1 and it increased cell proliferation and pax6 
and ngn2 expression, but fgf8 was additionally required in order to express the other 
dorsal marker emx1 (Gunhaga et al., 2003). The wnt antagonist, Frz receptor 8, 
blocked the expression of pax6 and emx1 in the developing chick telencephalon 
(Gunhaga et al., 2003). Inactivating the Wnt target, β-catenin, before neurogenesis 
led to a decrease in Emx1/2+ and Ngn2+ cells and an increase in the number of 
Gsx2+, Ascl1+ and Dlx2+ cells in the mouse pallium, and activating the canonical 
Wnt pathway in the subpallium decreased the expression of the ventral 
telencephhalic markers and up-regulated dorsal markers (Backman et al., 2005). 
Using lef1, a wnt nuclear effector, morpholino in zebrafish knocked down wnt 
signalling and reduced the expression of the pallial markers tbr1 and lhx5 (Danesin 
et al., 2009).  
BMP expression was also recorded as inhibiting ventral telencephalic fate and 
promoting a dorsal fate. BMP 2,4,5 & 7 were expressed in the pallium in the mouse 
and were important for the formation of the choroid plexus and expression of Msx1 
and Hfh4, Foxg1 expression was excluded from BMP expression domains (Furuta 
et al., 1997). BMP 4 & 5 inhibited expression of subpallial markers: nkx2.1, shh, 
dlx2, and the neural tube displayed excessive cell death in the developing chick 
embryo when ectopically expressed in the chick neural tube (Ohkubo et al., 2002, 
Golden et al., 1999). 
1.4.6 The role of FoxG1 
FoxG1 is a forkhead-containing transcription factor belonging to the HNF3 family of 
transcription factors. Its expression was first isolated in the rat neural tube and was 
subsequently localised to the developing telencephalon (Tao & Lai 1992). In a later 
study, Foxg1 was observed to be also expressed in the anterior optic vesicle, otic 
vesicle, facial and head ectoderm, olfactory epithelium, midbrain/hindbrain junction 
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and in the pharyngeal pouches (Hérbert & McConnell 2000). In the Foxg1 null 
mutant mouse, there was a severe decrease in the size of the cerebral hemispheres 
with a 95% decrease in their mass at birth and a reduction in striatal and 
hippocampal volumes (Xuan et al., 1995, Eagleson et al., 2007). The development 
of the ventral telencephalon was impaired more than the dorsal telencephalon, with 
the main problem that there was a decrease in cell proliferation, as the cell cycle 
time increases (Martynoga et al., 2005). The cells of the telencephalon were 
specified too early, with an accumulation of post-mitotic neurons in the MZ and a 
doubling of the number of βIII-tubulin+ cells in the SVZ, therefore depleting the 
progenitor population (Martynoga et al., 2005). The difference in phenotype, 
between wild type and Foxg1 knockout, was noticed at E10.5 when the 
telencephalic vesicles were noticeably smaller and the cortex had an irregular and 
uneven surface (Xuan et al., 1995). The ganglionic eminences were not present at 
E12.5 and comprised of a neuroepithelial sheet and all of the telencephalic tissue 
was Emx1/2+/Pax6+, and Dlx1/2 were undetectable (Xuan et al., 1995). In the 
Foxg1-/- mouse, the expression of Nkx2.1 was not observed in the prosencephalic 
neural plate of the prospective telencephalon at E8.5, but Nkx2.1 was expressed in 
the prospective diencephalon, Gsx2 and Ascl1 (ventral telencephalon markers) 
were not expressed later in development and at E10.5 there was a decrease in Fgf8 
expression (Martynoga et al., 2005). Using foxg1 morpholino knock down in 
zebrafish caused a deficiency of ventrally expressed genes including dlx2 and 
nkx2.1b (the zebrafish Nkx2.1) and ventral expansion of emx3 (Danesin et al., 
2009). Foxg1 in the zebrafish was shown to have a role of maintaining the 
dorsal/ventral boundary in the telencephalon and it also maintained ventral 
telencephalic progenitors, preventing them from aberrantly forming part of the 
hypothalamus, it also restricted the canonical wnt pathway to the dorsal 
telencephalon and was shown specifically to inhibit wnt8b (Danesin et al., 2009). 
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Foxg1 has been observed to act cell autonomously, as shown in chimeric mice, to 
ensure competence of the cells to respond to ventralising signals, as cells which 
were Foxg1-/- in wild type mice did not express Gsx2 and Ascl1 in the ventral 
telencephalon but surrounding wild type cells did express these ventral markers and 
these Foxg1-/- cells expressed dorsal markers including Pax6 and Ngn2 when in the 
dorsal telencephalon (Manuel et al., 2010). These Foxg1-/- cells had lower rates of 
proliferation and the expression of Pax6 (a cell cycle regulator) was lower in the 
dorsal telencephalon in these cells, overexpression of Pax6 in a Pax77 mouse line 
crossed with the Foxg1-/- chimeric mice restored the levels of Pax6 expression and 
increased cell proliferation in these mice, however proliferation was still below the 
levels seen in wild type mice, showing Foxg1 to be a cell autonomous regulator of 
progenitor proliferation (Manuel et al., 2011). 
1.4.7 The roles of Dlx1/2, Gsx1/2 and Ascl1 
Gsx2 is a dispersed homeobox gene resulting from a 2 kb transcript and was shown 
to be expressed in the ganglionic eminences of the telencephalon by in situ 
hybridisation (Hsieh-Li et al., 1995, Valerius et al., 1995). Gsx2 is a downstream 
target of SHH, first detected in the neuroepithelium of the E9 telencephalic vesicle in 
the mouse and the Gsx2 knockout showed a distinct decrease in the size of the 
LGE at E12.5-14.5, the striatal volume reduced by 55%, the expression of Dlx2 was 
still present in the MGE at E12 but lost from the LGE and there was an expansion of 
the expression domain of dorsal markers into the LGE (Szucsik et al., 1997, Corbin 
et al., 2000, Toresson & Campbell 2001). At E12.5 in the Gsx2-/- mouse there was 
also a decrease in Ascl1, Ebf1  and Gad67 expression and a decrease in Raldh3 
expression and retinoid production (Waclaw et al., 2004). Later, at E15.5, there was 
a partial rescue of molecular patterning but the striatum was smaller and gene 
expression levels did not reach the level seen in the wild type (Corbin et al., 2000). 
At later stages of development there was a decrease in the number of DARPP32 
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and ENK expressing cells in the nucleus accumbens and loss of DARPP32 
expression in the striatum (Corbin et al., 2000). Gsx2 has been shown to be an 
important gene involved in the formation of the pallio-subpallial boundary with Pax6, 
the expression of Gsx2 led to the expression of Ascl1 and Dlx1/2, Pax6 induced 
expression of Ngn1&2 and in the Gsx2 and Pax6 mutants, there was a ventral 
expansion of Ngn1&2 expression or a dorsal expansion of Dlx1/2 and Ascl1 
expression respectively (Toresson et al., 2000a, Waclaw et al., 2004). In the double 
Pax6-/-;Gsx2-/- mouse mutant, this expression was improved along with cortical and 
striatal development (Toresson et al., 2000a, Waclaw et al., 2004). However, the 
diminished expression of Raldh3 observed in the Gsx2-/- mouse was not rescued 
(Toresson et al., 2000a, Waclaw et al., 2004). As early as E10.5 in mouse the 
pallio/subpallial boundary was observed through the differential expression of pallial 
Tbr2, Ngn2 and of subpallial Gsx2, Ascl1 and Dlx2. (Yun et al., 2001). In the Gsx2-/- 
mouse there was a loss of the pallio-subpallial boundary and Pax6 and Ngn2 
expression was observed in the VZ of the LGE at E12.5, but this was recovered by 
E15.5 (Corbin et al., 2000) and seemed to be due to the expansion in expression of 
Gsx1 from the MGE into the LGE in the Gsx2-/-. This compensation was confirmed 
with the exacerbated striatal defects observed in the double Gsx1-/-;Gsx2-/- knockout 
mouse (Toresson & Campbell 2001). Gsx1 is normally expressed at the boundary 
between the VZ and SVZ and has been shown to promote the maturation of the 
cells between the two zones (Pei et al., 2011). The Gsx2-/- mouse also showed a 
reduction in DARPP32+ neurons but the matrix is relatively spared (Toresson & 
Campbell 2001). 
Ascl1 is a proneural bHLH transcription factor and in the mutant mouse there was a 
pronounced reduction in the size of both of the GEs and in the number of BrdU+ 
proliferating cells in the VZ and SVZ (Casarosa et al., 1999). However, the 
differentiation potential of the LGE seemed unaffected (Casarosa et al., 1999). In 
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the Ascl1 mutant mouse, there was a loss of Dll1 expression (Delta like, a notch 
ligand) and loss of notch target Hes5 expression, which was normally expressed in 
the VZ (Casarosa et al., 1999, Yun et al., 2002). Notch signalling regulated the 
normal expression of Ascl1 in the VZ, and in Ascl1 mutants SVZ and MZ markers 
were expressed earlier in the VZ and there was a loss of generation of mature 
neurons (Casarosa et al., 1999, Yun et al., 2002). In the Dll1-/- mutant there was a 
decrease in expression of Hes5 but the LGE retained the ability to make mature 
neurons, showing that Ascl1 with Notch signalling controlled the progression of cells 
from the VZ to the SVZ and that ASCL1 was required cell autonomously to generate 
mature neurons (Casarosa et al., 1999, Yun et al., 2002). Ascl1 was also shown to 
control cell cycle progression via genes such as E2f1 and Notch signalling (Yun et 
al., 2002, Castro et al., 2011). In the Dlx1/2-/- mouse, there was an increase in 
expression of Dll1, Hes5 and Ascl1 and the SVZ domain was expanded also there 
was a persistent expression of VZ markers; COUP-TF1 and GSX1/2 and a loss of 
OCT6 and DLX5/6 (SVZ markers) and even though mature neurons were produced, 
they lost their dopaminergic phenotype, losing DRD2 and DARPP32 expression 
(Yun et al., 2002). Ascl1 was expressed ectopically in the Ngn2-/- mutant mouse in 
the dorso-medial telencephalon at E12.5, but not in the Ngn1-/- mouse, and in the 
Ngn2-/- mutant mouse Dlx1,2 and 5 were expressed in the cortex with Ascl1 being 
required for the ectopic expression of Dlx1 dorsally, both Neurogenins were 
normally expressed in the Ascl1-/- mouse (Fode et al., 2000). Later in development, 
Ascl1 was shown to control the expression of genes involved for differentiation and 
neurite outgrowth (Castro et al., 2011). 
DLX2 (a homeodomain protein) was shown to be expressed in the VZ and SVZ of 
the forebrain and was co-expressed with Ascl1 but not with the mature neuron 
marker MAP2 (Porteus et al., 1994, Liu et al., 1997). Porteus et al., (1994) 
described the presence of 4 populations of cells in the developing LGE. A study by 
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Yun et al., (2002) went further to suggest there was an additional population present 
in the VZ that was ASCL1+, and a DLX2+ neuronal population. Dlx1/2 were also 
expressed with Dlx5 in the SVZ and both Dlx5/6 were highly expressed in the MZ 
(Liu et al., 1997). In the Dlx1/2-/- double mutant there was absence of Dlx5, Dlx6 and 
Oct6 at E12.5 and at E14.5 a decrease in Ctip2, Rarb, Ebf1 and FoxP1, but an 
increase in Gsx1/2 and  Ascl1, possibly to compensate for the loss of Dlx1/2 
(Anderson et al., 1997, Long et al., 2009). This change in expression of ventral 
markers was compounded with ectopic expression of cortical markers Ebf3, Id2 and 
Nhlh2 and there were defects in migration of later born cells to the MZ in the LGE 
with many proliferating cells present in the MZ (Anderson et al., 1997, Long et al., 
2009). The Dlx1/2-/- mouse showed a loss of matrix cells in the striatum. However, 
the striosomal patches formed fairly normally (Anderson et al., 1997). Necdin (a 
maternally imprinted gene which binds NRAGE) interacted with DLX2 or DLX5 with 
NRAGE and its overexpression increased the number of GABAergic, calbindin D-
28k cells (Kuwajima et al., 2006). 
As a result of the complex patterning and the fine balance that is needed in the 
telencephalon in order to obtain progenitors of the striatum, there needs to be 
a.protocol which generates ventral-forebrain like neural precursors utilising these 
signalling pathways. This should mean that on transfection of the post-mitotically 
expressed transcription factors, genes such as Gsx2, Ascl1, Dlx2 should already be 
expressed as a result of correct BMP and WNT inhibition, low levels of SHH 
signalling and FGF signalling during early differentiation in vitro. Currently a protocol 
has been optimised in the lab to produce these types of cells and follows these 
developmental instructions. 
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1.5 The Relevance of Transcription Factors in Striatal 
Development 
1.5.1 EBF1 
EBF1 (early B cell factor 1), also known as OLF1, is a transcription factor belonging 
to the COE family of transcription factors, which contain a non-basic helix loop helix 
domain, a novel zinc coordination motif responsible for DNA binding and when 
EBF1 binds to DNA it does so as a homodimer via the amino terminus (Figure 1.8) 
(Hagman et al., 1993, Hagman et al., 1995).  
 
 
EBF1 is the only member of the COE family expressed in the lateral ganglionic 
eminence. At E12.5 in the mouse, EBF1 was expressed in the mantle zone of the 
LGE and not in the SVZ/VZ as observed by a lack of co-localisation with DLX1+ 
cells or the GBX2+ cells of the MGE mantle zone (Garel et al., 1997). In the chick 
embryo, EBF1 has the ability to promote early onset of neural differentiation and 
migration of neuroepithelial progenitors, and the cells exit the cell cycle when 
expressed ectopically in the chick neural tube (Garcia-Dominguez et al., 2003). 
Adhesion markers on chick neural progenitors changed when EBF1 is expressed 
ectopically, with a decrease of the N-cadherin molecule (expressed on neural 
progenitors) and an increased expression of R-cadherin which is observed in 
neurons (Garcia-Dominguez et al., 2003). In situ hybridization studies, in the mouse, 
have showed that Ebf1 is expressed at E15.5 in a few cells of the LGE SVZ and in 
the mantle zone with a more caudal expression at the SVZ/MZ boundary on the 
Figure 1.8: Schematic highlighting the important domains of human EBF1 protein. The 
N terminally located DNA binding domain encompasses a zinc binding site, upstream from the 
Helix-loop-helix domain 
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MGE, this expression is decreased from E17.5 (Garel et al., 1999). At P0 in the 
mouse, most of the MZ of the striatum expressed Ebf1 mRNA and it is observed in 
the striatal matrix compartments as observed by lack of co-localisation with tyrosine 
hydroxylase staining of the patch compartments (Garel et al., 1999). In the Ebf1-/- 
mutant mouse, the LGE developed normally with no stable change in size or 
morphology (Garel et al., 1999). However, the transition from the SVZ to the mantle 
zone was perturbed with the mantle markers CRABP1 (cellular retinoic acid binding 
protein 1), involved in retinoic acid metabolism (Boylan & Gudas 1992), and 
cadherin 8, a type II class cadherin expressed in neuroepithelial cells and radial glia 
cells (reviewed by Redies and Takeichi 1996) with a possible role in neuronal 
migration, were either absent or markedly reduced (Garel et al., 1999). This resulted 
in persistence of the SVZ markers, EphA4, RARα, SCIP/Oct6 and Dlx5, in the 
mantle zone (Garel et al., 1999). These defects in expression of mantle and SVZ 
markers had an effect perinatally, with severe atrophy occurring in the striatum by 
E18.5 and also problems of axonal fasciculation and navigation of; internal capsule 
fibres, the posterior branch of the anterior commissure and thalamo-cortical fibres in 
and around the striatum (Garel et al., 1999). EBF1 was shown to interact with 
ZFP521, also known as EVI3, and they were both highly enriched in the striatonigral 
medium spiny neurons (Lobo et al., 2006). In the Ebf1-/- co-expressing EGFP either 
from the Chrm4 or D2d promoter mouse, the striatonigral MSNs were selectively 
lost postnatally as observed by a decrease in the number of GFP+ MSNs, the 
striatopallidal D2-EGFP+, enkephalin+ MSNs remain intact in the Ebf1-/- knockout 
mouse (Lobo et al., 2006), Ebf1 knockout also decreased the number of GFP+ 
neurons in the dorsal striatum of a dopamine D1a receptor-EGFP mouse line and a 
solute carrier 35d3-EGFP mouse line (Lobo et al., 2008), hence EBF1 is only 
required for striatonigral MSN development. It was also observed that a reduction of 
cells occurred in the matrix compartment, but the cells of the patch compartment still 
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remained which led to a decrease in the size of the matrix and the patches 
constituted a greater volume of the striatum (Lobo et al., 2008), so EBF1 is required 
for the development of the matrix, but not the striosomal patches of the striatum. 
ZFP521 is normally expressed in the mouse adult striatum (Lobo et al., 2008). 
However, in Ebf1-/- knockout mice, there was a decrease to 43.9% of wild type 
mouse expression of ZFP521 in the striatum, but expression in the septum was not 
affected (Lobo et al., 2008). Therefore Zfp521 is a specific EBF1 target in the 
striatum. HELIOS, a transcription factor involved in striatal development was 
expressed independently of EBF1 and Ebf1 expression was independent of a 
related transcription factor IKAROS, which was also expressed during striatal 
development (Martín-Ibáñez et al 2010, Martín-Ibáñez et al., 2012). Therefore, there 
are other transcription factors required for the whole development of the striatum. 
As a result of the marked defects in striatal development observed in the various 
Ebf1-/- mice with defects being limited to the striatonigral pathway and also the 
matrix compartment of the striatum, it is a suitable transcription factor to be used in 
transfections into neural stem cells in order to derive MSNs. 
1.5.2 FOXP1 
FOXP1 belongs to the forkhead box (Fox) family of transcription factors which all 
contain a ~100 amino acid winged helix/forkhead box DNA binding domain (Tang et 
al., 2012). The FOXP division of the transcription factor family also contain a zinc 
finger domain and a leucine zipper motif which is involved in transcriptional 
repression, these reside in the N-terminus of the protein and allow the transcription 
factors to form homo- and heterodimers with each other see Figure 1.9 (Tang et al., 
2012, Li et al., 2004, Shu et al., 2001). Foxp1 is widely expressed in E12.5 mice 
with high levels of expression in the lung, and lower levels expressed in intestinal, 
neural and cardiovascular tissue (Shu et al., 2001). There are at least four splice 
isoforms of Foxp1 two of which have been detected in the brain which are; 3.2 kb 
1. Introduction 
 
 
- 41 - 
and 2.4 kb and are expressed at similar levels, the FOXP1 consensus binding site 
in promoter regions is TATTTG/AT (Wang et al., 2003).  
 
Figure 1.9: Schematic highlighting the important features in human FOXP1. An N 
terminal Glutamine rich domain and a centrally located C2H2 zinc finger and leucine zipper, 
and the C terminal Forkhead domain and acidic sequence 
 
An alternative splice form of FoxP1 has been detected in human and mouse, which 
is expressed in pluripotent ES cells (Gabut et al., 2011). In human, exon 18 is 
substituted for exon 18b and in mouse exon 16 is substituted for 16b in the ES form; 
the expression of the “b form” of the exon decreases on differentiation, the splice 
variant alters the amino acid sequence of the forkhead domain affecting DNA 
binding (Gabut et al., 2011).  Foxp1 has been observed in the very early developing 
zebrafish from the one cell stage from the maternal transcript, decreasing in 
expression at the developmental stage of 30% epiboly and increasing again at 75% 
epiboly in the whole zebrafish embryo and at later stages localised to the 
developing midbrain, hindbrain and spinal cord (Cheng et al., 2007). There was a 
marked reduction of expression of Foxp1 in a Dlx1/2-/- mouse SVZ and MZ of the 
LGE and in maturing striatal neurones, suggesting that FoxP1 is an important 
transcription factor in later striatal development (Long et al., 2009). In the mouse, 
DLX5/6 were also expressed in the mantle zone and could induce the expression of 
Foxp1 (Tamura et al., 2004).  
At E12.5 in the mouse, Foxp1 was shown to be expressed in the developing spinal 
cord motor neurons and possesses a similar expression pattern to Islet1 (Shu et al., 
2001, Ericson et al., 1992, Tsuchida et al., 1994). However, its expression was 
observed later in the developing basal ganglia at E16.5 (Shu et al., 2001). Mouse in 
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situ hybridisation and immunohistochemistry showed FoxP1 protein and mRNA to 
be expressed in the SVZ of the ganglionic eminence at E14.5, therefore localised to 
the migratory/post-migratory neurons of the striatum (Ferland et al., 2003). Striatal 
expression of FOXP1 has been observed from later embryonic developmental 
stages right through to the adult mouse (Ferland et al., 2003). In the adult mouse, 
FOXP1 expression was observed elsewhere in the brain including the substantia 
nigra, the ventral striatum, anterior olfactory nucleus, olfactory tubercle, thalamus, 
pontine nucleus, inferior olive, deep layers of the superior colliculus and cortical 
layers III-V (Ferland et al., 2003). Tamura et al., (2003) performed in situ 
hybridisation in the mouse forebrain and detected Foxp1 expression earlier at E13.5 
in the post-mitotic neurons of the caudatoputamen. At E15.5, expression of Foxp1 
was also detected elsewhere including the paraventricular thalamic nucleus, lateral 
preoptic area and preoptic area (Tamura et al., 2003). At E17.5, the expression of 
Foxp1 increased in the caudatoputamen and paraventricular thalamic nucleus, but 
decreased in the lateral preoptic area and preoptic area but was also detected in the 
CA1 region of hippocampus (Tamura et al., 2003). Foxp1 mRNA was only 
expressed in MAP2+ neurons of the mouse striatum, with over two thirds of MSNs 
(DARPP32+/GluR2/3+) expressing Foxp1 mRNA, and no Foxp1 mRNA expressed in 
interneurons (Tamura et al., 2004). This expression pattern suggested Foxp1 is 
more likely to be a matrix marker than a striosomal patch marker in mouse (Tamura 
et al., 2004). More recent findings by Martín-Ibáñez et al., (2012) have localised 
FOXP1 expression to the matrix in the mouse as it co-localises with HELIOS 
expression. However, FOXP1 has been shown to be expressed in both the 
striosomal patches and matrix compartments in the P3-20 rat striatum (Takahashi et 
al., 2003), indicating possible species variations in the location of FOXP1 
expression in the striatum. Foxp1 mRNA was first detected in the rat at E14 in the 
mantle zone of the LGE, at E16-20 Foxp1 expression in the SVZ was lower than the 
1. Introduction 
 
 
- 43 - 
MZ, with low level expression in the primordium of septum and amygdala unlike the 
expression of the closely related transcription factor which was also striatally 
enriched, Foxp2 (Takahashi et al., 2003). FOXP1 was detected in the 11 week old 
human fetus in the LGE in both precursors and differentiated medium spiny neurons 
(Delli Carri et al., 2013a).  
FOXP1 overexpression in mouse striatal cells induced an increase in expression of 
Follistatin, Fos and activating transcription factor 3 (Tang et al., 2012). siRNA 
mediated knockdown of Foxp1 decreased their expression, suggesting these are 
targets of FoxP1 (Tang et al., 2012). FOXP1 overexpression also up-regulated 
genes involved in glutamate receptor function, GABA receptor signalling, G protein 
coupled receptor signalling and cAMP-mediated signal transduction (Tang et al., 
2012). In total, there are currently 40 FoxP1 targets associated with the 
Huntington’s disease signalling pathway, mainly involved in BDNF signalling, 
caspase activity and glutamate and calcium signalling (Tang et al., 2012). FOXP1 
regulates its own expression as well as increasing expression of Kcnip2 (Tang et 
al., 2012), KCNIP2 was significantly decreased in expression in human HD samples 
(Desplats et al., 2006). Interestingly, both FOXP1 and CTIP2 (another transcription 
factor involved in striatal development) showed a significant decrease in their 
expression in the striatum of an R6/1 HD transgenic mouse model compared to that 
of wild type littermates at 6 months of age (Desplats et al., 2006). The Foxp1 
promoter does not contain a CTIP2 binding site but Foxp2 does (Desplats et al., 
2008). However, Ctip2 does possess many FOXP1 binding sites in its promoter 
region (Tang et al., 2012). It may become apparent on transfection that Foxp1 
transfection up-regulates Ctip2 expression through direct activation of the promoter. 
FOXP1 may be involved in immunosuppression in the CNS and is predominantly 
expressed in the neurons as shown by co-labelling with NeuN, but has been 
detected in qRT-PCR analysis of activated microglia cultures (Tang et al., 2012). In 
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vivo, increased FOXP1 expression induced an increased expression of suppressor 
of cytokine signalling 5 (SOCS5), and so FOXP1 could be seen as being a neuro-
protective transcription factor by counteracting glia activation (Tang et al., 2012). 
FOXP1 has been shown to regulate retinoic acid signalling in the developing lateral 
motor column of the spinal cord at brachial and lumbar levels (Rousso et al., 2008), 
and could be important in the developing striatum since retinoic acid signalling has 
been shown to induce expression of DARPP-32 (Liao et al., 2005, Liao & Liu 2005). 
In the mouse Foxp1 knockout, there was a loss of the lateral motor column and an 
increased size of the medial motor column more laterally (Rousso et al., 2008). 
FOXP1 and ISLET1 are co-expressed in the lateral motor column (Rousso et al., 
2008) and in the more caudal regions of the brachial and lumbar divisions of the 
lateral motor column, expression of OCT6, another transcription factor important for 
striatal development, has been observed (Dasen et al., 2005, Luria & Laufer 2007), 
and so there could be activation of Foxp1 by OCT6 or vice versa and the same with 
Foxp1 and ISLET1. The Pitx3 gene promoter contains seven FOXP1 binding sites 
and FOXP1 is co-expressed in the Pitx3+ post mitotic midbrain dopamine neurons in 
the E12.5 mouse, FoxP1 forced expression in mES cells led to expression of 
Pitx3+/TH+ dopamine neurons when differentiated in monolayer culture 
(Konstantoulas et al., 2010). 
FoxP1 will be transfected into neural stem cells as it is important for MSN 
development as it is highly expressed in post-mitotic neurons of the developing 
striatum and co-localises in the developing and adult striatum with the MSN marker 
DARPP32. FOXP1 also co-localises with other transcription factors important for 
MSN development. The phenotype of FOXP1 transfected cells will need to be 
determined as there is disparity in the literature as to whether FOXP1+ cells 
correspond to matrix or a patch phenotype. 
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1.5.3 Islet1  
Islet 1 (ISL1) is a LIM homeodomain containing transcription factor with 2 
specialised zinc fingers functioning as the LIM domains, located N terminally of the 
homeodomain (Figure 1.10) (reviewed by Hobert & Westphal 2000). 
 
Figure 1.10: Schematic highlighting the important regions of the human ISL1 protein. 
The two N terminal LIM domains and the homeobox region 
 
It is expressed mainly in the pancreas and motor neurons as seen in loss of function 
studies (Hobert & Westphal 2000, Pfaff et al., 1996). Additionally, a population of 
Engrailed+ interneurons failed to form in the embryonic Isl1 mutant mouse (Pfaff et 
al. 1996). Mouse mutants for Isl1 experienced arrested development around E9.5 
with an abnormal dorsal aorta (Pfaff et al., 1996). Isl1 is also highly expressed in the 
basal ganglia; the Dlx1/2 mutation reduced Isl1 expression to 86% of the wild type 
level in the basal ganglia more specifically in the SVZ and MZ of the developing 
LGE at E15.5 (Long et al., 2009). Isl1 is also observed in the developing avian 
striatum (Abellan & Medina 2009) and ISL1 has been used in several studies to 
highlight the developing mouse striatum (Toresson et al., 2000, Toresson & 
Campbell 2001). ISL1 expression is co-localised with DLX1 expression and 
restricted to the ventral LGE SVZ and gives rise to striatal projection neurones 
(Stenman et al., 2003). More in depth work by Wang & Liu (2001) showed the 
expression of the Islet1 mRNA and protein in the developing striatum of the 
embryonic and postnatal rat with RT-PCR data that showed mRNA expression at 
E15 in the LGE and in the E20, P0 and adult striatum. ISL1 protein expression was 
observed from E13 with a thin layer of cells expressing ISL1 in the ventro-lateral 
telencephalon in the presumptive LGE (Wang & Liu 2001). At E15 there was a high 
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level of expression of ISL1 in the MZ of the mid and caudal LGE and by E18 a high 
to low medio-lateral gradient of ISL1+ cells in the mantle zone of the striatum, and a 
rostro-caudal gradient of ISL1+ cell expression from low to high (Wang & Liu 2001). 
By P0 the expression of ISL1 is starting to diminish with fewer cells showing 
positivity for ISL1 expression (Wang & Liu 2001). The majority of MAP2+ cells were 
ISL1+ and all DARPP32+ neurons were MAP2+, but there was little co-localisation of 
ISL1 with DARPP32, thus they hypothesised that ISL1+ precursors become 
DARPP32+ terminally differentiated neurons as ISL1 expression in the MAP2+ 
neurons decreased in the striatum during development and DARPP32 expression 
increased in terminal differentiation (Wang & Liu 2001).  
More recent studies have highlighted the importance of ISL1 expression in the 
development of the striatonigral pathway and its role in repressing expression of 
striatopallidal genes, as striatonigral pathway development was impaired and the 
expression of striatopallidal genes was up-regulated in the Nestin-Cre Isl1fl/fl mouse 
(Lu et al., 2014). A Foxg1-Cre Isl1fl-exonl/fl-exon3 mouse knockout with specific 
knockdown of Isl1 in the striatum showed a similar failure of the striatonigral 
pathway to form with a decrease in the striatal size and also problems of axonal 
navigation in striatonigral cells through the internal capsule due to synapse in the 
substantia nigra (Ehrman et al., 2013). 
The limited temporal expression of Islet1 during development shows that it is 
important for embryonic development and not required postnatally, the expression 
of ISL1 in the developing LGE and the possible role for turning on DARPP32 
expression in MSNs of the striatum, means that ISL1 expression is crucial for MSN 
development in the striatum. The important role that ISL1 has in the specification of 
striatonigral neurons is also of interest and will be investigated by monitoring of 
electrophysiological and morphological characteristics. 
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1.5.4 NOLZ1 
Nolz1 is a transcription factor that belongs to the NET (Noc/Nlz, Elbow, Tlp1) family 
of zinc finger proteins (Nakamura et al., 2004). The family of proteins share a 
conserved Sp motif, buttonhead box domain and a C2H2 zinc finger see Figure 1.11 
(Nakamura et al., 2004).  
 
Figure 1.11: Alignment of the two versions of human NOLZ1 protein. The important 
regions of the proteins, showing conservation of a Glycine rich domain, the Sp motif and 
C2H2 Zinc finger 
 
Amino acid alignment between several species has identified high sequence 
homology at the amino and carboxy termini with Drosophila nocA and zebrafish nlz 
and Xenopus XNolz (Chang et al., 2004). GSH2 has been shown to be required for 
Nolz1 expression (Urbán et al., 2010). Nolz 1 mRNA and protein has been shown to 
be expressed throughout embryonic development in the developing mouse striatum 
and LGE before being down-regulated in the postnatal and adult striatum (Chang et 
al., 2004, Urban et al., 2010, and Ko et al., 2013). NOLZ1 protein expression was 
first detected in the E11.5 mouse LGE and Nolz 1 protein and mRNA co-localised 
with TuJ1+ neurons in the E12.5 SVZ and MZ and not Ki67+ cells of the SVZ (Chang 
et al., 2004, Ko et al., 2013). Nolz 1 mRNA and protein was not expressed in the 
mouse MGE, except for a caudal strip across the border between LGE and MGE 
which forms a corridor of NKX2.1- cells and constitutes an axonal guidance pathway 
for thalamo-cortical projections (Chang et al., 2004, Ko et al., 2013). In the E16.5 
SVZ and MZ many neurons co-expressed NOLZ1 and ISL1, at E18.5 many NOLZ1+ 
cells also expressed FOXP1 and FOXP2 (Ko et al., 2013). In the Drd1-EGFP and 
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Drd2-EGFP BAC transgenic mice NOLZ1+ cells were co-localised with the GFP+ 
cells of the dopamine D1 receptor and dopamine D2 receptor cells (Ko et al., 2013). 
Nolz1 mRNA was co-expressed with DARPP32 protein in the MZ of the E18 and 
E20 rat striatum (Chang et al., 2004). In the developing rat striatum, 3 transcripts of 
Nolz1 have been identified and were temporally regulated in their expression 
(Chang et al., 2004). The first was a ~3.5kb transcript highly expressed in the 
striatum and also a ~4.0kb transcript which was expressed to a lesser extent, both 
were expressed at E20 in the rat striatum, although the time of expression of the 
~4.0kb transcript was limited to between E15 and P0 (Chang et al., 2004). A smaller 
transcript of ~3.0kb was detected postnatally in the rat striatum, the 3.5kb transcript 
was detected throughout striatal development before being down-regulated 
postnatally (Chang et al., 2004). NOLZ1 overexpression in primary neurosphere 
cultures has been shown to increase retinoic acid signalling by selectively up-
regulating Rarb (Retinoic acid receptor beta) expression and also promoted cell 
cycle exit (Urbán et al., 2010). Premature expression of NOLZ1 in the developing 
LGE under the promoter of Nestin caused a decrease in cell proliferation, early cell 
cycle exit, aberrant apoptosis and premature differentiation and maturation of cells 
in the SVZ (Chang et al., 2013). 
Nolz 1 has been selected as a candidate important for MSN development as NOLZ1 
is expressed throughout striatal development but is down-regulated postnatally 
therefore the function of NOLZ1 is specific to development, in addition to this 
NOLZ1 is able to up-regulate Rarb and retinoic acid signalling is important in MSN 
development through its ability to turn on DARPP32 expression. 
1.5.5 OCT6 
OCT6 is a member of the POU domain of transcription factors. The POU domain 
consists of a POU specific domain and a POU homeodomain, these are connected 
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by an unstructured linker domain and this complex of domains is involved in DNA 
binding and protein-protein interactions see Figure 1.12 (Sturm & Herr 1988).  
 
Figure 1.12: Schematic highlighting the important regions of the human OCT6 protein. 
The N terminally located Alanine rich, Glycine rich and Histidiene rich domains and the C 
terminal POU domain and homeodomain 
 
The role of OCT6 has been extensively characterised in Schwann cells, where it is 
involved in the conversion of promyelin cells into differentiated myelinating cells and 
is also expressed following nerve transection (Jaegle & Meijer 1998, Monuki et al., 
1989, Monuki et al., 1990, Jaegle, et al., 1996). Nuclear localisation of OCT6 has 
been shown to be dependent on its POU homeodomain, whereas the POU specific 
domain and POU homeodomain were both required for DNA binding (Sock et al., 
1996). Importin α2 was bound to OCT6 in ES cells and localised it to the cytoplasm, 
on binding another importin α family member it was translocated to the nucleus 
(Yasuhara et al., 2013). Oct6 was also detected in mouse brain, testis and F9 stem 
cells, specifically detected by in situ hybridisation at 10 days in the developing 
prosencephalon and at 12 days in the ventral portion of prospective striatum, at day 
14 there were collections of Oct6+ cells in the ventral portion of the prospective 
striatum (Suzuki et al., 1990). OCT6 was also expressed at the late streak stage in 
the anterior half of the mouse embryo, and through gastrulation and neurulation 
(Zwart et al., 1996). OCT6 expression was restricted to the walls of the neural 
groove, when the neuropore closes and OCT6 was also expressed in the mid- and 
fore-brain (Zwart et al., 1996). At E9.5 in the mouse, OCT6 was expressed at the 
ventral midline of the secondary prosencephalon, later extending into the 
telencephalon (Zwart et al., 1996). Oct6 was expressed in the SVZ of the LGE at 
E15.5 in the mouse, in the Ebf1-/- mutant mouse, there was aberrant expression of 
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Oct6 in the mantle zone of the LGE (Garel et al., 1999) and is, therefore, a 
transcription factor that is required in early post-mitotic development. In the 
developing rat forebrain vesicle, Oct6 mRNA was detected at E12 in the SVZ only of 
the telencephalon and completely excluded throughout development from the VZ 
(Alvarez-Bolado et al., 1995). Oct6 expression remained high through to E13 and 
slowly decreased thereafter in the SVZ, being highly expressed in the E13 mantle 
zone and E14 striatum (Alvarez-Bolado et al., 1995). Oct6 mRNA has also been 
shown to be expressed in the striatum of the adult rat and in the SVZ of the LGE at 
E13 and E15 (Frantz et al., 1994). OCT6 has been reported to be associated with 
the forebrain/midbrain (FM) enhancer region TAATTA in neural progenitor cells and 
in the embryonic forebrain and midbrain (Inoue et al., 2012). The human OCT6 
protein lacks the first 50 amino acids of its mouse counterpart and has been shown 
to activate transcription via the octamer TATA minimal promoter (Tobler et al., 1993) 
with other OCT6 binding sites being TAATGARAT, TTAAAATTCA and CTCATGA 
(reviewed by Schöler 1991). POU transcription factors have been shown to activate 
the dopamine D1 receptor gene (Imafuku et al., 1996). The regulation of Oct6 
expression has been shown to be in part by 17β-estradiol as this has enhanced 
Oct6 expression in glia, this was due to an estrogen response element found ~5kb 
upstream of the Oct6 mouse gene (Renner et al., 1996), consequently, OCT6 
expression in cortex and hippocampus was observed earlier in development in 
females than in males (Ilia et al., 2003b). When another POU transcription factor, 
Brn1, was inserted into the Oct6 gene locus in the mouse, the defect of Schwann 
cells in the peripheral nervous system of Oct6-/- mice was rescued (Wolf et al., 
2009). However, severe defects were observed in the developing forebrain of the 
Oct6Brn1 mouse, due to anterior expansion of cells expressing Wnt1 and from E10.5-
E18.5, there was severe truncation of the forebrain, in some cases the 
diencephalon and telencephalon were completely absent with the telencephalic 
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marker Emx1 absent at E9.5 even though the cell proliferation rate remained normal 
(Wolf et al., 2009).  
The Shh pathway has been shown, via GLI activators, to up-regulate the expression 
of Oct6, Shh is also required for striatal development (reviewed by Katoh & Katoh 
2008). Oct6 was expressed in both the cortex and basal ganglia, with a 2 fold higher 
expression in the basal ganglia; the level of expression in the basal ganglia was 
decreased to a quarter of its original level in the wild type compared to the Dlx1/2-/- 
mutant (Long et al., 2009). DLX1/2 seemed to be two of the transcription factors 
responsible for inducing expression either directly or indirectly of Isl1, Foxp1 and 
Oct6 (Long et al., 2009). In adult mice OCT6 protein was detected in the striatum, 
cerebral cortex and hippocampus (Ilia et al., 2003a). OCT6 expression, in the 
mouse striatum, was present at postnatal week 12-18 before decreasing at 20 
postnatal weeks (Ilia et al. 2003a). 
Oct6 is being used in forced transcription factor expression in neural stem cells to 
drive differentiation in to MSNs due to the limited expression during development of 
the striatum as OCT6 is limited temporally in its expression in the LGE SVZ and in 
the striatum to embryonic and early postnatal expression only and so is important in 
MSN development. Another reason for choosing OCT6 is when other important 
transcription factors for MSN development are not expressed such as EBF1, and 
then OCT6 expression is altered. The expression of OCT6 is required to inhibit 
Wnt1 expression which inhibits proper telencephalon development and so will be 
useful in preventing other more posterior fates of the neural tube development. 
The relationship and timing of expression of the transcription factors utilised in this 
study can be seen in Figure 1.13 
1. Introduction 
 
 
- 52 - 
 
Figure 1.13: Location, relationship and timing of expression, in mouse, of the 
transcription factors used in this study. The relationship between the transcription factors 
utilised in this thesis for transfection of neural precursors. All of the transcription factors are 
expressed in the SVZ or MZ. Above each of the transcription factors indicates the 
approximate timing of expression in the mouse LGE. Some of the functional roles of the 
transcription factors are also documented and whether their expression contributes to cells 
of the different compartments and pathways of the striatum. Figure created from information 
in Sections 1.4.7 and 1.5. 
1.6 Striatal neuronal differentiation in vitro 
The advent of mouse ESC culture (Evans & Kaufman 1981) and the establishment 
of human pluripotent stem cell lines (Thomson et al., 1998, Takahashi et al., 2007) 
have meant that we can try and reproduce the development of different cell types in 
vitro. In order to emulate embryonic striatal development in vitro, stem cells need to 
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be exposed to the developmental cues which are present in the developing brain. 
Many studies have been carried out thus far with molecular programming which 
mimics to some extent the environment to which the cells of the neuroepithelium, 
telencephalon, and LGE are exposed. Several factors are repeated between 
studies, such as the inclusion of SHH/purmorphamine, DKK1 (dickkopf1- WNT 
pathway inhibitor), brain derived neurotrophic factor (BDNF), dbcAMP and VPA at 
time points which vary between studies. So far no-one has been able to achieve a 
pure population of MSNs or even close to achieving a population of cells which can 
be defined as mostly MSNs, the main focus of most studies is increasing the levels 
and numbers of positive cells of DARPP32 expression as this is highly expressed by 
neurons of the striatum (Ouimet et al., 1994). 
1.6.1 Neural induction 
Early differentiation of pluripotent stem cells into cells comparable to those seen in 
the developing neural tube, termed rosettes, with specification for the telencephalon 
has been carried out. Small molecules and morphogens were used that inhibit the 
TGFβ/Activin/Lefty pathway and BMP signalling (Chambers et al., 2009). This 
suppressed BMP and Activin induced differentiation into mesoderm and endoderm 
and inhibited activin-dependent maintenance of pluripotency, and therefore allowed 
neuralisation to occur (Chambers et al., 2009). The morphogen, Noggin (BMP 
inhibitor) and small molecule, SB431542 (TGFβ/Activin/Lefty inhibitor) were 
included in culture medium for dissociated human ES differentiation (Chambers et 
al., 2009). The ESCs lost OCT4 expression, a pluripotent marker, by day 5 of 
culture and expressed an epiblast marker FGF5 before expressing SOX1 and a 
population of >80% PAX6+ cells after 7 days of culture were generated that went on 
to express Nestin after 11 days (Chambers et al., 2009). These cells showed an 
anterior neural fate as judged by the expression of FOXG1, with apical ZO-1 
expression (a tight-junction protein) and formed rosettes after passaging (Chambers 
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et al., 2009). Another method to force stem cells to undergo neural induction was by 
co-culture on murine stromal cells in 15% KSR (knockout-serum replacement) 
medium for 12 days then switched to a serum replacement medium, which 
produced neural rosettes 3 weeks post-induction that were Nestin+/PAX6+/FOXG1+ 
(Aubry et al., 2008). With the addition of the morphogen SHH, WNT inhibitor DKK1 
and BDNF a neurotrophic factor, the rosettes were ventralised as shown by DLX2 
and GSX2 mRNA expression after 1 week (Aubry et al., 2008). Another protocol 
utilising stromal cells and KSR containing medium later changed for N2-
supplemented medium has been shown to produce neural rosettes within 2-3 weeks 
and the resulting rosettes were then cultured as embryoid bodies (EB) (Jeon et al., 
2012). Detachment of ES cells to induce neuralisation by EB formation was also 
performed by several labs; a study by Joannides et al., (2007) maintained EBs in 
human neuralising medium and chopped the spheres every week, which led to 
extensive neural induction after 16 days. A method of culturing EBs in serum free 
media with SHH treatment at 3 days post induction led to the expression of GSX2, 
GAD67 and DLX2 and inhibited the expression of pallial markers (Danjo et al., 
2011). In contrast to this, when a 20% serum containing media was used in EB 
culture, this produced a 95% yield of Nestin+ SOX1+ PAX6+ neural stem cells from 
HD iPS cell lines (Zhang et al., 2010). A protocol that utilised an N2 supplemented 
media on EBs for 7 days, then plated the cells on laminin formed PAX6+ neural 
stem cells, 12 days from induction (Ma et al., 2012). With the addition of SHH or its 
agonist purmorphamine for 2 weeks post induction, there was a high percentage 
induction of ventral telencephalic progenitors which were MEIS2+, ASCL1+ and the 
expression of GSX2 mRNA was up-regulated (Ma et al., 2012). An amalgamation of 
two of the protocols has been shown by Delli Carri et al., (2013a&b) with neural 
induction by dual SMAD inhibition (noggin and SB431542 treatment) and 
ventralisation by SHHC-25II and DKK1, the resulting rosettes were over 50% 
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FOXG1+ and ~60% GSX2+ and expressed other rosette markers including DACH1 
LIX1 LMO3 and MSX1 mRNA. 
In order for the transfections of the transcription factors to produce the maximal 
benefit I needed to start with the correct neural stem cell population, dual SMAD 
inhibition seems to produce the best results along with subsequent WNT inhibition 
and SHH treatment, mimicking the in vivo situation and I have used an adaptation of 
these protocols to obtain neural rosettes of ventral forebrain character, which has 
been optimised by Joy et al., (unpublished data). 
1.6.2 Terminal differentiation into MSN 
The culture of primary mouse cells from different developmental time points has 
given clues as to the requirements of neuronal terminal differentiation in the 
striatum. The application of BDNF to culture of E13 and E17 mouse LGE and 
striatum, respectively, when cultured for 7 days, increased the proportion of 
DARPP32+/ARPP21+ cells from 25% to >50% DARPP32+ cells and from 10% 
to >29% ARPP21+ cells, the number of CALB1+ cells also increased (Ivkovic & 
Ehrlich 1999). In the BDNF null mouse, there was a decrease of DARPP32+ and 
ARPP21+ neurons present in the striatum at P0 and P10, and addition of 100 ng/ml 
BDNF to primary striatal cultures increased the expression of DARPP32 threefold 
after only 12 hours in vitro (Ivkovic & Ehrlich 1999, Ivkovic et al., 1997). Combining 
the effects of BDNF and NT3 and NT4/5 (neurotrophins 3 and 4/5) produced similar 
effects on DARPP32 and ARPP21 expression in primary culture, but the 
combinatorial action meant that the BDNF concentration could be reduced (Ivkovic 
& Ehrlich 1999). These studies showed that BDNF is required for the maturation of 
the MSN phenotype and increases the number of cells which undergo 
differentiation.  
The addition of the SHH agonist, purmorphamine, to primary human striatal cells, 
increased neuronal differentiation as seen by an increase in DARPP32 expression 
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and it decreased the rate of proliferation and astrocyte formation compared to 
culture without purmorphamine (El-Akabawy et al., 2011). After 21 DIV, 7% of the 
cells were DARPP32+ and the number of CALB1+ cells doubled (El-Akabawy et al., 
2011). The protocol utilised by Zhang et al., (2010), generated around 10% 
DARPP32+ neurons, which resulted from treatment of plated EBs with SHH, DKK1, 
BDNF and Y27632 (Rho kinase inhibitor to prevent cell death) and subsequent 
treatment with VPA (stimulated GABA neurogenesis), dbcAMP, BDNF and Y27632. 
In the two studies by Delli Carri et al., (2013a&b), mature neuronal proteins were 
detected from 45 days in vitro such as MAP2 and TAU, along with proteins of 
GABAergic phenotype: GAD65/67 and GABA, and striatal markers: CTIP2, 
calbindin, FOXP1, FOXP2, ARPP21 and DARPP32, with co-localisation of pairs of 
these striatal markers in a subset of neurons at 80 DIV. After 80DIV, from 15 DIV in 
N2 medium supplemented with B27 and 30 ng/ml BDNF, MAP2 expression was 
observed in 51% of cells and another 17% were expressing the immature neuronal 
marker βIII-tubulin, a quarter of the cell population were GFAP+ astrocytes and the 
rest were Nestin+ neuroprogenitors (Delli Carri et al., 2013 a&b). DARPP32 was 
expressed in 10% of the total population of cells and co-localised with CTIP2, CTIP2 
was also expressed in βIII-tubulin+ neuronal cells that expressed dopamine receptor 
D2 (DRD2) (Delli Carri et al., 2013 a&b). The neurons were also functionally active, 
displaying fast inactivating K+ currents resembling type A K+ currents, and showed 
the presence of Na+ channels and were able to fire induced action potentials in 
response to a suprathreshold current step (Delli Carri et al., 2013 a&b). For terminal 
differentiation of cells in the Aubry et al., (2008) protocol, cells that mostly 
expressed DLX2 and/or GSX2 were plated at a low density (20-50,000 cells/cm2) 
with dibutyryl cAMP and VPA and at 63 days post neural induction, ~20% of the 
neurons were MAP2+ and ~50% of these possessed DARPP32. However, there 
were a majority of immature cells in the culture with ~70% of cells expressing 
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Nestin, and PAX6 was expressed in ~60% of cells. When 45 DIV cells were 
transplanted into the QA lesioned rat, they expressed DARPP32+ in 21% of the 
NeuN+ cells, the cells possessed a bipolar morphology and extensive neurite 
outgrowth (Aubry et al., 2008). However, there was a problem of graft overgrowth 
(Aubry et al., 2008), which was expected due to the large contamination of 
progenitors present in the culture which are still proliferating. In order for the 
transcription factor transfection to be successful and drive differentiation to an MSN 
phenotype, the cells should be post-mitotic to mimic the in vivo expression and also 
to avoid “contamination” of overgrowth of mitotic cells. Terminal differentiation of the 
EBs in the Jeon et al., (2012) protocol involved plating whole EBs on to poly-L-
ornithine/fibronectin in DMEM media supplemented with BDNF and produced 
27±1.7% DARPP32+ neurons and 19.1±2.1% Calbindin+ neurons, these neurons 
also affected a behavioural improvement in a rat model of HD (Jeon et al., 2012). In 
the study by Ma et al., (2012), ventral progenitors were plated at 26 days post 
induction in media supplemented with VPA for 1 week before withdrawal and 
addition of neurotrophic factors and cyclic AMP. At 47 DIV, over 90% of the cells 
were process-bearing neurons that expressed βIII-tubulin and ~90% were 
GABAergic with 89.7±9.3% staining positive for DARPP32, which also expressed 
MEIS2 and had spiny processes on the dendrites (Ma et al., 2012). After 70 DIV, 
these cells were spontaneously active (Ma et al., 2012). At 40 DIV, cells were 
transplanted into the striatum of QA lesioned mice, which led to some functional 
recovery 4 months post-transplantation (Ma et al., 2012). Projections to the anterior 
substantia nigra were observed, and glutamatergic inputs were received from either 
the cortex, globus pallidus or thalamus, the grafts also had a >50% of cells 
expressing DARPP32, and synaptophysin was observed on MAP2+ dendrites (Ma 
et al., 2012). However, this protocol has yet to be replicated by other investigators 
and, where this has been attempted; the data do not indicate such high efficiency of 
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generating DARPP32+ neurones (E. Cattaneo, University of Milan, S. Joy, Cardiff 
University, C Svendsen, Cedars Sinai; all personal communication). Replication of 
ventral progenitor specification and terminal differentiation of the Aubry protocol and 
the use of BDNF, dbcAMP and VPA have been shown to produce 5% DARPP32+ 
neurons in vitro in long term differentiation (HD iPSC consortium 2012). Shin et al., 
(2012) obtained similar levels of DARPP32 expression with a monolayer method of 
differentiation using neurobasal medium supplemented with B27 that led to 30% of 
cells possessing βIII-tubulin and of these, 90% were GABAergic and 32% of these 
cells were DARPP32+ in reality there was only approximately a 9% population of 
DARPP32+ neurons achieved in vitro. Around 65% of these neurons demonstrated 
induced action potentials and inward and outward currents on depolarisation and a 
level of spontaneous post synaptic currents (Shin et al., 2012), the cells also 
expressed dopamine receptor D1, DARPP32 and GAD67 when grafted into the 
striatum of a mouse model of HD, with more than 50% of NeuN+ cells expressing 
DARPP32 (Shin et al., 2012).  
In order to obtain a higher percentage of MSNs, Danjo et al., (2011) used a 
Foxg1:venus cell line to FAC sort the fluorescent cells from the non-fluorescent cells 
at 9 days post induction, hence obtaining a pure Foxg1 expressing culture. 
Subsequent SHH (10nM low concentration) treatment led to an emergence of a cell 
population that expressed NOLZ1/CTIP2 and when cultured in rat glial conditioned 
medium ~50% DARPP32+ neurons were obtained (Danjo et al., 2011). Four days 
after FAC sorting, cells were implanted in the P2 striatum and were observed to 
fasciculate with corticofugal fibres that projected ipsilaterally, the majority of 
implanted cells became DARPP32+ and no tumorigenesis was observed (Danjo et 
al., 2011). 
The holy grail in the field of medium spiny neuronal differentiation, achieving 
differentiation of a population of cells into DARPP32+ MSNs, has not yet been met, 
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or if it has, it has not been able to be replicated. Increasing the number of 
DARPP32+ neurons in vitro, seems to require a pure population as shown by Danjo 
et al., (2011) and this needs to be considered for the cell populations which will 
undergo transfections and the cells afterwards, firstly does sorting of progenitors 
before transfection enable a better differentiation and secondly does removing all 
non-transfected cells do the same. 
1.7 Directed differentiation by transcription factor expression 
Multiple cell types and specification of neuronal cell types have been generated 
using forced transcription factor expression as a method of differentiating cells. The 
precursor cells also do not have to necessarily be pluripotent or multipotent as the 
use of fibroblasts and other differentiated cells have been used. Transcription factor 
driven expression for differentiation is not a new concept; one of the first studies 
utilised MyoD1 mouse cDNA stably expressed in 10T1/2 fibroblasts in order to 
generate myogenic cells (Tapscott et al., 1988). Different regions of the MyoD1 
protein could be deleted and the myogenic differentiation potential remained, 
however its nuclear localisation was disrupted, only 68 amino acids of the 318 
amino acid protein were found to be required for MyoD1 protein nuclear localisation 
and myogenic differentiation properties (Tapscott et al., 1988). Further studies using 
MyoD1 have been carried out with retroviral infection of MyoD1 into dermal 
fibroblasts, chondroblasts, gizzard smooth muscle and pigmented retinal epithelial 
cells in order to trans-differentiate these cells into mononucleated striated myoblasts 
(Choi et al., 1990). These cells were contractile and formed myotubes and were 
equivalent to in vivo and in vitro myoblasts (Choi et al., 1990). Since then, others 
have utilised transcription factors important in differentiation/cell identity in order to 
induce a change of cell fate. The first induction of functional neurons by the basic 
helix loop helix transcription factors neurogenin 2 (Ngn2) and Mash1 (Ascl1) in 
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astroglia formed neurons capable of firing action potentials (Berninger et al., 2007). 
Ngn2 has also been expressed in postnatal cerebral cortical astroglia to induce 
them to become glutamatergic neurons, in the same study; Dlx2 was used in order 
to produce GABAergic neurons (Heinrich et al., 2010). When Ngn2 was expressed 
in hESC and hiPSC, the resulting neurons were shown to integrate, when 
transplanted, into the mouse brain (Zhang et al., 2013). The first induced neurons 
(iN) were produced from mouse fibroblasts by infection with the transcription factors 
Ascl1, Myt1l and Brn2, which produced functional neurons that were capable of 
firing induced action potentials and expressed the synaptic marker, synapsin 
(Vierbuchen et al., 2010). Ascl1, Brn2 and Myt1l transcription factors were also 
expressed in human embryonic and postnatal fibroblasts; these cells formed 
neurons which fired action potentials in response to current injection (Pfisterer et al., 
2011). In addition to these transcription factors, forced expression of the 
dopaminergic neuron specific transcription factors; Lmx1a and FoxA2, led to the 
formation of dopaminergic neurons (Pfisterer et al., 2011). When NeuroD1 (another 
basic helix loop helix transcription factor) was added to the expression of Ascl1, 
Brn2 and Myt1 in human fetal fibroblasts, the efficiency of conversion to iN cells was 
improved and spontaneous post synaptic currents were generated (Pang et al., 
2011). iN generation efficiency was also improved by culturing fibroblasts in 5% O2, 
post infection with the 4 transcription factors (NeuroD1, Myt1l, Ascl1 and Brn2) 
(Davila et al., 2013). NeuroD2 was expressed in N18-RE-105 neuroblastoma cells, 
which promoted neurite formation, increased synaptotagmin (a synaptic marker) 
and βIII-tubulin expression along with an increased expression and redistribution of 
SNAP25 (a synaptic marker) to the cell membrane (Messmer et al., 2012). A 
microarray study, using single transcription factors expressed in mouse ESC lines, 
determined transcription factors which can induce cells into hepatocytes, blood 
cells, myocytes and neurons (Yamamizu et al., 2013). These neurons were 
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specified into neuronal subtypes and fired action potentials when induced, by 11 
days post induction (Yamamizu et al., 2013). Oligodendrocytes were induced from 
rat and mouse fibroblasts by Sox10, Olig2 and Zfp536 forced expression, these 
oligodendrocytes were shown to be functional, ensheathing dorsal root ganglion 
cells and myelinating cells in the shiverer dysmyelinated mouse (Yang et al., 2013). 
1.8 Aims & Objectives 
As outlined in the aforementioned sections differentiation of stem cells into MSNs 
has had limited success. Forced transcription factor expression has had a positive 
effect on differentiation of cells in to other neuronal populations. The knowledge of 
embryonic development has enabled the selection of several transcription factors 
important for MSN development. This thesis aims, to use transcription factors 
important for MSN development in order to force differentiation of partially specified 
ventral forebrain-like neural progenitors and characterise the resulting cells after 
differentiation with the specific aims of: 
 Clone transcription factors important for MSN development: and express 
them in a multicistonic plasmid. 
 Validate the transcription factor protein expression from the plasmids in 
HEK293 cells. 
 Characterise an additional protocol of neuronal maturation utilising protein 
expression of neurons. 
 Use the plasmids in transfections to differentiate ventral forebrain-like neural 
progenitors into MSNs and to determine a few plasmids for further 
characterisation. 
 Characterise the cells which have been differentiated with forced 
transcription factor transfection for protein markers of MSNs. 
 Characterise the cells morphologically by Sholl analysis. 
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 Characterise the cells using electrophysiology for functional maturity and 
physiological markers of MSNs. 
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2. Methods 
2.1 Materials 
Materials for experiments were purchased from various companies and more 
information can be obtained regarding catalogue numbers in the appendix. 
2.2 Sourcing transcription factors 
Plasmids containing the transcription factors of interest for cloning were purchased 
from PlasmID DNA resource core (Harvard, Boston, USA) or were cloned from total 
human fetal RNA (Amsbio, Abingdon, UK), or extracted from harvested sphere 
culture derived from human fetal WGE samples. 
2.2.1 RNA extraction 
Cells which had been harvested in buffer RLT (Qiagen, Hilden, Germany) with 143 
mM 2-Mercaptoethanol (Sigma, Dorset, UK) were provided by Kelly C.M., and RNA 
extraction was performed with a QIAGEN RNeasy kit (Qiagen, Hilden, Germany) as 
per manufacturer’s protocol. RNA was quantified using a Nanodrop 
Spectrophotometer ND1000. 
2.2.2 cDNA synthesis 
cDNA synthesis from RNA was performed using Superscript II ® (Life Technologies, 
Paisley, UK). 3 µg of random primers and 25 mM dNTPs (final [0.5 mM]) (Promega, 
Hampshire, UK) were added to 1 µg of RNA and made up to 12 µl with 
DNAse/RNAse free H2O (Life Technologies, Paisley, UK) in a 0.2 ml PCR tube 
(Amersham Biosciences, Bucks., UK). This was heated to 65oC for 5 minutes in a 
Techne TC512 thermocycler (Bibby Scientific Ltd., Staffordshire, UK) and 
subsequently chilled on ice. 5x first strand buffer was added for 1x buffer in total 20 
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µl volume, with 0.1 M DTT (final [10 mM]) and 40 U of RNAse OUT (all Life 
Technologies, Paisley, UK) were added to the PCR tube and heated to 25oC for 2 
minutes, then 200 U of Superscript II ® (Life Technologies, Paisley, UK) was added 
and heated to 25oC for 10 minutes, 42oC for 50 minutes and 70oC for 15 minutes. 
Samples were frozen at -20oC or used for PCR at 1:50 dilution in H2O.  
2.3 Cloning of transcription factors and subcloning into 
multicistronic vectors 
2.3.1 Cloning of transcription factors 
Table 2.1 Primer sequences used for cloning the transcription factors and optimised annealing 
temperatures. 
2.3.1.1 PCR 
Whole genes were cloned either from plasmids (PlasmID DNA resource core, 
Boston, MA, USA) or human fetal cDNA using primers designed to incorporate 
either a BamHI, BglII, NheI or XbaI restriction site at both the 5’ and 3’ ends of the 
Gene Position Restrictio
n enzyme  
Primer sequence (5’-3’) Annealing 
temperatur
e 
OCT6 5’section 5’-
3’ forward 
BamHI AACGGATCCATGGCCACCACCGCGCAGTACCTG 70
o
C 
  3’section 5’-
3’ reverse 
BamHI AACGGATCCCTGCACTGAGCCGGGCAGTGT 67
o
C 
  3’section 5’-
3’ forward 
HpyCH4III TACGGTAACGTGTTCTCGCAGACCACC 67
o
C 
  5’section 5’-
3’ reverse 
HpyCH4III ACCGTAGAGCGTGCCCAGCGCCAGCCC 70
o
C 
FOXP
1 
5’ end, 
forward 
BamHI AACGGATCCATGATGCAAGAATCTGGGACT 64.9
o
C 
  3’ end, 
reverse 
BamHI AACGGATCCCTCCATGTCCTCGTTTACTGGTTC 64.9
o
C 
ISL1 5’ end, 
forward 
NheI AACGCTAGCATGGGAGACATGGGAGATCCA 68.8
o
C 
  3’ end, 
reverse 
NheI AACGCTAGCTGCCTCAATAGGACTGGCTACCATG
CT 
68.8
o
C 
EBFf1 5’ end, 
forward 
NheI AACGCTAGCATGTTTGGGATTCAGGAAAGCATC 67.6
o
C 
  3’ end, 
reverse 
NheI AACGCTAGCCATAGGAGGAACAATCATGCCAGA 67.6
o
C 
NOLZ
1 
5’ end, 
forward 
BglII AACAGATCTATGAGCACAGCGCCCTCGCTTTCT 69.2
o
C 
  3’ 
end ,revers
e 
BglII AACAGATCTCTGATACCCCAGCGCCGAGGCGGT 69.2
o
C 
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gene (Table 2.1). PCRs were performed using 0.5U Platinum® Taq polymerase (Life 
Technologies, Paisley, UK), in 2 mM MgSO4, 1x buffer, 0.2 mM dNTPs 0.4 pmol 
primers, made up to 25 µl with DNAse free H2O, using annealing conditions optimal 
for the primers (Table 2.1) and following the Platinum® Taq standard protocol of 
initial denaturation 94oC for 1 minute and then 35 cycles of denature at 94oC for 30 
seconds, anneal for 30 seconds, extension for 1 minute/kb of DNA at 68oC, for 35 
cycles with a final extension at 68oC for 5 minutes.  
2.3.1.2 PCR product purification 
The PCR products were separated by gel electrophoresis at 80 V for 1 hour through 
a 0.8 % agarose 1x tris-acetate-ethylenediaminetetraacetic acid (TAE) gel (Melford 
Laboratories Ltd., Ipswich, UK & MP Biomedicals, Cambs., UK) (diluted with distilled 
H2O from 50X stock of Tris Base 2M; Acetic acid 1M; Ethylenediaminetetraacetic 
acid (EDTA) 0.05 M) containing 1 mM guanosine (Sigma-Aldrich, Dorset, UK) to 
protect DNA from 312 nm UV-light damage (Gründemann & Schömig 1996) and 
1:20000 dilution of SafeView nucleic acid stain (NBS Biologicals, Cambs, UK). 
Amplicons were visualised using a UV Transilluminator (Uvitec BTS-20-MS) at 312 
nm, the PCR product of the expected size excised using a razor blade and purified 
by gel extraction using the GeneClean® kit (MP Bio Biomedicals, Cambs., UK), 
according to the manufacturer’s protocol.  
2.3.1.3 Ligation into pGEM T Easy vector 
The PCR product of the gene of interest was ligated into the pGEM® T EASY vector 
(Promega, Hampshire, UK), using 3 U of T4 DNA ligase from the pGEM® T easy kit 
overnight at 4oC, using an PCR product:plasmid molar ratio of 1:1 in a 10 µl 
reaction, as per manufacturer’s protocol in a 0.2 ml PCR tube. A background and 
positive control were also performed using no insert and the control insert (1:1) from 
the pGEM® T easy kit, respectively.  
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2.3.1.4 Transformation 
Transformations of plasmid DNA were performed with either a vial of TOP10 (Life 
Technologies, Paisley, UK) E.coli or 50 μl of subcloning efficiency DH5α competent 
bacteria (Life Technologies, Paisley, UK) and 2 μl of the ligation reaction in a 1.5 ml 
microcentrifuge tube (Fisher Scientific, Loughborough, UK). These were incubated 
on ice for 30 minutes, heat shocked at 42oC for 20 seconds in a pre-heated water 
bath and incubated on ice again for 2 minutes, and subsequently grown in 950 μl of 
S.O.C medium (super optimal broth with catabolite repression) (Life Technologies, 
Paisley, UK) for 1 hour at 37oC in a shaker incubator (Jeio Tech SI-900) at 225 rpm. 
The transformed E.coli were grown as colonies by spreading 250 µl of the culture 
onto Luria-Bertani (LB) agar (Life Technologies, Paisley, UK) containing 50 μg/ml 
ampicillin (Sigma-Aldrich, Dorset, UK) in 100 mm Sterilin dishes (VWR, 
Leicestershire, UK) and inverted overnight at 37oC. The agar had been pre-treated 
with 40 µl of 20 mg/ml 5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside 
(XGAL) plus 40 µl 0.1 M isopropyl thiogalactoside (IPTG) (Melford Laboratories Ltd., 
Ipswich, UK) per 100 mm plate for blue/white colony selection. 
2.3.1.5 Colony selection and DNA preparation 
White colonies were selected with a sterile 200 µl pipette tip (VWR, Leicestershire, 
UK) and grown in 2 ml of LB broth (Life Technologies, Paisley, UK) containing 50 
μg/ml ampicillin at 37oC overnight in a shaker 225 rpm. DNA was extracted from 1 
ml of bacterial cultures using alkaline phosphatase lysis method (Sambrook et al., 
1989). 1 ml of bacterial culture was pelleted at 16,000 xg and re-suspended in 100 
µl of solution I (25 mM Tris pH 8.0 (Roche, Hertfordshire, UK); 10 mM EDTA pH 8.0 
(Sigma-Aldrich, Dorset, UK); 50 mM Glucose (BDH Merck, Leicestershire, UK) in 
distilled H2O), then 200 µl of fresh solution II (1% sodium dodecyl sulphate (SDS); 
0.2 M NaOH (both Sigma-Aldrich, Dorset, UK) in distilled H2O) and 150 µl of 
solution III added (3 M potassium acetate (Sigma-Aldrich, Dorset, UK); 11.5% 
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glacial acetic acid (Fisher Scientific, Loughborough, UK), in distilled H2O) was 
added sequentially and mixed by inversion of the tube and incubated on ice for 5 
minutes, this was then centrifuged in a Heraeus Biofuge Pico microcentrifuge at 
16,000 xg for 3 minutes and the supernatant was pipetted into a clean 
microcentrifuge tube. 1 volume of phenol:chloroform (Sigma-Aldrich, Dorset, UK) 
was added and the solution, mixed and centrifuged at 16,000 xg for 3 minutes at 
RT. The aqueous (upper) phase was transferred to a new microcentrifuge tube and 
2 volumes of 100% ethanol (Sigma-Aldrich, Dorset, UK) was added, mixed and 
incubated at room temperature for 5 minutes, then centrifuged for 5 minutes at 
16,000 xg. The DNA pellet was washed with 150 µl of 70% ethanol and centrifuged 
for 1 minute at 16,000 xg. The DNA pellet was left to air-dry at room temperature for 
5-10 minutes and was re-suspended in Tris-EDTA (10 mM Tris-HCl, 1 mM EDTA 
pH 7.4) (Sigma-Aldrich, Dorset, UK) containing 20 ng/ml bovine RNAse A (Life 
Technologies, Paisley, UK), the remaining culture was used to make a glycerol 
stock using 99% glycerol (Sigma-Aldrich, Dorset, UK) in a 2:1 ratio with overnight 
broth culture, for a final concentration of 66% glycerol stock, these were stored at -
80oC in 1.5 ml microcentrifuge tubes. 
2.3.1.6 Verification of PCR product insertion 
Restriction digests, utilising the sites which had been introduced through PCR 
(BamHI-HF, NheI-HF, BglII (NEB, Hertfordshire, UK)), were performed at 37oC for 
30 minutes using a Techne TC-512 PCR machine. 10 µl of DNA, 10x buffer (NEB, 
Hertfordshire, UK) specific for the restriction enzyme, 100 µg/ml bovine serum 
albumin (BSA) (NEB, Hertfordshire, UK) (for NheI-HF restriction enzyme activity), 
and 10 U of restriction enzyme and made up to 25 µl with DNAse free H2O in a 0.2 
ml PCR tube (Amersham Biosciences, Buckinghamshire, UK). The restriction digest 
DNA fragments were subsequently separated by gel electrophoresis in a 1% 
agarose TAE gel with 1:20,000 SafeView at 80 V, calibrating restriction digest 
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product size against 1 kb and 100 bp ladder (NEB, Hertfordshire, UK) on a BioRAD 
Gel Doc 2000.  
2.3.1.7 Sequencing of PCR products 
Samples with the correct size inserts, after digestion as determined by gel 
electrophoresis, were purified by DNA precipitation by adding ¼ volume of 1 M 
ammonium acetate (Fisher Scientific, Loughborough, UK) and 1 volume of 2-
propanol (Sigma-Aldrich, Dorset, UK). The samples were incubated at room 
temperature for 30 minutes and then centrifuged at 15,500 xg for 10 minutes at 4oC 
in a Sigma 3K18 centrifuge, the DNA pellet was washed with 80% ethanol and 
centrifuged again. The DNA pellet was re-suspended in 50 µl of DNAse free H2O 
(Life Technologies, Paisley, UK), the DNA concentration verified using a Nanodrop 
Spectrophotometer ND1000 and then diluted to 100 ng/ml and sent for sequencing 
using the MWG Eurofins sequencing facility. Sequencing primers T7 and SP6 were 
used as well as product-specific primers, which were designed for larger genes 
(Table 2.2), to sequence from the middle to the ends of the gene. Sequences were 
compared to human sequences using NCBI Nucleotide BLAST.  
 
Table 2.2 Primers used for sequence verification of transcription factor inserts. 
Gene Position 
(bp) 
Forward Reverse 
OCT6 400 CTGTACGCGCAGGCGGCCTACCCG CGGGTAGGCCGCCTGCGCGTACAG  
FOXP1 500 CAGTTGGCTTTTCAGCAGCAGCTTTTA  - 
FOXP1 1000 CTTGCAAAAGACAAAGAACGCCTGCAA TTGCAGGCGTTCTTTGTCTTTTGCAAG 
FOXP1 1500 - CCTGCCTAATTAAAGATGCATATG 
ISL1 500 CATCCAGCGCGGCCACTGCAAATGGC
A 
TGCCATTTGCAGTGGCCGCGCTGGAT
G 
EBF1 600 TGACATGCGGAGATTCCAGGTCGT  ACGACCTGGAATCTCCGCATGTCA 
EBF1 1200 CCACACAACAACCAGGAAATCATT AATGATTTCCTGGTTGTTGTGTGG  
NOLZ1 600 CCCTGCCTTCCACGCCGGTC GGCAGGGGCTGCAGGTACTC 
NOLZ1 1300 AGCCGGGCCAGACAGTGTTC CCCGGCTTGTAGGGTGACACG 
NOLZ1 2000 ACCCCAGCTCGTCGTCTCTGG CCGTATGGGTCCGCAAGTGGC 
2. Methods 
 
 
- 70 - 
2.3.2 Subcloning 
Once the open reading frame sequences were verified, the pGEM® T easy plasmids 
containing the transcription factors and the p3x2ApMA-T multicistronic plasmid were 
digested with the relevant restriction enzyme for the incorporated restriction enzyme 
site on the ends of the transcription factors, either BamHI-HF, NheI-HF or BglII (all 
NEB, Hertfordshire, UK) (Figure 2.1). The restriction enzyme digestion of the 
p3x2ApMA-T plasmid was also incubated with 1.25 U thermo-sensitive alkaline 
phosphatase (TSAP) (Promega, Hampshire, UK) to remove the 5’ phosphate 
groups from the ends of the linearised plasmid DNA in order to prevent re-
circularisation and increase the likelihood of ligation to the insert. DNA products of 
the expected size were purified by gel extraction as per Section 2.3.1.2 and ligated 
using 400 U of T4 DNA ligase (NEB, Hertfordshire, UK), in a 20 µl reaction using the 
supplied 10X buffer and made to volume with H2O. Varying insert:plasmid molar 
ratios were used, in order to optimise ligation, from 3:1 to 9:1. Ligation reactions 
were carried out for 12 hours at increasing temperatures from 16oC to 24oC in 2oC 
increments every 2 hours, with a final 2 hour step at 25oC. The ligation reaction was 
transformed into subcloning efficiency DH5α E. coli as per Section 2.3.14 and 
grown on 50 µg/ml ampicillin LB agar plates. Resulting colonies were grown up in 
LB broth containing 50 µg/ml ampicillin and the DNA purified as per Section 2.3.1.5. 
Diagnostic digests were carried out to verify insert orientation using specific 
restriction enzymes (Table 3.1 for a list of the restriction enzymes used and the 
fragments generated). E.coli colonies expressing constructs containing correctly 
orientated inserts were further cultured and midi prepped (Qiagen, Hilden, 
Germany) as per manufacturer’s protocol and glycerol stocks were made as per 
2.3.1.5. Then, either subsequent transcription factor gene insertions were performed 
using different restriction enzyme insertion sites in the multicistronic plasmid to 
create multi transcription factor plasmids, or the multicistronic section of the 
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plasmid, containing the transcription factor was subcloned into the pCAGG-IRES-
EGFP vector using the SalI sites either side of the multicistronic section. 
SalI-HF (NEB, Hertfordshire, UK) restriction enzyme digestion was used to isolate 
the transcription factor and flanking 3 x 2A sequences out of the p3x2ApMA-T 
plasmid and to linearise the pCAGG-IRES-EGFP plasmid, as above, the plasmid 
and insert were purified by gel extraction, ligated, transformed into subcloning 
efficiency DH5α E. coli, grown up in LB agar and LB broth containing 50 µg/ml 
kanamycin and then the DNA was purified as per Section 2.3.1.5. The orientation of 
the insert was checked by restriction digest (Table 3.1). Endo free maxi preps 
(Qiagen, Hilden, Germany) of plasmids, ready for transfection, were performed on 
positive clones as per manufacturer’s instructions and glycerol stocks were made 
and stored at -80oC.  
 
Figure 2.1: Schematic diagram showing the insertion sites for each of the cloned 
genes in the p3x2A-pMT multicistronic plasmid. Both OCT6 and FOXP1 are inserted into 
the BamHI restriction enzyme site, NOLZ1 is inserted into the BglII restriction site, ISL1 and 
EBF1 are inserted into the NheI site. The numbers demonstrate the order in which the genes 
are to be inserted in order to remain intact. 
 
2.4 Cell culture 
Unless otherwise stated, all cell culture reagents were supplied by Life 
Technologies, Paisley, UK. 
2. Methods 
 
 
- 72 - 
2.4.1 Transfection of HEK293 cells 
HEK293 cells were cultured in T25 flasks (BD Falcon, Oxford, UK) until 70% 
confluent in DMEM:F12 (1:1), supplemented with 10% FBS, 2 mM L-glutamine and 
1% PenStrep at 37oC in 95% air/5% CO2. Cells were washed with 1x phosphate 
buffered saline (PBS) pH 7.4 prior to dissociation with 1 ml of 0.05% trypsin-EDTA 
for 3 minutes at 37oC before being resuspended in 4 ml of culture medium, 
centrifuged at 230 xg for 3 minutes, washed with PBS, centrifuged again and re-
suspended in 100 µl Nucleofector cell solution V (Lonza, Basel, Switzerland). 5 µg 
of plasmid DNA was added to the cells and then placed into a cuvette and 
nucleofected using Nucleofector II, programme Q001. After transfection, 900 µl of 
culture medium was added to the cuvette before being placed in a fresh tube and 
centrifuged for 2 minutes at 230 xg. The supernatant was removed and the cells re-
suspended in culture medium for plating onto 13 mm coverslips (VWR, 
Leicestershire, UK) in a 24 well plate (Fisher Scientific, Loughborough, UK) and into 
a T25 flask. These cells were cultured for a further 48 hours in medium, as above. 
At 24 hours, the cells were observed on a fluorescent microscope (Olympus BX61, 
Southend-on-Sea, UK) and images of random fields of view were taken in order to 
determine transfection efficiency by calculating the number of GFP+ cells as a 
proportion of total cell number. 
2.4.2 iPS cell culture 
The control iPS cell line, referred to herein as 34D6, were a kind gift of Prof. 
Siddharthan Chandran, Edinburgh, UK and were generated as previously described 
(Bilican et al., 2012) iPS colonies were maintained at 37oC, 95% air/5% CO2, in 
mTESR™1 complete media (Stemcell technologies, Manchester, UK) containing 
1% Penstrep (Life Technologies, Paisley, UK), on Matrigel (hESC qualified) (VWR, 
Leicestershire, UK) coated, 60 mm Nunc dishes (VWR, Leicestershire, UK), diluted 
as per manufacturer’s specifications in knockout DMEM at 37oC for 1 hour. Cells 
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were passaged every 3-4 days using 1 ml dispase (Stemcell technologies, 
Manchester, UK) with 10 µM Y27632 dihydrochloride, the Rho kinase (ROCK) 
inhibitor,  (Abcam, Cambridge, UK), for 15-20 minutes, until the colony edges began 
to lift. The colonies were washed off of the plates with knockout DMEM (Life 
Technologies, Paisley, UK) using a P1000, collected in a 15 ml tube (VWR, 
Leicestershire, UK) centrifuged at 230 xg for 3 minutes in a Rotanta 460R benchtop 
centrifuge (Hettich, Tuttlinge, Germany) and the cell pellet re-suspended in 
mTESR™1 medium and re-plated onto fresh Matrigel-coated plates; medium was 
changed daily (100%).  
2.4.3 Early differentiation 
iPS colonies were differentiated when they were at 70-80% confluency. mTESR™1 
medium was removed, the colonies were washed with 1x PBS pH7.4 and the 
medium changed to SLI medium which contained Advanced DMEM/F12 (ADF) 
supplemented with 2 mM L-glutamine, 1% Penstrep, 2% Neurobrew 21 without 
vitamin A (Miltenyi, Surrey, UK), 10 µM  SB431542, (CHDI, Los Angeles, CA, USA), 
a TGF-β receptor kinase inhibitor, 1 µM LDN 193189, (CHDI, Los Angeles, CA, 
USA) a BMP receptor ALK2 & ALK3 antagonist and 1.5 µM IWR1, (CHDI, Los 
Angeles, CA, USA), an inhibitor of WNT signalling. This was defined as day 0 and 
the medium was fully changed daily. At day 4, when the cells were fully confluent, 
they were split 1:2. Cells were pre-treated with 10 µM Y27632 dihydrochloride for 30 
minutes before being washed with PBS pH 7.4 and treated with 1 ml neat Stempro® 
Accutase® containing 10 µM Y27632 dihydrochloride for 5 minutes at 37oC. Cells 
were washed off of the plate with ADF containing 10 µM Y27632 dihydrochloride 
using a P1000 pipette, collected into a 15 ml tube and centrifuged at 230 xg for 3 
minutes; cells were re-suspended in SLI medium and re-plated on Matrigel-coated 
60 mm Nunc dishes. At day 8, cells were split again 1:2 as above, and re-plated into 
LI medium (ADF supplemented with 2 mM L-glutamine, 1% Penstrep, 2% 
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Neurobrew 21 without RA, 0.2 µM  LDN 193189 and 1.5 µM IWR1). Cells were 
cultured in LI medium, with daily medium changes, until day 16, when they were 
frozen in Cryostor CS10 (Stemcell technologies, Manchester, UK) with 10 µM 
Y27632 dihydrochloride after being dissociated from the dishes with Stempro® 
Accutase® containing 10 µM Y27632 dihydrochloride, as above, plated for terminal 
differentiation or transfected with the transcription factors (Section 2.4.4 & 2.4.5).  
2.4.4 Terminal differentiation 
Day 16 cells were either thawed or dissociated from the plates using Stempro® 
Accutase®  with 10 µM Y27632 dihydrochloride, washed in ADF with 10 µM Y27632 
dihydrochloride, centrifuged at 230 xg for 3 minutes, and re-suspended in 1 ml 
SCM1 medium (ADF supplemented with 2 mM L-glutamine, 1% Penstrep, 2% 
Neurobrew 21 with retinoic acid (Miltenyi, Surrey, UK), 2 µM PD 0332991 (CHDI, 
Los Angeles, CA, USA), a CDK4/6 inhibitor, 10 µM DAPT (CHDI, Los Angeles, CA, 
USA), an inhibitor of γ-secretase, 10 ng/ml brain-derived neurotrophic factor (BDNF, 
Miltenyi, Surrey, UK), 10 µM Forskolin (CHDI, Los Angeles, CA, USA), an adenylate 
cyclase activator, 3 µM CHIR 99021 (CHDI, Los Angeles, CA, USA), an inhibitor of 
glycogen synthase kinase 3 (GSK3) , 300 µM γ-amino butyric acid (GABA, Tocris, 
Oxfordshire, UK), supplemented with CaCl2 to final concentration of 1.8 mM (Sigma-
Aldrich, Dorset, UK) and 200 µM Ascorbic acid (Sigma-Aldrich, Dorset, UK)). 10 µl 
of cells was added to 10 µl of trypan blue (Sigma-Aldrich, Dorset, UK) and were 
counted using a haemocytometer to allow accurate plating at 50,000 cells per well 
of a 24 well plate in 50 µl of medium on nitric acid etched/Poly-D-Lysine-/Matrigel-
coated glass coverslips (Section 2.4.4.2) and allowed to settle for 90 minutes. A 
50% medium change was performed on day 18 and 21, then fully changed on day 
23 to SCM2 medium (1:1 ADF:Neurobasal A (Life Technologies, Paisley, UK) 
supplemented with 2 mM L-glutamine, 1% Penstrep, 2% Neurobrew 21 with retinoic 
acid, 2 µM PD 0332991, 10 ng/ml BDNF, 3 µM CHIR 99021, 1.8 mM CaCl2 and 200 
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µM Ascorbic acid). 1:1 medium changes continued for the remaining days: 25, 28, 
30, 32, 35, 37 and 39. Occasionally, cells were maintained for a 4 th week in SCM2, 
changing medium at 42 & 44 days. 
2.4.4.2 Coverslip preparation for cell plating 
Round 13 mm glass coverslips (VWR, Leicestershire, UK) were washed by 
treatment with nitric acid (Sigma-Aldrich, Dorset, UK) in a 50 ml centrifuge tube 
(VWR, Leicestershire, UK) on a Stuart mini see saw rocker SSM4 (Bibby Scientific 
Ltd., Stafforshire, UK) overnight at room temperature, 15 osc/min (as per Beaudoin 
et al., 2012). Coverslips were removed from the acid and washed 3 times with 
distilled water (Life Technologies, Paisley, UK) and a final wash in 70% ethanol 
before being spread in a borosilicate glass petri dish (Fisher Scientific, 
Loughborough, UK) and baked overnight in an oven (Swallow, LTE Scientific Ltd., 
Lancashire, UK) at 150oC. These coverslips were then placed into 24 well plates 
using ethanol-sterilised tweezers and the coverslips were coated with 50 µl drops of 
100 µg/ml of Poly-D-Lysine (Sigma-Aldrich, Dorset, UK) in borate buffer pH 8.4 for 1 
hour at room temperature and then washed with distilled water (Life Technologies, 
Paisley, UK)) and coated with 50 µl drops of Matrigel (as 2.4.1). 
2.4.5 Transfection of plasmids for differentiation 
At day 16, cells were transfected with pCAGG-TF-IRES-EGFP plasmids using 
nucleofection. The cells were pretreated with 10 µM Y27632 dihydrochloride for one 
hour and then dissociated from the plate using Stempro® Accutase® containing 10 
µM Y27632 dihydrochloride. Cells were then washed off the dish with ADF 
containing 10 µM Y27632 dihydrochloride into a 15 ml tube and then centrifuged at 
230 xg  for 3 minutes, washed with PBS pH 7.4, centrifuged again, then re-
suspended in AMAXA Nucleofector mouse neural stem cell solution (Lonza, Basel, 
Switzerland) at 1 x 106 cells/100 µl of solution per transfection, with 5 µg of plasmid 
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DNA, in the AMAXA cuvette; provided and nucleofection was facilitated using 
programme A-033 on the Nucleofector II device (Lonza, Basel, Switzerland). 
Following nucleofection, 900 µl ADF containing 10 µM Y27632 dihydrochloride was 
added to the cell suspension, and then transferred into a 15 ml tube and centrifuged 
for 3 minutes at 230 xg. The cells were then re-suspended in 1 ml of SCM1 medium 
containing 10 µM Y27632 dihydrochloride and plated at 80,000 cells per well (as 
above, 2.4.4). Transfection efficiency was analysed 1 day later, by monitoring GFP 
expression microscopically on a Olympus BX61 epifluorescent microscope 
(Olympus, Southend-on-Sea, UK). Medium was changed, as detailed in section 
2.4.4. 
2.4.6 G418 Kill curve 
After initial screening of plasmids by transfection for MSN differentiation, later 
transfections with fewer plasmids for more in depth analysis were treated with 
Geneticin® G418 to enrich the population for cells expressing the given plasmid. At 
24 hours post plate-down of transfected cells, SCM1 medium was replaced with 
SCM1 medium containing G418 at 150 µg/ml, 300 µg/ml and 600 µg/ml or no G418 
added. Media were changed then at the time points as described in Section 2.4.4 
using medium containing G418. Cells were viewed every 48-96 hours and the 
proportion of GFP-positive cells was determined. 
2.5 Protein analysis 
2.5.1 Western blotting 
At 48 hours post transfection, HEK293 cells were harvested by treatment with 1 ml 
of 0.05% trypsin-EDTA for 3 minutes at 37oC, resuspended in media and 
centrifuged at 120 xg for 2 minutes before re-suspension in radio-
immunoprecipitation assay buffer (RIPA buffer) (Sigma-Aldrich, Dorset, UK) 
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containing one Complete Mini EDTA-free Protease Inhibitor Cocktail Tablet (Roche, 
Hertfordshire, UK)/10 ml and left on ice for 10 minutes. The lysate was centrifuged 
at 15,500 xg for 30 minutes at 4oC, after which the supernatant was aspirated and 
placed in to a fresh tube and frozen at -80oC. 
Samples were thawed on ice in order to perform a bicinchoninic acid (BCA) assay 
(Thermo, Waltham, MA, USA) to determine the concentration of protein per sample. 
The microplate procedure was performed in a 96 well plate (Fisher Scientific, 
Loughborough, UK) as per manufacturer’s instructions and protein concentration 
determined by plotting a protein concentration vs. absorbance at 562 nm calibration 
graph. Western blotting was performed using 1.5 mm polyacrylamide gel with a 10% 
resolving gel and 7.5% stacking gel (Table 2.3).   
10% Resolving gel 7.5% Stacking 
gel 
Transfer buffer Running buffer 
0.31 M Tris pH 
8.8 
0.14 M Tris pH 
6.8 
25 mM Tris base  25 mM Tris Base 
10% 
(v/v) 
Acrylamid
e 
7.5% 
(v/v)  
Acryla
mide 
192 mM Glycine 192 mM Glycine 
0.002% 
(w/v) 
SDS 0.002% 
(w/v) 
SDS 20% (v/v) 
Methanol 
0.1% (w/v) SDS 
0.0003
% (w/v) 
Ammoniu
m 
persufate 
(APS) 
0.001% 
(w/v) 
APS To 1 L with H2O To 1 L with ddH2O 
30 µl TEMED 30 µl TEMED   
ddH2O to 21.03 ml ddH2O to 6.9225 
ml 
  
Table 2.3 Composition of gels and buffers for Western blotting  
Samples of 30 µg protein were made up to 12.5 µl with H2O and added to 12.5 µl of 
2x Laemmli sample buffer (Sigma-Aldrich, Dorset, UK) in a 0.2 ml PCR tube and 
denatured at 95oC for 5 minutes in a Techne TC512 thermocycler (Bibby Scientific 
Ltd., Staffordshire, UK) before being loaded onto the gel. Novex protein ladder (Life 
Technologies, Paisley, UK) was used as a size marker and 6 µl of this was loaded 
in an additional lane. Separation of proteins was performed by running the samples 
at 100 V until the dye front of the loading buffer reached the bottom of the stacking 
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gel and at 200 V for the dye front to reach the bottom of the resolving gel in 1x 
running buffer. The gel was removed from the glass moulds and placed between 
blotting paper (Sigma-Aldrich, Dorset, UK) and nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK) to perform transfer of the protein from the gel to 
nitrocellulose and placed into a Mini-PROTEAN apparatus set-up as per 
manufacturer’s instructions (BioRad, Hertfordshire, UK). Transfer of protein on to 
the nitrocellulose membrane was carried out at 100 V for 1 hour in transfer buffer 
(Table 2.3) from gel to nitrocellulose. The nitrocellulose membrane was then 
immersed in Ponceau S to check whether the transfer of protein from gel to 
nitrocellulose had been successful. Membranes were washed with transfer buffer 
and tris buffered saline (TBS, see appendix) before being placed in blocking 
solution for 1 hour at room temperature and then incubated with primary antibody 
(Table 2.4 for concentration of antibodies and specific blocking conditions). After 
incubation, primary antibodies were removed and stored at 4oC for future use. 
Membranes were washed 3 x 5 minutes in TBS/Tween and then incubated with the 
relevant secondary antibody (Table 2.5 for dilutions) for 1 hour at room temperature. 
The secondary antibody was then removed and the membranes were washed twice 
for 3 minutes in TBS, 3 x 3 minutes in TBS/0.1%Tween and twice for 3 minutes in 
TBS. The protein bands on the membrane were visualised by incubating with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, 
MA, USA) or with SuperSignal West Dura Chemiluminescent Substrate (Thermo 
Scientific, Waltham, MA, USA) and exposed to X-ray film/Lumi-Film 
Chemiluminescent Detection Film (Roche, Hertfordshire, UK) in a Hypercassette 
(Amersham Biosciences, Buckinghamshire, UK) and the film was developed using 
an automatic developer (Xograph Compact X4). 
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Antibody Species Block Dilution Diluent Incubation  
2A 
peptide 
Rabbit 5% Marvel PBS 0.1% 
Tween 0.05% Azide 
1:1,000 1% block Overnight 4
o
C 
β-actin Mouse - 1:10,000 1% block 2 hours room 
temperature 
Oct6 Rabbit 5% BSA 1% ovalbumin 
TBS 0.1% Tween 0.05% 
Azide 
1:500 1% block Overnight 4
o
C 
FoxP1 Rabbit 5% BSA 1% ovalbumin 
TBS 0.1% Tween 0.05% 
Azide 
1:5,000 1% block Overnight 4
o
C 
Islet1 Rabbit 5% BSA 1% ovalbumin 
TBS 0.1% Tween 0.05% 
Azide 
1:10,000 1% block Overnight 4
o
C 
Nolz1 Rabbit 5% Milk TBS 0.1% Tween 
0.05% Azide 
1:1,000 1% block Overnight 4
o
C 
Ebf1 Rabbit 5% BSA 1% ovalbumin 
TBS 0.1% Tween 0.05% 
Azide 
1:1,000 1% block Overnight 4
o
C 
Table 2.4: Antibody conditions and dilutions for western blotting of HEK293 protein samples. 
 
 Table 2.5: Secondary antibody dilutions and conditions for corresponding primary 
antibodies 
2.5.2 Immunofluorescence 
Cells on coverslips were washed with PBS and fixed with 4% paraformaldehyde, pH 
7.4 (see appendix for recipe) for 10 minutes at room temperature. The cells were 
then washed with PBS before permeabilisation (Table 2.6 for specific conditions) 
and blocked for 1 hour at room temperature and then incubated with primary 
antibody overnight at 4oC. After removing the primary antibody, cells were washed 3 
x 5 minutes with PBS and then incubated with secondary antibody (Table 2.7 for 
secondary antibodies and concentration used) in blocking solution for 2 hours at 
room temperature in the dark. The secondary antibody was removed and the cells 
were washed 3 x 5 minutes with PBS and incubated with Hoechst 33342 at 
1:10,000 in PBS before being washed a further 3 x 5 minutes with PBS and 
mounted on glass slides (VWR, Leicestershire, UK) with Vectashield™ (Vector 
laboratories Ltd., Peterborough, UK) or Fluoromount-G® (Southern Biotech, 
Cambridgeshire, UK). Cells were viewed on an Olympus BX61 fluorescent 
Antibody Host Dilution Diluent Incubation 
Rabbit Donkey 1:20,000 TBS 0.1% Tween 2 hours room temperature 
Mouse Sheep 1:10,000 TBS 0.1% Tween 1 hour room temperature 
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microscope (Olympus, Southend-on-Sea, UK) and digital images saved for later 
analyses. Cell counts were either performed manually in Image J 
(imagej.nih.gov/ij/), or nuclei and nuclear staining was performed using Cell Profiler 
v2.1.0 (Carpenter et al., 2006, http://www.cellprofiler.org/citations.shtml). 
2.5.2.2 Quantification of DARPP32 immunofluorescence. 
Cells were determined as positive for DARPP32 immunofluorescence by eye, with 
cytoplasmic localisation of staining. Initial GFP transfection efficiencies were used to 
determine induction efficiency of DARPP32 expression, by dividing the percentage 
of DARPP32+ cells by the percentage of GFP+ cells and this value was normalised 
to the CAG- transfected cells. 
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Antibody Species Permeabilisation Block Dilution Incubation 
2A peptide Rabbit 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
OCT6 Rabbit Methanol fixed 10% Goat serum 1% 
BSA 0.3M glycine 
0.1% PBS Tween 
1:200 in 
block 
Overnight 
4
o
C 
FOXP1 Rabbit 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
FOXP1 Mouse Ice cold ethanol 2 
minutes 
3% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
ISL1 Rabbit 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
EBF1 Rabbit 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
MAP2 Rabbit 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
MAP2 Mouse 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
Synaptop
hysin 
Mouse - 2% Goat serum, 3% 
BSA in 0.05% Tween 
PBS 
1:200 in 
block 
Overnight 
4
o
C 
PSD-95 Rabbit - 2% Goat serum, 3% 
BSA in 0.05% Tween 
PBS 
1:100 in 
block 
Overnight 
4
o
C 
S100β Mouse 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
DCX Goat - 1% BSA in 0.3% 
Triton-X PBS 
1:100 in 
block 
Overnight 
4
o
C 
DARPP32 Rabbit 0.3% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:200 in 
block 
Overnight 
4
o
C 
CTIP2 Rat 0.3% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
Calbindin Rabbit 0.3% Triton-X in 
PBS for 10 
minutes 
3% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
GFAP Mouse 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:500 in 
block 
Overnight 
4
o
C 
GFP Chicken 0.25% Triton-X in 
PBS for 10 
minutes 
2% Goat serum, 3% 
BSA in 0.1% Triton-X 
PBS 
1:1000 
in block 
Overnight 
4
o
C 
Table 2.6 Primary antibody dilutions and conditions for immunocytochemistry on 
cells. 
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Secondary antibody Dilution 
Alexa Fluor 594 goat α rabbit IgG (H&L) 1:500 
Alexa Fluor 594 goat α mouse IgG (H&L) 1:500 
Alexa Fluor 488 goat α rabbit IgG (H&L) 1:500 
Alexa Fluor 488 goat α rat IgG (H&L) 1:500 
Alexa Fluor 488 goat α mouse IgG (H&L) 1:500 
Alexa Fluor 488 donkey α goat IgG (H&L) 1:500 
Alexa Fluor 488 goat α chicken IgG (H&L) 1:1000 
Alexa Fluor 350 goat α mouse IgG (H&L) 1:500 
Alexa Fluor 350 goat α rat IgG (H&L) 1:500 
Table 2.7 Secondary antibody dilutions and conditions for immunocytochemistry on 
cells  
2.6 Sholl analysis 
At day 23 and 30, coverslips of transfected cells were fixed with 4% PFA and the 
coverslips mounted with Fluoromount G® as per Section 2.5.2. Day 37 cells 
underwent a GFP immunocytochemistry in order to ensure GFP was still visible as 
per Section 2.3.2. GFP expressing cells were imaged on a confocal microscope 
Leica DM6000 (Leica, Milton Keynes, UK) taking a full z-stack throughout the cell 
every 0.6 µm. A 2D image was constructed using a maximum projection of each of 
the pixels on the image using the Leica LCS confocal software (Leica, Milton 
Keynes, UK). Images were stitched together, when required using Microsoft Image 
Composite Editor (Microsoft, Berkshire, UK). Images were converted to black and 
white by splitting the RGB channels of the image and the green channel selected for 
the axons and neurites to be traced using the simple neurite tracer plugin on Fiji 
software (http://fiji.sc/Simple_Neurite_Tracer). A line stack of the traces was created 
using the simple neurite tracer plugin, this was used for subsequent Sholl analysis. 
Data relating to neurite length and branching points was also obtained using the 
simple neurite tracer plugin. Sholl analysis was performed using the Sholl analysis 
plugin (http://fiji.sc/Sholl_Analysis) with a starting radius of 5 µm and final radius 
at the furthest point of the cell in increments of 1 µm. 
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2.7 Electrophysiology 
Whole cell patch clamp was performed at 2 and 3 weeks post transfection for basic 
neuronal function by Dr Vsevelod Telezhkin (VT) and whole cell patch clamp for 
collecting data on GABA currents, and NMDA currents with dopamine D1 agonist 
enhancement and miniature synaptic currents was performed by Dr Christian 
Schnell (CS), who both provided the raw data files. All data analysis was performed 
by myself.  
2.7.1 Electrodes 
The patch electrode was silver/silver chloride wire (0.25 mm, Harvard Apparatus 
Ltd., Kent, UK), chloride coated using electrolysis of NaCl solution with a 9 V 
battery, and the bath/reference electrode was an Ag/AgCl pellet (Harvard Apparatus 
Ltd., Kent, UK) connected to the PC head stage. 
2.7.2 Patch pipettes 
Thin walled, filamented, borosilicate glass tubes (World Precision Instruments, 
Hertfordshire, UK) were pulled using a 2 stage pipette puller (PP-830, Naristige, 
Japan) to produce patch pipettes with a tip resistance of ~8-10 MΩ, when filled with 
standard pipette solution.  
2.7.3 Whole cell patch clamp 
Cells on glass coverslips which were at day 29-31 (termed week 2) and day 35-38 
(termed week 3) were placed in the perfusion chamber on the stage of an inverted 
microscope (Olympus IX70 (VT), Olympus CK40 (CS), Olympus, Southend-on-Sea, 
UK) both with phase contrast and fluorescence optics. The microscope was 
mounted in a Faraday cage on an anti-vibration air table (Wentworth Laboratories, 
Oxfordshire, UK). Bath solution was perfused continuously in to the perfusion 
chamber using gravity flow at a rate of 2-4 ml/minute. A rapid solution changer 
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(RSC-160, Biologic, Claix, France) was utilised to perfuse other solutions onto the 
cells (Section 2.8.4.2), which was connected to parallel glass tubes with capillary 
tubing (Cole-Parmer, London, UK), which were positioned adjacent to the cells. A 
controlled flow rate from the RSC of 0.5-1.5 ml/minute and fully-automated 
switching of solutions allowed reproducible applications of various 
neurotransmitters. Waste solution was removed by vacuum suction through a flame-
pulled glass tube into a Büchner flask. 
Patch pipettes were filled with pipette solution (Table 2.8 for composition) through a 
0.2 µm syringe filter (Sartorius Stedim, Surrey, UK) using a carbon-fibre flexible 
needle (Microfil, World Precision Instruments, Hertfordshire, UK). Pipettes were 
mounted on a CV 201AU headstage connected to an Axopatch 200B amplifier (VT), 
or Multiclamp 700A amplifier (CS) and DigiData 1322A A/D interface (Axon 
Instruments, Forster City, CA, USA). Recordings were digitized at 10 kHz and low-
pass filtered using an 8-pole Bessl. 
Cell bodies, which were accessible and GFP+ (suggesting transgene expression) 
were patched. The patch pipette was lowered using the macromanipulator (Burleigh 
PCS-PS60 (VT) (ThorLabs, Ely, UK), Scientifica Patchstar (CS) (Scientifica, East 
Sussex, UK)), when in the bath solution a seal test was performed using the 
pClamp 8.2 software (Molecular Devices, Sunnyvale, CA, USA), 10 mV for 10 ms at 
50 Hz and the resistance between patch pipette and both electrodes calculated, 
pipette voltage offset was zeroed either manually (VT) or using MultiClamp 
commander software (CS, Molecular Devices, Sunnyvale, CA, USA). 
Micromanipulation of the patch pipette was used to lower the tip to the cell 
membrane until they touched and a decrease in amplitude of current was observed 
due to the increased resistance at the patch pipette due to touching the cell 
membrane. Negative pressure was applied to the patch pipette using a syringe, and 
the position of the patch pipette lowered by micromanipulation to improve the 
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membrane-pipette seal. A holding potential of -60 mV(VT)/-70 mV(CS) was applied 
across the membrane to prevent depolarisation of the cell upon whole-cell access. If 
the seal was >1 GΩ the cell was used, the capacitance currents were compensated 
using fast and slow capacitance compensation either performed manually on the 
amplifier (VT) or with the MultiClamp commander software (CS). 
Whole cell access was gained by applying negative pressure to the patch pipette 
until capacitance transients were observed from the seal test protocol and these 
were compensated as above. Series resistance was compensated 60-90%, cells 
with a leak current greater than 200 pA were rejected.  
Voltage and current-clamp protocols were generated using pClamp 10 software 
(Molecular devices, Sunnyvale, CA, USA) and the recordings were taken online 
using pClamp 8.2 and analysed offline using Clampfit 10 (Molecular devices, 
Sunnyvale, CA, USA), Microsoft Excel and GraphPad Prism 6 (GraphPad Software, 
Inc., La Jolla, CA, USA). Basic electrophysiology properties were recorded using the 
standard pipette (Table 2.8) and standard bath solutions (Table 2.9). 
Standard pipette solution (VT) Pipette solution for NMDA/GABA 
currents (CS) 
Reagent Concentration Reagent Concentration 
KCl 117 mM HEPES 40 mM 
NaCl 10 mM EGTA 10 mM 
N-2-
hydroxyethylpiperazine-
N’-2-ethanesulfonic 
acid (HEPES) 
11 mM MgCl2 2 mM 
Na3-GTP 2 mM Na3-GTP 0.2 mM 
Na2-ATP 2 mM Na2-ATP 2 mM 
Phosphocreatine 1.2 mM N-Methyl-D-
Glucamine 
(NMDG) 
175 mM 
MgCl2 2 mM Phosphocreatine 12 mM 
CaCl2 1 mM Leupeptin 0.1 mM 
Ethylene-glycol-tetra-
acetic acid (EGTA) 
11 mM   
pH adjusted to 7.2 with KOH  pH adjusted to 7.2 with H2SO4 
Table 2.8 Composition of pipette solutions for whole cell patch clamp recordings 
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Table 2.9 Composition of bath solutions for whole cell patch clamp recordings 
2.7.4 Current clamp  
2.7.4.1 Basic properties (VT) 
Measurement of resting membrane potential (Vm) and monitoring the presence or 
absence of spontaneous action potentials in each cell was performed in fast current 
clamp with 0 pA current injection for 60-120 s. The Vm was determined by averaging 
a section of the trace containing no events. The membrane potential was also 
manipulated by manual variable current injection to obtain a membrane potential of -
70 mV and see if cells were able to fire action potentials.  
In order to analyse action potentials, a current clamp protocol involving variable 
current injection to hold the cell membrane potential at -70 mV and from this, 
specific current injection was applied for 1 second from -10 pA to 180 pA in 10 pA 
increments. The action potentials elicited were analysed in Clampfit 10.2 for 
parameters indicative of neuronal maturity and type. In order to determine the input 
resistance of the cells, the last 50 ms from up to the first 5 sweeps from the current 
clamp protocol without action potential attempts were averaged to create a linear I-V 
graph. The gradient of the linear regression equation is equal to the input resistance 
due to Ohm’s law:  
Standard bath solution (VT) Bath solution for NMDA/GABA 
currents (CS) 
Reagent Concentration Reagent Concentration 
NaCl 135 mM NaCl 127 mM 
KCl 5 mM HEPES 10 mM 
MgCl2 1.2 mM D-Glucose 12 mM 
CaCl2 1.25 mM CaCl2 2 mM 
D-Glucose 10 mM BaCl2 5 mM 
HEPES 5 mM CsCl 20 mM 
 Tetrodotoxin 0.001 mM 
 Glycine 0.02 mM 
pH adjusted to 7.4 with NaOH pH adjusted to 7.3 with NaOH 
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𝑂ℎ𝑚′𝑠 𝑙𝑎𝑤: 𝑉 =
𝐼
𝑅
 𝑜𝑟 𝑉 = 𝐼𝐺 
𝐿𝑖𝑛𝑒𝑎𝑟 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛: 𝑦 = 𝑚𝑥 + 𝑐 
𝐼 = 𝑉𝑅−1 + 𝑐  
 
Where V=voltage, I=current, R=resistance, g=conductance 
2.74.2 GABA & NMDA currents (CS) 
2.7.4.2.1 GABA currents 
Cells were held in current clamp mode at -40 mV, with 3 x 5 second applications of 
γ-amino butyric acid (GABA, 100 µM) with a 90 second wash-out and recovery 
phase between each application. The average of the three sweeps was taken to 
determine the peak current.  
The currents elicited were analysed by averaging the sets of three sweeps, then 
setting the baseline to the average current 2 seconds before GABA application and 
then measuring the peak current, which was positive-going for GABA  
2.7.4.2.2 NMDA currents and dopamine D1 regulation 
Investigation of dopamine enhancement of N-methyl-D-aspartic acid (NMDA, 100 
µM) was performed by 9 x 5 second applications, with 90 second recovery of 3 x 
NMDA alone applications, the second three applications were of NMDA with the 
dopamine D1 agonist SKF81297 (10 µM) and the final three applications were of 
NMDA alone. The currents elicited were analysed by averaging the sets of three 
sweeps, then setting the baseline to the average current 2 seconds before NMDA 
application and then measuring the peak current, which was negative-going NMDA. 
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2.7.4.3  Mini excitatory post-synaptic currents (CS) 
Cells were held in current clamp at -40 mV and recorded for 120 seconds as 
described in Flores-Hernández et al., (2002). The final 60 seconds of the recording 
were analysed for the presence of mini excitatory post-synaptic currents (EPSCs). 
Recordings were analysed using Mini Analysis 6.0.7 (Synaptosoft Inc., Decatur, GA, 
USA). 
2.7.5 Voltage Clamp (VT) 
Measurement of Na+ and K+ currents and voltage-dependent Na+ channel 
activation/inactivation was performed in voltage clamp. Cell membrane voltage was 
held at -70 mV before a voltage step for 200 ms from -120 mV increasing to 80 mV 
in 5 mV increments per sweep then a final voltage step to 0 mV for a further 200 
ms. K+ currents were measured by averaging the last 50 ms of the variable section 
of the sweep. Na+ activation and inactivation currents were analysed from the initial 
15 ms and 15 ms around the negative peak after the variable sweeps. 
2.8 Statistical analysis 
Analysis of data was performed using a suitable test for the data distribution and the 
hypothesis to be tested. Data were analysed in GraphPad Prism v 6.0 (GraphPad 
Software, Inc., La Jolla, CA, USA), and significant differences in data were analysed 
using one-way ANOVA with Tukey’s multiple comparison, Kruskal-Wallis with 
Dunn’s multiple comparison, unpaired two-tailed t-tests with Welch correction, 
Mann-Whitney U test. 
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3. Transcription factor cloning and plasmid 
validation 
 
Figure 3.0: Summary of the data in chapter 3. In this chapter, is the cloning and validation 
of five transcription factors important for MSN development. 
3.1 Introduction 
The transcription factors EBF1, FOXP1, ISLET1, NOLZ1 & POU3F1 (OCT6), have 
been shown to play important roles in early striatal development and specification of 
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MSNs. In the Ebf1 knockout mouse the transition of cells between the SVZ and MZ 
was disrupted and the postnatal mouse striatum was decreased in size (Garel et al., 
1999). FOXP1 mRNA and protein were shown to be expressed from E14.5 to adult 
in the SVZ of the LGE (Ferland et al., 2004), ISLET1 mRNA and protein were 
shown to be expressed in the SVZ of the LGE throughout development (Stenman et 
al., 2003, Wang & Liu 2001), NOLZ1 mRNA and protein expression was observed 
during development of the early striatum before being downregulated postnatally 
(Chang et al., 2004, Urbán et al., 2010, Ko et al., 2013), and OCT6 mRNA and 
protein expression was seen in the SVZ of the LGE from E12 (Alvarez-Bolado et al., 
1995), through to E15.5 (Garel et al., 1999) and in the adult (Frantz et al., 1994). 
Differential transcriptional profiling of the two MSN populations expressing either 
one of the two receptors; dopamine receptor D1a (Drd1a), the striatonigral 
population and dopamine receptor D2 (Drd2), the striatopallidal population, the 
results showed Isl1 to be preferentially expressed in the striatonigral population and 
that the expression of FoxP1, Nolz1 and Ebf1 was upregulated in the striatum in 
comparison with the whole brain RNA (Heiman et al., 2008). 
The developmental importance of these transcription factors, as highlighted above, 
due to their levels of expression during striatal development and the consequences 
of the absence of their expression are why these transcription factors have been 
chosen. These five key MSN-relevant transcription factors ISLET1, NOLZ1 
(ZNF503), EBF1 (OLF1), OCT6 (POU3F1) and FOXP1, were cloned from plasmids, 
which contained the protein coding sequences of the human genes, or from human 
brain cDNA. These transcription factors were then subcloned into a multicistronic 
plasmid. The multicistronic plasmid contains three 2A peptide cleavage sites 
separated and flanked by four different restriction enzyme sites. The 2A peptide is 
18 amino acid residues in length terminating with a glycine, a 19 amino acid 
sequence was discovered to be sufficient in order to induce cleavage of the 2A 
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peptide at the C terminus in the foot and mouth disease virus (FMDV) (Ryan et al., 
1991). The 2A peptide is followed by the 2B peptide, which is 19 amino acid 
residues long starting with a proline. The 2A peptides in the multicistronic plasmid 
originated from: i) the porcine teschovirus, termed P2A (Kim et al., 2011); ii) the 
equine rhinitis A virus, E2A; and; iii) insect virus Thosea asigna, T2A (Szymczak et 
al., 2004). These peptides induced self-cleavage by interacting with the exit tunnel 
of the ribosome during translation, this interaction induced a “skip” mechanism and 
as a result the peptide bond was not formed between the final residue of the 2A 
peptide (glycine) and the first residue of the 2B peptide (proline) (de Felipe 2004). 
The two peptides remained separate and the ribosome continues to translate the 
downstream sequence of the 2B peptide (de Felipe 2004). This means that the 
upstream proteins are tagged with a C terminal 18 amino acids and the downstream 
proteins are tagged with an N terminal proline residue, these have been shown to 
have a minimal effect on protein-protein interaction and activity, and have no effect 
on protein stability (de Felipe 2004).  
This method was selected in order to express multiple genes in equal amounts, 
from a single promoter, and has advantages over other multicistronic transgene 
expression strategies such as the use of internal ribosomal entry sites (IRES) in 
which downstream genes are expressed at much lower levels, usually only at 50% 
of the upstream gene in the expression vector (Mizuguchi et al., 2000). Another 
method for multiple gene expression using Fusagenes, which contain enzyme target 
sites between genes e.g. furin, the Golgi endoprotease, relies on the presence of 
the enzyme and efficient cleavage with the translated protein, which may not always 
be possible (Gäken et al., 2000). 
Once the genes had been cloned into this multicistronic plasmid, the entire insert 
was subcloned into a pCAGG-IRES-EGFP expression vector (created by E L Cope) 
for forced expression of these transcription factors in stem cell-derived neural 
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progenitors in an attempt to drive their differentiation towards a MSN phenotype. 
The fact that the plasmid contains GFP coding sequence for GFP expression 
means the cells which have been transfected can be identified for 
electrophysiological characterisation and Sholl analysis (Chapter 5). The plasmid 
also contains a neomycin resistance gene to allow for selection of transfected cells 
by G418 treatment, in order to try and increase the proportion of the cell population 
which is expressing the transcription factors. 
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3.2 Cloning, Subcloning & Plasmid Verification  
 
Table 3.1 The enzymes used to check the orientation of transcription factor insert in 
the p3x2ApMT vector and pCAGG-IRES-EGFP vector by restriction digest and the 
sizes of bands produced with the restriction enzymes  
Vector Enzyme Correct Incorrect 
p3x2ApMT-ISLET1 NcoI-HF 2683bp + 978bp 3241bp + 420bp 
p3x2ApMT-
NOLZ1(variant) 
NcoI-HF 2675bp + 686bp 
 
3156bp + 303bp 
p3x2ApMT-EBF1 NcoI-HF 2629bp + 1748bp 3996bp + 388bp 
p3x2ApMT-OCT6 NcoI-HF 2731bp + 1221bp + 12bp 137bp + 3325bp 
p3x2ApMT-
NOLZ1(variant)-ISLET1 
(NOLZ1) 
NcoI-HF 2680bp + 1140bp  
+ 686bp 
2680bp + 1523bp 
 + 303bp 
p3x2ApMT-FOXP1-
NOLZ1(variant)-ISLET1 
(FOXP1) 
EcoRI-HF 4884bp + 1679bp 6113bp + 450bp 
pCAGG-ISLET1-IRES-
EGFP 
XmnI 6649bp + 1032bp  6963bp + 718bp 
pCAGG-NOLZ1(variant)-
IRES-EGFP 
NotI-HF 5791bp + 1699bp 5432bp + 2058bp 
pCAGG-NOLZ1-IRES-
EGFP 
NheI-HF 7841bp + 735bp 7151bp + 1425bp 
pCAGG-NOLZ1-ISLET1-
IRES-EGFP (NOLZ1) 
NheI-HF 7841bp + 1053bp + 753bp 7151bp + 1425bp + 
1053bp 
pCAGG-EBF1-IRES-
EGFP 
SmaI 6753bp + 1654bp 8027bp + 380bp 
pCAGG-OCT6-IRES-
EGFP 
SmaI 6870bp + 861bp + 201bp 
+ 59bp 
7234bp + 497bp + 
201bp + 59bp 
pCAGG-NOLZ1(variant)-
ISLET1-IRES-EGFP 
SmaI 7043bp + 1490bp 7863bp + 670bp 
pCAGG-FOXP1-
NOLZ1(variant)-ISLET1-
IRES-EGFP 
Sma1 7082bp + 2018bp 
+1490bp 
7863bp + 2018bp + 
709bp 
pCAGG-NOLZ1(variant)-
ISLET1-IRES-EGFP 
(ISL1) 
PflM1 6735bp + 1136bp + 672bp 6735bp + 918bp + 
890bp 
pCAGG-NOLZ1(variant)-
ISLET1-IRES-EGFP 
(ISL1) 
XmnI 7514bp + 1029bp 8025bp + 518bp 
pCAGG-NOLZ1-ISLET1-
IRES-EGFP (ISL1) 
PflM1 6735bp + 1136bp + 672bp 7824bp + 915bp + 
890bp 
pCAGG-ISLET1-IRES-
EGFP (ISL1) 
PflM1 6542bp + 1139bp 6788bp + 890bp 
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3.3 EBF1 
EBF1 was selected to be cloned and used for forced expression in neural stem cells 
to impose a MSN phenotype because i) EBF1 is expressed in the SVZ and MZ of 
the LGE (Garel et al., 1997, Garel et al., 2999); ii) Ebf1 overexpression forced cells 
to exit the cell cycle and undergo premature neural differentiation in the chick 
embryo (Garcia-Dominguez et al., 2003); iii) during development in the Ebf1-/- 
mouse, there was a defect in the transition of cells from the SVZ to the MZ in the 
LGE (Garel et al., 1999), with a marked decrease in the expression of striatally 
enriched genes (Lobo et al., 2008). 
1. Cloning of EBF1 
Human EBF1 was cloned from a plasmid clone ID: HsCD00296820 (PlasmID 
Harvard Medical School, Boston, U.S.A.), into the pGEM® T easy vector using PCR 
primers to incorporate NheI restriction enzyme sites onto the 5’ and 3’ ends of the 
gene (Figure 3.1a) and the stop codon omitted, the PCR product at ~1.7 kb can be 
observed as per Figure 3.1b. NheI sites were chosen for incorporation to insert the 
EBF1 gene into the multicistronic plasmid as there are no NheI sites in the EBF1 
gene. White colonies were screened by restriction digestion using NheI, as insertion 
of the EBF1 gene interrupts the lacZ gene of the pGEM® T easy vector. The 
restriction digest consisted of 2 DNA fragments of ~3kb and ~1.7kb (Figure 3.1c). 
Positive clones were sequenced at MWG Eurofins and verified by analysing the 
sequence on NCBI Nucleotide BLAST, the sequence homology was 100% with 
Homo sapiens EBF1 (NM_024007.3), the 5’ and 3’ ends of the alignment as per 
Figure 3.2d (Appendix for full alignment). 
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Figure 3.1: Cloning of EBF1. a) Schematic showing PCR primers incorporation of NheI 
sites (red) onto the 5’ and 3’ ends of EBF1 and removing the stop codon. b) EBF1 was 
cloned from Plasmid Harvard vector: HsCD00296820 by high fidelity PCR. The fragment 
was extracted and ligated into pGEM
®  
T easy cloning vector, colonies were screened by 
utilising blue/white selection as a result of the lacZ gene being interrupted in the cloning 
vector. c) Restriction digest of a mini prep from a white colony to check that EBF1 was 
inserted by NheI digestion, as seen by the pGEM
®
 T easy vector backbone band at ~3kb 
and the insert at ~1.7kb. d) Alignment of EBF1 sequencing data to NM_024007.3 100% 
homology.  
2. Subcloning of EBF1 
EBF1 was then subcloned into the p3x2A-pMT multicistronic plasmid with NheI 
(Figure 3.2a & 3.2b) and checked for orientation by restriction digest with NcoI to 
produce fragments of 2629bp and 1748bp (Table 3.1). EBF1 in the multicistronic 
fragment was then subcloned into the pCAGG-IRES-EGFP plasmid (Figure 3.2c) 
with SalI and the orientation of the insert was verified with SmaI to produce 
fragments of 6753bp and 1654bp as per Figure 3.2e (Table 3.1).  
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Figure 3.2: Plasmid design and formation of pCAGG-EBF1-IRES-EGFP. a) p3x2A-EBF1 
plasmid map highlighting important restriction enzyme sites for cloning strategy, red ringed sites 
correspond to those in a, NcoI sites ringed in yellow at 420 and 2168 were used for checking 
EBF1 insertion orientation as seen in the gel in (b). b) NcoI digest producing fragments of p3x2A-
EBF1 producing bands of 2629bp and 1748bp c) Schematic showing the insertion of EBF1 into 
the pCAGG-IRES-EGFP vector by SalI digestion. d) Plasmid map of pCAGG-EBF1-IRES-EGFP, 
red circles highlighting the SalI sites and SmaI sites ringed in yellow at 2101 and 3755 which were 
used for checking the orientation of EBF1 insertion. e) SmaI digestion of pCAGG-EBF1-IRES-
EGFP to check orientation producing fragments of 6753bp and 1654bp 
3. Transcription factor cloning and plasmid validation 
 
 
- 98 - 
3. Validation of EBF1 protein expression  
In order to validate that the EBF1 protein was being expressed correctly, transient 
transfections of pCAGG-EBF1-IRES-EGFP into HEK293 cells were performed. 
Protein molecular weight was determined by western blot and immunocytochemistry 
was performed to determine cell localisation of EBF1 protein, which should be 
nuclear. The initial analysis of GFP expression from the pCAGG-EBF1-IRES-EGFP 
vector can be seen in Figure 3.3a and exemplifies the mean transfection efficiency 
of 13.2±1.1% (N=1; n=3). Western blot and immunocytochemistry were 
unsuccessful, using two different antibodies for EBF1 expression as seen in Figure 
3.3b with non-specific staining observed in the cytoplasm of the cells in both the 
empty plasmid control and EBF1 containing plasmid. The use of the anti-2A peptide 
antibody would not provide any signal as EBF1 is inserted into the final position in 
the multicistronic plasmid and therefore does not possess a 2A peptide tag.  
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Figure 3.3: Analysis of protein expression in cells expressing pCAGG-EBF1-IRES-
EGFP. HEK293 cells were transfected with pCAGG-EBF1-IRES-EGFP or pCAGG-IRES-
EGFP (control). Images were taken 24 hours later. A) Bright field shown in left panels, GFP 
fluorescence of same field shown in right panels expression. Upper four panels show EBF1 
plasmid, lower two panels show control plasmid. Transfection efficiency: 13.2% ± 1.1. 
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Scalebar = 50 µm b) Immunocytochemistry 48 hours post transfection of stem cell derived 
neural stem cells. Images of EBF1 expression in red and GFP expression from the plasmids  
in green, nuclei are stained blue. Scalebar = 50 µm 
3.4 ISLET1 
ISLET1 was chosen to be utilised in transfections of neural stem cells as ISLET1 is 
an essential protein in striatal development and is highly expressed in the 
developing LGE and striatum (Wang & Liu 2001, Long et al., 2009, Stenman et al., 
2003). 
1. Cloning of ISLET1 
ISLET1 was cloned from a plasmid clone ID HsCD00076385 (PlasmID) into the 
pGEM® T easy vector with primers incorporating the NheI restriction enzyme sites 
on to the 5’ and 3’ ends of the gene (Figure 3.4). NheI sites were chosen due to 
ISLET1 being one of the two genes chosen which did not contain NheI sites in the 
protein coding sequence and as ISLET1 did not contain XbaI, BglII and BamHI 
restriction sites (the other restriction sites for insertion in the p3x2A-pMT plasmid), 
ISLET1 was the first gene to be inserted into the p3x2A-pMT vector before insertion 
of the other transcription factor genes. Colonies were screened by restriction 
digestion using NheI to check for insertion (Figure 3.4c). Positive clones were 
sequenced at MWG Eurofins and verified by NCBI Nucleotide (Figure 3.4d), where 
the sequence was identified as sharing >99% homology with Homo sapiens ISLET1 
(NM_002202.2), with a base substitution at position 1052 of an A to a G. Upon 
searching the SNP database (NCBI), it was confirmed to be a known SNP (Figure 
3.4e) and did not result in a change of amino acid residue, with proline remaining 
intact.  
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Figure 3.4: Cloning of ISL1. a) Schematic showing PCR primers incorporation of NheI sites 
(in red) onto the 5’ and 3’ ends of ISL1 and removing the stop codon. b) ISL1 was cloned 
from Plasmid Harvard vector: HsCD00076385  by high fidelity PCR. The fragment was 
extracted and ligated into pGEM® T easy cloning vector, colonies were screened by utilising 
blue/white selection as a result of the lacZ gene in the cloning vector. c) Restriction digest of 
a mini prep from a white colony to check that ISL1 was inserted by NheI digestion, as seen 
by the pGEM® T easy vector backbone fragment at ~3kb and the insert at ~1kb. d) 
Alignment of ISL1 sequencing data to NM_002202.2, 100% homology achieved apart from 
at base 1052 where a SNP was observed A to G, final adenine nucleotide missing on 
second inspection. e) Schematic to show that the resulting SNP still produces a proline 
residue. f) Alignment of recloned ISL1 sequencing data to NM_002202.2, 100% homology 
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achieved apart from at base 1052 where a SNP was observed A to G, final adenine 
nucleotide incoroporated. g) Restriction digest with NheI and PflM1 of a mini prep from a 
colony to check that ISL1 was inserted by NheI digestion into the pCAGG-IRES-EGFP, as 
seen by the fragment at about 1.2kb with NheI digest. h) Restriction digest of a mini prep 
from a colony to check that ISL1 was inserted by NheI digestion into the pCAGG-
NOLZ1(variant)-IRES-EGFP, as seen by the PflM1 digest producing fragments of 6.7kb and 
1.1kb . i) Restriction digest of a mini prep from a colony to check that ISL1 was inserted by 
NheI digestion into pCAGG-NOLZ1-IRES-EGFP, as seen by the XmnI digest resulting in 
fragments of 7.8kb and 1.1kb and PflM1 digest of 6.7kb and 1.2kb. 
2. Subcloning of ISLET1 
ISLET1 was subcloned into the multicistronic p3x2A-pMT vector (insert:vector = 3:1) 
using NheI and checked for orientation by restriction digestion with NcoI to produce 
fragments of 2683bp and 978bp (Table 3.1 and Figure 3.5). ISLET1 and the 
multicistronic section of the vector was subcloned into the pCAGG-IRES-EGFP 
vector by SalI digestion (insert:vector = 6:1) and checked for orientation by XmnI 
digestion producing fragments of 6649bp and 1032bp (Figure 3.5e). 
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Figure 3.5: Plasmid design of pCAGG-ISL1-IRES-EGFP. a) p3x2A-ISL1 plasmid map 
highlighting important restriction enzyme sites for cloning strategy, red ringed sites 
correspond to those on the schematic in a, NcoI sites ringed in yellow at 1392 and 420 were 
used for checking ISL1 insertion orientation as seen in the gel in (b). B) NcoI digest 
producing fragments of p3x2A-ISL1 producing fragments of 2683bp and 978bp c) Schematic 
showing the insertion of ISL1 into the pCAGG-IRES-EGFP vector by SalI digestion. d) 
Plasmid map of pCAGG-ISL1-IRES-EGFP, red circles highlighting the SalI sites and XmnI 
sites ringed in yellow at 2216 and 3248 which were used for checking the orientation of ISL1 
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insertion. e) XmnI digestion of pCAGG-ISL1-IRES-EGFP to check orientation producing 
fragments of 6649bp and 1032bp 
3. Validation of ISLET1 protein expression  
Once the vector had been validated by restriction digestion, it was grown up and 
purified for transfection into HEK293 cells. The GFP expression was monitored on a 
fluorescent microscope ~24 hours post transfection (Figure 3.6a), the transfection 
efficicency was 22.9 ± 7.4% (N=1; n=3). Cells were allowed to grow for a further 24 
hours before being harvested for protein expression analysis by western blot and 
immunocytochemistry and the resulting protein expression as per Figure 3.6b. By 
western blot (Figure 3.7a) the protein was larger than the expected 39 kDa. Upon 
checking the DNA sequencing results, the final nucleotide adenine was seen to be 
missing (Figure 3.4d&f alignment). This produces a frame-shift mutation and results 
in a protein which is 368 amino acid residues and estimated at 41kDa, potentially 
explaining the larger band. This is as a result of the stop codon at the end of the 
multicistronic region being out of frame and a later stop codon being used to 
terminate translation. The primer sequence for cloning was checked and this was 
found to be the cause of the omitted nucleotide. ISLET1 protein expression was 
restricted to the nuclei (Figure 3.7b). In order to overcome the error in ISLET1, the 
gene was re-cloned with a new set of primers to reintroduce the adenine at the 3’ 
end of the ISLET1 sequence. ISLET1 was then subcloned into pCAGG-ISLET1-
IRES-EGFP, pCAGG-NOLZ1-ISLET1-IRES-EGFP and pCAGG-NOLZ1(variant)-
ISLET1-IRES-EGFP plasmids by NheI digestion removing the incorrect version of 
ISLET1 and incorporating the correct version (Figure 3.5g-i) so the protein can be 
made appropriately and be used in future transfection studies. The new ISL1 protein 
expression vector was verified by transfection into iPSC-derived neural stem cells 
(Figure 3.7b). Western blot analysis did not seem to show a difference in size 
between the old and new forms of the protein. 
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Figure 3.6: Analysis of protein expression in cells expressing pCAGG-ISL1-IRES-
EGFP and pCAGG-IRES-EGFP. HEK293 cells transfected with pCAGG-ISL1-IRES-EGFP 
or pCAGG-IRES-EGFP (control). Images were taken 24 hours later. A) Bright field shown in 
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top panels and GFP fluorescence of same field shown in bottom panels. Left 4 panels show 
ISL1 plasmid and right 2 panels show control plasmid. Transfection efficiency: 22.89% ± 
7.41. Scalebar = 50 µm. b) Immunocytochemistry at 48 hours post transfection using Abcam 
ab109517 ISL1 antibody images showing nuclei in blue and ISL1 expression in red (αRabbit 
IgG Alexa fluor 594 secondary antibody). Scale bars = 50 µm. 
 
Figure 3.7: HEK293 cells transfected with pCAGG-ISL1-IRES-EGFP and pCAGG-IRES-
EGFP a) Western blot to ISL1 on samples 48 hours post transfection showing a fragment of 
39kDa for ISL1 and the bottom panel showing β-actin expression. b) Day 16 rosettes 
transfected with ISL1 containing plasmids. Western blot to ISL1 on samples 48 hours post 
transfection showing a fragment of 39kDa for ISL1 and the bottom panel showing β-actin 
expression 
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3.5 NOLZ1 
NOLZ1 mRNA was shown to be expressed in developing striatum in the post-mitotic 
cells of the SVZ and MZ (Chang et al., 2004, Urbán et al., 2010, Ko et al., 2013) and 
has also been observed to be co-expressed with DARPP32 in rat striatum (Chang 
et al., 2004). NOLZ1 overexpression upregulated retinoic acid signalling (Urbán et 
al., 2010), which is important in the striatum as it has been shown to be required for 
the expression of DARPP32 (Liao & Liu 2005). Consequently NOLZ1 was chosen to 
be expressed in neural stem cells in an attempt to drive differentiation into MSNs in 
vitro. 
1. Cloning of NOLZ1 
Two versions of NOLZ1 were cloned, incorporating BglII sites onto the 5’ and 3’ 
ends of the genes, one from human fetal 22 week diencephalon cDNA and human 
primary fetal (Swift REF:765) cDNA, referred to as NOLZ1(variant) (Figure 3.8a-c) 
and the other version from a plasmid provided by our collaborators in Barcelona 
(J.M. Canals), referred to as NOLZ1 (full length)/NOLZ1 (Figure 3.8e-g).  
Once cloned into the pGEM® T easy vector, white colonies containing either gene 
were sent for sequencing at MWG Eurofins and were verified on NCBI Nucleotide, 
where it was found that the variant version of NOLZ1 showed 100% homology to 
BC_007494.2 which had previously been cloned from skin, melanotic melanoma 
(Strausberg et al., 2002). NOLZ1(full length) showed 100% homology to 
NM_032772.4. NOLZ1(variant) was 849bp in length making a 283 amino acid 
protein, under half the size of the full length 646 amino acid NOLZ1. NOLZ1(full 
length) contained two exons running from nucleotide 1-651 and the second from 
652-3182, the coding sequence was located from nucleotide 337-2277. The 
sequence homology of the variant to the full length version was 100% between 
nucleotides 1-729 and 1811-2542 of the gene and subsequent amino acid 
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sequence homology between 1-130 and 492-646 of the full length protein, therefore 
the variant form hasn’t resulted from exon skipping. The zinc finger domain in 
NOLZ1 is between amino acid residues 514-542 and so the variant form of NOLZ1 
contains the zinc finger domain, and also the Sp motif of the protein, but not the 
buttonhead box domain. Deletion of buttonhead box domain in the Sp1 protein led 
to a loss of activation of the LDL receptor promoter, and there was loss of stimulus 
for Sp1 DNA binding by the transcription factor; sterol regulatory binding element 
binding protein 1 (SREBP1) (Athanikar et al., 1997). Deletion of buttonhead box 
domain did not seem to affect Nlz1 self-association, HDAC binding, nuclear 
localisation of the protein nor gene repression of krox20 in the developing zebrafish 
rhombomeres, whereas deletion of Sp motif leads to a disruption of krox20 and nlz1 
gene expression in rhombomeres 3-5 of the developing zebrafish embryo (Runko & 
Sagerström 2004). Therefore the variant form of the NOLZ1 protein should be able 
to function normally. 
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Figure 3.8: Cloning of NOLZ1 (variant) and NOLZ1. a) Schematic showing insertion of 
BglII restriction sites (in red) onto the 5’ and 3’ ends of NOLZ1 and omission of a stop codon. 
b) NOLZ1 (variant) cloned from human diencephalon cDNA into pGEM® T easy and a 
positive clone confirmed by BglII digest NOLZ1(variant) insert at 849bp and pGEM® T easy 
vector backbone at ~3kb. c) Sequence alignment of NOLZ1 (variant) of the 5’ and 3’ ends. 
d) The middle section of sequence alignment of NOLZ1 (variant) aligned to the full length 
form of NOLZ1, 100% homology observed with the previously cloned version of 
NOLZ1(variant): BC_007494.2. e) Schematic showing insertion of BglII restriction sites (in 
red) onto the 5’ and 3’ ends of NOLZ1 and omission of a stop codon. f) Cloning of NOLZ1 
from pCAGG-NOLZ1 vector (Barcelona) by PCR. g) Sequence alignment of NOLZ1 of the 5’ 
and 3’ ends 100% homology observed to NM_032772.4 . 
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2. Subcloning of NOLZ1 
The NOLZ1(variant) was subcloned into the p3x2A-pMT vector (Figure 3.9) and 
p3x2A-pMT-ISLET1 (Figure 3.10) by BglII digest and orientation was checked in 
both by NcoI digestion (Table 3.1), both these inserts were then subcloned into the 
pCAGG-IRES-EGFP vector using SalI digestion and the orientation of the insert 
was checked by restriction digest with NotI for pCAGG-NOLZ1(variant)-IRES-EGFP 
(Figure 3.9e) and SmaI for pCAGG-NOLZ1(variant)-ISLET1-IRES-EGFP (Figure 
3.10g, Table 3.1). 
NOLZ1 (full length) was subcloned into the pCAGG- NOLZ1(variant)-IRES-EGFP 
(Figure 3.11a-c) and the pCAGG- NOLZ1(variant)-ISLET1-IRES-EGFP (Figure 
3.11d-f) with BglII digestion, hence removing the variant form of NOLZ1 from both 
vectors before insertion, and the orientation was checked of the full length NOLZ1 
was checked by restriction digest with NheI (Table 3.1).  
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Figure 3.9: Plasmid design of pCAGG-NOLZ1(variant)-IRES-EGFP. a) p3x2A-
NOLZ1(variant) plasmid map highlighting important restriction enzyme sites for cloning 
strategy, red ringed sites correspond to the SalI sites ringed red in (c), NcoI sites ringed in 
yellow at 420 and 1106 which were used for checking NOLZ1 insertion orientation as seen 
in the gel in (b). b) NcoI digest producing fragments of p3x2A-NOLZ1(variant) producing 
fragments of 2767bp and 686bp. c) Schematic focussed showing the insertion of 
NOLZ1(variant) into the pCAGG-IRES-EGFP vector after SalI digestion. d) Plasmid map of 
pCAGG-NOLZ1(variant)-IRES-EGFP, red circles highlighting the SalI sites as in (a) and NotI 
sites ringed in yellow at 2458 and 4157 which were used for checking the orientation of 
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NOLZ1(variant) insertion. e) NotI digestion of pCAGG-NOLZ1(variant)-IRES-EGFP to check 
orientation producing fragments of 5791bp and 1699bp. 
 
 
Figure 3.10: Plasmid design of pCAGG-NOLZ1(variant)-ISL1-IRES-EGFP a) Schematic 
to show important features of the p3x2A-ISL1 vector and where the NOLZ1(variant) is 
inserted into the BglII site showing the 2A cleavage sites and the incorporation of a final stop 
codon b) NOLZ1(variant) PCR fragment at 849bp cloned from human foetal diencephalon 
cDNA. c) p3x2A-NOLZ1(variant)-ISL1 plasmid map highlighting important restriction enzyme 
sites for cloning strategy, red ringed sites correspond to those on the schematic in (a) and 
NcoI sites ringed in yellow at 420, 1106 and 2246 which were used for checking NOLZ1 
insertion orientation as seen in the gel in d) NcoI digest producing fragments of p3x2A-
NOLZ1(variant)-ISL1 producing fragments of 2680bp, 1140bp and 686bp e) Schematic 
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showing the insertion of NOLZ1(variant)-ISL1 into the pCAGG-IRES-EGFP vector after SalI 
digestion f) Plasmid map of pCAGG-NOLZ1(variant)-ISL1-IRES-EGFP, red circles 
highlighting the SalI sites as in (a) and SmaI sites ringed in yellow at 2391 and 3881 used for 
checking the orientation of NOLZ1(variant)-ISL1 insertion. g) SmaI digestion of pCAGG-
NOLZ1(variant)-ISL1-IRES-EGFP to check orientation producing fragments of 7043bp and 
1490bp 
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Figure 3.11: Plasmid design of pCAGG-NOLZ1-IRES-EGFP and pCAGG-NOLZ1-ISL1-
IRES-EGFP. a) Schematic showing the insertion of NOLZ1 into the pCAGG-IRES-EGFP 
vector after removal by BglII digestion of NOLZ1(variant). b) Plasmid map of pCAGG-
NOLZ1-IRES-EGFP, red circles highlighting the SalI sites as in (a) and NheI sites ringed in 
yellow at 3163 and 3898 used for checking the orientation of NOLZ1 insertion. c) NheI 
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digestion of pCAGG-NOLZ1-IRES-EGFP to check orientation producing fragments of 
7841bp and 735bp. d) Schematic showing the insertion of NOLZ1 into the pCAGG-ISL1-
IRES-EGFP vector after removal by BglII digestion of NOLZ1(variant). e) Plasmid map of 
pCAGG-NOLZ1-ISL1-IRES-EGFP, red circles highlighting the SalI sites as in (a) and NheI 
sites ringed in yellow at 3163, 3898 and 4951 which were used for checking the orientation 
of NOLZ1 insertion. f) NheI digestion of pCAGG-NOLZ1-ISL1-IRES-EGFP to check 
orientation producing fragments of 7841bp, 1046bp and 735bp 
 
3. Validation of NOLZ1 protein expression  
Once the orientation of the inserts in the pCAGG-IRES-EGFP vector were 
confirmed by digestion, the 4 vectors were then transiently transfected into HEK293 
cells and subsequently observed under a fluorescent microscope at 24 hours post 
transfection to detect expression of the GFP from the expression plasmid, the 
transfection efficiency for the plasmids was NOLZ1: 41.5 ± 0.76% (N=1; n=2), 
NOLZ1(variant): 28.1 ± 2.29% (N=1; n=3) (Figure 3.12). The cells were then 
harvested 48 hours post transfection and processed for immunocytochemistry and 
western blot. There was not a commercially available antibody which will recognise 
the variant form of NOLZ1. Thus, this protein could only be detected using the 2A 
peptide tag, which shows nuclear staining (Figure 3.13a). Full length NOLZ1 was 
detected by western blot (Figure 3.13b at ~65kDa). 
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Figure 3.12: pCAGG-NOLZ1(variant)-IRES-EGFP, pCAGG-NOLZ1-IRES-EGFP, pCAGG-
IRES EGFP control and sham transfected HEK293 cells 24 hours post transfection. 
Images of bright field in 1
st
 and 3r4d column and GFP fluorescence in the 2
nd
 and 4
th
 
columns. Transfection efficiency: NOLZ1 (variant): 28.12% ± 2.29 control:  4.07% ±1.28. 
NOLZ1: 41.5% ± 0.76 control: 49.08% ± 17.85  Scalebar = 50 µm 
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Figure 3.13: Analysis of protein expression in cells transfected with pCAGG-
NOLZ1(variant)-IRES-EGFP, pCAGG-NOLZ1-IRES-EGFP and pCAGG-IRES-EGFP. a) 
Immunocytochemistry using Millipore ABS31 anti-2A antibody images showing nuclei in blue 
and 2A tagged NOLZ1(variant) expression in red (αRabbit IgG Alexa fluor 594 secondary 
antibody). Left panels show nuclei, middle panels show 2A peptide expression and the right 
panels show the merge images. Upper 3 panels show Nolz1(variant plasmid, lower 3 panels 
show control plasmid. Scale bar = 50 µm b) Protein was harvested 48 hours post 
transfection for western blot with NOLZ1 antibody showing a fragment of ~62kDa for full 
length NOLZ1 and the bottom panel showing β-actin expression as loading control. 
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3.6 FOXP1 
FOXP1 was chosen to be used in this study due to its expression in the developing 
striatum (Ferland et al., 2003, Shu et al., 2001, Tamura et al., 2003), with over two-
thirds of MSNs expressing this transcription factor (Tamura et al., 2004). 
Furthermore, Foxp1 overexpression, in mouse striatal cells, has been demonstrated 
to increase the expression of striatally enriched genes (Tang et al., 2012). FOXP1 
was also shown to regulate retinoic acid signalling in the spinal cord (Rousso et al., 
2008) and could be important for the same function in the striatum, as retinoic acid 
signalling was shown to be required for the induction of DARPP32 expression (Liao 
& Liu 2005). 
1. Cloning of FOXP1 
FOXP1 was cloned (Figure 3.14) from a plasmid clone ID:HsCD00297105 
(PlasmID), incorporating BamHI restriction sites onto the 5’ and 3’ ends of the gene 
(Figure 3.14a&b). BamHI restriction enzyme sites were chosen to insert FOXP1 as 
the coding sequence contains BglII & NheI restriction sites and therefore would 
have been unsuitable to use BglII or NheI sites to insert FOXP1 into the 
multicistronic plasmid. FOXP1 was ligated into the pGEM® T easy vector and 
colonies were screened for the FOXP1 insert by BamHI digestion (Figure 3.14c). 
Positive clones were sent for sequencing at MWG Eurofins (Figure 3.14d and 
Appendix for alignment) and checked against NCBI Nucleotide database. The 
cloned FOXP1 showed 100% homology to Homo sapiens FOXP1 transcript variant 
1 (NM_032682.5). 
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Figure 3.14: Cloning of FOXP1. a) Schematic showing PCR primers incorporation of 
BamHI sites (in red) onto the 5’ and 3’ ends of FOXP1 and removing the stop codon. b) 
FOXP1 was cloned from Plasmid Harvard vector: HsCD00297105 by high fidelity PCR. The 
fragment was extracted and ligated into pGEM® T easy cloning vector, colonies were 
screened by utilising blue/white selection as a result of the lacZ gene in the cloning vector. c) 
Restriction digest of a mini prep from a white colony to check that FOXP1 was inserted by 
BamHI digestion, as seen by the pGEM® T easy vector backbone fragment at ~3kb and the 
insert at ~2kb. d) Alignment of FOXP1 sequencing data to NM_032682.5 100% homology. 
e) Schematic to show important features of the p3x2A-NOLZ1(variant)-ISL1 vector and 
where the FOXP1 is inserted into the BamHI site showing the 2A cleavage sites and the 
incorporation of a final stop codon. f) p3x2A-FOXP1-NOLZ1(variant)-ISL1 plasmid map 
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highlighting important restriction enzyme sites for cloning strategy, red ringed sites 
correspond to those on the schematic in (a) and EcoRI sites ringed in yellow at 392 and 
2071 which were used for checking FOXP1 insertion orientation as seen in the gel in (g). G) 
EcoRI digestion of p3x2A-FOXP1-NOLZ1(variant)-ISL1 producing fragments of 4884bp and 
1679bp 
 
2. Subcloning of FOXP1 
Subcloning of FOXP1 into the p3x2A-pMT vector (Figure 3.14e-g) was performed 
by restriction digest with BamHI, ligated into the p3x2A-pMT vector and then the 
orientation of the insert checked by restriction digest with EcoRI to produce 
frangments of 2986bp and 1679bp (Table 3.1 and Figure 3.14g). Subsequent 
subcloning of FOXP1 into the pCAGG-IRES-EGFP vector was unsuccessful. 
However, FOXP1 was successfully subcloned into the p3x2A-pMT-NOLZ1(variant)-
ISLET1 plasmid. This was done by digestion of FOXP1 and of p3x2A-pMT-
NOLZ1(variant)-ISLET1 plasmid by BamHI (Figure 3.15) and then ligated together, 
the orientation was checked by EcoRI digestion to produce fragments of 4884bp 
and 1679bp. The insert of FOXP1-NOLZ1(variant)-ISLET1 was removed from the 
plasmid and the pCAGG-IRES-EGFP plasmid linearised by SalI digestion and 
subsequently ligated together. The resulting clones were checked for orientation by 
SmaI digestion to produce fragments of 7082bp, 2018bp and 1490bp (Figure 3.15c 
& Table 3.1).  
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Figure 3.15: Plasmid design for pCAGG-FOXP1-NOLZ1(variant)-ISL1-IRES-EGFP a) 
Schematic showing the insertion of FOXP1-NOLZ1(variant)-ISL1 into the pCAGG-IRES-
EGFP vector by SalI digestion. b) Plasmid map of pCAGG-FOXP1-NOLZ1(variant)-ISL1-
IRES-EGFP, red circles highlighting the SalI sites and SmaI sites ringed in yellow at 2430, 
4448 and 5938 which were used for checking the orientation of FOXP1-NOLZ1(variant)-ISL1 
insertion. c) SmaI digestion of pCAGG-FOXP1-NOLZ1(variant)-ISL1-IRES-EGFP to check 
orientation of the insert producing fragments of 7082bp,  2018bp and 1490bp 
 
3. Validation of FOXP1 & ISLET1 protein expression  
The pCAGG-FOXP1-NOLZ1(variant)-ISLET1-IRES-EGFP plasmid was then 
transfected into HEK293 cells, transfection efficiency was determined at 24 hours 
post transfection (Figure 3.17a), which was 14.5 ± 6% (N=1; n=2). Cells were 
harvested for protein analysis at 48 hours post transfection. Immunocytochemistry 
of the HEK293 cells (Figure 3.16) shows FOXP1 and ISLET1 to be expressed in a 
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small number of cell nuclei corresponding with the low transfection efficiency (Figure 
3.17a). Western blot analysis showed FOXP1 protein at ~53kDa and 80kDa to be 
expressed in both the empty vector and pCAGG-FOXP1-NOLZ1(variant)-ISLET1-
IRES-EGFP vector transfection (Figure 3.17b), expression of ISLET1 protein was 
observed at ~39kDa. This means that HEK293 cells seem to express FOXP1 and 
ISLET1, however, in the case of FOXP1, this could be non-specific binding of the 
antibody as there is cytoplasmic staining in the empty plasmid control transfection 
(Figure 3.16). ISLET1 expression is lower in the empty plasmid control transfection 
by western blot and so the ISLET1 plasmid is increasing the levels of ISLET1 
expression after transfection. 
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Figure 3.16: Analysis of protein expression of neural stem cells transfected with 
pCAGG-FOXP1-NOLZ1(variant)-ISL1-IRES-EGFP and pCAGG-IRES-EGFP. 
Immunocytochemistry for FOXP1 and ISL1 were performed 48 hours post transfection. Top 
2 panels show expression of FOXP1 in the control plasmid (top panel) and FOXP1-
NOLZ1(variant)-ISL1 plasmid (second panel). The bottom two panels show ISL1 expression 
in the sham transfected (third panel) and FOXP1-NOLZ1(variant)-ISL1 plasmid (bottom 
panel). Nuclei are stained blue and FOXP1 and ISL1 are stained red. Scalebar = 50 µm 
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Figure 3.17: HEK293 cells transfected with pCAGG-FOXP1-NOLZ1(variant)-ISL1-IRES-
EGFP and pCAGG-IRES-EGFP. a) Images of bright field (left panel) and GFP fluorescence 
of the same field (right panel) at 24 hours post transfection. Transfection efficiency: 14.52% 
± 6.06 Scalebar = 50 µm. b) Protein from HEK293 cells transfected with pCAGG-FOXP1-
NOLZ1(variant)-ISL1-IRES-EGFP and pCAGG-IRES-EGFP harvested 48 hours post 
transfection western blot for FOXP1 (top panel) showing fragments at ~53kDa and ~80kDa, 
western blot for ISL1 (middle panel) showing a fragment of ~39kDa for ISL1 and loading 
control β-actin (bottom panel) ~42kDa 
 
3.7 OCT6 
OCT6 was chosen as one of the candidate genes for expression in neural stem 
cells to drive differentiation in to MSNs because OCT6 expression has been 
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detected in the developing striatum localised to the SVZ and MZ of the LGE (Suzuki 
et al., 1990, Garel et al., 1999, Alvarez-Bolado et al., 1995, Frantz et al., 1994). 
When Oct6 was replaced with POU family member, Brn2, forebrain development 
was severely affected producing severe forebrain truncation (Wolf et al., 2009). 
Oct6 expression, in the striatum, was down regulated several weeks after birth (Ilia 
et al., 2003a).  
1. Cloning of OCT6 
OCT6 was cloned from another plasmid, clone ID: HsCD00082889 (PlasmID), but 
unlike the rest of the genes, it was unable to be cloned as the full gene (possibly 
due to formation of primer dimer during PCR being more favourable to binding the 
template DNA). Therefore, primers were designed to clone the gene in two parts 
and then ligate them back together (Figure 3.18). The primers for the 5’ and 3’ ends 
of OCT6 coding sequence incorporated BamHI restriction enzyme sites, the other 
primers were designed to bind midway through the gene itself, with an overlapping 
sequences (Figure 3.19d). The two sections of the gene named; OCT6-5’ (855bp) 
and OCT6-3’ (504bp), were cloned by PCR into the pGEM® T easy vector (Figure 
3.19b&c) and white colonies were sent for sequencing at MWG Eurofins, the 
sequence was verified using NCBI Nucleotide. The start, end and overlap 
alignments as per Figure 3.19d, the full sequence alignment is in the appendix, the 
sequence was 100% homologous to Homo sapiens POU3F1 NM_002699.3.  
After this, the mid-section of the gene was digested out of the original plasmid using 
naturally occurring restriction enzyme sites NcoI and SphI (Figure 3.18) and ligated 
into the 3’ end of the gene in the pGEM® T easy vector by cutting with the same 
enzymes. The 5’ section of OCT6 was then digested and ligated into the pGEM® T 
easy-OCT6 middle & 3’section vector using XmnI and NarI restriction enzymes 
(Figure 3.18b), the full gene was checked for size by EcoRI digest (Figure 3.18c).  
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Figure 3.18: OCT6 cloning diagram. A) Both the 5’ and 3’ ends are cloned by PCR to 
incorporate a BamHI restriction site at each end of the gene. These are cloned into pGEM
® 
T 
easy vectors. The middle section of OCT6 is then digested out of the original pENTR223.1 
vector with SphI and NcoI, this is then inserted into the pGEM
® 
T easy OCT6-3’ end vector 
which has been cut with the same restriction enzymes. Finally the 5’ end of OCT6 is cut out 
of the pGEM
 ® 
Teasy vector with XmnI & NarI restriction enzymes, the pGEM
® 
T Easy OCT6 
middle & 3’ vector is cut with the same enzymes and ligated together. B) Subcloning of 
middle section of OCT6 by digest with NcoI and SphI into pGEM
® 
T easy-OCT6-3’ vector 
checked for insertion with EcoRI. c) Subcloning of OCT6 5’ into pGEM
® 
T easyOCT6-
middle&3’ end vector using XmnI and NarI and checked with EcoRI. 
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Figure 3.19: Cloning of OCT6. a) Schematic showing PCR primers incorporation of BamHI 
sites (in red) onto the 5’ and 3’ ends of OCT6 and removing the stop codon. b) OCT6 5’ and 
3’ sections were cloned from PlasmID vector: HsCD00082889 by high fidelity PCR. The 
fragments were extracted and ligated into pGEM
® 
T easy cloning vector, colonies were 
screened by utilising blue/white selection as a result of the lacZ gene in the cloning vector. c) 
Restriction digest of a mini prep from white colonies to check that OCT6 5’ and 3’ sections 
were inserted by EcoRI digestion, as seen by the pGEM
® 
T easy vector backbone fragment 
at ~3kb and the insert at 855bp (for 5’ section) and 504bp (for 3’ section). d) Alignment of 
OCT6 5’ and 3’ sequencing data to NM_002699.3 shows 100% homology.  
 
2. Subcloning of OCT6 
OCT6 was subcloned into the p3x2A-pMT vector using BamHI and checked for 
orientation with NcoI to produce fragments of 2731bp, 1221bp and 12bp (Table 3.1 
and Figure 3.20). Then the OCT6 gene and rest of the multicistronic section of 
p3x2A-pMT plasmid was subcloned into the pCAGG-IRES-EGFP plasmid using SalI 
(Figure 3.20c) and checked for orientation using restriction digest with SmaI to 
produce fragments of 6870bp, 863bp, 201bp and 59bp (Table 3.1 & Figure 3.20e). 
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Figure 3.20: Plasmid design of pCAGG-OCT6-IRES-EGFP. a) p3x2A-OCT6 plasmid map 
highlighting important restriction enzyme sites for cloning strategy, red ringed sites are SalI 
sites and NcoI sites ringed in yellow at 420, 432 and 1653 were used for checking OCT6 
insertion orientation as seen in the gel in (b). B) NcoI digest of p3x2A-OCT6 producing 
fragments of 2731bp and 1221bp (12bp unable to be detected). c) Schematic showing the 
insertion of OCT6 into the pCAGG-IRES-EGFP vector by SalI digestion. d) Plasmid map of 
pCAGG-OCT6-IRES-EGFP, red circles highlighting the SalI sites and SmaI sites ringed in 
yellow at 2218, 2277, 2478 and 3339 used for checking the orientation of OCT6 insertion. e) 
Digestion of pCAGG-OCT6-IRES-EGFP to check orientation producing fragments of  6,870 
bp  861 bp  (201 bp & 59 bp unable to be detected but unaltered between OCT6 orientation). 
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3. Validation of OCT6 protein expression  
Once the orientation of OCT6 insert was verified, the protein expression from the 
plasmid was determined by transfection of the pCAGG-OCT6-IRES-EGFP into 
HEK293 cells. GFP expression was monitored at 24 hours post transfection and 
protein analysis, using immunocytochemistry and western blot, was carried out at 
48 hours. Although the GFP expression at 24 hours, 19.7 ± 9.43% (N=1; n=3), 
(Figure 3.21a) was lost in the process of fixing and subsequent 
immunocytochemistry, there are a number of cells which show OCT6 protein 
expression (Figure 3.21b). The western blot for OCT6 (Figure 3.22) has showed 
several bands, two of which could be considered possibilities for being OCT6 as 
they have a higher level of expression and are not present in the empty plasmid 
control. However, neither is at the expected size of 45 kDa. It is noteworthy that the 
Abcam literature shows that the antibody detects a protein at 50 kDa but that this 
needs to be optimised, as protein bands are observed at ~42 kDa and ~58 kDa. 
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Figure 3.21: Analysis of protein expression of HEK293 cells transfected with pCAGG-
OCT6-IRES-EGFP and pCAGG-IRES-EGFP. a) Images of bright field shown in top panel 
and GFP fluorescence for the same field in bottom panel, left panel shows control plasmid 
and right two panel show OCT6 plasmid at 24 hours post transfection. Transfection 
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efficiency: 19.71% ± 9.43 Scalebar = 50 µm. b) Immunocytochemistry of HEK293 cells 48 
hours after transfection with pCAGG-OCT6-IRES-EGFP (top 2 panels) and sham 
transfected control (bottom panel). OCT6 expression in red, nuclei stained blue. Scalebar = 
50 µm 
 
 
 
Figure 3.22: HEK293 cells transfected with pCAGG-OCT6-IRES-EGFP. Cells were 
harvested 48 hours post transfection. Top panel western blot with OCT6 antibody showing a 
fragment of ~57kDa and ~42kDa specific to OCT6 transfected cells and the bottom panel 
showing equal β-actin expression, as a loading control. 
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3.8 Conclusions 
Single transcription factor plasmids Multiple transcription factor plasmids 
EBF1 NOLZ1-ISL1 
ISL1 NOLZ1(variant)-ISL1 
NOLZ1 FOXP1-NOLZ1(variant)-ISL1 
NOLZ1 (variant)  
OCT6  
Table 3.2 Summary table of transcription factors and their combinations available for 
transfection in to neural stem cells 
 
The plasmids (Table 3.2) have been validated by: 
i) Sequencing of each of the cloned genes using primers in the cloning 
plasmid and primers designed to sequence from within the transcription 
factor 
ii) Confirming the orientation of the inserted gene by restriction digestions  
iii) Confirming the proteins: expression of GFP and each of the specific 
transcription factors by immunocytochemistry or western blot or both.  
3.8.1 The transcription factors 
Which transcription factors were selected and then cloned were determined by their 
biology, particularly their documented importance during striatal development in 
vivo. Thus, EBF1 and OCT6 are expressed in the developing LGE SVZ and MZ, 
(Garel et al., 1997, Suzuki et al., 1990, Garel et al., 1999, Alvarez-Bolado et al., 
1995, Frantz et al., 1994); the Ebf1 knockout mouse shows a defect of SVZ to MZ 
transition (Garel et al., 1999). ISL1 has also been shown to be an important 
transcription factor in the development of the LGE and striatum (Wang & Liu 2001, 
Long et al., 2009, Stenman et al., 2003) and more specifically the striatonigral 
pathway (Lu et al., 2014, Ehrman et al., 2013). NOLZ1 seems to activate indirectly 
downstream expression of DARPP32 via its action on RARβ (Liao & Liu 2005, 
Urbán et al., 2010) and is therefore likely to be an important transcription factor of 
MSN development. Here, a variant form of NOLZ1 was cloned from the human 
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WGE and diencephalon, which had only been previously cloned from a skin 
melanotic melanoma (Strausberg et al., 2002). This was an interesting discovery 
which suggested that variant forms of NOLZ1 protein might be expressed 
differentially in different regions during development and postnatally. As the full 
length form of NOLZ1 could not be cloned successfully from human WGE or 
diencephalon cDNA, this particular short variant form may be the version which is 
expressed in the WGE in vivo early in striatal development. FOXP1 was cloned and 
expressed in a plasmid with NOLZ1 (variant) and ISL1 as it was unable to be sub-
cloned into the plasmid as a singular transcription factor. FOXP1 is important during 
MSN development and is expressed in two-thirds of MSNs (Tamura et al., 2004) 
and up-regulates the expression of striatally enriched genes (Tang et al., 2012).  
3.8.2 Plasmid design features 
The use of the multicistronic p3x2A-pMT plasmid has allowed the expression of 
multiple transcription factors in HEK293 cells in order to validate their protein 
expression. The use of the 2A peptide has allowed the expression of multiple 
transcription factors, all in an equal amount. The 2A peptide allows the separation of 
the transcription factors during translation by self-cleavage (de Felipe 2004). This 
has allowed exploitation of the highly efficient CAGG promoter (Miyazaki et al., 
1989) for the equal expression of up to three genes (in the case of FOXP1-
NOLZ1(variant)-ISL1 plasmid) from one promoter within a single plasmid.  
With the GFP being expressed downstream of an IRES, the levels of expression of 
the GFP (as a reporter of transfection efficiency) will be up to 50% lower than the 
level of expression of the transcription factors themselves (Mizuguchi et al., 2000). 
This means that any determination of transfection efficiency using GFP will most 
likely underestimate the transfection efficiency and levels of the transcription factors 
themselves. With only up to three of the four insertion sites being utilised for the 
expression of transcription factors in the multicistronic plasmid, the GFP could 
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possibly be inserted into the final restriction site, which is XbaI, in order to gain a 
more accurate, live readout of transcription factor expression. However, this was not 
possible with the current pCAGG-IRES-EGFP plasmid, as there are two extra XbaI 
sites in the plasmid, therefore XbaI restriction digestion would lead to the 
disintegration of the plasmid. However, such a strategy would be made possible by 
employing the p3x2A-pMT multicistronic plasmid. Other sites in the plasmid, 
including BglII (where NOLZ1/NOLZ1(variant) were inserted) and NheI (where 
EBF1/ISL1 were inserted) could be utilised for insertion of other transcription factors 
of interest, either for MSN development or perhaps to drive cortical neuronal 
differentiation; the resulting neurons could be used in co-culture with the developing 
iPS-MSN neurons, since co-culture with other neuronal types has been shown to be 
beneficial for specification and maturation (Penrod et al., 2011, Segal et al., 2003). 
The GFP in the plasmid could be switched for an alternate fluorescent protein colour 
and therefore allow identity of the separate populations, but selection for both with 
G418 due to the neomycin resistance.. 
The transfection efficiency was variable between the plasmids, and was relatively 
poor in some cases, meaning that the percentage of cells expressing the 
transcription factors will be always limited by this low efficiency. In the future, and 
beyond the scope of this study, the use of viruses to infect neuroprogenitors with the 
transcription factor constructs would ultimately result in a higher percentage of 
positively expressing cells and neurons.  
However, in the following chapters, the neomycin resistance gene in the pCAGG-
IRES-EGFP plasmid backbone was exploited as a way to obtain a more pure 
population of cells by G418 treatment of the cells post-transfection. These plasmids 
were transfected into neural progenitors derived from iPS cells, in order to drive 
differentiation into medium spiny neurones. Firstly, an initial screen of plasmids was 
performed in order to narrow down the number of plasmids to be used for full 
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analysis. This involved transfection of the neural stem cells with the plasmids and 
subsequent analysis of DARPP32 protein expression, a protein enriched in MSNs 
(Ouimet et al., 1984). 
3.8.3 Limitations of the methods 
In order to validate the expression of the protein, the methods of 
immunofluoresence and western blotting were used. The limitations of these 
methods mean they need to be used in conjunction as both size of protein and the 
nuclear localisation of the transcription factor have to be shown. The problem with 
western blotting with the low transfection efficiencies means that protein expression 
of the transcription factors was harder to visualise, therefore the 
immunofluorescence validation of the protein was more likely to show protein 
expression. Separation of the proteins was observed by cleavage of the 2A peptide 
tag, for example, in the case of NOLZ1-ISL1 transfections and so the 2A self-
cleaving peptides worked in the system employed herein. 
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4. Protein characterisation of differentiation 
protocol
 
Figure 4.0: Summary of the data in chapter 4. In this chapter, is the characterisation of 
the SCM1/2 differentiation protocol, which was subsequently used for further protein 
characterisation of neurons that have been transfected with NOLZ1, ISL1 or NOLZ1-ISL1 
combined. 
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4.1 Introduction 
In order to produce functionally mature neurons, our lab generated a new protocol 
for differentiation of neural stem cells into mature neurons. However, the neurons 
were not specified to be a certain neuronal subtype, but the precursors have been 
patterned to be ventral forebrain-like. The medium has been formulated based on 
several previous papers, to include several compounds with specific roles; firstly N-
[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a Notch 
signalling inhibitor targeting γ-secretase, a molecule that delays G1/S phase 
transition in the cell cycle, caused cell cycle exit, committing cells to neurogenesis 
(Borghese et al., 2010). Cell cycle arrest has also been targeted by the compound 
PD 0332991, a cyclin dependent kinase 4 & 6 inhibitor which arrests the cell cycle 
at G1 (Fry et al., 2004, Toogood et al., 2005). A compound added in order to 
promote neuronal maturation was forskolin (an adenylate cyclase activator); this 
compound activates presynaptic release of neurotransmitters and increases the 
frequency of spontaneous mini EPSCs (Robbe et al, 2001; Chen and Regehr, 1997; 
Chavez-Noriega and Stevens, 1994). Foskolin also induces the phosphorylation of 
methyl CpG binding protein 2 (MeCP2) in vivo which, in vitro induces 
phosphorylation of the protein kinase A target, CREB at Ser133 (Hutchinson et al., 
2012). The medium also contains brain-derived neurotrophic factor (BDNF), which 
in combination with phosphorylated CREB has been postulated to induce DARPP32 
expression in medium spiny neurons (Keilani et al., 2012). A recent study has also 
shown that the addition of Ca2+ and γ-amino butyric acid (GABA, a neurotransmitter) 
mimics the effects of culturing with astrocyte conditioned medium by maturing 
neurons, so that they fire spontaneous action potentials and the resting membrane 
potential is decreased significantly (Rushton et al., 2013).  
The new protocol mostly aimed to improve maturation, whereas for specification to 
MSNs, utilising the method of forced transcription factor expression (as per Section 
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1.7). As part of the new protocol, the validation of expression of mature neuronal 
proteins and synaptic markers was carried out. This has been further extended to 
be utilised in conjunction with the transcription factor transfection of 8 different 
plasmids plus the empty plasmid control in order to try and improve levels of 
DARPP32 expression in the neurons, 4 weeks post transfection. Once these were 
analysed, the transcription factors which improved the proportion of DARPP32 
expression, were further analysed for protein expression which are observed in 
MSNs. 
4.2 Immunofluorescence of differentiation 
The new protocol for differentiation was validated for making mature neurons. This 
was done by immunofluorescence in order to analyse the expression of MAP2 (a 
mature neuronal marker), S100β (an astrocyte marker), synaptophysin and PSD95 
(pre- and post-synaptic proteins, respectively) and doublecortin (an early marker of 
neurogenesis, usually expressed for approximately 2 weeks of differentiation). 
Cells were differentiated for 16 days to form forebrain specified neural progenitors, 
these were plated for differentiation following the SCM protocol and were harvested 
for immunofluorescence at fixed time points over the following 20 days in order to 
characterise the cell expression of the immature neurogenesis protein; doublecortin, 
the mature neuronal protein; MAP2, the astrocyte marker; S100β and the synaptic 
proteins; synaptophysin and PSD95. 
4.2.1 Doublecortin expression 
Immunofluorescence for doublecortin was performed throughout from day 18 of the 
experiment. The percentage of cells that expressed doublecortin is approximately 
90% at day 18 (Figure 4.1) as expected, indicating these cells were undergoing 
neurogenesis. The level of expression of doublecortin remained at a similar level 
throughout differentiation. 
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Figure 4.1: Doublecortin expression during differentiation of 34D6 iPS from day 18 to 
day 36 of neuronal differentiation. iPS cells were differentiated to neural progenitors for 16 
days, then plated as progenitors for neuronal differentiation. Cells were fixed at the time 
points indicated (every 3-5 days) and immunofluorescence performed for doublecortin (DCX) 
using goat DCX (1:100 sc8066) in block overnight @ 4
o
C. Scale bar = 20 µm N=3; n=9 
4.2.2 MAP2/S100β expression 
Immunofluorescence for both MAP2 and S100β were performed throughout from 
day 18 of the experiment. As shown in Figure 4.2 and 4.3, the majority of cells 
expressed MAP2 (Figure 4.2). The numbers of MAP2+ cells steadily increased 
during differentiation and reached 89.9% ± 3.05 by day 36 (Mean ± SEM across 
N=3; n=9), the proportion of S100β+ cells was 2.60% ± 2.43 at day 36 (N=3; n=9). 
This suggests that the population of cells generated was neuronal and contained 
few astrocytes. 
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Figure 4.2: MAP2 and S100β expression during differentiation of 34D6 iPS from day 18 
to day 36 of neuronal differentiation. iPS cells were differentiated to neural progenitors for 
16 days, then plated as progenitors for neuronal differentiation. Cells were fixed at the time 
points indicated (every 3-5 days) and immunofluorescence performed for MAP2 using rabbit 
α MAP2 (1:500) and S100β using mouse α S100β (1:500 S2532) in block overnight @ 4
o
C. 
Scale bar = 20 µm N=3; n=9 
4.2.3 MAP2/synaptophysin expression 
Immunofluorescence for both MAP2 and synaptophysin were performed from day 
18 of the experiment and are shown in Figure 4.3. As per Figure 4.2, the majority of 
cells expressed MAP2 and the levels of expression of synaptophysin steadily 
increased throughout the differentiation, peaking at around day 27/28. This co-
staining was performed in order to determine localisation of synaptophysin to the 
axons, due to the punctate nature of the staining, making sure that it stained the 
cells and was not background staining. The localisation of synaptophysin to the 
axons was apparent from the staining, and highlights the formation of presynaptic 
terminals through the length of the axon. Co-staining with PSD-95 confirmed both 
pre- and post-synaptic boutons are developing, indicating the formation of functional 
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synapses (Figure 4.4 and 4.5). 
 
Figure 4.3: MAP2 & synaptophysin expression during differentiation of 34D6 iPS from 
day 18 to day 36 of neuronal differentiation. iPS cells were differentiated to neural 
progenitors for 16 days, then plated as progenitors for neuronal differentiation. Cells were 
fixed at the time points indicated (every 3-5 days) and immunofluorescence performed for 
rabbit α MAP2 (1:500 ab32454), mouse α synaptophysin (1:200 ab8049) in block overnight 
@ 4
o
C. Scale bar = 20 µm N=3; n=9 
 
4.2.4 PSD95/Synaptophysin expression 
Co-localisation of PSD95 and synaptophysin was determined throughout the time 
course of the experiment, using immunofluorescence (Figure 4.4). As seen above 
(Figure 4.3), the levels of expression of synaptophysin steadily increased 
throughout the differentiation, and peaked at around day 27/28. The localisation of 
PSD95 started in the cell bodies at day 21 where it appeared to remain throughout 
differentiation. However, there was evidence of axonal staining at day 27/28, 
coinciding with the peak expression of synaptophysin. Confocal microscopy images 
of day 31 cells can be seen in Figure 4.5. These were taken in order to confirm the 
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co-registration of synaptophysin and PSD95, which can be clearly observed 
(indicated by the white arrows) these data suggest that the differentiating iPSCs are 
beginning to form synapses by 27/28 DIV. 
 
Figure 4.4: Synaptophysin & PSD95 expression during differentiation of 34D6 iPS 
from day 18 to day 36 of neuronal differentiation. iPS cells were differentiated to neural 
progenitors for 16 days, then plated as progenitors for neuronal differentiation. Cells were 
fixed at the time points indicated (every 3-5 days) and immunofluorescence performed for 
rabbit α PSD95 (1:100 ab18258), mouse α synaptophysin (1:200 ab8049) in block overnight 
@ 4
o
C. Scale bar = 20 µm N=3; n=9 
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Figure 4.5: Confocal images of immunofluorescence of synaptophysin and PSD95 on 
34D6 iPS derived neurons, 31 days post neuronal induction. The co-localisation of 
synaptophysin and PSD95 puncta can be observed. Rabbit α PSD 95 (1:100 ab18258) in 
red, mouse α Synaptophysin (1:200 ab8049) in green, blue nuclei. Arrows  indicate areas 
where co-localisation of synaptophysin and PSD95 are seen and therefore indicating 
possible synapses 
4.3 Initial transfection of the 9 plasmids for driven differentiation 
of neural stem cells 
In order to select transcription factor vectors for detailed analysis their ability to 
differentiate neural progenitors into MSNs was tested by transfecting each of the 9 
plasmids described in Chapter 3 into day 16 neural progenitors. At 1 day post 
transfection, the transfection expression/efficiency of each plasmid was determined 
by GFP expression (Figure 4.6 for example pictures and transfection efficiencies). 
The transfection efficiencies varied depending on the plasmid used. The plasmids 
which produced the higher transfection efficiencies were CAG- (24.9% ± 1.70 N=3; 
n=9), ISL1 (22.8% ± 0.70 N=3; n=9), NOLZ1 (variant) (22.5% ± 2.66 N=3; n=9) and 
NOLZ1(variant)-ISL1 (19.1% ± 1.79 N=2; n=6). Lower transfection efficiencies were 
observed for NOLZ1-ISL1 (11.0% ± 3.55 N=3; n=9), OCT6 (10.9% ± 2.15 N=3; 
n=9), FOXP1-NOLZ1(variant)-ISL1 (10.9% ± 1.24 N=3; n=9), EBF1 (8.57% ± 2.41 
N=3;n=9), with the lowest efficiency observed for NOLZ1 transfected cells (5.96% ± 
4. Protein characterisation of differentiation protocol 
 
 
- 145 - 
2.21 N=3;n=9). The cells were differentiated in the SCM1/2 media until 4 weeks 
post transfection, when the cells were fixed for DARPP32 immunofluorescence.  
 
Figure 4.6: GFP expression in 34D6 D17 cells 1 day post transfection. Transfections 
were performed on 34D6 iPS derived day 16 neural progenitors with the pCAGG-
Transcription Factor-IRES-EGFP plasmid, using nucleofection. These cells were then 
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imaged 1 day post transfection in order to determine the transfection efficiency. A) Example 
images of the brightfield and FITC channel of cells 1 day post transfection with each of the 9 
plasmids. These images were used in order to calculate the transfection efficiencies of the 
individual plasmids, scale bars = 50 µm. B) Mean transfection efficiencies generated by 
counting the number of GFP
+
 cells compared to total number of cells. The efficiencies were 
calculated by counting cells in at least 3 fields of view were captured per transfection per 
biological replicate (N), N=2;n=6 where * otherwise N=3;n=9. Mean ± SEM across each field 
of view. 
  
The percentage of DARPP32 expressing cells resulting from each plasmid 
transfection was determined (Figure 4.7 for example images). The expression 
efficiency of the plasmids and the percentage of DARPP32 expression for each of 
the plasmids can be seen in Figure 4.8a and 4.8b, respectively. The transfection 
efficiency varied between the plasmids and as the levels of GFP were unable to be 
determined at the 4 week time point for all the plasmids, transfection efficiency at 
the beginning of the experiment was used to determine efficiency of DARPP32 
induction. The percentage of DARPP32 expression in control cultures transfected 
with empty vector was 14.62% ± 2.59% (N=3; n=9) which was comparable to 
previous studies of differentiated hPSCs (Zhang et al., 2010, El-Akabawy et al., 
2011, Delli Carri et al., 2013a&b, Aubry et al., 2008, Shin et al., 2012). Cultures 
transfected with the NOLZ1(variant)-ISL1 plasmid had a higher percentage of 
DARPP32 expressing neurons than those with empty vector at 18.7% ± 3.33% 
(N=2; n=8). The remaining transcription factors did not produce a cell population 
expressing DARPP32 in greater proportion, than the negative control.  
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Figure 4.7 (above): DARPP32 expression in 34D6 iPS-derived neurons 4 weeks post 
transfection. 34D6 iPS derived neural stem cells were transfected at 16 days post neural 
induction with the 8 pCAGG-Transcription factor-IRES-EGFP plasmids & the negative 
control. These cells were differentiated for a further 4 weeks in SCM1/2 media. Cells were 
harvested for immunofluorescence of DARPP32 using rabbit α DARPP32 antibody (abcam 
ab40801 1:200) @ 4
o
C overnight in block. A) Example images from the DARPP32 
immunofluorescence, nuclei stained green with SYTO16 nuclear stain and DARPP32 
stained red with Alexa-fluor 594 goat α rabbit IgG. Scale bar = 50 µm. B) Bar graphs 
showing the percentage of DARPP32 expression in the total number of cells, calculated from 
at least 4 fields of view per biological replicate (N), N=3;n=12 unless marked with *N=2;n=8. 
Error bars showing SEM of mean across each field of view.  
 
The levels of DARPP32 expression were normalised to transfection efficiency of the 
plasmids and subsequently to the normalised value for DARPP32 expression level 
of the negative control (Figure 4.8c for graph of DARPP32 induction efficiency). The 
transcription factors which had an efficiency of DARPP32 induction of greater than 1 
(i.e. above the control transfection level) were all of the transcription factors 
excluding ISL1 alone and NOLZ1 (variant), with NOLZ1 having the highest induction 
efficiency of DARPP32 out of all the transcription factors of 2.96.  
In summary, it has been determined that NOLZ1 transfection induces the 
expression of DARPP32 with the greatest efficiency. As a result of the initial 
transcription screen in Section 4.3, NOLZ1 was used as a transcription factor to be 
expressed in day 16 rosettes and the resulting cells analysed for molecular (Section 
4.4), morphological and physiological (Chapter 5) characteristics. A recent study 
has also revealed that premature expression of Nolz1 in vivo under control of the 
Nestin promoter stimulates cell cycle exit and differentiation of neural stem cells, in 
the mouse ventricular zone of the lateral ganglionic eminence (Chang et al., 2013). 
The other transcription factor that was investigated further was ISL1, although it was 
determined to not have a high efficiency of DARPP32 induction, the ISL1 plasmid 
used in this experiment was the incorrect form, missing the final nucleotide of the 
coding sequence, as this was discovered after the experiment. This may have 
impaired the functionality of ISL1 with the frame shift mutation causing an 
elongation of the protein due to the stop codon at the end of the multicistronic 
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section of the plasmid being out of frame and the resulting protein being 19 amino 
acids larger than it should be, with no understanding how this affects the 
transcription factor’s function. The sequence data was re-analysed after the ISL1 
protein was judged to be larger than expected by Western blotting (chapter 3) and 
as a result of two recent papers supporting its role with regard to striatonigral 
medium spiny neuron development (Ehrman et al., 2013). ISL1 promotes 
striatonigral pathway development of medium spiny neurons and represses 
striatopallidal fate as seen when Isl1 is conditionally knocked out in the striatum (Lu 
et al., 2014). 
 
Figure 4.8: Induction efficiency of the transcription factors of DARPP32 expression. 
GFP expression was used as a determinant of transcription factor expression and therefore 
the proportion of cells which were expressing the transcription factor. The levels of 
DARPP32 were determined at 4 weeks. The DARPP32 proportion of expression was divided 
by the percentage of GFP expression, then each of the transcription factor transfections 
were normalised to the CAG- transfected cells. A) Transfection efficiency graph from 4.6B. 
B) Percentage of DARPP32 expressing cells graph from figure 4.7B. C) Bar graph showing 
induction of DARPP32 expression. N=3;n=12 unless marked with *N=2;n=8. Mean ± SEM 
across each field of view. 
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4.4 Further investigation into the use of NOLZ1 and ISL1 
transfection for differentiation 
4.4.1 G418 kill curves 
In order to enrich the population of neurons expressing the transcription factor that 
had been transfected, cells were selected with G418, as the expression vector also 
conferred G418 resistance. Obtaining an enriched population was more important 
for the molecular characterisation than the morphological or physiological 
characterisation of transfected neurons as cells could be selectively patched or 
imaged for Sholl analysis based on their GFP expression. 
Initial transfections were conducted with a short selection of cells with G418 at 800 
µg/ml, at 2 days post transfection, for 1 day, following a protocol developed by Sali 
Bagabir. This was then followed by re-plating of the selected cells for differentiation. 
This proved to be unsuccessful with cells not surviving the second plating. This was 
possibly due to the changed initial protocol which the cells had been differentiated 
with, as the cells under selection were starting to form neurons, rather than remain 
as progenitors, even at high density. This meant they did not survive re-plating and 
therefore a new protocol was required, without a second re-plating.  
Cells were transfected at day 16 with each of the 4 plasmids to be used in further 
study: empty plasmid control (CAG-), NOLZ1, ISL1 and the NOLZ1-ISL1 combined 
plasmid. These were allowed to recover for 1 day before being changed to SCM1 
medium supplemented with G418 at, 150 µg/ml, 300 µg/ml and 600 µg/ml, or no 
G418 added. These were then imaged every 2 days and the percentage of GFP 
expression and the total number of cells calculated per field of view was recorded. 
At 7 days post transfection, half of the cultures exposed to 300 µg/ml G418 
treatment were changed to medium without G418 to see if this could improve 
survival whilst increasing the percentage of GFP+ cells in vitro.  
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For all transfections, G418 treatment increased the percentage of GFP+ cells by the 
final time point, 600 µg/ml G418 treatment increased the percentage of GFP+ cells 
the most, by the final time point the percentage of GFP+ cells varied from 45% to 
80% depending on the transfection, but as a result of the initial transfection 
efficiency being fairly low (1.30% for CAG- to 14.7% for ISL1) the percentage of 
GFP expression still increased. The number of cells that were still alive and 
attached was also very low after treatment with 600 µg/ml G418 varying, on 
average, from 3 to 10.3 cells per field of view, an 8 fold decrease from the numbers 
observed without G418 treatment (Figure 4.9). In conjunction with this analysis, 
cells underwent basic electrophysiological characterisation by Dr. Vsevelod 
Telezhkin, which showed cells selected at 150 µg/ml G418 to be the most neuronal 
with spontaneous activity at 2 weeks post transfection and were comparable to 
those without G418 treatment (data not shown). Cells treated with 600 µg/ml G418 
were not viable to be analysed by whole cell patch clamp at 2 weeks post 
transfection. Cells treated with 300 µg/ml G418 also showed deterioration in their 
ability to be analysed by whole cell patch clamp.  
An enrichment of GFP+ cells was beginning to be observed with 150 µg/ml G418 
treatment at 11 days post transfection, initial transfection efficiencies of 1.30% 
(CAG-), 14.7% (ISL1), 11.2% (NOLZ1) and 7.54% (NOLZ1-ISL1) were raised to 
levels of expression of GFP in the cell population of 2.80% (CAG-), 15.5% (ISL1), 
18.8% (NOLZ1) and 13% (NOLZ1-ISL1) by 11 days post transfection. With further 
analysis being undertaken at 14 days and 21 days post transfection, cell viability 
was important and as a result ruled out 600 µg/ml G418 treatment as an option of 
enrichment of cells expressing the plasmid, as cell density was at 6.07 ± 1.74% 
(N=4; n=12) of the 0 µg/ml G418 treated cells. The number of cells per field of view 
compared to 0 µg/ml G418 treated cells, across all transfections, was at 50.2 ± 
6.82% (N=4; n=12) with 150 µg/ml G418 treatment as opposed to 20.9 ± 9.17% 
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(N=4; n=12, 300 µg/ml G418 treatment for the whole experiment) or 22.2 ± 4.68% 
(N=4; n=12, 300 µg/ml G418 for up to 1 week post transfection). This showed that 
the viability was decreased at higher concentrations of G418 selection, which was to 
be expected, but with the variable transfection efficiencies, the cells are not 
necessarily comparable between the transfections. 
As a result of; the deterioration in electrophysiological properties, the improvement 
of GFP+ cells apparent at 11 days post transfection and the cell density/viability, 150 
µg/ml G418 selection was used in order to enrich the population of cells for GFP+ 
expression in further experiments. 
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Figure 4.9: G418 kill curves of cells transfected with pCAGG-IRES-EGFP plasmids.  
34D6 D16 neural rosettes were transfected with the four plasmids, CAG- control, NOLZ1, 
ISL1 and NOLZ1-ISL1 At 1 day post transfection, the cells were imaged and placed in media 
containing various G418 concentrations, no G418, 150 µg/ml, 300 µg/ml for whole 
experiment, 300 µg/ml until 7 days and 600 µg/ml.  Left column shows percentage of GFP
+
 
cells. Right column shows total number of cell bodies per field of view. From top to bottom, 
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CAG- control, ISL1, NOLZ1, and NOLZ1-ISL1 transfected cells. Mean ± SEM across the 
fields of view (N=1, n≥3) 
4.4.2 Characterisation of transfections by immunofluorescence 
Cells were fixed with paraformaldehyde (4%) at 3 weeks post transfection; the cells 
had received treatment with 150 µg/ml G418 for 6 days, in order to enrich the 
population of cells expressing the plasmids. In conjunction with G418 selection, a 
GFP antibody was used for immunofluorescence to co-localise any GFP expression 
observed with the expression of the protein of interest in order to characterise these 
cells. However, this did not account for cells which had been transfected with the 
plasmid but had stopped expressing it and therefore ceased expression of GFP, 
prior to analysis by immunofluorescence. The transfection efficiency in the cells was 
higher in CAG- (28.9% ± 1.56 N=2;n=9) and NOLZ1 (33.5% ± 4.27 N=2;n=9) 
transfected cells than ISL1 (25.5% ± 3.41 N=2;n=9) and NOLZ1-ISL1 cells (11.5% ± 
1.37, N=2;n=9).  
4.4.2.1 Calbindin expression 
One of the proteins investigated was calbindin-28K (Figure 4.10A), a calcium 
binding protein expressed in the projection neurons of the matrix compartment 
which has been shown to be expressed in the medium sized-spiny neurons of the 
rat striatum (Gerfen & Wilson 1996, Bennett & Bolam 1993). The proportion of 
calbindin expression in GFP+ cells (Figure 4.10B) did not change significantly 
between CAG- (95.0% ± 1.44), ISL1 (85.0% ± 3.79), NOLZ1 (88.8% ± 3.27) or 
NOLZ1-ISL1 (82.5% ± 4.42) (Kruskal-Wallis statistic=3.28, p=0.35 (N=2, n=30)).  
When considering the total population, (Figure 4.10C), the proportion of calbindin 
expressing cells was 17.6% ± 1.13 in CAG- transfected cells, which is the highest 
observed, ISL1 (15.6% ± 0.91), NOLZ1 (12.8% ± 1.43) and NOLZ1-ISL1 (13.8% ± 
1.56) transfections lead to slightly lower percentage of calbindin expression. 
Calbindin expression in the CAG- control was significantly greater than NOLZ1 
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(Kruskal-Wallis statistic=10.4, Dunn’s multiple comparison p=0.02 N=2, n=30). As 
transfections with the NOLZ1-ISL1 plasmid resulted in the lowest transfection 
efficiency, this in turn resulted in the highest level of cell death during selection with 
G418. Therefore, the NOLZ1-ISL1 transfected cells were at a lower density, relative 
to the other transfections during differentiation. This lower density during 
differentiation could have adversely effected neuronal maturation and therefore 
resulted in the lower levels of calbindin expression. 
With calbindin expression at a similar proporition in all transfections, when 
considered as a percentage of GFP+ cells, it may be likely the continued expression 
of the plasmid in the cells does not have an effect on calbindin expression. 
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Figure 4.10: Calbindin and GFP expression in neurons 3 weeks post transfection. 
Neural progenitors differentiated from 34D6 iPS cells for 16 days were transfected with 1 of 
the 4 plasmids either CAG-, ISL1, NOLZ1 or NOLZ1-ISL1. 1 day later they were place into 
150 µg/ml G418 selection media until 7 days post-transfection and then differentiated for a 
further 2 weeks. Cells were fixed for immunofluorescence at 3 weeks post transfection and 
stained with anti-GFP and anti-calbindin antibodies. A) Example images captured on an 
epifluorescent microscope showing GFP (green) and nuclei (blue), calbindin (red) and the 
merged image at the bottom. Scale bar for all images in bottom right image=50 µm. B) 
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Percentage of calbindin expressing cells at 3 weeks post transfection calculated as 
percentage of the number of GFP
+
 cells (N=2, n=30). C) Percentage of calbindin expressing 
cells at 3 weeks post transfection calculated as percentage of the total number of cells, 
(N=2, n=30). Error bars on all graphs displaying standard error across the field s of view. N= 
biological replicates, n = field of view 
 
4.4.2.2 FOXP1 expression 
The expression of the transcription factor, FOXP1, was analysed by 
immunofluorescence at 3 weeks post transfection (Figure 4.11A). The percentage of 
GFP+ cells expressing FOXP1 at 3 weeks post transfection (Figure 4.11B) was not 
significantly different between transfections (Kruskal-Wallis Statistic=5.31, p=0.15 
(N=2, n=30, except ISL1 N=1, n=15)). However, ISL1-transfected cells (83.7% ± 
2.75) had a slightly higher percentage of FOXP1 expression than the other 
transcription factor transfected cells (CAG-=80.2% ± 2.67, NOLZ1=74.2% ± 6.01, 
NOLZ1-ISL1=69.1% ± 4.52). The percentage of the total population of cells 
expressing FOXP1 (Figure 4.11C), was not significantly different between 
transfections (Kruskal-Wallis Statistic=3.88, p=0.28 (N=2, n>29, except ISL1 N=1, 
n=15)), the NOLZ1 transfected cell population had the highest percentage of 
FOXP1 expressing cells (19.1% ± 3.38)  and the ISL1 transfected cell population 
had the lowest proportion of FOXP1+ cells (11.0% ± 0.96), with CAG- transfected 
cells (17.4% ± 2.22) and NOLZ1-ISL1 transfected cell population (15.4 ± 1.16) 
between the two other transfections. The proportion of total cells expressing FOXP1 
in ISL1 transfected cells seems to counter the data seen when considering the 
GFP+ population, however ISL1 transfections had lower transfection efficiency, so 
as a proportion of total cells less expression is seen. 
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Figure 4.11: FOXP1 and GFP expression in neurons 3 weeks post transfection. Neural 
progenitors differentiated from 34D6 iPS cells for 16 days were transfected with 1 of the 4 
plasmids either CAG-, ISL1, NOLZ1 or NOLZ1-ISL1. 1 day later they were place into 150 
µg/ml G418 selection media until 7 days post-transfection and then differentiated for a 
further 2 weeks. Cells were fixed for immunofluorescence at 3 weeks post transfection and 
stained with anti-GFP and anti-FOXP1 antibodies. A) Example images captured on an 
epifluorescent microscope showing GFP (green) and nuclei (blue), FOXP1 (red) and the 
merged image at the bottom. Scalebar for all images in bottom right image = 50 µm. B) 
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FOXP1 expression at 3 weeks post transfection calculated as percentage of the number of 
GFP
+
 cells. C) FOXP1 expression at 3 weeks post transfection calculated as percentage of 
the total number of cells. (N=2, n>29, except ISL1 N=1, n=15). Error bars on all graphs 
displaying standard error across the data set. N= biological replicates, n = field of view. 
4.4.2.3 DARPP32/CTIP2 expression 
Analysis of DARPP32 and CTIP2 protein expression was carried out on terminally 
differentiated cells (Figure 4.12A & 4.13A), analysed separately and for co-
expression, as although both are striatally enriched proteins, their co-expression is 
reported to be specific to the striatum (Delli-Carri et al., 2013 a). The percentage of 
GFP+ cells which were CTIP2+ at 3 weeks post transfection with G418 selection 
(Figure 4.12B) was not significantly different between transfections (one-way 
ANOVA F(3,56)=1.14, p=0.34 (N=1, n=15)). ISL1 transfected cells (70.8% ± 7.37) 
had a slightly higher proportion of CTIP2 expression than CAG- (66.5% ± 6.69), 
NOLZ1 (56.4% ± 9.51) and NOLZ1-ISL1 (52.3% ± 8.53) transfected cells. The 
percentage of GFP+ cells expressing DARPP32 (Figure 4.12C) at 3 weeks post 
transfection showed no significant difference between transfections NOLZ1 
transfected cells had the highest proportion of DARPP32 expression (66.1% ± 9.54) 
with CAG- plasmid (64.1% ± 5.50) and NOLZ1-ISL1 (64.0% ± 9.14) and ISL1 
(58.1% ± 7.86) transfected cells only having slightly lower DARPP32 expression 
(one-way ANOVA F(3,56)=0.18, p=0.91 (N=1, n=15)). ISL1 transfected cells had a 
slightly higher proportion of DARPP32+/CTIP2+ cells (54.7% ± 7.53, figure 4.12D), 
but there was no significant difference between ISL1, CAG- (51.5% ± 5.39), NOLZ1 
(53.2% ± 10.2) and NOLZ1-ISL1 (50.1% ± 8.95) in the proportion of GFP+ cells co-
expressing DARPP32 and CTIP2 (Kruskal-Wallis statistic = 0.36, p=0.95 (N=1, 
n=15)).  
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Figure 4.12: DARPP32 CTIP2 and GFP expression in neurons 3 weeks post 
transfection. Neural progenitors differentiated from 34D6 iPS cells for 16 days were 
transfected with 1 of the 4 plasmids either CAG-, ISL1, NOLZ1 or NOLZ1-ISL1. 1 day later 
they were place into 150 µg/ml G418 selection media until 7 days post-transfection and then 
differentiated for a further 2 weeks. Cells were fixed for immunofluorescence at 3 weeks post 
transfection and stained with anti-CTIP2 and anti-DARPP32 antibodies. A) Example images 
captured on an epifluorescent microscope showing GFP and nuclei (green), CTIP2 (blue), 
DARPP32 (red) and the merged image at the bottom. Scale bar for all images in bottom right 
image = 50 µm B) CTIP2 expression at 3 weeks post transfection calculated as percentage 
of GFP
+
 cells (N=1, n=15) C) DARPP32 expression at 3 weeks post transfection calculated 
as percentage of GFP
+
 cells (N=1, n=15). D) DARPP32/CTIP2 co-expression cells at 3 
weeks post transfection calculated as percentage of GFP
+
 cells. (N=1, n=15). Error bars on 
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all graphs displaying standard error across the data set. N= biological replicates, n = field of 
view 
 
The percentage of the total population of cells, which were expressing CTIP2 at 3 
weeks post transfection (Figure 4.13B), was not significantly different between 
transfections (Kruskal-Wallis statistic=3.30, p=0.35 (N=2, n≥24)), ISL1 transfected 
cells (45.5% ± 10.8, n=25) had the highest percentage of cells expressing CTIP2 
and CAG- (29.3% ± 4.30 n=25), NOLZ1 (19.9% ± 3.47 n=24) and NOLZ1-ISL1 
(24.1% ± 4.59 n=25) transfected cells had a lower proportion of cells that expressed 
CTIP2. The percentage of cells expressing DARPP32 (Figure 4.13C) at 3 weeks 
post transfection, showed no significant difference between transfections (Kruskal-
Wallis statistic=6.64, p=0.08 (N=2, n≥24)), ISL1 transfected cells (12.2% ± 1.98 
n=25) showed a higher proportion of DARPP32 expression than CAG- (9.89% ± 
0.99 n=25), NOLZ1 (6.92% ± 0.82 n=24) and NOLZ1-ISL1 transfected cells (7.98% 
± 1.30 n=25).  
The proportion of DARPP32+/CTIP2+ cells (Figure 4.13D) at 3 weeks post 
transfection showed a significant difference between transfections (Kruskal-Wallis 
statistic=10.2, p=0.02, Dunn’s multiple comparison (N=2, n≥24)). The ISl1 
transfected cell population (9.99% ± 1.74 n=25) showed a significantly increased 
percentage of co-expression of DARPP32 and CTIP2 compared to NOLZ1 (4.37% ± 
0.64 n=24 p=0.04) and was higher than their expression in CAG- control (7.44% ± 
0.89 n=25) and NOLZ1-ISL1 transfected cells (5.94% ± 0.96 n=25). 
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Figure 4.13: DARPP32 and CTIP2 expression in neurons 3 weeks post transfection 
G418 selected. Neural progenitors differentiated from 34D6 iPS cells for 16 days were 
transfected with 1 of the 4 plasmids either CAG-, ISL1, NOLZ1 or NOLZ1-ISL1. 1 day later 
they were place into 150 µg/ml G418 selection media until 7 days post-transfection and then 
differentiated for a further 2 weeks. Cells were fixed for immunofluorescence at 3 weeks post 
transfection and stained with anti-CTIP2 and anti-DARPP32 antibodies. A) Example images 
captured on a confocal microscope showing nuclei (blue), CTIP2 (green), DARPP32 (red) 
and the merged image at the bottom. Scale bar for all images in bottom right image = 50 µm 
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B) CTIP2 expression cells at 3 weeks post transfection calculated as percentage of the total 
number of cells (N=2, n>24). C) DARPP32 expression at 3 weeks post transfection 
calculated as percentage of the total number of cells, (N=2, n>24). D) DARPP32/CTIP2 co-
expression at 3 weeks post transfection calculated as percentage of the total number of cells 
(N=2, n>24). Error bars on all graphs displaying standard error across the fields of view. N= 
biological replicates, n = field of view 
 
4.5 Conclusions 
Protein characterisation of the SCM1/2 protocol showed that the majority of cells 
~90% were neuronal, expressing MAP2 from early in differentiation and then during 
differentiation, the synaptic markers were increased in expression and co-localised. 
In order to concentrate on a few transcription factors, an initial screen of plasmids 
was carried out, and highlighted NOLZ1 as a candidate for inducing DARPP32 
expression.  
Further characterisation was then carried out with NOLZ1, ISL1 and NOLZ1-ISL1 
plasmids in comparison with control transfections. Immunofluorescence for 
calbindin, FOXP1, CTIP2 and DARPP32 expression were performed. This showed 
that ISL1 induced the most MSN-like phenotype with an increased expression of 
CTIP2, FOXP1 and combined DARPP32/CTIP2 expression, in comparison to the 
control and other transcription factor transfections. 
4.5.1  Protein characterisation of the SCM1/2 protocol 
Previous studies have utilised different methods to obtain neurons from pluripotent 
stem cells, most involving the formation of embryoid bodies (EB) and inclusion of 
basic fibroblast growth factor (bFGF) in the medium (Okabe et al., 1996, Li et al., 
1998, Bain et al., 1995, Jones-Villeneuve et al., 1982). These generate a relatively 
high percentage of neurons, with 50% of the proliferative (SOX2+) cells producing 
MAP2+ neurons with expression of the synaptic marker, synapsin I (Li et al., 1998). 
Exposure of EBs to retinoic acid also aids the neural induction process, and with 
subsequent dissociation, increases neuronal markers such as βIII-tubulin and 
neurofilament M (Bain et al., 1995, Jones-Villeneuve et al., 1982). However, EB 
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formation often results in a non-uniform differentiation, with different areas of the EB 
being subjected to different signalling cues and varied concentration gradients of 
medium supplements/growth factors/drugs, which can result in incomplete 
differentiation into different germ layers or cell types. Other methods of neural 
induction have involved the use of undefined signalling by co-culture with other cell 
types e.g. stromal cells (Perrier et al., 2004, Kawasaki et al., 2000) or conditioned 
medium from human hepatocellular carcinoma cells (Shin et al., 2006). 
The use of monolayer differentiation culture in mouse ESCs by Ying et al., (2003), 
resulted in more rapid differentiation, with neural tube like rosettes forming after only 
4 days. The expression of the mature neuronal protein marker, Tau, was switched 
on in these cultures from day 5 (Ying et al., 2003) and the mature neuronal marker, 
MAP2 was observed from day 18 (although since nearly all cells were expressing 
the protein and earlier time points were not investigated, it seems likely that MAP2 
was activating rather earlier in the protocol). A monolayer protocol employing 
retinoic acid and bFGF in serum-free medium generated similar data and, although 
rosettes were mechanically dissociated before re-plating, >90% of cells expressed 
MAP2, synaptophysin and neurofilament protein at 30 days post-induction 
(Baharvand et al., 2007). Throughout this thesis, a monolayer differentiation 
protocol was utilised, where re-plating of early differentiating neural progenitors was 
carried out at day 4, and which resulted in the formation of neural rosettes from day 
5 onwards. This protocol was comparable to other protocols in terms of protein 
expression of mature neuronal markers and synaptic proteins. 
The data suggest that the cells are undergoing neurogenesis, evidenced by the fact 
that approximately 90% of the cell population stained positive for the neurogenesis 
marker, doublecortin, from day 18 onwards (Figure 4.1). The data also suggest that 
the majority of cells were neurons as nearly 90% of the population stained positive 
for MAP2 and less than 3% of the cells stained positive for the astrocyte marker, 
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S100β (Figure 4.2). Finally, expression and localisation of the synaptic markers; 
synaptophysin and PSD95 showed how they gradually increased in expression 
during differentiation, with a peak at 27 days post neural induction (Figure 4.4). 
These proteins are co-localised throughout differentiation (Figure 4.5), implying that 
synapses begin to form almost as soon as the neural rosettes are plated at day 16 
post neural induction. 
Once able to generate neurons, the objective of this chapter was to specify the 
neurons to MSNs. The forced expression of five transcription factors, important in 
MSN development, was carried out in ventral forebrain-like neural progenitors, in 
order to try and specify a DARPP32+ MSN phenotype (Figure 4,7). The data 
showed that NOLZ1 had the highest efficiency of DARPP32 induction (Figure 4.8). 
G418 kill curves were also performed to determine the best concentration of G418 
for selection after transfection (Figure 4.9). 
4.5.2 ISL1 is a likely candidate for specifying a MSN phenotype 
Of all the transfection manoeuvres, ISL1 transfection seemed to result in 
differentiation into neurons with a phenotype most similar to MSNs.  
Calbindin expression in GFP+ cells (Figure 4.10) was similar between transfections 
with the various transcription factors and so more biological replicates may be 
required to show a significant change. The general trend is that the CAG- control 
transfected cells produce the highest percentage of calbindin+ neurons, but this is 
only a slight increase from that seen with the transcription factor transfections. This 
may be a result of calbindin not being a downstream target of NOLZ1 or ISL1 and 
so is not affected by their transfection. It may also be that as calbindin is a matrix 
marker in the striatum (Pickel & Heras 1996, Gerfen & Wilson 1996), it is possible 
with ISL1 specifying cells of the striatonigral pathway (Ehrman et al., 2013, Lu et al., 
2014), which is neither limited to or excluded from the matrix compartment of the 
4. Protein characterisation of differentiation protocol 
 
 
- 166 - 
striatum (Gerfen & Young 1988) that ISL1 does not play a role in switching on 
calbindin expression.  
There also needs to be analysis of whether the calbindin+ population are 
interneurons, by investigating expression of somatostatin/parvalbumin or analysing 
for co-expression with CTIP2 (Delli Carri et al., 2013b). Although from separate 
coverslips, the fact that the overwhelming majority of cells which were GFP+ were 
calbindin+ and 55% of GFP+ cells after ISL1 transfection were CTIP2+, indicated the 
ISL1 transfections were not necessarily generating just calbindin+ interneurons. 
FOXP1 (Figure 4.11) was also increased by ISL1 transfections. FOXP1 is an 
important transcription factor in the developing striatum and has been implicated in 
the switching on of glutamate receptor genes and GABA receptor signalling genes, 
when overexpressed (Tang et al., 2012). Furthermore, FOXP1 is co-expressed with 
GluR2/3 in two-thirds of mouse MSNs (Tamura et al., 2004), supporting its role in 
switching on expression of glutamate receptors, which are required by MSNs to 
receive glutamatergic input from the cortex (Ferino et al., 1987, Jones et al., 1977, 
Royce 1982, Wilson 1987). FOXP1 is also co-expressed with ISL1 in the spinal 
motor column (Ericson et al., 1992, Tsuchida et al., 1994, Shu et al., 2001, Dasen et 
al., 2005, Luria & Laufer 2007). With the co-expression of FOXP1 and ISL1 
observed in other regions, and the induction of expression observed in this chapter, 
speculation arises as to whether FOXP1 is a target of ISL1, a previously undefined 
role. 
CTIP2 (Figure 4.12, 4.13) is an important transcription factor of MSN development 
and is first detected at E12.5 in the mouse LGE (Arlotta et al., 2005), MSN 
neurogenesis occurs from E13.5 and persists in the adult mouse and CTIP2 
expression increases in cells during MSN migration, but is restricted to the mantle 
zone, therefore only expressed in postmitotic neurons (Arlotta et al., 2008). In the 
developing human, CTIP2 is expressed in the striatal anlage of the 11 week brain 
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(Delli Carri et al., 2013a). In this chapter, data pointed towards ISL1 being the most 
efficient inducer of this MSN marker. Interestingly, CTIP2 may have a role of 
transcriptional repression of NOLZ1 and ISL1 as in the mouse, there are 3 CTIP2 
binding sites in the 1kb promoter region upstream of the translation start site of Isl1 
and 1 site in Nolz1 promoter region (Desplats et al., 2008). Due to the limited time of 
expression of these transcription factors (Wang & Liu 2001, Chang et al., 2004), this 
could be a role for CTIP2, but needs  further investigation. 
CTIP2 protein co-localises with DARPP32 and FOXP1 in the MSNs of the mouse 
striatum and is excluded from the interneurons (Arlotta et al., 2008). In the 11 week 
old human fetal striatum, the CTIP2+ cells of the caudate nucleus also express 
DARPP32 (Delli Carri et al., 2013a). In this chapter ISL1 (Figure 4.12, 4.13) has 
also induced the highest levels of DARPP32/CTIP2 co-expression. NOLZ1 
transfection had a positive influence on DARPP32 expression, but not CTIP2 
expression and therefore did not induce co-expression of the two striatal markers as 
well as ISL1.  
4.5.3 NOLZ1-ISL1 co-expression in the differentiation 
The co-expression of NOLZ1 and ISL1 in the neural progenitors did not yield the 
expected improvement of MSN specification, perhaps because they may not specify 
the same types of MSN in vivo (Ko et al., 2013, Lu et al., 2014, Ehrman et al., 
2013).However, NOLZ1 and ISL1 are co-expressed at E16.5 in the SVZ and MZ of 
the mouse LGE (Ko et al., 2013), so they are likely to play a complimentary role in 
MSN specification. The likely cause of the unexpected result is the transfection 
efficiencies between the plasmids varied according to plasmid size, with the largest 
plasmid, NOLZ1-ISL1, resulting in the lowest transfection efficiencies (~11%). With 
G418 selection, the dramatically reduced cell density may not have been optimal for 
effective differentiation. This may have masked any beneficial effects of this 
particular co-transfection strategy; co-expression of DARPP32+/CTIP2+ in the GFP+ 
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cells was around 50%, compared to 51% observed for the CAG- control. Therefore, 
if the reduction in cell density was having a detrimental effect on differentiation, it 
may have led to the decrease in the expression of markers of differentiation, in 
comparison to the single transfections.  
 
In summary, ISL1 transfection improved the proportion of FOXP1, CTIP2 and 
DARPP32/CTIP2 combined expression in cells differentiated utilising the SCM1/2 
protocol. 
4.5.4 Limitations of the methods in this chapter 
Immunofluorescence was utilised to determine a molecular phenotype of the 
neurons generated. Semi quantitative methods were used to compare the different 
transfections and quantify the protein expression in the GFP+ cells and in the total 
population. Due to the method chosen, definitive quantification couldn’t be 
performed due to the limitations of not being able to analyse the entire population, 
but analyse a proportion of the population. The levels of protein expression could 
also be measured using western blotting, but would only be able to account for the 
whole population and not differentiate between the GFP+ cells and the rest of the 
population. Another method for protein quantification that could be used was flow 
cytometry; however this could be more troublesome to perform with neurons, due to 
their morphology. The mRNA could be quantified with qRT-PCR, which would allow 
accurate quantification of the mRNA, but as with western blotting, the total 
population would be analysed and would not allow differentiation between the 
GFP+/GFP- cells. 
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5. Morphological and electrophysiological 
characterisation of transfected neurons 
 
Figure 5.0: Summary of the data in chapter 5. In this chapter, is the characterisation of 
the morphological and physiological phenotype of the neurons, which have been transfected 
with NOLZ1, ISL1 or NOLZ1-ISL1 combined. 
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5.1 Introduction 
Characterisation of neuronal maturity and phenotype can be performed by looking 
at the morphological characteristics, such as dendrite complexity, number and 
length, and investigating physiological properties such as ability to fire action 
potentials, responses to certain neurotransmitters and presence of particular ionic 
currents.  
Sholl analysis was first introduced in 1953, looking at the complexity of neurons in 
the visual and motor cortices in the cat, by using concentric circles centred on the 
cell body of the neuron and at each circle, counting the number of intersections by 
the neuron (Sholl 1953). Sholl analysis has been used to investigate the complexity 
of neurons in a HD knock-in mouse, and it demonstrated that as the disease 
progressed, the neurons of the striatum decreased in dendritic complexity (Lerner et 
al., 2012). This suggests that Sholl analysis would be a useful tool for modelling the 
disease in vitro. BAC transgenic mice with eGFP expressed from the dopamine D1 
or D2 receptor has allowed electrophysiological and morphological data to be 
acquired of cells of the different striatal efferent pathways (Gertler et al., 2008). 
There is a morphological difference between the D1+ and D2+ neurons, with more 
intersections by Sholl analysis, longer dendritic length and more primary dendrites 
in D1+ MSNs in comparison to D2+ MSNs (Gertler et al., 2008). Passive electrical 
differences are also observed, with dopamine D1 receptor expressing MSNs having 
a larger capacitance, indicating a larger cell surface area than D2+ MSNs, 
supporting the morphological data (Gertler et al., 2008). The D1+ MSNs also show a 
greater rheobase current, the current injection required to elicit an action potential 
(Ashley et al., 2005), reflected in a right-ward shift in the current injection against 
action potential spike frequency graph, and a sign of decreased excitability (Gertler 
et al., 2008). Another electrophysiological characteristic of MSNs, which is lacking in 
DARPP32-/- mice, is dopamine D1 enhancement of NMDA currents and attenuation 
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of GABA currents, suggesting this is a function of DARPP32 (Flores-Hernández et 
al., 2002).  
To elucidate the morphological and electrophysiological characteristics of the 
neurons transfected at day 16 with either empty CAG- plasmid, NOLZ1, ISL1 or the 
combination of NOLZ1-ISL1, neurons were analysed by Sholl analysis to determine 
morphological complexity at 1, 2 and 3 weeks and by whole-cell patch clamp to 
determine the electrophysiological properties of the neurons at 2 and 3 weeks post-
transfection. 
5.2 Morphological analysis of differentiated neurons 
Cells which had been differentiated for 16 days to form neural progenitors were 
transfected with the 4 different plasmids pCAGG-IRES-EGFP (CAG-), pCAGG-
NOLZ1-IRES-EGFP (NOLZ1), pCAGG-ISL1-IRES-EGFP (ISL1), pCAGG-NOLZ1-
ISL1-IRES-EGFP (NOLZ1-ISL1), and differentiated for up to 3 weeks on coverslips, 
then harvested for analysis at 1, 2 and 3 weeks post transfection. Cells which were 
harvested at 1 and 2 weeks post transfection were selected with 150 µg/ml G418 
from 24 hours post transfection in order to enrich the population of cells which had 
been transfected, cells which were differentiated for 3 weeks were un-selected with 
G418 as electrophysiological characterisation showed this treatment to be 
detrimental to the cells. 
5.2.1 Week 1 
Cells harvested at 1 week post transfection were analysed for total neurite length, 
total number of branches, Sholl analysis and then a linear regression of branch 
number against neurite length, in order to classify the neurons based on 
morphological characteristics (Figure 5.1). At 1 week, the CAG-control and ISL1 
neurons showed more complex dendrites, closer to the soma, than the NOLZ1 and 
NOLZ1-ISL1 neurons; NOLZ1 and NOLZ1-ISL1 were less complex closer to the 
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soma, and more complex at the end of the axon (Figure 5.1B&C). Further from the 
cell soma at 50 µm, NOLZ1-ISL1, ISL1 and NOLZ1 transfected cells were less 
complex than the control transfection (Figure 5.1C). This could have resulted from 
the fact that the distance from the soma reached by CAG- transfected cells is 
shorter than the other neurons after transfection (Figure 5.1B) and the increased 
number of branches observed for CAG- transfected neurons (Figure 5.1D). Further 
from the cell soma (230 µm) the complexity of NOLZ1-ISL1 was increased 
compared to the CAG- transfected neurons (Figure 5.1C).  
The mean number of branches per cell at 1 week post transfection, was comparable 
between CAG- (31.1 ± 8.64 N=3; n=47), ISL1 (26.0 ± 3.52 N=3; n=51) and NOLZ1-
ISL1 (28.8 ± 8.54 N=3;n=49) transfected cells, all three were greater than NOLZ1 
transfected cells (18.1 ± 3.30 N=3; n=46), but this was not significant (Figure 5.1D). 
The mean total neurite length of the cells was also comparable between the 4 
transfections: CAG- (686.0 µm ± 140.1 N=3; n=47); ISL1 (701.6 µm ± 85.8 
N=3;n=51); NOLZ1 (560.2 µm ± 55.5 N=3; n=46), and; NOLZ1-ISL1 (675.4 µm ± 
69.8 N=3; n=49) (Figure 5.1E). The cells were each plotted onto a scatter graph, in 
order to determine the types of neurons being formed (Figure 5.1F). Cells in the top 
left of the graph are longer with fewer branches, cells in the top right are longer and 
more branched, cells in the bottom left are shorter with fewer branches and cells in 
the bottom right are shorter with more branches. NOLZ1-ISL1 produced more cells 
which were long & branched neurons, ISL1 transfections produced the more cells 
that were long & basic neurons and CAG- transfected neurons produced the most 
short & basic neurons. Most of the cells were long & branched, with fewer cells in 
each of the other classifications. 
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5.2.2 Week 2 
Cells at 2 weeks post transfection were harvested and analysed for the same 
parameters as cells at week 1. Sholl analysis revealed differences between 
transfections (Figure 5.2B). CAG- transfected cells were more complex closer to the 
cell soma at 20 µm. ISL1 transfected cells were consistently more complex than 
CAG- transfected cells further from the cell soma. Both NOLZ1 and NOLZ1-ISL1 
transfected cells showed an increase in complexity further from the cell soma 
compared to CAG- transfected cells (Figure 5.2B&C). At 230 µm there was a 
significant difference between all transfections in complexity (Kruskal-Wallis =7.72, 
p=0.02, figure 5.2B) ISL1 was more complex than CAG- cells but this was not 
significant (Dunn’s multiple comparisons p=0.08). 
The number of branches was increased between ISL1 and NOLZ1-ISL1 cells (ISL1 
= 19.2 ± 3.00 N=3;n=52 and NOLZ1-ISL1 = 13.2 ± 0.75, N=3; n=46), which could 
have resulted from the decreased transfection efficiency of NOLZ1-ISL1 plasmid 
into cells (9.28 ± 2.47% N=3; n=18) in comparison to ISL1 plasmid (24.1 ± 2.90%, 
N=3; n=18). This decrease in transfection efficiency would have subsequently 
resulted in a decrease in cell density in NOLZ1-ISL1 cells under selection with 
G418, and could have led to a negative effect on cell complexity as there were 
fewer cells available with which to make synaptic connections. The number of 
Figure 5.1 (above): Sholl analysis of cells 1 week post transfection. Neural progenitors 
were transfected after 16 days of differentiation with each of the 4 plasmids and further 
differentiated for 1 week, under selection, before being harvest for Sholl analysis.  A) Example 
images of neurons at 1 week post transfection, captured for Sholl analysis and the number of 
cells used for each group stated underneath, scale bar= 40 µm. B) Scatter plot of the mean of 
the Sholl analysis from each transfection, no significant difference was observed between 
transfections, two way ANOVA repeated measures F=1.34, DF=3,189 p=0.26. C) Scatter plot 
showing selected data points analysed for differences between transfections, samples taken at 
5 µm, 20 µm and then every 30 µm thereafter. There was no significant difference at any point 
between the transfections. D) Bar charts showing the mean number of branches on the 
neurons, with the number of branches being higher in CAG- and NOLZ1-ISL1 transfected 
neurons. E) Bar chart showing mean neurite length, which was highest in ISL1 and NOLZ1-
ISL1 transfected neurons F) Scatter plots showing the branch number plotted against neurite 
length for each cell in order to determine whether cells are longer and branched, or more basic 
with fewer branches. Lines show linear regression. CAG- cells tended to be shorter and more 
branched, NOLZ1-ISL1 were longer and more branched. Data mean ± SEM across the 
biological replicates N=3;n≥46 
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branches in CAG- (17.1 ± 4.30 N=3; n=49) and NOLZ1 (15.4 ± 1.36 N=3; n=43) 
transfected cells were comparable and in between that observed for ISL1 and 
NOLZ1-ISL1 ISL1 transfected cells. ISL1 transfected cells (645.4 µm ± 93.9, 
N=3;n=52) had longer total neurite length in comparison to CAG- (441.6 µm ± 83.8,  
N=3;n=49) and NOLZ1-ISL1 transfected cells (493.9 µm ± 46.6, N=3;n=46), both 
NOLZ1 (546.7 µm ± 49.2, n=43) and NOLZ1-ISL1 had a greater neurite length than 
CAG- transfected but this was not statistically significant (figure 5.2E). When the 
cells were plotted on a scatter plot, the majority of cells from all transfections were 
long & branched cells, with ISL1 and NOLZ1 transfected cells having more cells, 
CAG- control transfections had a higher proportion of short cells with a comparable 
number of branches and so may not induce a complex cell phenotype (Figure 5.2F) 
and also may be responsible for the increased complexity of cells closer to the cell 
soma as seen from the Sholl analysis. The intercept of the regression line showed a 
significant difference between transfections (F=5.99, DF3, 185, p<0.001), therefore 
a variation in the number of branches between transfections. 
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5.2.3 Week 3 
Cells at 3 weeks post transfection were harvested after no G418 treatment. This 
was done in order to determine changes in cell complexity between transfections 
when at the same density and also as a result of improved electrophysiology of cells 
when not under selection (Section 5.3 onwards). NOLZ1-ISL1 has the greatest 
number of intersections and therefore more complex at the peak of the Sholl 
analysis curve (figure 5.3B), but further from the cell soma, CAG- control transfected 
neurons are significantly more complex than NOLZ1 at 80 µm (Kruskal-Wallis=11.4, 
p<0.01 Dunn’s multiple comparisons p=0.02, N=1;n=20) and NOLZ1-ISL1 at 80 µm 
from the cell soma (p=0.04 N=1;n=20). Further from the cell soma at >100 µm, ISL1 
transfected neurons become more complex than CAG- control and NOLZ1 
transfected cells. NOLZ1-ISL1 transfected neurons were more complex than NOLZ1 
transfected neurons (Figure 5.3B).  
The number of branches (Figure 5.3D) and total neurite length (Figure 5.3E) were 
greater in the neurons transfected with NOLZ1 (neurite length: 1186.9 ± 240.2 µm 
N=1; n=20, branches: 16.9 ± 2.01 N=1; n=20), ISL1 (1095.6 ± 116.9 µm N=1; n=18, 
22.5 ± 3.72 N=1; n=18) or the combination of the two genes (1355.7 ± 186 µm N=1; 
n=20, 18.2 ± 2.32 N=1; n=20) compared to control transfected cells (968.8 ± 104.3 
µm N=1; n=20, 16.3 ± 1.67 N=1; n=20), but was not statistically significant for either 
Figure 5.2 (above): Sholl analysis of cells 2 weeks post transfection. Neural progenitors were 
transfected after 16 days of differentiation with each of the 4 plasmids and further differentiated for 
2 weeks, under selection, before being harvested for Sholl analysis.  A) Example images of 
neurons captured for Sholl analysis and the number of cells used for each group stated 
underneath, scale bar= 40 µm. B) Scatter plot of the mean of the Sholl analysis from each 
transfection, CAG- and ISL1 transfected cells were more complex closer to the cell soma, then the 
transcription factor transfected cells were more complex than the CAG- transfected cells further 
from the soma. C) Scatter plot showing selected data points analysed for differences between 
transfections, samples taken at 5 µm, 20 µm and then every 30 µm thereafter. There was a 
significant difference in complexity at 230 µm from the cell soma with ISL1 transfected cells being 
more complex than CAG- transfected cells, Kruskal-Wallis=7.72, p=0.02, Dunn’s multiple 
comparison CAG- vs ISL1 p=0.08. D) Bar charts showing the mean number of branches on the 
neurons, ISL1 transfected cells have more branches than the other transfections. E) Bar chart 
showing mean neurite length, ISL1 had the longest neurites observed between the transfections 
F) Scatter plots showing the branch number plotted against neurite length for each cell in order to 
determine whether cells are longer and branched, or more basic with fewer branches. Lines show 
linear regression. ISL1 neurons tend to be longer than the rest, and CAG- cells being the shortest. 
Data mean ± SEM across the biological replicates N=3; n≥43. 
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the number of branches or the neurite length. ISL1 cells tended to have more short 
cells with more branches (Figure 5.3F) and NOLZ1-ISL1 cells possessed longer 
neurites with a slightly more branched phenotype. 
 
Figure 5.3 (above): Sholl analysis of cells 3 weeks post transfection. Neural progenitors 
were transfected after 16 days of differentiation with each of the 4 plasmids and further 
differentiated for 3 weeks, without selection, before being harvested for Sholl analysis. A) 
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Example images of neurons captured for Sholl analysis and the number of cells used for 
each group stated underneath, scale bar= 40 µm. B) Scatter plot of the mean of the Sholl 
analysis from each transfection, no significant difference between transfections was 
observed. C) A zoomed in section of B from 5 to 100 µm D) Bar charts showing the mean 
number of branches on the neurons, there was no significant difference between the 
transfections, which is increased in ISL1 and NOLZ1-ISL1 transfected cells. E) Bar chart 
showing mean neurite length, no significant difference between the transfections, but is 
increased on transfection with transcription factors in comparison to control . All error bars 
represent SEM. N=1;n=20 (except ISL1 n=18)  
 
5.3 Basic electrophysiological characterisation. 
The electrophysiological properties of transfected neurons were assessed at 2 and 
3 weeks post-transfection using whole cell patch clamp. In early experiments, cells 
were selected with 150 µg/ml G418 in an attempt to obtain a higher proportion of 
transfected cells within the population. However, it became clear that this selection 
resulted in a drastically reduced success rate for seal formation. As a consequence, 
all electrophysiological experiments described herein did not use G418 selection.  
5.3.1 Passive properties of transfected neurons 
No significant differences were observed in mean resting membrane potential (Vm) 
values across multiple transfections at either time point (Figure 5.4A, week 2: 
Kruskal-Wallis=7.43 p=0.06, n>14, week 3: Kruskal-Wallis=3.00, p=0.39, n>15). 
However, the Vm for CAG- control transfected cells became modestly, but 
significantly hyperpolarised between 2 (-22.7 mV ± 1.38 n=15) and 3 weeks (-27.5 
mV ± 1.13 n=22, unpaired two-tailed t-test Welch correction t=2.73, DF=29.98, 
p=0.01). The Vm values were not significantly changed between weeks 2 and 3 for 
NOLZ1 (-30.2 mV ± 2.17 n=22, -29.9 mV ± 1.81 n=20), ISL1 (-25.4 mV ± 1.55 n=26, 
-27.2 mV ± 3.00 n=16) and NOLZ1-ISL1 (-28.4 mV ± 1.69 n=24, -29.2 mV ± 2.31 
n=20).  
The cell capacitance, which is a measure of membrane surface area, was 
determined in voltage clamp by iterative elimination of transient current caused by 
the charging and discharging of the cell membrane, elicited by a 10 mV, 10 ms 
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voltage step (Figure 5.4B). The cell capacitance data broadly support the Sholl 
analysis at week 3 (Figure 5.3 D&E) in that the capacitance tended to increase 
when cells transfected with a transcription factor, as opposed to control, and the 
cells were morphologically more complex. However, there were no significant 
differences between CAG- and any of the transcription factors at either week. Cell 
capacitance was increased at week 2, in cells transfected with ISL1 (17.8 pF ± 1.98 
n=18), NOLZ1 (19.0 pF ± 2.75 n=18), and NOLZ1-ISL1 (16.0 pF ± 2.27, n=17) 
compared to CAG- (14.9 pF ± 3.87 n=9) and at week 3, ISL1 (23.0 pF ± 3.94 n=11) 
and NOLZ1-ISL1 transfected cells (24.4 pF ± 3.41 n=18) have a greater 
capacitance than the CAG- transfected cells (18.1 pF ± 1.96 n=14). NOLZ1-ISL1 
transfected cells have a significantly greater capacitance than cells transfected with 
NOLZ1 (14.4 pF ± 1.66 n=16, one way ANOVA F=2.79 DF=3, 55 p<0.05 Tukey’s 
multiple comparison: NOLZ1 vs  NOLZ1-ISL1 p<0.05). 
The input resistance (Rin) is a measure of the cells permeability to ions when at 
rest. The input resistance for the cells as per Figure 5.4C. There was no significant 
difference between the transfection conditions, the exception was at week 2 where 
the Rin was increased in cells transfected with ISL1(0.59 GΩ ± 0.11 n=22), NOLZ1 
(0.85 GΩ ± 0.13 n=22) or both (0.93 GΩ ± 0.12 n=22) compared to CAG- control 
transfected cells (0.45 GΩ ± 0.08 n=14, one-way ANOVA F=3.20(3,76) p=0.03). By 
contrast, at 3 weeks this was reversed and CAG- transfected cells (1.05 GΩ ± 0.15 
n=18) have a greater input resistance compared to the cells transfected with ISL1 
(0.68 GΩ ± 0.15 n=14), NOLZ1 (0.71 GΩ ± 0.16 n=18) or both (0.63 GΩ ± 0.10 
n=18), although this was not significant. The input resistance of CAG- transfected 
cells is significantly increased from week 2 to week 3 post transfection (Mann-
Whitney U=45, p=0.002).  
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Figure 5.4: Bar graphs showing the passive properties of cells. Whole cell patch clamp 
recordings were performed at 2 and 3 weeks post transfection. A) Bar graph showing the 
mean resting membrane potential of neurons, analysed from a current clamp protocol of I=0. 
There was no significant difference in resting membrane potential between transfection 
conditions at each time point but there was a significant hyperpolarisation between week 2 
and week 3 CAG- transfected cell’s Vm unpaired two-tailed t-test Welch correction t=2.73, 
DF=29.98, p=0.01 n>13. B) Bar graph showing the mean cell capacitance of neurons. Data 
obtained from voltage clamp of cells analysing the charging and discharging of the cell 
membrane. There was no significant difference in cell capacitance between transfection 
conditions. At week 3, there was a significant difference between transfections one way 
ANOVA F=2.79 DF=3, 55 p<0.05 Tukey’s multiple comparison: NOLZ1 vs NOLZ1-ISL1 
p<0.05, n>6 for each condition. C) Bar graph showing the input resistance of neurons. Data 
were obtained from current clamp recordings, analysing the final 50 ms of the first 5 sweeps. 
There was no significant difference in input resistance between transfection conditions 
except at week 2 one way ANOVA F=3.2, DF=3, 76 p=0.03, significant difference between 
CAG- at week2 vs week 3 Mann-Whitney U test=45 p=0.002. All graph error bars = SEM. 
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5.3.2 Induced action potentials and trains 
A crucial property of neurons is the ability to fire action potentials. To induce action 
potentials in the differentiated neurons, cells were hyperpolarised using continuous 
current injection (to remove inactivation of Na+ channels) then a 1 second current 
injection was applied to depolarise the cell membrane, which increased with each 
successive sweep.  
5.3.2.1 Proportion of cells firing action potentials & frequency of the action 
potentials 
In order to generate current-frequency (I-F) scatter plots, the number of action 
potentials generated during a single 1s current step were counted and plotted 
against injected current. All conditions resulted in a time-dependent increase in the 
proportion of cells which were able to produce trains of action potentials, as 
exemplified in figure 5.5. At 2 weeks, NOLZ1 (59.1%) and NOLZ1-ISL1 transfected 
cells (54.6%) had the highest proportion of cells which fired trains of action 
potentials in comparison to the ISL1 (9.09%) and CAG- (20%) transfected neurons. 
At 3 weeks post transfection, all NOLZ1-ISL1 transfected cells fired induced action 
potentials, mostly as trains of action potentials, this proportion was increased from 
week 2, as was seen for the other transfections CAG- 27.8%, ISL1 61.5%, NOLZ1-
ISL1 83.3%, except for NOLZ1 (50%), which decreased slightly. The other two 
transfections, NOLZ1 and ISL1 individually, both gave rise to neurons which were 
more excitable than the CAG- transfected cells at 3 weeks post transfection. Thus, 
NOLZ1-ISL1 co-transfection was most beneficial in terms of facilitation of the 
generation of neurons capable of firing repetitive trains of action potentials. 
Furthermore, the excitability of cells (Figure 5.6) which generated trains of action 
potentials within each transcription factor group was different from the control group 
(although not significant). NOLZ1 (Figure 5.6 C&G) and NOLZ1-ISL1 (Figure 5.6 
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D&H) transfected cells showed a similar pattern of neuronal firing frequency, where 
both showed a higher number of action potentials fired at lower current injection 
where by comparison the ISL1 (Figure 5.6 B&F) transfected cells remained firing 
when a higher current injection is delivered at a similar rate. Interestingly, the ISL1 
transfected neurons have a similar action potential firing pattern to dopamine D1 
receptor-positive striatonigral neurons, with a rightward shift in the I-F curve, 
therefore firing trains of a higher number of action potentials at higher current 
injection (Gertler et al., 2008). Also importantly, this is seen as a more mature 
marker of neurons as the cells decrease in excitability (Mongiat et al., 2009). 
 
Figure 5.5: The proportions of neurons producing induced action potentials. Cells 
were recorded in current clamp mode at 2 and 3 weeks post transfection. Pie charts 
representing the proportions of cells which show induced action potentials left panel = week 
2, right panel = week 3. Key for all pie charts is below the figure. n is below each pie chart. 
N=2 
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Figure 5.6: Spike frequency of induced action potential trains of neurons at 2 and 3 
weeks post transfection. Cells were recorded in current clamp mode at 2 and 3 weeks 
post transfection A) An exemplar trace from a CAG- transfected neuron 2 weeks post 
transfection in whole cell patch clamp when there was a 60 pA current injection for 1 second, 
showing induction of a train of action potentials. B) Scatter plot showing mean spike 
frequency of trains of action potentials of CAG- (n=3) and ISL1 (n=2) transfected neurons at 
2 weeks post transfection against current injected, ISL1 cells were not as excitable as 
control at increased current steps. C) Scatter plot showing mean spike frequency of trains of 
action potentials of CAG- and NOLZ1 (n=11) transfected neurons at 2 weeks post 
transfection against current injected, NOLZ1 cells were not as excitable as control. D) 
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Scatter plot showing mean spike frequency of trains of action potentials of neurons at 2 
weeks post transfection of CAG- and NOLZ1-ISL1 (n=10) against current injected, NOLZ1-
ISL1 cells were not as excitable as control at higher current steps. E) An exemplar trace 
from a neuron 3 weeks post transfection in whole cell patch clamp when there was a 90 pA 
current injection for 1 second, showing induction of a train of action potentials. F) Scatter plot 
showing mean spike frequency of trains of action potentials of CAG- (n=4) and ISL1 (n=8) 
transfected neurons at 3 weeks post transfection against current injected, ISL1 cells were 
comparable to control at smaller  current steps, but ISL1 cells fired increased numbers of 
action potentials at higher current steps. C) Scatter plot showing mean spike frequency of 
trains of action potentials of CAG- and NOLZ1 (n=9) transfected neurons at 3 weeks post 
transfection against current injected, NOLZ1 cells were more excitable than control and 
comparable to the cells at week 2. D) Scatter plot showing mean spike frequency of trains of 
action potentials of neurons at 3 weeks post transfection of CAG- and NOLZ1-ISL1 (n=15) 
against current injected, NOLZ1-ISL1 cells were not as excitable as control at higher current 
steps, and comparable to the cells at week 2.  
5.3.2.2 Anatomy of the action potential 
The different parameter contribution to the anatomy of the action potentials (Figure 
5.7A) generated by the current clamp protocol were measured for each of the 
different transfected cells at each of the time points, as discussed in Bean (2007).  
The threshold voltage (figure 5.7B) was calculated as the maximum of the third 
differential of the rate of change in voltage versus time. The threshold voltages did 
not significantly change between the transfection conditions or between time points 
(one-way ANOVA, week 2: F=1.06, DF=3, 65, p=0.37 n>10 and week 3: F=2.63, 
DF=3, 56, p=0.06, n>10). At 2 weeks post transfection, the threshold voltage was 
more hyperpolarised in the CAG- transfection (-30.3 mV ± 2.88 n=11), compared to 
the cells transfected with ISL1 (-24.5 mV ± 1.64 n=17), NOLZ1 (-27.1 mV ± 1.62 
n=20) or both (-27.0 mV ± 2.11 n=21). At 3 weeks, there was a more pronounced 
difference between control transfected cells (-23.2 mV ± 2.47 n=14) and NOLZ1 (-
30.6 mV ± 2.09 n=17), ISL1 (-24.4 mV ± 2.80 n=11) or NOLZ1-ISL1 transfected 
cells (-30.8 mV ± 2.55 n=18) with threshold voltage becoming more hyperpolarised. 
Threshold voltage becomes more depolarised during maturation (Mongiat et al., 
2009, Pirchio et al., 1997), which was seen for the control and ISL1 transfected cells 
between week 2 and week 3 post transfection but not for NOLZ1 and NOLZ1-ISL1 
transfected cells. 
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The overshoot of the action potential was calculated by measuring the peak of the 
action potential (Figure 5.7A). The overshoot of the action potential (figure 5.7C) 
increased between week 2 and week 3 post transfection for the control (16.2 mV ± 
6.23 n=11 and 18.3 mV ± 5.78 n=14 respectively) and significantly increased for 
ISL1 (9.62 mV ± 2.32 n=17 and 33.6 mV ± 5.16 n=11, respectively, unpaired two-
tailed t-test Welch corrected: t=4.25 DF=14.1 p=0.0008) and NOLZ1-ISL1 
transfected cells (19.9 mV ± 3.43 n=21 and 31.1 mV ± 4.19 n=18 respectively, 
unpaired two-tailed t-test Welch corrected: t=2.05 DF=34.3 p=0.05), ISL1 and 
NOLZ1-ISL1 transfected cells had the greatest overshoot at 3 weeks post-
transfection. There was a significant difference in overshoot, only at week 2 
between ISL1 (see above) and NOLZ1 transfected cells (30.1 mV ± 4.00 n=20, 
Kruskal-Wallis statistic=14.1 p=0.0027, Dunn’s multiple comparison p<0.01).  
The afterhyperpolarisation of the action potential was calculated as the lowest 
voltage which was achieved immediately after the action potential (figure 5.7A). The 
afterhyperpolarisation of the action potential (Figure 5.7D) remained consistent from 
week 2 to week 3 and between transfection conditions. 
The spike height was calculated as the difference between the overshoot and 
afterhyperpolarisation voltages (Figure 5.7G). There was significant difference in 
spike height between NOLZ1 (81.8 mV ± 4.76 n=20) and ISL1 (53.0 mV ± 3.63 
n=17) transfected cells at 2 weeks (Kruskal-Wallis=14.3 p<0.005 Dunn’s multiple 
comparison p<0.01). The ISL1 transfected cells showed a significant increase in 
spike height from week 2 (see above) to week 3 (81.3 mV ± 7.40 n=11, unpaired 
two-tailed t-test Welch corrected: t=3.42, DF=14.9, p<0.01) and there was a slight 
increase for NOLZ1-ISL1 transfected cells (week 2: 70.4 mV ± 5.78 n=21 week 3: 
83.7 mV ± 6.01 n=18). There was a slight increase in spike height in CAG- (week 2: 
64.4 mV ± 9.47 n=11, week 3: 64.7 mV ± 6.63 n=14) and in contrast, a decrease in 
NOLZ1 transfected cells spike height (week 3: 75.2 mV ± 7.11 n=17). ISL1, NOLZ1 
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and NOLZ1-ISL1 transfections increased spike height at 3 weeks in comparison 
with control transfected cells; therefore more likely forms a more mature neuron 
than the control (Johnson et al., 2007). 
The depolarisation rate (Figure 5.7E) and repolarisation rate (Figure 5.7F) were 
determined for each of the action potentials, a faster rate of depolarisation and 
repolarisation tends to show a more mature neuron (Mongiat et al., 2009). At week 
2, NOLZ1 (85.8 mV/ms ± 10.9 n=20) had a significantly increased rate of 
depolarisation than ISL1 transfected cells (44.5 mV/ms ± 5.63 n=17, one-way 
ANOVA F=3.95, DF=3,65, p=0.02, Tukey’s multiple comparison, ISL1 vs NOLZ1 
p=0.01), and NOLZ1-ISL1 transfected cells (58.6 mV/ms ± 8.28 n=21) had a higher 
rate of depolarisation than control (51.9 mV/ms ± 11.9 n=11) and ISL1 transfected 
cells. At 3 weeks post transfection, the rate of depolarisation increased from week 2 
in NOLZ1-ISL1 (115.8 mV/ms ± 19.9 n=18) and significantly increased in ISL1 
transfected cells (98.2 mV/ms ± 16.5 n=11, unpaired two-tailed t-test Welch 
corrected  t=3.08, DF=12.4, p<0.01, n>10), but decreased for NOLZ1 (73.3 mV/ms 
± 12.2 n=17) which was greater than the depolarisation rate of CAG- transfected 
cells (52.3 mV/ms ± 9.73 n=14).  
There was a significant difference in repolarisation rate between transfections at 2 
weeks, NOLZ1 (-63.2 mV/ms ± 5.48 n=20) had a greater rate of repolarisation than 
CAG- (-44.1 mV/ms ± 9.18 n=11), ISL1: -43.4 mV/ms ± 5.52 n=17 and NOLZ1-ISL1: 
-46.7 mV/ms ± 5.30 n=21, Kruskal-Wallis=8.31, p=0.04). At 3 weeks post-
transfection, NOLZ1-ISL1 transfected cells (-63.8 mV/ms ± 8.74 n=18) had the 
fastest rate of repolarisation of the action potential, compared to the other 
transfections. NOLZ1 (-57.7 mV/ms ± 8.59 n=17) and ISL1 transfected cells (-62.2 
mV/ms ± 7.39 n=11) had an increased rate of repolarisation in comparison to control 
cells (-39.9 mV/ms ± 8.84 n=14). At 3 weeks post transfection, the rate of 
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repolarisation increased from week 2 in ISL1 and NOLZ1-ISL1 transfected cells, but 
decreased for NOLZ1 and CAG- control transfected cells. 
The half-width was calculated for the action potential by measuring the time taken to 
reach 50% of the height of the action potential, using afterhyperpolarisation as the 
base-line (Figure 5.7A). The half-width of the action potential decreases with 
neuronal maturity (Johnson et al., 2007). At week 2 (figure 5.7H), NOLZ1 (3.11 ms ± 
0.32 n=20) and NOLZ1-ISL1 transfected cells (3.55 ms ± 0.33 n=21) had a smaller 
half-width than the CAG- transfected cells- (3.99 ms ± 0.42 n=11). There was also a 
significant decrease between ISL1 (4.92 ms ± 0.48 n=17) and NOLZ1 transfected 
cells in half-width (Kruskal-Wallis=11.6, p<0.01 Dunn’s multiple comparison: ISL1 
vs. NOLZ1 p<0.01). At 3 weeks there was a decrease in half width for NOLZ1 (1.92 
ms ± 1.56 n=17) and NOLZ1-ISL1 transfected cells (2.95 ms ± 0.41 n=18), and a 
significant decrease in half-width for ISL1 transfected cells (2.72 ms ± 0.40 n=11, 
Mann-Whitney U=31, p<0.01). The half-width is decreased for all the transfections 
in comparison to CAG- transfected cells at 3 weeks post-transfection (4.65 ms ± 
0.60 n=14) an increase from 2 weeks, therefore implying a more neuronal 
phenotype (Johnson et al., 2007) when transfected with any of the transcription 
factors. 
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Figure 5.7 (above): Properties of the induced action potential. Cells were recorded in 
current clamp mode at 2 and 3 weeks post transfection. The analysis was performed on the 
first trace which elicited the action potential type for the cell, i.e. either singular action 
potential, attempting train, or train of action potentials. A) A typical induced action potential 
with the different properties which were measured marked on the action potential trace. B) 
Bar graph showing the mean threshold voltage at which action potentials were initiated in 
neurons. There was no significant difference between the transfections at either of the time 
points. C) Bar graph showing the mean overshoot of the action potentials of the neurons. 
There was no significant difference in overshoot between transfection conditions, except at 
week 2 Kruskal-Wallis test=14.12 p=0.0027, NOLZ1 increased compared to ISL1 Dunn’s 
multiple comparison p<0.01. Overshoot was significantly increased between 2 and 3 weeks 
for NOLZ1-ISL1 t=2.06, DF = 34.3, p<0.05, and ISL1 t=4.25, DF=14.1, p<0.001 both 
unpaired two-tailed t tests Welch corrected. D) Bar graph showing the mean 
afterhyperpolarisation of the action potentials of the neurons. Afterhyperpolarisation 
generally increased from week 2 to week 3 and was increased in cells transfected with 
NOLZ1 plasmids. E) Bar graph showing the mean depolarisation rate of action potentials in 
neurons, there was a significant increase between the NOLZ1 and ISL1 transfections at 2 
weeks one-way ANOVA F=3.95, DF=3,65, p=0.02, Tukey’s multiple comparison, p=0.01. 
There was a significant increase between ISL1 transfected cells at 2 and 3 weeks post 
transfection unpaired two-tailed t-test Welch corrected  t=3.08, DF=12.4, p<0.01 F) Bar 
graph showing the mean repolarisation rate of the action potentials of the neurons. There 
was a significant difference in repolarisation rate between transfection conditions at 2 weeks, 
Kruskal-Wallis test=8.31, p=0.04. G) Bar graph showing the mean spike height of the action 
potentials of the neurons. There was no significant difference in spike height between 
transfection conditions except there was an increase between NOLZ1 and ISL1 at 2 weeks 
post transfection, Kruskal-Wallis test=14.3 p<0.005 Dunn’s multiple comparison NOLZ1 vs. 
ISL1 p<0.01. Between 2 and 3 weeks post transfection there was a significant increase for 
ISL1 transfected cells, unpaired two-tailed t-test t=3.42, DF=14.9, p<0.01. H) Bar graph 
showing the mean half width of the action potentials of the neurons. There was a significant 
decrease in half-width between ISL1 an NOLZ1 at 2 weeks post transfection Kruskal-Wallis 
test=11.6, p<0.01 Dunn’s multiple comparison: ISL1 vs. NOLZ1 p<0.01. There was also a 
significant decrease in ISL1 transfected cells between 2 and 3 weeks post transfection 
Mann-Whitney U test =31, p<0.01, also there was a significant difference observed between 
G418 treatment at 2 weeks post transfection in NOLZ1-ISL1 transfected cells Mann-Whitney 
U test =51, p=0.02. All graph error bars = SEM n>9 for each condition. Key for all graphs at 
bottom of figure. 
5.3.3 Spontaneous activity of transfected cells 
A crucial property of mature neurons is the ability to fire action potentials 
spontaneously. In order to determine if the cells which had been transfected and 
differentiated were spontaneously active, recordings were obtained by current 
clamp at I=0 for approximately 1 minute. They were classified into three groups 
depending on the types of action potentials observed either non action potentials 
(Figure 5.8A), or whether they attempted to fire action potentials, but they didn’t 
reach 0 mV (Figure 5.8B) or if they were in fact firing action potentials which fired 
over 0 mV (Figure 5.8C). The proportions of cells which fitted into these categories 
were calculated and plotted as pie charts (Figure 5.8D).  
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At 3 weeks post transfection, the proportion of cells with spontaneous activity was 
increased by transfection with NOLZ1 (from week 2 9.09% to week 3 10%) or ISL1 
(from 0% to 12.5%), compared to CAG- transfection (from 13.3% to 0%). This was 
increased further with the transfection of NOLZ1-ISL1 (from 8.33% to 35%), where 
less than half the cells showed no attempt at spontaneous activity. 
 
Figure 5.8: The proportions of neurons producing spontaneous action potentials. 
Cells were analysed in gap free protocol in current clamp I=0 at 2 and 3 weeks post 
transfection. A) A typical trace from a neuron in whole cell patch clamp when there was 0 pA 
current injection, showing no spontaneous activity, B) A typical trace from a neuron in whole 
cell patch clamp with 0 pA current injection, showing attempts at spontaneous activity, but 
the action potential not reaching 0 mV  C) A typical trace from a neuron in whole cell patch 
clamp with 0 pA current injection, showing spontaneous activity. D) Pie charts representing 
the proportions of cells which show no spontaneous activity as in trace A (red), attempts at 
spontaneous activity as in trace B (orange) or spontaneous activity as in trace C (green). 
Left panel representing the different transfections at week 2, right panel representing the 
different transfections at week 3. n is below each pie chart. N=2 
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Recordings were also performed in current clamp following current injection to 
hyperpolarise the membrane potential to approximately -70 mV (Figure 5.9). This 
allowed us to discriminate between cells which could not generate spontaneous 
activity at all, and cells which did not generate spontaneous activity because the Vm 
had inactivated the Na+ current. This artificial hyperpolarisation increased the 
proportion of cells firing action potentials which reached 0 mV (figure 5.9). 
Consistent with results using their native Vm, the NOLZ1-ISL1 transfected cells 
produced the highest proportion of cells which fired action potentials (week 2: 75%, 
week 3: 89.5%). NOLZ1 (week 2: 68.2%, week 3: 68.4%), and ISL1 (week 3: 
56.3%), individually transfected cells had a higher proportion of cells which fired 
action potentials compared to the CAG- transfected cells (week 2: 46.7%, week 3: 
33.3%) except for ISL1 transfected cells at 2 weeks (30.8%).  
 
Figure 5.9: The proportions of neurons producing spontaneous action potentials 
when Vm was hyperpolarised. Cells were analysed in gap free protocol with an artificially 
hyperpolarised membrane potential to approx. -70 mV by variable current injection at 2 and 
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3 weeks post transfection. Pie charts representing the proportions of cells which show no 
spontaneous activity as in trace 5.5A (red), attempts at spontaneous activity as in trace 5.5B 
(orange) or spontaneous activity as in trace 5.5C (green). Left panel representing the 
different transfections at week 2, 0 µg/ml G418, right panel representing the different 
transfections at week 3, 0 µg/ml G418. n is below each pie chart. N=2 
 
5.3.4 Na+ and K+ currents  
A voltage clamp protocol was employed to evoke voltage activated currents. From a 
holding voltage of -70 mV a 200 ms voltage step was applied, starting at -120 mV 
and increasing to +80 mV in 5 mV increments per sweep. Voltage gated Na+ 
channels were activated at approximately -35 mV generating rapidly activating 
inward (depolarising) current which then rapidly inactivated. The K+ channels 
activated around 0 mV, with slower activation kinetics than Na+ current and which 
did not inactivate signifcantly during the test pulse (Figure 5.10A&B). The resulting 
currents were firstly corrected for leak current and then converted to current density. 
Leak current is the flow of ions through leak channels and the seal resistance, and 
was determined by the linear regression of the initial linear section. The calculated 
slope and offset for the linear regression were used to subtract leak currents from 
the voltage-activated currents. Current densities were calculated by dividing the 
currents, corrected for leak current, by the cell capacitance, in order to normalise 
current to the cell membrane surface area, therefore normalising to the number of 
voltage gated channels present per unit of membrane area.  
At week 2 (Figure 5.10C), CAG- transfected cells (-282.8 pA/pF ± 121.8 n=8) had a 
greater Na+ maximal current density than the other transfected cells (NOLZ1-ISL1: -
202.2 pA/pF ± 41.0 n=15),  ISL1 (-121.9 pA/pF ± 40.0 n=14) and NOLZ1 (-248.4 
pA/pF ± 40.3 n=16) with a significant increase in Na+ current density between 
NOLZ1 and ISL1 (Kruskal-Wallis=9.28, p=0.03, Dunn’s multiple comparison 
p=0.02). At 3 weeks post transfection, the maximal Na+ current density of the 
neurons was greater in the cells which have been transfected with NOLZ1 (-321.0 
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pA/pF ± 99.3 n=12), ISL1 (-428.9 pA/pF ± 187.8 n=4) and was significant in NOLZ1-
ISL1 transfected cells (-431.2 pA/pF ± 74.4 n=17) compared to CAG- (-139.1 pA/pF 
± 30.2 n=10, Kruskal-Wallis=10.3, p=0.02, Dunn’s multiple comparison CAG- vs. 
NOLZ1-ISL1, p<0.01), with NOLZ1-ISL1 having the largest Na+ current density 
which was significantly increased from week 2 (Mann-Whitney U=53, p<0.005). The 
Na+ current density-voltage curves (Figure 5.10E) represent the maximal data, at 2 
and 3 weeks post transfection. 
The maximal K+ current density (Figure 5.10D) at 2 weeks post-transfection, 
showed an increase in CAG- transfected cells (306.3 pA/pF ± 52.3 n=8) compared 
to NOLZ1 (262.7 pA/pF ± 38.4 n=16) and ISL1 (235.9 pA/pF ± 67.5 n=14). NOLZ1-
ISL1 transfected cells (330.8 pA/pF ± 37.5 n=15) had a greater maximal K+ current 
density than CAG- transfected cells. From week 2 to week 3 post-transfection there 
was an increase in maximal K+ current density for NOLZ1 (361.7 pA/pF ± 74.7 
n=12), ISL1 (430.4 pA/pF ± 79.5 n=4) and NOLZ1-ISL1 transfected cells (417.2 
pA/pF ± 49.6 n=17), but a decrease for CAG- transfected cells (232.7 pA/pF ± 37.6 
n=10). ISL1 transfected cells had the greatest maximal K+ current density. The 
CAG- transfected cells having a greater K+ current density at week 2, then having 
the smallest K+ current density at week 3 was observed in the IV curves (Figure 
5.10E). 
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Figure 5.10: The sodium and potassium currents of neurons 2 and 3 weeks post 
transfection. Cells were analysed in voltage clamp protocol in order to elicit Na
+ 
and K
+ 
currents. The currents were subsequently normalised to the cell capacitance. A) An 
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exemplar trace from a neuron 2 weeks post transfection in voltage clamp, top panel shows 
current generated, bottom panel the stimulus. B) An exemplar trace from a neuron 3 weeks 
post transfection in voltage clamp, top panel shows current generated C) Bar graph showing 
the maximal Na
+
 current from each of the transfections, at 2 and 3 weeks post transfection. 
There was a  significant increase at week 2 between NOLZ1 & ISL1 p=0.02 Dunn’s multiple 
comparison Kruskal-Wallis test=9.284 p=0.03. At week 3 there was a significant increase 
between CAG- and NOLZ1-ISL1 Kruskal-Wallis test=10.31, p=0.02 Dunn’s multiple 
comparison p<0.01. Between week 2 and week 3, there was a significant increase in Na
+
 
current in NOLZ1-ISL1 transfected cells Mann-Whitney U=53, p<0.005. D) Bar graph 
showing the maximal K
+
 current from each of the transfections. No significant difference at 
either of the time points, week 2 Kruskal-Wallis test=6.54 p=0.09, week Kruskal-Wallis 
test=6.71 p=0.08. E) Scatter plots showing the mean current density of Na
+
 (top panel) and 
K
+
 (bottom panel) at 2 (left) and 3 (right) weeks post transfection. Error bars on all graphs 
represent SEM. 
5.3.5 Voltage gated Na+ channel activation and inactivation 
To measure the voltage-dependant activation and inactivation of the voltage-gated 
Na+ channels, a protocol was performed to activate the Na+ channels (as per 5.3.4) 
and inactivate them by stepping from the variable voltage sweep (-120 mV and up) 
to 0 mV.  
The voltage at which the hypothetical peak Na+ window current occurs is where the 
activation and inactivation relationships of the Na+ channels meet. This was 
determined because it allows a comparison of both the activation and inactivation 
voltages of the Na+ current, with different subtypes of voltage-gated Na+ channels 
showing different voltage ranges for both (Rush et al., 2005). The larger the sodium 
window is, the more likely a cell is to be able to fire spontaneous action potentials as 
there is a wider range of voltages in which the cells Na+ channels are not inactivated 
and so Na+ ions can move across the membrane from outside of the cell to inside, 
depolarising the membrane potential, which if depolarised enough by the flow of Na+ 
into the cell, causes an action potential to be generated. In order to plot the Na+ 
current activation and inactivation, the non-leak subtracted currents were corrected 
for the driving force of Na+ ions across the membrane, which is +66.68 mV, 
determined from the Nernst equation of Na+ ions, then normalised to the maximal 
current per cell. 
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Nernst equation: 
𝐸𝑁𝑎.+ = 2.303.
𝑅𝑇
𝑍𝐹
. 𝑙𝑜𝑔
[𝑁𝑎+]𝑜
[𝑁𝑎+]𝑖
 
Where R=gas constant (1.98 cal deg-1 mole-1), T=temperature in Kelvin (273.15 + 
temperature in centigrade), Z=valence of ion, F=Faraday constant (23,060 cal volt-1 
equiv-1), [Na+]o=Na
+ concentration outside the cell (135 mM), [Na+]i= Na
+ 
concentration inside the cell (127 mM). 
The Na+ window current of the cells at 2 weeks post transfection (Figure 5.11) was 
larger in cells which have been transfected with ISL1, NOLZ1 or NOLZ1-ISL1 in 
comparison to CAG- transfected cells; this was also evident at 3 weeks post 
transfection. The voltage at which the peak of the Na+ window current was observed 
was determined by the crossing point of the fitted sigmoidal Boltzmann curves. This 
was more hyperpolarised in CAG- transfected cells (-42.7 mV) at week 2 than in the 
NOLZ1 (-41.1 mV), ISL1 (-38.4 mV) or NOLZ1-ISL1 (-39.8 mV) transfected cells. At 
3 weeks, this was depolarised for all the cells (CAG-: -41.3 mV, ISL1: -35.5 mV, and 
NOLZ1: -39.0 mV), with the exception of NOLZ1-ISL1 transfected cells (-40.7 mV).  
When the Na+ channel activation and inactivation data are separated by whether the 
cell was spontaneously firing, attempting to fire or not firing action potentials at all, 
then there also tends to be an increase in the size of the Na+ window in the cells 
which are spontaneously active (week 2: Figure 5.12 and week 3: 5.13). Also cells 
which are spontaneously active at resting Vm, tend to have a resting Vm which lies 
within the Na+ window. 
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Figure 5.11 (above): The sodium window of neurons 2 and 3 weeks post transfection. 
Scatter plots showing the Na+ activation window indicated with arrows under the activation 
and inactivation curves. First column are data from 2 weeks after transfection and the 
second column 3 weeks post transfection. Activation and inactivation data were fitted with 
Sigmoidal Boltzmann equations, to determine the peak of the Na
+
 window. Error bars 
represent SEM. Number of cells analysed stated under each graph.
 
Figure 5.12: The sodium current window of neurons 2 weeks post transfection plotted 
with Vm. Break down of scatter plots showing the Na+ activation window of cells which were 
not spontaneous (1
st
 column), attempting spontaneous activity (2
nd
 column) and 
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spontaneously active cells (3
rd
 column). The resting membrane potentials of the cells are 
also plotted. Top row CAG-, 2
nd
 row, ISL1, 3
rd
 row NOLZ1, 4
th
 row NOLZ1-ISL1. Error bars 
represent SEM.
 
Figure 5.13: The sodium current window of neurons 3 weeks post transfection plotted 
with Vm. Break down of scatter plots showing the Na+ activation window of cells which were 
not spontaneous (1st column), attempting spontaneous activity (2nd column) and 
spontaneously active cells (3rd column). The resting membrane potentials of the cells are 
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also plotted. Top row CAG-, 2nd row, ISL1, 3rd row NOLZ1, 4th row NOLZ1-ISL1. Error bars 
represent SEM.  
  
5.4 GABA currents and NMDA currents with enhancement by 
dopamine D1 agonist 
In order to determine if the neurons were able to respond to GABA and NMDA, a 
characteristic of MSNs, cells at 3 weeks post transfection were recorded in whole 
cell patch clamp utilising bath and pipette solutions from Flores-Hernández et al., 
(2002). This bath solution contained no Mg2+ so not to inactivate the NMDA 
receptors; a holding voltage of -40 mV was used to inactivate the Na+ and Ca2+ 
conductances. The bath and pipette solutions allowed the distinction between 
NMDA- and GABA-evoked currents and between NMDA and GABA miniature 
synaptic currents, with NMDA evoking an inward current and GABA evoking an 
outward current. This was because NMDA channels allow the flow of cations and 
GABA receptors are Cl- channels.  
Dopamine D1 agonist enhancement of NMDA currents were investigated, as this 
has been found to be a characteristic of MSNs and one physiological role of 
DARPP32 in MSNs (Flores-Hernández et al., 2002). 
5.4.1 GABA miniature post synaptic currents 
In order to determine whether cells were forming synapses, the cells were recorded 
to see if they generated any GABAA miniature synaptic currents indicative of 
spontaneous release of GABA at the presynaptic terminal, as exemplified in Figure 
5.14A.  
The proportion of cells which demonstrated GABA miniature synaptic currents was 
7% for the CAG- controls (Figure 5.14B) but rose to 26.3% for ISL1 and 27.8% for 
NOLZ1; interestingly, both together, suppressed GABA currents, only 5.88% of cells 
demonstrated GABA miniature synaptic currents. The number of miniature synaptic 
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currents recorded per cell (Figure 5.14C) showed that on average NOLZ1 
transfected cells had the highest frequency of miniature synaptic currents (26.4 ± 
13.1 per minute, n=5) compared to ISL1 (4.4 ± 0.68 n=5), NOLZ-ISL1 (25, n=1) and 
CAG- transfected cells (18, n=1). NOLZ1 transfected cells also had the largest 
amplitude of GABA miniature synaptic currents (10.9 pA ± 1.31 n=5) in comparison 
to ISL1 (8.87 pA ± 0.95 n=5), CAG- (8.50 pA n=1) and NOLZ1-ISL1 (8.83 pA, n=1, 
Figure 5.14D). The inter-event interval was longest in ISL1 transfected cells 
(11364.6 ms ± 2183.9 n=5, Figure 5.14E) in comparison to NOLZ1 (3641.9 ms ± 
1316.3 n=5), NOLZ1-ISL1 (2357.1 ms, n=1) and CAG- transfected cells (3225.0 ms, 
n=1), this was to be expected as they had the fewest number of miniature synaptic 
currents per cell. No cells showed NMDA miniature synaptic currents. 
5. Morphological and electrophysiological characterisation of transfected neurons 
 
 
- 204 - 
 
Figure 5.14: GABA miniature synaptic currents in neurons 3 weeks post transfection. 
A) An exemplar trace of GABA induced miniature synaptic currents in a neuron B) Bar graph 
showing the percentage of cells which possess GABA miniature synaptic currents, number 
of cells with GABA miniature synaptic currents was indicated on each bar. C) Bar graph 
showing the mean no. of GABA miniature synaptic currents in the neurons. D) Bar graph 
showing the mean current amplitude of GABA miniature synaptic currents of the neurons. E) 
Bar graph showing the inter-event interval of GABA mini miniature synaptic currents in 
neurons. 
5.4.2 GABA currents  
In order to measure post-synaptic GABA currents, cells were held at -40 mV by 
current injection and underwent 3 applications of GABA (100 µM) for 5 seconds, 
5. Morphological and electrophysiological characterisation of transfected neurons 
 
 
- 205 - 
with 90 seconds recovery between each repeat before the next application. The 
average of 3 repeats was taken for GABA application. 
All of the cells responded to GABA (100 µM). The current densities for the cells 
(figure 5.16B) showed that ISL1 transfected cells (46.46132 pA/pF ± 9.99, n=11) 
marginally had the biggest current density in response to GABA, compared to 
NOLZ1 (37.2 pA/pF ± 9.00, n=12), CAG- (41.7 pA/pF ± 7.25, n=13) and NOLZ1-
ISL1 transfected cells (41.4 pA/pF ± 7.60, n=11).  
 
Figure 5.15: GABA currents in neurons 3 weeks post transfection. Neurons were 
analysed at 3 weeks post-transfection by whole cell patch clamp using GABA (100 µM) 
application to elicit GABA currents. All cells which were tested responded to GABA. A) 
Exemplar average trace of GABA currents, averaging 3 GABA applications B) Bar graph 
showing the mean GABA current densities from averaged traces. All graph error bars = 
SEM.  
5.4.3 NMDA currents with D1 enhancement 
In order to determine whether the cells expressed NMDA receptors post-
synaptically, and investigate whether the NMDA current could be potentiated by the 
dopamine D1 agonist, SKF 81297, cells were held at -40 mV and underwent 
between 3 and 9 repeats of NMDA (100 µM) application for 5 seconds, with 90 
seconds recovery each repeat before the next application. The average of 3 repeats 
were taken for each application period; NMDA application, NMDA with dopamine D1 
agonist SKF 81297 (10 µM) application and the final 3 sweeps of NMDA only wash. 
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Not all of the cells responded to NMDA (100 µM). The percentage of cells that 
responded to NMDA was 35.7% for control, 61.5% for NOLZ1, 35.7% in NOLZ1-
ISL1 transfected cells and 53.9% of ISL1 transfected cells. The average current 
densities for the cells for the 3 sweeps, which did respond (Figure 5.16B) show that 
NOLZ1 transfected cells (-2.69 pA/pF ± 0.57, n=7) had the biggest current density in 
response to NMDA, which was increased from  ISL1 (-1.67 pA/pF ± 0.40, n=7) and 
significantly increased from the currents in CAG- (-1.51 pA/pF ± 0.55, n=5) and 
NOLZ1-ISL1 transfected cells (-1.29 pA/pF ± 0.36, n=5, two-way ANOVA F=4.09 
DF=3, 60 p=0.01 Tukey’s multiple comparisons CAG- vs. NOLZ1 p<0.05, NOLZ1-
ISL1 vs NOLZ1 p<0.05). The proportion of cells which responded to NMDA and that 
were then enhanced by SKF 81297 application, a specific dopamine D1 agonist, 
(Figure 5.16C) shows that ISL1 (-1.74 pA/pF ± 0.34, n=7) and NOLZ1-ISL1 
transfected cells (-1.47 pA/pF ± 0.44, n=5) showed enhancement of NMDA current 
with dopamine D1 agonist application in comparison to the CAG- (-1.40 pA/pF ± 
0.63, n=5) or NOLZ1 transfected cells (-2.58 pA/pF ± 0.52, n=7). The cells which 
showed enhancement of NMDA currents by dopamine D1 application showed an 
average increase of current of 24% for ISL1 (range 1-77% n=4), 12.9% for NOLZ1 
(range 1-15% n=3), 25.1% for NOLZ1-ISL1 (range 18.5-35.5% n=3) and for CAG- 
10.5% (range 10-11% n=2). The response of the cells to NMDA in this manner 
showed that they may be of a medium spiny neuronal phenotype (Flores-Hernández 
et al., 2002). This is the first time that this has been reported for human stem cell 
derived neurons. 
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Figure 5.16: NMDA currents in neurons. Neurons were analysed at 3 weeks post-
transfection by whole cell patch clamp using NMDA (100 µM) application to elicit NMDA 
currents. Dopamine D1 agonist SKF 81297 (10 µM) was co-applied with NMDA to try and 
elicit a potentiation of NMDA current. A) An exemplar trace of NMDA currents observed in a 
neuron with an increase in current when the dopamine D1 agonist was applied to cells B) 
Line graph showing the mean NMDA current from averaged traces with or without the 
addition of the D1 dopamine agonist. There was a significant difference between 
transfections two-way repeated measures ANOVA F=4.09 DF=3, 60 p=0.01 with Tukey’s 
multiple comparisons NOLZ1 current densities are significantly different from CAG- and 
NOLZ1-ISL1 both p<0.05. C) Pie charts showing the proportion of cells which showed an 
enhanced/decreased NMDA current after application of the dopamine D1 agonist. Error bars 
= SEM. 
5.5 Conclusions 
At the end of the differentiation protocol (3 weeks): 
Neurons were morphologically more complex with any of the transcription factor 
transfections, alone or in combination than with the control plasmid (Figure 5.3), the 
capacitance of the cells supports this finding at week 3 (Figure 5.4B). The cells 
transfected with NOLZ1-ISL1 displayed a more mature neuronal phenotype, with 
enhanced levels of spontaneous and induced activity, and increased Na+ and K+ 
current densities (Figures 5.5, 5.6, 5.7, 5.8, and 5.10). All the neurons responded to 
GABA (Figure 5.15), and an increased number of neurons which responded to 
Enhanced 
Not enhanced 
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NMDA was seen in NOLZ1 and ISL1 transfected cells compared to control. The 
neurons did not show NMDA miniature synaptic currents, but did show GABA 
miniature synaptic currents; this suggests that there may be NMDA and GABA 
receptors extra-synaptically, but only GABA receptors synaptically in the transfected 
cultures (Figure 5.14). Finally, ISL1 and NOLZ1-ISL1 transfected cells 
demonstrated a functional phenotype that more closely matched that reported for 
rodent MSNs, as judged by NMDA current potentiation by dopamine D1 agonist 
(Figure 5.16). 
5.5.1 Cells become less complex during in vitro culture 
Comparison of complexity between cells at week 1 (Figure 5.1) and week 2 (Figure 
5.2) during differentiation for each of the transfections, showed a decrease in 
complexity with time, in terms of Sholl analysis and number of branches recorded 
per cell. This may have been as a result of axonal pruning (reviewed by 
Vanderhaegen & Cheng 2010). This takes place during brain development, to 
compensate for the overproduction of neurons and synaptic connections between 
neurons (reviewed by Vanderhaegen & Cheng 2010).  These are removed by 
programmed cell death and axosome degradation of aberrant dendrites, to produce 
a mature neuronal network (reviewed by Vanderhaegen & Cheng 2010). Different 
signalling molecules are involved in the pruning of different neuronal populations, 
the striatonigral pathway requires the correct signalling of PlexinD1 expression by 
striatonigral neurons and Sema3E expression in the globus pallidus to repel the 
striatonigral axons, in order to form the correct pathway though the internal capsule 
(Ehrman et al., 2013, Chauvet et al., 2007). The genetic deletion of Plxnd1 
(encoding PlexinD1) in the striatum, results in aberrant synapse formation in the 
thalamo-striatal neurons (Ding et al., 2011). This could be investigated by examining 
the expression of the polysialylated form of neural cell adhesion molecule (PSA-
NCAM) in vitro to analyse if the cells are undergoing dendritic pruning. PSA-NCAM 
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was expressed during rat neuritogenesis, with progressive localisation to the 
synapse in the postnatal rat dorsolateral striatum and undetectable post synaptic 
pruning (Butler et al., 1998).  
The cells are also not as complex as those observed in native MSNs, when cultured 
in vitro (Lerner et al., 2012, Gertler et al., 2008). This could be as a result of not 
receiving the correct external inputs. Mono-culture of E16 (Penrod et al., 2011), E19 
(Segal et al., 2003) and postnatal mouse MSNs (Tian et al., 2010) produced stunted 
dendritic growth. Spine density and dendrite complexity was improved by co-culture 
with mouse E16-19 cortical neurons (Penrod et al., 2011, Tian et al., 2010) or P1 
cortical neurons (Segal et al., 2003). However, there was still a decrease in 
complexity with mouse E16 striatal cultures from 14 to 21 DIV (Penrod et al., 2011). 
Another issue could be that the cells are differentiated in a 2D in vitro system, which 
does not replicate the in vivo environment. Protocols have been developed which try 
to replicate the in vivo conditions, by culturing the cells in scaffolds. Although there 
have been no reports of this with MSNs, cortical neurons have been cultured in 3D 
scaffolds, with improved complexity of morphology, with matrigel and increased 
collagen concentration in the scaffold proving beneficial to neurite outgrowth and 
turning (Srinivasan et al., 2014). Another culture system exploiting the use of 
laminin I in PuraMatrix™, also increased neurite outgrowth, compared with no 
laminin and monolayer culture (Ortinau et al., 2010). 
5.5.2 NOLZ1/ISL1 combined transfections improved the neuronal phenotype at 
week 3 
Morphologically, the most complex neurons at 3 weeks post-platedown were the 
NOLZ1-ISL1 transfected neurons (Figure 5.3). These neurons were the least 
complex when under selection, most likely due to the lower transfection efficiency, 
and consequently, the reduced cell density. The levels of spontaneous and induced 
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electrical activity, as well as the density of the Na+ and K+ currents, were also 
increased in the NOLZ1-ISL1 transfected cells.  
Comparisons between the striatonigral and striatopallidal pathway neurons often 
show little difference in the basic electrophysiological properties in the cells with a 
Vm of approximately -80 mV, but the threshold voltage for action potentials is 
increased in D2+ receptor neurons from -45 mV to -50 mV (Cepeda et al., 2008). 
The threshold voltages observed in the cells transfected with any of the transcription 
factors and control had a threshold voltage of induced action potentials of ~ -30 mV 
(Figure 5.7B), which were not as hyperpolarised as those observed in the mouse 
(Cepeda et al., 2008). The action potential half-width of ~ -0.5-1 ms was observed in 
slices in vivo (Cepeda et al., 2008, Planert et al., 2013), which was smaller than that 
which was observed in vitro in this chapter (Figure 5.7H). Therefore it is likely that 
the cells need to be matured further in vitro, either by co-culture with the correct 
inputs from cortical co-culture, or maintained for longer in vitro, in order to observe 
the decrease in halfwidth, increase in threshold voltage and hyperpolarisation of the 
Vm. However, the amplitude of the action potentials generated by current injection 
was comparable to that seen in vivo. NOLZ1-ISL1 transfected cells had a mean 
spike height of 85.7 mV, which compared to the range observed for cells in vivo was 
comparable (78-100 mV) (Klapstein et al., 2001, Cepeda et al., 2008, Planert et al., 
2013). 
5.5.3 ISL1 and NOLZ1-ISL1 were the best at inducing a MSN-like phenotype 
In support of the protein characterisation (Chapter 4), the morphological and 
physiological data provided an observation that upon ISL1 transfection, a phenotype 
most similar to striatonigral neurons was generated. Sholl analysis of cells 
transfected with ISL1 showed that they formed the more complex neurons at 1 and 
2 weeks with G418 selection (Figure 5.1 and 5.2). At 3 weeks (Figure 5.3), when not 
under selection, NOLZ1-ISL1, followed by ISL1 transfected cells, were the most 
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complex. Evaluation of the neurons of the striatonigral pathway, in comparison to 
the cells of the striatopallidal pathway showed that morphologically, they were more 
complex by Sholl analysis at 10-135 µm from the cell soma and there was a greater 
cumulative neurite length and cell capacitance (Gertler et al., 2008). ISL1 
transfected cells (Figure 5.6) showed decreased excitability in evoked action 
potentials at 3 weeks, but NOLZ1-ISL1 transfected cells more closely resembled 
NOLZ1-transfected cells in terms of excitability of induced action potentials. 
Physiologically, the neurons of the striatonigral pathway are less excitable, with a 
higher rheobase current and the neurons have a more hyperpolarised resting 
membrane potential (Gertler et al., 2008). 
ISL1 and NOLZ1-ISL1 transfected cells also showed an increase in the proportion 
of cells which had NMDA current potentiation by the dopamine D1 agonist (Figure 
5.16). This regulation by dopamine D1 receptors has been shown to be a 
characteristic of rodent MSNs (Flores-Hernándes et al., 2002). The majority of 
research supports the idea that the striatonigral neurons are the MSN cell 
population which express dopamine D1 receptors (Gertler et al., 2008, Gerfen et al., 
1990, Hersch et al., 1995, LeMoine & Bloch 1995), suggesting the forced 
expression of ISL1 might result in more efficient specification of striatonigral 
neurons. The differential expression of some proteins such as the dopamine D1 
receptor, substance P and dopamine D2 receptors, enkephalin and Adora2a 
(Schiffman & Vanderhaegen 1993, LeMoine & Bloch 1995) could be exploited for 
validation that ISL1 transfection causes differentiation to cells of the D1+ striatonigral 
pathway.  
The observation that the neurons in all transfections responded to GABA (Figure 
5.15), showed they expressed GABA receptors. While not all cells responded to 
NMDA, 35.7% of NOLZ1-ISL1 transfected cells and 53.9% of ISL1 transfected cells 
responded to NMDA, showing that these cells have the glutamate receptors 
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required to receive glutamatergic input (Ferino et al., 1987, Jones et al., 1977, 
Royce 1982, Wilson 1987). The fact that no NMDA miniature synaptic currents were 
observed in vitro, showed that there are not likely to be synaptic glutamatergic 
currents generated by neurons in the differentiation protocol. 
In summary, co-transfection of NOLZ1-ISL1 produced cells which were both 
morphologically and electrophysiologically more similar to mature MSNs than cells 
transfected with the control plasmid. Dopamine D1 enhancement of NMDA currents 
were observed in the majority of cells which were transfected with ISL1 or NOLZ1-
ISL1 constructs, in comparison to control.   
5.5.4 Limitations of the methods in this chapter 
The use of electrophysiology allows a vast array of data to be obtained on a cell by 
cell basis. The ability to patch the GFP+ cells means that the cells analysed are only 
those which have been transfected. However, due to the time-consuming nature of 
data collection, there is a limit to the number of cells which can be analysed. 
Therefore data collected is from a small proportion of the population, although 
differences were still observed between the transfections. More cells could be 
analysed with the use of calcium imaging, using a fluorescent Ca2+-sensitive dye to 
monitor responses to different neurotransmitters, however more information could 
not be gathered on the neuronal phenotype. 
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6. Discussion & Future work 
6.1 Summary of data in this thesis 
This thesis is the first report of attempting to make MSNs in vitro from neural 
progenitors derived from pluripotent stem cells by transcription factor transfection. In 
Chapter 3, the formation of the plasmids to be used in Chapters 4 and 5 was 
detailed. The resulting 8 plasmids and control were utilised in the newly validated 
SCM1/2 protocol (Chapter 4) and as a result of an initial screen of plasmids, NOLZ1 
was chosen for further investigation, along with ISL1 and the combination of the two 
transcription factors in plasmids. Further protein characterisation (Chapter 4) at 3 
weeks post-transfection, highlighted ISL1 transfected cells as the most efficient at 
inducing FOXP1, CTIP2 and DARPP32/CTIP2 combined expression.  
These plasmids were also utilised to analyse the form and function of the neurons 
which had been transfected (Chapter 5). The resulting morphology data showed 
ISL1 transfected cells to possess the more complex dendritic arborisation at 1 and 2 
weeks post transfection when selected with G418, to enrich the transfected cell 
population. At 3 weeks NOLZ1-ISL1 and ISL1 transfected cells were the most 
complex. The complexity of the cells decreased from week 1 to week 2. The 
electrophysiological properties of the neurons were also analysed at weeks 2 and 3 
post-transfection and showed transfection of NOLZ1-ISL1 to increase excitability, 
spontaneous activity and the size of the Na+ and K+ current densities. 
Electrophysiological properties which replicate those observed in MSNs, such as 
NMDA currents and potentiation of the current by a dopamine D1 agonist, were 
observed in ISL1 and NOLZ1-ISL1 transfected cells. 
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6.2 ISL1 transfections improve MSN phenotype 
In comparison to the majority of other protocols, the percentage of DARPP32/CTIP2 
co-localisation and FOXP1 expression was increased in the GFP+ cells after ISL1 
transfection. In another protocol, FOXP1 expression was analysed during 
differentiation, where it was observed at 45 DIV post differentiation (Delli Carri et al., 
2013 a&b), and FOXP1 was co-expressed with CTIP2 at 18 DIV in ~30% of cells 
(Danjo et al., 2011). The proportion of DARPP32/CTIP2 co-expression in the 
protocol described in this thesis was higher than has been previously reported by 
the HD iPSC consortium (2012) with results of 5% population of DARPP32+/CTIP2+ 
neurons. The proportion of cells that expressed DARPP32 after ISL1 transfection 
(~12% of the total population) was increased above the 10% observed in several 
protocols (Aubry et al., 2008, Delli Carri et al., 2013 a&b, Shin et al., 2012, El 
Akabawy et al., 2011), but less than others. Indeed, Ma et al., (2012) report having 
made a population of neurons in which 89% of the GABA+ population were 
DARPP32+, and Danjo et al., (2011), show ~50% of cells expressing DARPP32.  
In comparison to MSNs generated from either iPS or ES cells previously 
(highlighted in Chapter 1), the functional properties of the neurons generated here 
by the co-transfection of NOLZ1-ISL1 are certainly comparable, if not superior, to 
those described by other protocols, and are generated in a comparatively short 
period. In the protocol using monolayer differentiation with N2:B27 medium, only 
65% of the cells produced induced action potentials (Shin et al., 2012). In addition to 
this, the differentiation protocol which used dual SMAD inhibition for neuronal 
induction and subsequent use of N2:B27 media, produced a population of neurons 
13% of which showed no firing and 57% showed repetitive firing at 87 days post 
induction (Delli Carri et al., 2013a). In comparison to this study, the NOLZ1-ISL1 
transfected cells produced action potentials in 100% of the cells and 75% of cells 
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produced action potential trains. These results were also obtained after only 37 DIV 
post neural induction, which by comparison shows a dramatic improvement. 
With regards to GABA responses, only 74% of neurons responded to GABA 
application (Delli Carri et al., 2013a), in comparison to 100% of neurons in this 
study, no matter which plasmid was transfected. Comparing Na+ and K+ currents 
between these protocols cannot be performed effectively, due to the way in which 
results have been reported. However, looking at the raw traces (Delli Carri et al., 
2013a), it seemed that cells transfected with NOLZ1-ISL1 produce larger Na+ and 
K+ currents than do those of the Delli Carri protocol. Delli Carri et al., (2013a) also 
report that in a fraction of cells there was a significant attenuation of GABA current 
by dopamine D1 agonist (Delli Carri et al., 2013a). The protocol described herein, 
showed that ISL1 and NOLZ1-ISL1 transfected cells showed enhancement of the 
NMDA current by dopamine D1 agonist, a characteristic of rodent MSNs that has 
never been reported for pluripotent stem cell derived neurons.  
A comparable capacitance and a decreased input resistance was seen at 3 weeks 
post transfection with NOLZ1-ISL1 transfection to a previously reported protocol 
using Shh and VPA for differentiation and recorded at 10 weeks post differentiation 
(Ma et al., 2012). The transfection of NOLZ1-ISL1 gave comparable results for 
physiological properties to the differentiation protocol from the HD iPSC consortium 
which showed spontaneously active cells at 2 weeks and also the cells responded 
to GABA application and produced Na+ and K+ currents during voltage clamp (HD 
iPSC consortium 2012). 
Reports of differentiating HD patient-derived stem cells (ES or iPS) have been 
limited, and have not necessarily been aimed at generating MSNs. MAP2+ neurons 
were made within 3 weeks of neural induction of HD hES cells (Feyeux et al., 2012), 
and Tuj1+/MAP2+ neurons have also been generated (Lu & Palacino 2013). Others 
have had issues with control cells differentiating better than HD lines with a 
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decrease in MAP2+ neurons from 80% (H9 control) to 36-43% in the HD hESC lines 
(Chae et al., 2012). GABAergic neurons have been formed from HD72 iPSCs (Jeon 
et al., 2012), which also express DARPP32 in 27% of the neurons (Jeon et al., 
2014). 
The increase in effectiveness of differentiation towards MSN phenotype of 
neuroprogenitors transfected with ISL1 and NOLZ1 was not surprising as both play 
a major role in development of the striatum and MSNs.  
NOLZ1 has been shown to be co-expressed with GFP in the Drd1:EGFP and 
Drd2:EGFP BAC transgenic mice implicating it in both the striatonigral and 
striatopallidal pathways (Ko et al., 2013). NOLZ1 overexpression led to the up-
regulation of DARPP32 expression in both the initial screen of plasmids and the 
further characterisation, most likely due to its role in activation of RARβ, which in 
turn activates expression of DARPP32 (Liao & Liu 2005, Urbán et al., 2010). 
ISL1 has been shown to have a more specific role in the development of the 
striatonigral pathway and inhibits the differentiation of cells into the striatopallidal 
pathway (Ehrman et al., 2013, Lu et al., 2014). ISL1 is expressed in the MAP2+ 
precursors in the rat, and these cells continue developing in the rat in order to form 
the DARPP32+ neurons (Wang & Liu 2001): ISL1 may therefore play a role 
switching on DARPP32 expression. ISL1 overexpression led to an increased 
expression of FOXP1. As ISL1 is expressed with FOXP1 not only in the striatum, 
but also in the spinal cord (Shu et al., 2001, Ericson et al., 1992, Tsuchida et al., 
1994) it may therefore play a role in switching on FOXP1 expression in both 
locations.  
NOLZ1 and ISL1 are co-expressed in the SVZ and MZ at E16.5, and later in 
development NOLZ1 is co-expressed with FOXP1 (Ko et al., 2013), further 
reinforcing the idea that ISL1 plays a role in switching on FOXP1 expression  
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6.3 Driving differentiation with forced expression of NOLZ1 and 
ISL1 
In comparison with other transcription factor driven protocols, the protocol outlined 
in this thesis has been fairly successful, with MSN markers being expressed and 
functional characteristics similar to MSNs being observed. Other protocols 
(summarised in Chapter 1) often utilise viruses in order to gain a higher efficiency of 
differentiation. These protocols have also started with a variety of cell types, either 
fibroblasts (Vierbuchen et al., 2010, Pfisterer et al., 2011), astroglia (Berninger et 
al., 2007, Heinrich et al., 2010) or PSCs (Zhang et al., 2013). With the cells in this 
thesis already being partially specified into ventral forebrain like precursors possibly 
aided in differentiation, as the fact the method of transcription factor delivery was 
less efficient than these other protocols. The use of viruses would allow for 
improved transcription factor delivery in order to specify a higher proportion of the 
population of cells with the view to making a higher proportion of MSNs in vitro. 
These other protocols have managed to induce neurons which are functionally 
active (Berninger et al., 2007, Vierbuchen et al., 2010, Pfisterer et al., 2011), 
express markers of glutamatergic or GABAergic neurons (Heinrich et al., 2010), and 
have been shown to integrate into the mouse brain (Zhang et al., 2013). Therefore 
improving transcription factor delivery, would likely result in a higher percentage of 
MSNs. 
6.4 Limitations of the thesis 
The molecular, morphological and electrophysiological characteristics of the 
neurons presented herein are characteristic of but not specific to MSNs. FOXP1 is a 
transcription factor that is also expressed in the spinal cord motor column (Shu et 
al., 2001, Ericson et al., 1992, Tsuchida et al., 1994). In the adult mouse, it is also 
expressed (although not exclusively) in the substantia nigra, cerebral cortical layers 
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III-V, pontine nucleus, superior colliculus thalamus, olfactory tubercle and inferior 
olive (Ferland et al., 2003), but it is expressed in the developing striatum and the 
MSNs (Tamura et al., 2003, Takahashi et al., 2003, Tamura et al., 2004).  
CTIP2 is another marker which has widespread expression in the brain, and is 
localised to cerebral cortical layers IV and VI, hippocampal neurons, olfactory cortex 
and the amygdala (Leid et al., 2004). CTIP2 is also expressed in the GABA 
interneurons of the accessory olfactory bulb (Enomoto et al., 2011). 
Supplementary to calbindin as a marker of striatal matrix, it is also considered a 
marker of interneurons (Pickel & Heras 1996, Prensa et al., 1998). Therefore co-
localisation with other markers (of MSNs) was required to determine that it was 
MSNs and not interneurons that were arising from differentiation. 
Similarly, DARPP32, is not specific to the MSNs. The original report of DARPP32 
expression showed it was enriched in the striatum, but was also expressed in 
astrocytes of the medial habenula, along with neurons of the deep perirhinal, 
cingulate and prefrontal cortex (Ouimet et al., 1994). Thus, although DARPP32 
expression alone is not definitive of MSNs, the dopamine enhancement of NMDA 
currents is a physiological characteristic of MSNs, which is dependent upon 
DARPP32 expression (Flores-Hernández et al., 2002). 
As a result of there currently being no definitive MSN marker, these factors need to 
be used together, in order to confirm identity, which is what has been attempted in 
this thesis. 
6.4 Future work:  
6.4.1 Improving the transcription factor delivery 
In order to improve efficiency of conversion into MSNs, there is a need to improve 
transcription factor delivery either with viruses, or by performing drug screens to 
replace NOLZ1 and ISL1 transfection. This has been done for the induction of 
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pluripotent stem cells in a study by Hou et al., (2013), and for the differentiation of 
neural stem cells into neurons ISX9 which activates NeuroD1 expression 
(Schneider et al., 2008) and so it is feasible that this could be done in order to 
replace the need for transfection. Such a small molecule based approach might 
both increase the uniformity of differentiation and by virtue of being able to generate 
neurons by GMP, increase the potential use of the resultant cells in replacement 
therapies. 
6.4.2 A Huntington’s disease model 
The main motivation behind the development of the differentiation protocol was to 
utilise the protocol in iPSCs derived from HD patient fibroblasts, in order to create 
an in vitro disease model. This seems very possible now, with an increased 
percentage of cells which have a phenotype similar to that seen in MSNs, but one 
major consideration needs to be addressed. It has already been shown that there is 
differential transcription factor expression in HD samples in comparison to control 
(Desplats et al., 2008, HD iPSC consortium 2012). In mouse ESCs expressing a 
mutated form of Htt with 150 CAG repeats, there was differential expression of ISL1 
and NOLZ1 compared to control (Lorincz & Zawitowski 2009). NOLZ1 was 
upregulated with a greater than 2-fold change in the CAG150 cells, and ISL1 was 
decreased in the CAG150 cells in comparison to control after 7 days of 
differentiation (Lorincz & Zawitowski 2009). This will need to be addressed by using 
an inducible system of expression of the transcription factors in order to aid 
differentiation, which can be effectively switched off before it masks any disease 
phenotype. 
 
 
  
7. Thesis conclusion 
 
 
- 222 - 
7. Thesis conclusion 
This thesis has shown that ventral forebrain-like neuroprogenitors can be 
differentiated into cells of an MSN phenotype by NOLZ1-ISL1 and ISL1 transfection. 
Technical limitations notwithstanding, this thesis presents data which give us cause 
for optimism. Forced expression of neuron-specific transcription factors may 
represent an exciting way by which to specify homogeneous populations of neurons 
from patient-derived iPS cells for high throughput drug screening, high content 
disease modelling and, potentially, cell-replacement therapies. 
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9. Appendix 
9.1 Sequencing alignments 
Line breaks indicate where sequencing alignments have been run off separate 
primers in order to obtain accurate sequencing data for each gene. 
9.1.1.1  Homo sapiens ISL LIM homeobox 1 (ISL1), mRNA 
Sequence ID: ref|NM_002202.2| 
Query  1     ATGGGAGACATGGGAGATCCACCaaaaaaaaaaCGTCTGATTTCCCTATGTGTTGGTTGC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  549   ATGGGAGACATGGGAGATCCACCAAAAAAAAAACGTCTGATTTCCCTATGTGTTGGTTGC  608 
Query  61    GGCAATCAGATTCACGATCAGTATATTCTGAGGGTTTCTCCGGATTTGGAATGGCATGCG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  609   GGCAATCAGATTCACGATCAGTATATTCTGAGGGTTTCTCCGGATTTGGAATGGCATGCG  668 
Query  121   GCATGTTTGAAATGTGCGGAGTGTAATCAGTATTTGGACGAGAGCTGTACATGCTTTGTT  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  669   GCATGTTTGAAATGTGCGGAGTGTAATCAGTATTTGGACGAGAGCTGTACATGCTTTGTT  728 
Query  181   AGGGATGGGAAAACCTACTGTAAAAGAGATTATATCAGGTTGTACGGGATCAAATGCGCC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  729   AGGGATGGGAAAACCTACTGTAAAAGAGATTATATCAGGTTGTACGGGATCAAATGCGCC  788 
Query  241   AAGTGCAGCATCGGCTTCAGCAAGAACGACTTCGTGATGCGTGCCCGCTCCAAGGTGTAT  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  789   AAGTGCAGCATCGGCTTCAGCAAGAACGACTTCGTGATGCGTGCCCGCTCCAAGGTGTAT  848 
Query  301   CACATCGAGTGTTTCCGCTGTGTGGCCTGCAGCCGCCAGCTCATCCCTGGGGACGAATTT  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  849   CACATCGAGTGTTTCCGCTGTGTGGCCTGCAGCCGCCAGCTCATCCCTGGGGACGAATTT  908 
Query  361   GCGCTTCGGGAGGACGGTCTCTTCTGCCGAGCAGACCACGATGTGGTGGAGAGGGCCAGT  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  909   GCGCTTCGGGAGGACGGTCTCTTCTGCCGAGCAGACCACGATGTGGTGGAGAGGGCCAGT  968 
Query  421   CTAGGCGCTGGCGACCCGCTCAGTCCCCTGCATCCAGCGCGGCCACTGCAAATGGCAGCG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  969   CTAGGCGCTGGCGACCCGCTCAGTCCCCTGCATCCAGCGCGGCCACTGCAAATGGCAGCG  1028 
Query  481   GAGCCCATCTCCGCCAGGCAGCCGGCCCTGCGGCCCCACGTCCACAAGCAGCCGGAGAAG  540 
             ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  1029  GAGCCCATCTCCGCCAGGCAGCCAGCCCTGCGGCCCCACGTCCACAAGCAGCCGGAGAAG  1088 
Query  541   ACCACCCGCGTGCGGACTGTGCTGAACGAGAAGCAGCTGCACACCTTGCGGACCTGCTAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1089  ACCACCCGCGTGCGGACTGTGCTGAACGAGAAGCAGCTGCACACCTTGCGGACCTGCTAC  1148 
 
Query  601   GCCGCAAACCCGCGGCCAGATGCGCTCATGAAGGAGCAACTGGTAGAGATGACGGGCCTC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  1149  GCCGCAAACCCGCGGCCAGATGCGCTCATGAAGGAGCAACTGGTAGAGATGACGGGCCTC  1208 
Query  661   AGTCCCCGTGTGATCCGGGTCTGGTTTCAAAACAAGCGGTGCAAGGACAAGAAGCGAAGC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1209  AGTCCCCGTGTGATCCGGGTCTGGTTTCAAAACAAGCGGTGCAAGGACAAGAAGCGAAGC  1268 
Query  721   ATCATGATGAAGCAACTCCAGCAGCAGCAGCCCAATGACAAAACTAATATCCAGGGGATG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1269  ATCATGATGAAGCAACTCCAGCAGCAGCAGCCCAATGACAAAACTAATATCCAGGGGATG  1328 
Query  781   ACAGGAACTCCCATGGTGGCTGCCAGTCCAGAGAGACACGACGGTGGCTTACAGGCTAAC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1329  ACAGGAACTCCCATGGTGGCTGCCAGTCCAGAGAGACACGACGGTGGCTTACAGGCTAAC  1388 
Query  841   CCAGTGGAAGTACAAAGTTACCAGCCACCTTGGAAAGTACTGAGCGACTTCGCCTTGCAG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1389  CCAGTGGAAGTACAAAGTTACCAGCCACCTTGGAAAGTACTGAGCGACTTCGCCTTGCAG  1448 
Query  901   AGTGACATAGATCAGCCTGCTTTTCAGCAACTGGTCAATTTTTCAGAAGGAGGACCGGGC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1449  AGTGACATAGATCAGCCTGCTTTTCAGCAACTGGTCAATTTTTCAGAAGGAGGACCGGGC  1508 
Query  961   TCTAATTCCACTGGCAGTGAAGTAGCATCAATGTCCTCTCAACTTCCAGATACACCTAAC  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1509  TCTAATTCCACTGGCAGTGAAGTAGCATCAATGTCCTCTCAACTTCCAGATACACCTAAC  1568 
Query  1021  AGCATGGTAGCCAGTCCTATTGAGGC  1046 
             |||||||||||||||||||||||||| 
Sbjct  1569  AGCATGGTAGCCAGTCCTATTGAGGC  1594 
9.1.1.2  Re-cloned Homo sapiens ISL LIM homeobox 1 (ISL1), mRNA 
Sequence ID: ref|NM_002202.2|Length: 2729Number of Matches: 1 
Query  50    ATGGGAGACATGGGAGATCCACCaaaaaaaaaaCGTCTGATTTCCCTATGTGTTGGTTGC  109 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  549   ATGGGAGACATGGGAGATCCACCAAAAAAAAAACGTCTGATTTCCCTATGTGTTGGTTGC  608 
Query  110   GGCAATCAGATTCACGATCAGTATATTCTGAGGGTTTCTCCGGATTTGGAATGGCATGCG  169 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  609   GGCAATCAGATTCACGATCAGTATATTCTGAGGGTTTCTCCGGATTTGGAATGGCATGCG  668 
Query  170   GCATGTTTGAAATGTGCGGAGTGTAATCAGTATTTGGACGAGAGCTGTACATGCTTTGTT  229 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  669   GCATGTTTGAAATGTGCGGAGTGTAATCAGTATTTGGACGAGAGCTGTACATGCTTTGTT  728 
Query  230   AGGGATGGGAAAACCTACTGTAAAAGAGATTATATCAGGTTGTACGGGATCAAATGCGCC  289 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  729   AGGGATGGGAAAACCTACTGTAAAAGAGATTATATCAGGTTGTACGGGATCAAATGCGCC  788 
Query  290   AAGTGCAGCATCGGCTTCAGCAAGAACGACTTCGTGATGCGTGCCCGCTCCAAGGTGTAT  349 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  789   AAGTGCAGCATCGGCTTCAGCAAGAACGACTTCGTGATGCGTGCCCGCTCCAAGGTGTAT  848 
Query  350   CACATCGAGTGTTTCCGCTGTGTGGCCTGCAGCCGCCAGCTCATCCCTGGGGACGAATTT  409 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  849   CACATCGAGTGTTTCCGCTGTGTGGCCTGCAGCCGCCAGCTCATCCCTGGGGACGAATTT  908 
Query  410   GCGCTTCGGGAGGACGGTCTCTTCTGCCGAGCAGACCACGATGTGGTGGAGAGGGCCAGT  469 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  909   GCGCTTCGGGAGGACGGTCTCTTCTGCCGAGCAGACCACGATGTGGTGGAGAGGGCCAGT  968 
Query  470   CTAGGCGCTGGCGACCCGCTCAGTCCCCTGCATCCAGCGCGGCCACTGCAAATGGCAGCG  529 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  969   CTAGGCGCTGGCGACCCGCTCAGTCCCCTGCATCCAGCGCGGCCACTGCAAATGGCAGCG  1028 
Query  530   GAGCCCATCTCCGCCAGGCAGCCGGCCCTGCGGCCCCACGTCCACAAGCAGCCGGAGAAG  589 
             ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  1029  GAGCCCATCTCCGCCAGGCAGCCAGCCCTGCGGCCCCACGTCCACAAGCAGCCGGAGAAG  1088 
Query  590   ACCACCCGCGTGCGGACTGTGCTGAACGAGAAGCAGCTGCACACCTTGCGGACCTGCTAC  649 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1089  ACCACCCGCGTGCGGACTGTGCTGAACGAGAAGCAGCTGCACACCTTGCGGACCTGCTAC  1148 
Query  650   GCCGCAAACCCGCGGCCAGATGCGCTCATGAAGGAGCAACTGGTAGAGATGACGGGCCTC  709 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1149  GCCGCAAACCCGCGGCCAGATGCGCTCATGAAGGAGCAACTGGTAGAGATGACGGGCCTC  1208 
 
Query  1     TGCGGCCCCACGTCCACAAGCAGCCGGAGAAGACCACCCGCGTGCGGACTGTGCTGAACG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1057  TGCGGCCCCACGTCCACAAGCAGCCGGAGAAGACCACCCGCGTGCGGACTGTGCTGAACG  1116 
Query  61    AGAAGCAGCTGCACACCTTGCGGACCTGCTACGCCGCAAACCCGCGGCCAGATGCGCTCA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1117  AGAAGCAGCTGCACACCTTGCGGACCTGCTACGCCGCAAACCCGCGGCCAGATGCGCTCA  1176 
Query  121   TGAAGGAGCAACTGGTAGAGATGACGGGCCTCAGTCCCCGTGTGATCCGGGTCTGGTTTC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1177  TGAAGGAGCAACTGGTAGAGATGACGGGCCTCAGTCCCCGTGTGATCCGGGTCTGGTTTC  1236 
Query  181   AAAACAAGCGGTGCAAGGACAAGAAGCGAAGCATCATGATGAAGCAACTCCAGCAGCAGC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1237  AAAACAAGCGGTGCAAGGACAAGAAGCGAAGCATCATGATGAAGCAACTCCAGCAGCAGC  1296 
Query  241   AGCCCAATGACAAAACTAATATCCAGGGGATGACAGGAACTCCCATGGTGGCTGCCAGTC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1297  AGCCCAATGACAAAACTAATATCCAGGGGATGACAGGAACTCCCATGGTGGCTGCCAGTC  1356 
Query  301   CAGAGAGACACGACGGTGGCTTACAGGCTAACCCAGTGGAAGTACAAAGTTACCAGCCAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1357  CAGAGAGACACGACGGTGGCTTACAGGCTAACCCAGTGGAAGTACAAAGTTACCAGCCAC  1416 
Query  361   CTTGGAAAGTACTGAGCGACTTCGCCTTGCAGAGTGACATAGATCAGCCTGCTTTTCAGC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1417  CTTGGAAAGTACTGAGCGACTTCGCCTTGCAGAGTGACATAGATCAGCCTGCTTTTCAGC  1476 
Query  421   AACTGGTCAATTTTTCAGAAGGAGGACCGGGCTCTAATTCCACTGGCAGTGAAGTAGCAT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1477  AACTGGTCAATTTTTCAGAAGGAGGACCGGGCTCTAATTCCACTGGCAGTGAAGTAGCAT  1536 
Query  481   CAATGTCCTCTCAACTTCCAGATACACCTAACAGCATGGTAGCCAGTCCTATTGAGGCA  539 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1537  CAATGTCCTCTCAACTTCCAGATACACCTAACAGCATGGTAGCCAGTCCTATTGAGGCA  1595 
9.1.2 Homo sapiens zinc finger protein 503 (ZNF503), mRNA 
Sequence ID: ref|NM_032772.4|Length: 3198Number of Matches: 1 
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Query  29    ATGAGCACAGCGCCCTCGCTTTCTGCCCTAAGAAGCAGTAAGCACAgcggcggcggcggc  88 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337   ATGAGCACAGCGCCCTCGCTTTCTGCCCTAAGAAGCAGTAAGCACAGCGGCGGCGGCGGC  396 
Query  89    ggcggaggcggaggcggcggTGCAGACCCTGCCTGGACCAGCGCGCTCTCTGGAAATAGC  148 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  397   GGCGGAGGCGGAGGCGGCGGTGCAGACCCTGCCTGGACCAGCGCGCTCTCTGGAAATAGC  456 
Query  149   TCCGGCCCCGGCCCAGGCTCGTCCCCGGCCGGCAGCACCAAGCCTTTTGTGCACGCCGTG  208 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  457   TCCGGCCCCGGCCCAGGCTCGTCCCCGGCCGGCAGCACCAAGCCTTTTGTGCACGCCGTG  516 
Query  209   CCCCCCTCTGACCCCCTGCGCCAGGCCAACCGCCTGCCAATCAAGGTGCTGAAGATGCTG  268 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  517   CCCCCCTCTGACCCCCTGCGCCAGGCCAACCGCCTGCCAATCAAGGTGCTGAAGATGCTG  576 
Query  269   ACGGCACGAACTGGCCACATTTTGCACCCCGAGTACCTGCAGCCCCTGCCTTCCACGCCG  328 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  577   ACGGCACGAACTGGCCACATTTTGCACCCCGAGTACCTGCAGCCCCTGCCTTCCACGCCG  636 
Query  329   GTCAGCCCCATCGAGCTCGATGCCAAGAAGAGCCCGCTGGCGCTGTTGGCGCAAACATGT  388 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637   GTCAGCCCCATCGAGCTCGATGCCAAGAAGAGCCCGCTGGCGCTGTTGGCGCAAACATGT  696 
Query  389   TCGCAGATCGGGAAGCCCGACCCCTCGCCCTCCTCCAAACTCTCCTCGGTTGCCTCCAAc  448 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  697   TCGCAGATCGGGAAGCCCGACCCCTCGCCCTCCTCCAAACTCTCCTCGGTTGCCTCCAAC  756 
Query  449   gggggcggcgcgggcggtgccggcggcggtgctgcgggcgACAAGGACACCAAATCGGGC  508 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  757   GGGGGCGGCGCGGGCGGTGCCGGCGGCGGTGCTGCGGGCGACAAGGACACCAAATCGGGC  816 
Query  509   CCCCTGAAGCTGAGCGACATCGGCGTGGAGGACAAGTCGAGTTTCAAGCCGTACTCCAAA  568 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  817   CCCCTGAAGCTGAGCGACATCGGCGTGGAGGACAAGTCGAGTTTCAAGCCGTACTCCAAA  876 
Query  569   CCCGGCTCGGATAAGAAGGAGCcgggaggcggcggtggaggcggtggcggtggcgggggc  628 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  877   CCCGGCTCGGATAAGAAGGAGCCGGGAGGCGGCGGTGGAGGCGGTGGCGGTGGCGGGGGC  936 
Query  629   ggcggcgggggtgTTTCGTCGGAGAAGTCGGGATTCCGGGTACCGAGCGCCACCTGCCAG  688 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  937   GGCGGCGGGGGTGTTTCGTCGGAGAAGTCGGGATTCCGGGTACCGAGCGCCACCTGCCAG  996 
Query  689   CCATTCACGCCCAGGACAGGCAGCCCGAGCTCCAGCGCCTCGGCCTGCTCGCCGGGAGGT  748 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  997   CCATTCACGCCCAGGACAGGCAGCCCGAGCTCCAGCGCCTCGGCCTGCTCGCCGGGAGGT  1056 
Query  749   ATGCTGTCCTCGGCCGGGGGTGCCCCGGAGGGCAAGGACGACAAGAAAGACACCGACGTG  808 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1057  ATGCTGTCCTCGGCCGGGGGTGCCCCGGAGGGCAAGGACGACAAGAAAGACACCGACGTG  1116 
 
Query  421   AGACACCGACGTGGGCGGCGGTGGCAAGGGCACCGGGGGCGCCTCGGCCGAAGGGGGACC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1104  AGACACCGACGTGGGCGGCGGTGGCAAGGGCACCGGGGGCGCCTCGGCCGAAGGGGGACC  1163 
Query  481   CACGGGGCTGGCACACGGCCGGATTAGCTGCGGCGGCGGGATTAATGTGGATGTGAACCA  540 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1164  CACGGGGCTGGCACACGGCCGGATTAGCTGCGGCGGCGGGATTAATGTGGATGTGAACCA  1223 
Query  541   GCATCCGGATGGGGGCCCGGGAGGCAAGGCTCTGGGCTCGGACTGCGGCGGTTCATCGGG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1224  GCATCCGGATGGGGGCCCGGGAGGCAAGGCTCTGGGCTCGGACTGCGGCGGTTCATCGGG  1283 
Query  601   CTCCAGCTCCGGCTCCGGCCCCAGCGCGCCCACCTCCTCCTCAGTGTTGGGCTCTGGGCT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1284  CTCCAGCTCCGGCTCCGGCCCCAGCGCGCCCACCTCCTCCTCAGTGTTGGGCTCTGGGCT  1343 
Query  661   GGTGGCTCCCGTGTCACCCTACAAGCCGGGCCAGACAGTGTTCCCTCTGCCTCCCGCGGG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1344  GGTGGCTCCCGTGTCACCCTACAAGCCGGGCCAGACAGTGTTCCCTCTGCCTCCCGCGGG  1403 
Query  721   TATGACCTACCCAGGCAGCCTGGCCGGGGCCTACGCCGGCTACCCGCCCCAGTTCCTGCC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1404  TATGACCTACCCAGGCAGCCTGGCCGGGGCCTACGCCGGCTACCCGCCCCAGTTCCTGCC  1463 
Query  1     AGCCTGGCCGGGGCCTACGCCGGCTACCCGCCCCAGTTCCTGCCACACGGCGTGGCACTT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1420  AGCCTGGCCGGGGCCTACGCCGGCTACCCGCCCCAGTTCCTGCCACACGGCGTGGCACTT  1479 
Query  61    GACCCCACCAAGCCGGGCAGCCTGGTGGGGGCGCAGCTGGCGGCGGCCGCGGCCGGGTCT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1480  GACCCCACCAAGCCGGGCAGCCTGGTGGGGGCGCAGCTGGCGGCGGCCGCGGCCGGGTCT  1539 
Query  121   CTGGGCTGCAGTAAGCCGGCCGGCTCCAGTCCTTTGGCCGGAGCGTCTCCGCCGTCCGTG  180 
             ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
Sbjct  1540  CTGGGCTGCAGTAAGCCGGCCGGCTCCAGCCCTTTGGCCGGAGCGTCTCCGCCGTCCGTG  1599 
Query  181   ATGACAGCCAGTTTGTGCCGGGACCCTTACTGCCTCAGCTACCACTGCGCTAGCCACCTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1600  ATGACAGCCAGTTTGTGCCGGGACCCTTACTGCCTCAGCTACCACTGCGCTAGCCACCTG  1659 
Query  241   GCAGGGGCGGCGGCCGCCAGCGCTTCTTGCGCACATGATCCGGCTGCTGCGGCTGCGGCG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1660  GCAGGGGCGGCGGCCGCCAGCGCTTCTTGCGCACATGATCCGGCTGCTGCGGCTGCGGCG  1719 
Query  301   CTGAAGTCCGGATACCCGCTGGTGTACCCCACGCACCCGCTGCACGGTGTGCACTCCTCG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1720  CTGAAGTCCGGATACCCGCTGGTGTACCCCACGCACCCGCTGCACGGTGTGCACTCCTCG  1779 
Query  361   CTAACGGCCGCCGCGGCTGCTGGCGCCACACCGCCCTCCCTGGCCGGCCACCCCCTCTAC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1780  CTAACGGCCGCCGCGGCTGCTGGCGCCACACCGCCCTCCCTGGCCGGCCACCCCCTCTAC  1839 
Query  421   CCCTACGGCTTTATGCTCCCTAACGACCCACTCCCCCACATCTGCAACTGGGTGTCGGCC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1840  CCCTACGGCTTTATGCTCCCTAACGACCCACTCCCCCACATCTGCAACTGGGTGTCGGCC  1899 
Query  481   AACGGGCCGTGCGACAAGCGCTTCGCCACGTCCGAAGAGCTGCTGAGCCACTTGCGGACC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1900  AACGGGCCGTGCGACAAGCGCTTCGCCACGTCCGAAGAGCTGCTGAGCCACTTGCGGACC  1959 
Query  541   CATACGGCATTTCCCGGGACAGACAAACTGCTGTCGGGCTACCCCAGCTCGTCGTCTCTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1960  CATACGGCATTTCCCGGGACAGACAAACTGCTGTCGGGCTACCCCAGCTCGTCGTCTCTG  2019 
Query  601   GCCAGCGCTGCCGCGGCCGCCATGGCTTGCCACATGCACATCCCCACCTCGGGCGCACCG  660 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2020  GCCAGCGCTGCCGCGGCCGCCATGGCTTGCCACATGCACATCCCCACCTCGGGCGCACCG  2079 
Query  661   GGCAGCCCTGGGACGCTGGCGCTGCGCAGCCCCCACCACGCGCTGGGACTCAGCAGCCGC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2080  GGCAGCCCTGGGACGCTGGCGCTGCGCAGCCCCCACCACGCGCTGGGACTCAGCAGCCGC  2139 
Query  721   TACCACCCCTACTCCAAGAGCCCGCTTCCCACGCCTGGCGCCCCCGTGCCGGTGCCCGCC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2140  TACCACCCCTACTCCAAGAGCCCGCTTCCCACGCCTGGCGCCCCCGTGCCGGTGCCCGCC  2199 
Query  781   GCCACCGGACCGTACTACTCCCCCTACGCCCTCTACGGACAGAGACTGACCACCGCCTCG  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2200  GCCACCGGACCGTACTACTCCCCCTACGCCCTCTACGGACAGAGACTGACCACCGCCTCG  2259 
Query  841   GCGCTGGGGTATCAG  855 
             ||||||||||||||| 
Sbjct  2260  GCGCTGGGGTATCAG  2274 
Query L G C S K P A G S S P L A G A S P P S V 
Subject L G C S K P A G S S P L A G A S P P S V 
MSTAPSLSALRSSKHSGGGGGGGGGGGADPAWTSALSGNSSGPGPGSSPAGSTKPFVHAVPPSDPLRQANR
LPIKVLKMLTARTGHILHPEYLQPLPSTPVSPIELDAKKSPLALLAQTCSQIGKPDPSPSSKLSSVASNGG
GAGGAGGGAAGDKDTKSGPLKLSDIGVEDKSSFKPYSKPGSDKKEPGGGGGGGGGGGGGGGGVSSEKSGFR
VPSATCQPFTPRTGSPSSSASACSPGGMLSSAGGAPEGKDDKKDTDVGGGGKGTGGASAEGGPTGLAHGRI
SCGGGINVDVNQHPDGGPGGKALGSDCGGSSGSSSGSGPSAPTSSSVLGSGLVAPVSPYKPGQTVFPLPPA
GMTYPGSLAGAYAGYPPQFLPHGVALDPTKPGSLVGAQLAAAAAGSLGCSKPAGSSPLAGASPPSVMTASL
CRDPYCLSYHCASHLAGAAAASASCAHDPAAAAAALKSGYPLVYPTHPLHGVHSSLTAAAAAGATPPSLAG
HPLYPYGFMLPNDPLPHICNWVSANGPCDKRFATSEELLSHLRTHTAFPGTDKLLSGYPSSSSLASAAAAA
MACHMHIPTSGAPGSPGTLALRSPHHALGLSSRYHPYSKSPLPTPGAPVPVPAATGPYYSPYALYGQRLTT
ASALGYQ 
 
9.1.3 Homo sapiens zinc finger protein 503, mRNA (cDNA clone 
IMAGE:2967616), complete cds 
Query  52    CTGATACCCCAGCGCCGAGGCGGTGGTCAGTCTCTGTCCGTAGAGGGCGTAGGGGGAGTA  111 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1185  CTGATACCCCAGCGCCGAGGCGGTGGTCAGTCTCTGTCCGTAGAGGGCGTAGGGGGAGTA  1126 
Query  112   GTACGGTCCGGTGGCGGCGGGCACCGGCACGGGGGCGCCAGGCGTGGGAAGCGGGCTCTT  171 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1125  GTACGGTCCGGTGGCGGCGGGCACCGGCACGGGGGCGCCAGGCGTGGGAAGCGGGCTCTT  1066 
Query  172   GGAGTAGGGGTGGTAGCGGCTGCTGAGTCCCAGCGCGTGGTGGGGGCTGCGCAGCGCCAG  231 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1065  GGAGTAGGGGTGGTAGCGGCTGCTGAGTCCCAGCGCGTGGTGGGGGCTGCGCAGCGCCAG  1006 
Query  232   CGTCCCAGGGCTGCCCGGTGCGCCCGAGGTGGGGATGTGCATGTGGCAAGCCATGGCGGC  291 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1005  CGTCCCAGGGCTGCCCGGTGCGCCCGAGGTGGGGATGTGCATGTGGCAAGCCATGGCGGC  946 
Query  292   CGCGGCAGCGCTGGCCAGAGACGACGAGCTGGGGTAGCCCGACAGCAGTTTGTCTGTCCC  351 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  945   CGCGGCAGCGCTGGCCAGAGACGACGAGCTGGGGTAGCCCGACAGCAGTTTGTCTGTCCC  886 
Query  352   GGGAAATGCCGTATGGGTCCGCAAGTGGCTCAGCAGCTCTTCGGACGTGGCGAAGCGCTT  411 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  885   GGGAAATGCCGTATGGGTCCGCAAGTGGCTCAGCAGCTCTTCGGACGTGGCGAAGCGCTT  826 
Query  412   GTCGCACGGCCCGTTGGCCGACACCCAGTTGCAGATGTGGGGGAGTGGGTCGTTAGGGAG  471 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  825   GTCGCACGGCCCGTTGGCCGACACCCAGTTGCAGATGTGGGGGAGTGGGTCGTTAGGGAG  766 
Query  472   CATAAAGCCGTAGGGGTAGAGGGGGTGGCCGGCCAGGGAGGGCGAGGGGTCGGGCTTCCC  531 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  765   CATAAAGCCGTAGGGGTAGAGGGGGTGGCCGGCCAGGGAGGGCGAGGGGTCGGGCTTCCC  706 
Query  532   GATCTGCGAACATGTTTGCGCCAACAGCGCCAGCGGGCTCTTCTTGGCATCGAGCTCGAT  591 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  705   GATCTGCGAACATGTTTGCGCCAACAGCGCCAGCGGGCTCTTCTTGGCATCGAGCTCGAT  646 
Query  592   GGGGCTGACCGGCGTGGAAGGCAGGGGCTGCAGGTACTCGGGGTGCAAAATGTGGCCAGT  651 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645   GGGGCTGACCGGCGTGGAAGGCAGGGGCTGCAGGTACTCGGGGTGCAAAATGTGGCCAGT  586 
Query  652   TCGTGCCGTCAGCATCTTCAGCACCTTGATTGGCAGGCGGTTGGCCTGGCGCAGGGGGTC  711 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  585   TCGTGCCGTCAGCATCTTCAGCACCTTGATTGGCAGGCGGTTGGCCTGGCGCAGGGGGTC  526 
Query  712   AGAGGGGGGCACGGCGTGCACAAAAGGCTTGGTGCTGCCGGCCGGGGACGAGCCTGGGCC  771 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  525   AGAGGGGGGCACGGCGTGCACAAAAGGCTTGGTGCTGCCGGCCGGGGACGAGCCTGGGCC  466 
Query  772   GGGGCCGGAGCTATTTCCAGAGAGCGCGCTGGTCCAGGCAGGGTCTGCAccgccgcctcc  831 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  465   GGGGCCGGAGCTATTTCCAGAGAGCGCGCTGGTCCAGGCAGGGTCTGCACCGCCGCCTCC  406 
Query  832   gcctccgccgccgccgccgccgcTGTGCTTACTGCTTCTTAGGGCAGAAAGCGAGGGCGC  891 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  405   GCCTCCGCCGCCGCCGCCGCCGCTGTGCTTACTGCTTCTTAGGGCAGAAAGCGAGGGCGC  346 
Query  892   TGTGCTCAT  900 
             ||||||||| 
Sbjct  345   TGTGCTCAT  337 
9.1.4 Homo sapiens early B-cell factor 1 (EBF1), mRNA 
Sequence ID: ref|NM_024007.3|Length: 5288Number of Matches: 1 
Query  35    CATGTTTGGGATTCAGGAAAGCATCCAACGGAGTGGAAGCAGCATGAAGGAAGAGCCGCT  94 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  302   CATGTTTGGGATTCAGGAAAGCATCCAACGGAGTGGAAGCAGCATGAAGGAAGAGCCGCT  361 
Query  95    GGGCAGCGGCATGAACGCGGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAA  154 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362   GGGCAGCGGCATGAACGCGGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAA  421 
Query  155   CACGGCGGCGCAGAGCGGGGTGGGTCTGGCCCGGGCTCACTTTGAGAAGCAGCCGCCTTC  214 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  422   CACGGCGGCGCAGAGCGGGGTGGGTCTGGCCCGGGCTCACTTTGAGAAGCAGCCGCCTTC  481 
Query  215   CAATCTGCGGAAATCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGGGCCA  274 
9. Appendix 
 
 
- 247 - 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  482   CAATCTGCGGAAATCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGGGCCA  541 
Query  275   GCCCGTGGAGATCGAGAGGACAGCGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAAGCCAA  334 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  542   GCCCGTGGAGATCGAGAGGACAGCGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAAGCCAA  601 
Query  335   CAGCGAAAAGACCAATAACGGAATTCACTACCGGCTTCAGCTTCTCTACAGCAATGGGAT  394 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  602   CAGCGAAAAGACCAATAACGGAATTCACTACCGGCTTCAGCTTCTCTACAGCAATGGGAT  661 
Query  395   AAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATGACAAAACAAGCCATAGT  454 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  662   AAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATGACAAAACAAGCCATAGT  721 
Query  455   GTATGAAGGCCAAGACAAGAACCCAGAAATGTGCCGAGTCTTGCTCACACATGAGATCAT  514 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  722   GTATGAAGGCCAAGACAAGAACCCAGAAATGTGCCGAGTCTTGCTCACACATGAGATCAT  781 
Query  515   GTGCAGCCGCTGTTGTGACAAGAAAAGCTGTGGCAACCGAAATGAGACTCCCTCAGATCC  574 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  782   GTGCAGCCGCTGTTGTGACAAGAAAAGCTGTGGCAACCGAAATGAGACTCCCTCAGATCC  841 
Query  575   AGTGATAATTGACAGGTTCTTCTTGAAATTTTTCCTCAAATGTAACCAAAATTGCCTAAA  634 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  842   AGTGATAATTGACAGGTTCTTCTTGAAATTTTTCCTCAAATGTAACCAAAATTGCCTAAA  901 
Query  635   GAATGCGGGAAACCCACGTGACATGCGGAGATTCCAGGTCGTGGTGTCTACGACAGTCAA  694 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  902   GAATGCGGGAAACCCACGTGACATGCGGAGATTCCAGGTCGTGGTGTCTACGACAGTCAA  961 
Query  695   TGTGGATGGCCATGTCCTGGCAGTCTCTGATAACATGTTTGTCCATAATAATTCCAAGCA  754 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  962   TGTGGATGGCCATGTCCTGGCAGTCTCTGATAACATGTTTGTCCATAATAATTCCAAGCA  1021 
Query  755   TGGGCGGAGGGCTCGGAGGCTTGACCCCTCGGAAGGTACGCCCTCTTATCTGGAACATGC  814 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1022  TGGGCGGAGGGCTCGGAGGCTTGACCCCTCGGAAGGTACGCCCTCTTATCTGGAACATGC  1081 
Query  815   TACTCCCTGTATCAAAGCCATCAGCCCGAGTGAAGGATGGACGACGGGAGGTGCGACTGT  874 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1082  TACTCCCTGTATCAAAGCCATCAGCCCGAGTGAAGGATGGACGACGGGAGGTGCGACTGT  1141 
Query  875   GATCATCATAGGGGACAATTTCTTTGATGGGTTACAGGTCATATTCGGTACCATGCTGGT  934 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1142  GATCATCATAGGGGACAATTTCTTTGATGGGTTACAGGTCATATTCGGTACCATGCTGGT  1201 
Query  935   CTGGAGTGAGTTGATCACTCCTCATGCCATCCGTGTGCAG  974 
             |||||||||||||||||||||||||||||||||||||||| 
Sbjct  1202  CTGGAGTGAGTTGATCACTCCTCATGCCATCCGTGTGCAG  1241 
 
Query  241   TCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCCCTGGTGTTGTGGAAG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1216  TCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCCCTGGTGTTGTGGAAG  1275 
Query  301   TCACACTGTCCTACAAATCTAAGCAGTTCTGCAAAGGAACACCAGGCAGATTCATTTATA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1276  TCACACTGTCCTACAAATCTAAGCAGTTCTGCAAAGGAACACCAGGCAGATTCATTTATA  1335 
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Query  361   CAGCGCTCAACGAACCCACCATCGATTATGGTTTCCAGAGGTTACAGAAGGTCATTCCTC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1336  CAGCGCTCAACGAACCCACCATCGATTATGGTTTCCAGAGGTTACAGAAGGTCATTCCTC  1395 
Query  421   GGCACCCTGGTGACCCTGAGCGTTTGCCAAAGGAAGTAATACTCAAAAGGGCTGCGGATC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1396  GGCACCCTGGTGACCCTGAGCGTTTGCCAAAGGAAGTAATACTCAAAAGGGCTGCGGATC  1455 
Query  481   TGGTAGAAGCACTGTATGGGATGCCACACAACAACCAGGAAATCATTCTGAAGAGAGCGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1456  TGGTAGAAGCACTGTATGGGATGCCACACAACAACCAGGAAATCATTCTGAAGAGAGCGG  1515 
Query  541   CCGACATTGCCGAGGCCCTGTACAGTGTTCCCCGCAACCACAACCAACTCCCGGCCCTTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1516  CCGACATTGCCGAGGCCCTGTACAGTGTTCCCCGCAACCACAACCAACTCCCGGCCCTTG  1575 
Query  601   CTAACACCTCGGTCCACGCAGGGATGATGGGCGTGAATTCGTTCAGTGGACAACTGGCCG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1576  CTAACACCTCGGTCCACGCAGGGATGATGGGCGTGAATTCGTTCAGTGGACAACTGGCCG  1635 
Query  661   TGAATGTCTCCGAGGCATCACAAGCCACCAATCAGGGTTTCACCCGCAACTCAAGCAGCG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1636  TGAATGTCTCCGAGGCATCACAAGCCACCAATCAGGGTTTCACCCGCAACTCAAGCAGCG  1695 
Query  721   TATCACCACACGGGTACGTGCCGAGCACCACTCCCCAGCAGACCAACTATAACTCCGTCA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1696  TATCACCACACGGGTACGTGCCGAGCACCACTCCCCAGCAGACCAACTATAACTCCGTCA  1755 
Query  781   CCACGAGCATGAACGGATACGGCTCTGCCGCAATGTCCAATTTGGGCGGCTCCCCCACCT  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1756  CCACGAGCATGAACGGATACGGCTCTGCCGCAATGTCCAATTTGGGCGGCTCCCCCACCT  1815 
Query  841   TCCTCAACGGCTCAGCTGCCAACTCCCCCTATGCCATAGTGCCATCCAGCCCCACCATGG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1816  TCCTCAACGGCTCAGCTGCCAACTCCCCCTATGCCATAGTGCCATCCAGCCCCACCATGG  1875 
Query  901   CCTCCTCCACAAGCCTCCCCTCCAACTGCAGCAGCTCCTCGGGCATCTTCTCCTTCTCAC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1876  CCTCCTCCACAAGCCTCCCCTCCAACTGCAGCAGCTCCTCGGGCATCTTCTCCTTCTCAC  1935 
Query  961   CAGCCAACATGGTCTCAGCCGTGAAACAGAAGAGTGCTTTCGCACCAGTCGTCAGACCCC  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1936  CAGCCAACATGGTCTCAGCCGTGAAACAGAAGAGTGCTTTCGCACCAGTCGTCAGACCCC  1995 
 
Query  421   GAAACAGAAGAGTGCTTTCGCACCAGTCGTCAGACCCCAGACCTCCCCACCTCCCACCTG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1958  GAAACAGAAGAGTGCTTTCGCACCAGTCGTCAGACCCCAGACCTCCCCACCTCCCACCTG  2017 
Query  481   CACCAGCACCAACGGGAACAGCCTGCAAGCGATATCTGGCATGATTGTTCCTCCTATG  538 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2018  CACCAGCACCAACGGGAACAGCCTGCAAGCGATATCTGGCATGATTGTTCCTCCTATG  2075 
9.1.5 Homo sapiens POU class 3 homeobox 1 (POU3F1), mRNA 
Query  23   TTACCGTAGAGCGTGCCCAGCGCCAGCCCCACGTCGGCCTGCGTAAAGCCCAGCTTGATG  82 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  892  TTACCGTAGAGCGTGCCCAGCGCCAGCCCCACGTCGGCCTGCGTAAAGCCCAGCTTGATG  833 
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Query  83   CGCCGCTGCTTGAACTGCTTGGCGAACTGCTCCAGGTCGTCCGAGCTGGGCGCATCCTCG  142 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  832  CGCCGCTGCTTGAACTGCTTGGCGAACTGCTCCAGGTCGTCCGAGCTGGGCGCATCCTCG  773 
Query  143  TCCGAGTGCTCGCCCACCGATGAgccgccgccgcccgcgcccgggtgcaggtgcgccgcc  202 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  772  TCCGAGTGCTCGCCCACCGATGAGCCGCCGCCGCCCGCGCCCGGGTGCAGGTGCGCCGCC  713 
Query  203  gccgcgtgcaggccgcccgcgtgtgcatgtccgtgtgcgtgtccgtgggcgccCAGATGC  262 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  712  GCCGCGTGCAGGCCGCCCGCGTGTGCATGTCCGTGTGCGTGTCCGTGGGCGCCCAGATGC  653 
Query  263  GGCGGCGGCGACGGCTCCAGCTGCGCCTCGTGGCCATCCTCGTGCAGCGCGTGGTGCAgg  322 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  652  GGCGGCGGCGACGGCTCCAGCTGCGCCTCGTGGCCATCCTCGTGCAGCGCGTGGTGCAGG  593 
Query  323  cccggccccgcgccgccaccgcccgccgccagcatcccggccaggccgccgccgccgccc  382 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  592  CCCGGCCCCGCGCCGCCACCGCCCGCCGCCAGCATCCCGGCCAGGCCGCCGCCGCCGCCC  533 
Query  383  cccgggtaggccgccTGCGCGTACAGCCCGAGCGGCTGGGGCTGGTGGCCCCCGCTGGCC  442 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  532  CCCGGGTAGGCCGCCTGCGCGTACAGCCCGAGCGGCTGGGGCTGGTGGCCCCCGCTGGCC  473 
Query  443  CCGGGCGAGGGCGACATGGCCGGGCCCAAGTGGTGCGCTGTGCTGCCCTGCGCCCATGCC  502 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  472  CCGGGCGAGGGCGACATGGCCGGGCCCAAGTGGTGCGCTGTGCTGCCCTGCGCCCATGCC  413 
Query  503  GCGCCCGCGTGGGCCGCCCCCTGGTGCACCAGGCGCGCGTGGAAACCTccgccgccgccg  562 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  412  GCGCCCGCGTGGGCCGCCCCCTGGTGCACCAGGCGCGCGTGGAAACCTCCGCCGCCGCCG  353 
Query  563  ccgtcgtcggctcggccggtgccgccgccgcctgccttgccgtgttctaggtgcgggccg  622 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  352  CCGTCGTCGGCTCGGCCGGTGCCGCCGCCGCCTGCCTTGCCGTGTTCTAGGTGCGGGCCG  293 
Query  623  ccggcccaatcgccgccgccgccTCCTCCCGTGGGTAGCCACTGGGGGTGCGCTAGGCCC  682 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  292  CCGGCCCAATCGCCGCCGCCGCCTCCTCCCGTGGGTAGCCACTGGGGGTGCGCTAGGCCC  233 
Query  683  ACGGGGTGGCCCGCGCCCGCGCCCAGCCACTCGTGGTGCATCAGCTTCTGCACTTCGCGG  742 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  232  ACGGGGTGGCCCGCGCCCGCGCCCAGCCACTCGTGGTGCATCAGCTTCTGCACTTCGCGG  173 
Query  743  TACGCGGCCCCTGCATGCAATCGCTCCGCGgccgccgccgccgccgccgccgccgcGGCG  802 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  172  TACGCGGCCCCTGCATGCAATCGCTCCGCGGCCGCCGCCGCCGCCGCCGCCGCCGCGGCG  113 
Query  803  TCCGGGTGCATAAGCGGCCCGGTGCCCCCGGCTCCGCCACCGGGGCCCCGCGGCAGGTAC  862 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  112  TCCGGGTGCATAAGCGGCCCGGTGCCCCCGGCTCCGCCACCGGGGCCCCGCGGCAGGTAC  53 
Query  863  TGCGCGGTGGTGGCCATG  880 
            |||||||||||||||||| 
Sbjct  52   TGCGCGGTGGTGGCCATG  35 
 
Query  25    TACGGTAACGTGTTCTCGCAGACCACCATCTGCCGCTTCGAGGCCCTGCAGCTGAGCTTC  84 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  885   TACGGTAACGTGTTCTCGCAGACCACCATCTGCCGCTTCGAGGCCCTGCAGCTGAGCTTC  944 
 
 
Query  85    AAGAACATGTGCAAGCTCAAGCCGCTGCTCAACAAGTGGCTGGAGGAGACCGACTCGTCC  144 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  945   AAGAACATGTGCAAGCTCAAGCCGCTGCTCAACAAGTGGCTGGAGGAGACCGACTCGTCC  1004 
Query  145   AGCGGCAGCCCCACCAACCTGGACAAGATCGCGGCGCAGGGCCGCAAGCGCAAGAAGCGC  204 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1005  AGCGGCAGCCCCACCAACCTGGACAAGATCGCGGCGCAGGGCCGCAAGCGCAAGAAGCGC  1064 
Query  205   ACGTCCATCGAGGTGGGGGTCAAAGGCGCGCTCGAGAGCCACTTTCTCAAGTGCCCCAAG  264 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1065  ACGTCCATCGAGGTGGGGGTCAAAGGCGCGCTCGAGAGCCACTTTCTCAAGTGCCCCAAG  1124 
Query  265   CCCTCGGCGCACGAGATCACCGGCTTGGCAGACAGCCTGCAGCTGGAGAAGGAGGTGGTG  324 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1125  CCCTCGGCGCACGAGATCACCGGCTTGGCAGACAGCCTGCAGCTGGAGAAGGAGGTGGTG  1184 
Query  325   CGCGTCTGGTTCTGCAACCGGCGGCAGAAGGAGAAGCGCATGACCCCTGCGGCCGGCGCG  384 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1185  CGCGTCTGGTTCTGCAACCGGCGGCAGAAGGAGAAGCGCATGACCCCTGCGGCCGGCGCG  1244 
Query  385   GGCCACCCGCCCATGGACGATGTATACGCGCCTGGGGAGCTAGGGCCTGGCGGGGGCGGC  444 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1245  GGCCACCCGCCCATGGACGATGTATACGCGCCTGGGGAGCTAGGGCCTGGCGGGGGCGGC  1304 
Query  445   GCATcgccaccctccgcgcccccaccgcccccgccggcggcgctgcaccaccaccaccac  504 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1305  GCATCGCCACCCTCCGCGCCCCCACCGCCCCCGCCGGCGGCGCTGCACCACCACCACCAC  1364 
Query  505   cacacacTGCCCGGCTCAGTGCAG  528 
             |||||||||||||||||||||||| 
Sbjct  1365  CACACACTGCCCGGCTCAGTGCAG  1388 
9.1.6 Homo sapiens forkhead box P1 (FOXP1), transcript variant 1, mRNA 
Sequence ID: ref|NM_032682.5|Length: 7102Number of Matches: 1 
 
Query  1     TTCAGCCATCCAGAATGGGTCGGGCGGCAGCAACCACTTACTAGAGTGCGGCGGTCTTCG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  565   TTCAGCCATCCAGAATGGGTCGGGCGGCAGCAACCACTTACTAGAGTGCGGCGGTCTTCG  624 
Query  61    GGAGGGGCGGTCCAACGGAGAGACGCCGGCCGTGGACATCGGGGCAGCTGACCTCGCCCA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  625   GGAGGGGCGGTCCAACGGAGAGACGCCGGCCGTGGACATCGGGGCAGCTGACCTCGCCCA  684 
Query  121   CGCCcagcagcagcagcaacaggcacttcaggtggcaagacagctccttcttcagcagca  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  685   CGCCCAGCAGCAGCAGCAACAGGCACTTCAGGTGGCAAGACAGCTCCTTCTTCAGCAGCA  744 
Query  181   acagcagcagcaaGTTAGTGGATTAAAATCTCCCAAGAGGAATGACAAACAACCAGCTCT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  745   ACAGCAGCAGCAAGTTAGTGGATTAAAATCTCCCAAGAGGAATGACAAACAACCAGCTCT  804 
Query  241   TCAGGTTCCCGTGTCAGTGGCTATGATGACACCTCAAGTTATCACTCCCCAGCAAATGCA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  805   TCAGGTTCCCGTGTCAGTGGCTATGATGACACCTCAAGTTATCACTCCCCAGCAAATGCA  864 
Query  301   GCAGATCCTCCAGCAACAAGTGCTGAGCCCTCAGCAGCTCCAGGTTCTCCTCCAGCAGCA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  865   GCAGATCCTCCAGCAACAAGTGCTGAGCCCTCAGCAGCTCCAGGTTCTCCTCCAGCAGCA  924 
Query  361   GCAGGCCCTCATGCTTCAACAGCAGCAGCTTCAAGAGTTTTATAAAAAACAACAGGAACA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  925   GCAGGCCCTCATGCTTCAACAGCAGCAGCTTCAAGAGTTTTATAAAAAACAACAGGAACA  984 
Query  421   GTTGCAGCTTCAACTTTTACAACAACAACATGCTGGAAAACAGCCTAAAGAGCAACAGCA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  985   GTTGCAGCTTCAACTTTTACAACAACAACATGCTGGAAAACAGCCTAAAGAGCAACAGCA  1044 
Query  481   GGTGGCTACCcagcagttggcttttcagcagcagcttttacagatgcagcagttacagca  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1045  GGTGGCTACCCAGCAGTTGGCTTTTCAGCAGCAGCTTTTACAGATGCAGCAGTTACAGCA  1104 
Query  541   gcagcaCCTCCTGTCTTTGCAGCGCCAAGGCCTTCTGACAATTCAGCCCGGGCAGCCTGC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1105  GCAGCACCTCCTGTCTTTGCAGCGCCAAGGCCTTCTGACAATTCAGCCCGGGCAGCCTGC  1164 
Query  601   CCTTCCCCTTCAACCTCTTGCTCAAGGCATGATTCCAACAGAACTGCAGCAGCTCTGGAA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1165  CCTTCCCCTTCAACCTCTTGCTCAAGGCATGATTCCAACAGAACTGCAGCAGCTCTGGAA  1224 
Query  661   AGAAGTGACAAGTGCTCATACTGCAGAAGAAACCACAGGCAACAATCACAGCAGTTTGGA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1225  AGAAGTGACAAGTGCTCATACTGCAGAAGAAACCACAGGCAACAATCACAGCAGTTTGGA  1284 
Query  721   TCTGACCACGACATGTGTCTCCTCCTCTGCACCTTCCAAGACCTCCTTAATAATGAACCC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1285  TCTGACCACGACATGTGTCTCCTCCTCTGCACCTTCCAAGACCTCCTTAATAATGAACCC  1344 
Query  781   ACATGCCTCTACCAATGGACAGCTCTCAGTCCACACTCCCAAAAGGGAAAGTTTGTCCCA  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1345  ACATGCCTCTACCAATGGACAGCTCTCAGTCCACACTCCCAAAAGGGAAAGTTTGTCCCA  1404 
Query  841   TGAGGAGCACCCCCATAGCCATCCTCTCTATGGACATGGTGTATGCAAGTGGCCAGGCTG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1405  TGAGGAGCACCCCCATAGCCATCCTCTCTATGGACATGGTGTATGCAAGTGGCCAGGCTG  1464 
Query  901   TGAAGCAGTGTGCGAAGATTTCCAATCATTTCTAAAACATCTCAACAGTGAGCATGCGCT  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1465  TGAAGCAGTGTGCGAAGATTTCCAATCATTTCTAAAACATCTCAACAGTGAGCATGCGCT  1524 
Query  961   GGACGATAGAAGTACAGCCCAATGTAGAGTACAAATGCAGGTTGTACAGCAGTTAGAGCT  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1525  GGACGATAGAAGTACAGCCCAATGTAGAGTACAAATGCAGGTTGTACAGCAGTTAGAGCT  1584 
Query  1     AATCTGGACTGTGGTTGGCTGTTGTCACTAAGGACAGGGGCCCTTCAGCTTCCTCTGGAT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2507  AATCTGGACTGTGGTTGGCTGTTGTCACTAAGGACAGGGGCCCTTCAGCTTCCTCTGGAT  2448 
Query  61    CGAGGGGCTCTTCTTTGACGTGTACAGGATGCACGGCTTGCATAGGAGATCTGCCTGGAC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2447  CGAGGGGCTCTTCTTTGACGTGTACAGGATGCACGGCTTGCATAGGAGATCTGCCTGGAC  2388 
Query  121   TGCTGTCACTCTCGTTGCTGTTGGTATGCTCCATTGCCCCGTTCAGCTCTTCCCGTATTG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
9. Appendix 
 
 
- 252 - 
Sbjct  2387  TGCTGTCACTCTCGTTGCTGTTGGTATGCTCCATTGCCCCGTTCAGCTCTTCCCGTATTG  2328 
Query  181   CGCTGGCTAAGTTGCCCAGAGTGGGATTTCCCATGGAAGCGGTAGTGTATAGAGGTATAC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2327  CGCTGGCTAAGTTGCCCAGAGTGGGATTTCCCATGGAAGCGGTAGTGTATAGAGGTATAC  2268 
Query  241   TATTCTCAGCCATTGAAGCCTGTAAAGCTGCATTGAGAGGTGTGCAGTAGGCGTGGCTGC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2267  TATTCTCAGCCATTGAAGCCTGTAAAGCTGCATTGAGAGGTGTGCAGTAGGCGTGGCTGC  2208 
Query  301   TCTGCATGTTTTTAATAAGGGAAGGGTTACCACTGATCTTTTGTGGCCTTCGTTTTTGGA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2207  TCTGCATGTTTTTAATAAGGGAAGGGTTACCACTGATCTTTTGTGGCCTTCGTTTTTGGA  2148 
Query  361   ATTCTACTTCATCCACTGTCCATACTGCCCCTTTAACGTTTTCTACTCGCACAAAACACT  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2147  ATTCTACTTCATCCACTGTCCATACTGCCCCTTTAACGTTTTCTACTCGCACAAAACACT  2088 
Query  421   TGTGAAGACTAAGATTATGACGCACTGCATTCTTCCACGTGGCCGCGTTGCGTCGGAAGT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2087  TGTGAAGACTAAGATTATGACGCACTGCATTCTTCCACGTGGCCGCGTTGCGTCGGAAGT  2028 
Query  481   AAGCAAACATTCGTGTGAACCAGTTATAGATCTCATTTAGTGTTAGCTGCTTTTCTGGAG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2027  AAGCAAACATTCGTGTGAACCAGTTATAGATCTCATTTAGTGTTAGCTGCTTTTCTGGAG  1968 
Query  541   ATTCGAGAATGGCCTGCCTAATTAAAGATGCATATGTAAATGGTGGTCTAACTTCTGCGT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1967  ATTCGAGAATGGCCTGCCTAATTAAAGATGCATATGTAAATGGTGGTCTAACTTCTGCGT  1908 
Query  601   TCTTATAAAATTCTTGGTTCTGCGCAATATCTGCTGACGAAATGGGCACGTTGTATTTGT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1907  TCTTATAAAATTCTTGGTTCTGCGCAATATCTGCTGACGAAATGGGCACGTTGTATTTGT  1848 
Query  661   CTGAGTACCGCCTGCGGATGGGTCCCACCGTGTGCATGCTGGTGGTTGTGATGACAGAGG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1847  CTGAGTACCGCCTGCGGATGGGTCCCACCGTGTGCATGCTGGTGGTTGTGATGACAGAGG  1788 
Query  721   GGCCTTGGGTGACGGGAGTCAGGGGGGCGGTTGGGGTCGTTGGAGTATGAGGTAAGCTCT  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1787  GGCCTTGGGTGACGGGAGTCAGGGGGGCGGTTGGGGTCGTTGGAGTATGAGGTAAGCTCT  1728 
Query  781   GTGGAGAAGCCTCCGATGCGGACTTGGAGAGAGTGACACTTGATACCAGATTCAAGGGCT  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1727  GTGGAGAAGCCTCCGATGCGGACTTGGAGAGAGTGACACTTGATACCAGATTCAAGGGCT  1668 
Query  841   GAGGGGCGGCTTTGGGTTCTGTAGACTTCACATGCAGGTGGGTCATCATGGCTTGCAGGC  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1667  GAGGGGCGGCTTTGGGTTCTGTAGACTTCACATGCAGGTGGGTCATCATGGCTTGCAGGC  1608 
Query  901   GTTCTTTGTCTTTTGCAAGCTGTAGCTCTAACTGCTGTACAACCTGCATTTGTACTCTAC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1607  GTTCTTTGTCTTTTGCAAGCTGTAGCTCTAACTGCTGTACAACCTGCATTTGTACTCTAC  1548 
Query  961   ATTGGGCTGTACTTCTATCGTCCAGCGCATGCTCACTGTTGAGATGTTTTAGAAATGATT  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1547  ATTGGGCTGTACTTCTATCGTCCAGCGCATGCTCACTGTTGAGATGTTTTAGAAATGATT  1488 
Query  1021  GGAAATCTTCGCACACTGCTTCACAGCC  1048 
             |||||||||||||||||||||||||||| 
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Sbjct  1487  GGAAATCTTCGCACACTGCTTCACAGCC  1460 
Query  1     GCACCTCCTGTCTTTGCAGCGCCAAGGCCTTCTGACAATTCAGCCCGGGCAGCCTGCCCT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1108  GCACCTCCTGTCTTTGCAGCGCCAAGGCCTTCTGACAATTCAGCCCGGGCAGCCTGCCCT  1167 
Query  61    TCCCCTTCAACCTCTTGCTCAAGGCATGATTCCAACAGAACTGCAGCAGCTCTGGAAAGA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1168  TCCCCTTCAACCTCTTGCTCAAGGCATGATTCCAACAGAACTGCAGCAGCTCTGGAAAGA  1227 
Query  121   AGTGACAAGTGCTCATACTGCAGAAGAAACCACAGGCAACAATCACAGCAGTTTGGATCT  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1228  AGTGACAAGTGCTCATACTGCAGAAGAAACCACAGGCAACAATCACAGCAGTTTGGATCT  1287 
Query  181   GACCACGACATGTGTCTCCTCCTCTGCACCTTCCAAGACCTCCTTAATAATGAACCCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1288  GACCACGACATGTGTCTCCTCCTCTGCACCTTCCAAGACCTCCTTAATAATGAACCCACA  1347 
Query  241   TGCCTCTACCAATGGACAGCTCTCAGTCCACACTCCCAAAAGGGAAAGTTTGTCCCATGA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1348  TGCCTCTACCAATGGACAGCTCTCAGTCCACACTCCCAAAAGGGAAAGTTTGTCCCATGA  1407 
Query  301   GGAGCACCCCCATAGCCATCCTCTCTATGGACATGGTGTATGCAAGTGGCCAGGCTGTGA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1408  GGAGCACCCCCATAGCCATCCTCTCTATGGACATGGTGTATGCAAGTGGCCAGGCTGTGA  1467 
Query  361   AGCAGTGTGCGAAGATTTCCAATCATTTCTAAAACATCTCAACAGTGAGCATGCGCTGGA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1468  AGCAGTGTGCGAAGATTTCCAATCATTTCTAAAACATCTCAACAGTGAGCATGCGCTGGA  1527 
Query  421   CGATAGAAGTACAGCCCAATGTAGAGTACAAATGCAGGTTGTACAGCAGTTAGAGCTACA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1528  CGATAGAAGTACAGCCCAATGTAGAGTACAAATGCAGGTTGTACAGCAGTTAGAGCTACA  1587 
Query  481   GCTTGCAAAAGACAAAGAACGCCTGCAAGCCATGATGACCCACCTGCATGTGAAGTCTAC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1588  GCTTGCAAAAGACAAAGAACGCCTGCAAGCCATGATGACCCACCTGCATGTGAAGTCTAC  1647 
Query  541   AGAACCCAAAGCCGCCCCTCAGCCCTTGAATCTGGTATCAAGTGTCACTCTCTCCAAGTC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1648  AGAACCCAAAGCCGCCCCTCAGCCCTTGAATCTGGTATCAAGTGTCACTCTCTCCAAGTC  1707 
Query  601   CGCATCGGAGGCTTCTCCACAGAGCTTACCTCATACTCCAACGACCCCAACCGCCCCCCT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1708  CGCATCGGAGGCTTCTCCACAGAGCTTACCTCATACTCCAACGACCCCAACCGCCCCCCT  1767 
Query  661   GACTCCCGTCACCCAAGGCCCCTCTGTCATCACAACCACCAGCATGCACACGGTGGGACC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1768  GACTCCCGTCACCCAAGGCCCCTCTGTCATCACAACCACCAGCATGCACACGGTGGGACC  1827 
Query  721   CATCCGCAGGCGGTACTCAGACAAATACAACGTGCCCATTTCGTCAGCAGATATTGCGCA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1828  CATCCGCAGGCGGTACTCAGACAAATACAACGTGCCCATTTCGTCAGCAGATATTGCGCA  1887 
Query  781   GAACCAAGAATTTTATAAGAACGCAGAAGTTAGACCACCATTTACATATGCATCTTTAAT  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1888  GAACCAAGAATTTTATAAGAACGCAGAAGTTAGACCACCATTTACATATGCATCTTTAAT  1947 
Query  841   TAGGCAGGCCATTCTCGAATCTCCAGAAAAGCAGCTAACACTAAATGAGATCTATAACTG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  1948  TAGGCAGGCCATTCTCGAATCTCCAGAAAAGCAGCTAACACTAAATGAGATCTATAACTG  2007 
Query  60    AAGCTGCTGCTGTTGAAGCATGAGGGCCTGCTGCTGCTGGAGGAGAACCTGGAGCTGCTG  119 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  955   AAGCTGCTGCTGTTGAAGCATGAGGGCCTGCTGCTGCTGGAGGAGAACCTGGAGCTGCTG  896 
Query  120   AGGGCTCAGCACTTGTTGCTGGAGGATCTGCTGCATTTGCTGGGGAGTGATAACTTGAGG  179 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  895   AGGGCTCAGCACTTGTTGCTGGAGGATCTGCTGCATTTGCTGGGGAGTGATAACTTGAGG  836 
Query  180   TGTCATCATAGCCACTGACACGGGAACCTGAAGAGCTGGTTGTTTGTCATTCCTCTTGGG  239 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  835   TGTCATCATAGCCACTGACACGGGAACCTGAAGAGCTGGTTGTTTGTCATTCCTCTTGGG  776 
Query  240   AGATTTTAATCCACTAACttgctgctgctgttgctgctgaagaaggagctgtcttgccac  299 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  775   AGATTTTAATCCACTAACTTGCTGCTGCTGTTGCTGCTGAAGAAGGAGCTGTCTTGCCAC  716 
Query  300   ctgaagtgcctgttgctgctgctgctgGGCGTGGGCGAGGTCAGCTGCCCCGATGTCCAC  359 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  715   CTGAAGTGCCTGTTGCTGCTGCTGCTGGGCGTGGGCGAGGTCAGCTGCCCCGATGTCCAC  656 
Query  360   GGCCGGCGTCTCTCCGTTGGACCGCCCCTCCCGAAGACCGCCGCACTCTAGTAAGTGGTT  419 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  655   GGCCGGCGTCTCTCCGTTGGACCGCCCCTCCCGAAGACCGCCGCACTCTAGTAAGTGGTT  596 
Query  420   GCTGCCGCCCGACCCATTCTGGATGGCTGAACCGTTACTTTTTGTCTCAGTCCCAGATTC  479 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  595   GCTGCCGCCCGACCCATTCTGGATGGCTGAACCGTTACTTTTTGTCTCAGTCCCAGATTC  536 
Query  480   TTGCATCAT  488 
             ||||||||| 
Sbjct  535   TTGCATCAT  527 
Query  60    GTCACTCTCTCCAAGTCCGCATCGGAGGCTTCTCCACAGAGCTTACCTCATACTCCAACG  119 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1691  GTCACTCTCTCCAAGTCCGCATCGGAGGCTTCTCCACAGAGCTTACCTCATACTCCAACG  1750 
Query  120   ACCCCAACCGCCCCCCTGACTCCCGTCACCCAAGGCCCCTCTGTCATCACAACCACCAGC  179 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1751  ACCCCAACCGCCCCCCTGACTCCCGTCACCCAAGGCCCCTCTGTCATCACAACCACCAGC  1810 
Query  180   ATGCACACGGTGGGACCCATCCGCAGGCGGTACTCAGACAAATACAACGTGCCCATTTCG  239 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1811  ATGCACACGGTGGGACCCATCCGCAGGCGGTACTCAGACAAATACAACGTGCCCATTTCG  1870 
Query  240   TCAGCAGATATTGCGCAGAACCAAGAATTTTATAAGAACGCAGAAGTTAGACCACCATTT  299 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1871  TCAGCAGATATTGCGCAGAACCAAGAATTTTATAAGAACGCAGAAGTTAGACCACCATTT  1930 
Query  300   ACATATGCATCTTTAATTAGGCAGGCCATTCTCGAATCTCCAGAAAAGCAGCTAACACTA  359 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1931  ACATATGCATCTTTAATTAGGCAGGCCATTCTCGAATCTCCAGAAAAGCAGCTAACACTA  1990 
Query  360   AATGAGATCTATAACTGGTTCACACGAATGTTTGCTTACTTCCGACGCAACGCGGCCACG  419 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1991  AATGAGATCTATAACTGGTTCACACGAATGTTTGCTTACTTCCGACGCAACGCGGCCACG  2050 
Query  420   TGGAAGAATGCAGTGCGTCATAATCTTAGTCTTCACAAGTGTTTTGTGCGAGTAGAAAAC  479 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  2051  TGGAAGAATGCAGTGCGTCATAATCTTAGTCTTCACAAGTGTTTTGTGCGAGTAGAAAAC  2110 
Query  480   GTTAAAGGGGCAGTATGGACAGTGGATGAAGTAGAATTCCAAAAACGAAGGCCACAAAAG  539 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2111  GTTAAAGGGGCAGTATGGACAGTGGATGAAGTAGAATTCCAAAAACGAAGGCCACAAAAG  2170 
Query  540   ATCAGTGGTAACCCTTCCCTTATTAAAAACATGCAGAGCAGCCACGCCTACTGCACACCT  599 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2171  ATCAGTGGTAACCCTTCCCTTATTAAAAACATGCAGAGCAGCCACGCCTACTGCACACCT  2230 
Query  600   CTCAATGCAGCTTTACAGGCTTCAATGGCTGAGAATAGTATACCTCTATACACTACCGCT  659 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2231  CTCAATGCAGCTTTACAGGCTTCAATGGCTGAGAATAGTATACCTCTATACACTACCGCT  2290 
Query  660   TCCATGGGAAATCCCACTCTGGGCAACTTAGCCAGCGCAATACGGGAAGAGCTGAACGGG  719 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2291  TCCATGGGAAATCCCACTCTGGGCAACTTAGCCAGCGCAATACGGGAAGAGCTGAACGGG  2350 
Query  720   GCAATGGAGCATACCAACAGCAACGAGAGTGACAGCAGTCCAGGCAGATCTCCTATGCAA  779 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2351  GCAATGGAGCATACCAACAGCAACGAGAGTGACAGCAGTCCAGGCAGATCTCCTATGCAA  2410 
Query  780   GCCGTGCATCCTGTACACGTCAAAGAAGAGCCCCTCGATCCAGAGGAAGCTGAAGGGCCC  839 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2411  GCCGTGCATCCTGTACACGTCAAAGAAGAGCCCCTCGATCCAGAGGAAGCTGAAGGGCCC  2470 
Query  840   CTGTCCTTAGTGACAACAGCCAACCACAGTCCAGATTTTGACCATGACAGAGATTACGAA  899 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2471  CTGTCCTTAGTGACAACAGCCAACCACAGTCCAGATTTTGACCATGACAGAGATTACGAA  2530 
Query  900   GATGAACCAGTAAACGAGGACATGGAG  926 
             ||||||||||||||||||||||||||| 
Sbjct  2531  GATGAACCAGTAAACGAGGACATGGAG  2557 
Query  60    TTGTATTTGTCTGAGTACCGCCTGCGGATGGGTCCCACCGTGTGCATGCTGGTGGTTGTG  119 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1857  TTGTATTTGTCTGAGTACCGCCTGCGGATGGGTCCCACCGTGTGCATGCTGGTGGTTGTG  1798 
Query  120   ATGACAGAGGGGCCTTGGGTGACGGGAGTCAGGGGGGCGGTTGGGGTCGTTGGAGTATGA  179 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1797  ATGACAGAGGGGCCTTGGGTGACGGGAGTCAGGGGGGCGGTTGGGGTCGTTGGAGTATGA  1738 
Query  180   GGTAAGCTCTGTGGAGAAGCCTCCGATGCGGACTTGGAGAGAGTGACACTTGATACCAGA  239 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1737  GGTAAGCTCTGTGGAGAAGCCTCCGATGCGGACTTGGAGAGAGTGACACTTGATACCAGA  1678 
Query  240   TTCAAGGGCTGAGGGGCGGCTTTGGGTTCTGTAGACTTCACATGCAGGTGGGTCATCATG  299 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1677  TTCAAGGGCTGAGGGGCGGCTTTGGGTTCTGTAGACTTCACATGCAGGTGGGTCATCATG  1618 
Query  300   GCTTGCAGGCGTTCTTTGTCTTTTGCAAGCTGTAGCTCTAACTGCTGTACAACCTGCATT  359 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1617  GCTTGCAGGCGTTCTTTGTCTTTTGCAAGCTGTAGCTCTAACTGCTGTACAACCTGCATT  1558 
Query  360   TGTACTCTACATTGGGCTGTACTTCTATCGTCCAGCGCATGCTCACTGTTGAGATGTTTT  419 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1557  TGTACTCTACATTGGGCTGTACTTCTATCGTCCAGCGCATGCTCACTGTTGAGATGTTTT  1498 
Query  420   AGAAATGATTGGAAATCTTCGCACACTGCTTCACAGCCTGGCCACTTGCATACACCATGT  479 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  1497  AGAAATGATTGGAAATCTTCGCACACTGCTTCACAGCCTGGCCACTTGCATACACCATGT  1438 
Query  480   CCATAGAGAGGATGGCTATGGGGGTGCTCCTCATGGGACAAACTTTCCCTTTTGGGAGTG  539 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1437  CCATAGAGAGGATGGCTATGGGGGTGCTCCTCATGGGACAAACTTTCCCTTTTGGGAGTG  1378 
Query  540   TGGACTGAGAGCTGTCCATTGGTAGAGGCATGTGGGTTCATTATTAAGGAGGTCTTGGAA  599 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1377  TGGACTGAGAGCTGTCCATTGGTAGAGGCATGTGGGTTCATTATTAAGGAGGTCTTGGAA  1318 
Query  600   GGTGCAGAGGAGGAGACACATGTCGTGGTCAGATCCAAACTGCTGTGATTGTTGCCTGTG  659 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1317  GGTGCAGAGGAGGAGACACATGTCGTGGTCAGATCCAAACTGCTGTGATTGTTGCCTGTG  1258 
Query  660   GTTTCTTCTGCAGTATGAGCACTTGTCACTTCTTTCCAGAGCTGCTGCAGTTCTGTTGGA  719 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1257  GTTTCTTCTGCAGTATGAGCACTTGTCACTTCTTTCCAGAGCTGCTGCAGTTCTGTTGGA  1198 
Query  720   ATCATGCCTTGAGCAAGAGGTTGAAGGGGAAGGGCAGGCTGCCCGGGCTGAATTGTCAGA  779 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1197  ATCATGCCTTGAGCAAGAGGTTGAAGGGGAAGGGCAGGCTGCCCGGGCTGAATTGTCAGA  1138 
Query  780   AGGCCTTGGCGCTGCAAAGACAGGAGGtgctgctgctgtaactgctgcatctgtaaaagc  839 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1137  AGGCCTTGGCGCTGCAAAGACAGGAGGTGCTGCTGCTGTAACTGCTGCATCTGTAAAAGC  1078 
9.2 Recipes 
4% Paraformaldehyde Ponceau S 
2 g Paraformaldehyde 0.1% (w/v) Ponceau S 
5 ml 10x PBS pH 7.4 5% (v/v) Acetic acid 
To 500 ml ddH2O 
30 ml H2O  
pH to 7.4  
To 50 ml H2O  
Stripping buffer 5x TBS 10x 
40 g SDS 24.2 g Tris Base 
125 ml 1 M Tris pH 6.7 87.6 g NaCl 
To 400 ml H2O To 900ml with H2O 
 pH 7.5 then to 1L with H2-
O 
  
  
Alkaline phosphatase 
lysis Solution I 
 
Tris  
EDTA  
Glucose  
H2O  
  
Alkaline phosphatase 
lysis Solution II 
 
50 µl 4 M NaOH  
50 µl 20% SDS  
900 µl H2O  
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Alkaline phosphatase 
lysis Solution III 
 
5 M Potassium acetate  
Acetic acid  
H2O  
9.3 Materials 
Product Company Cat. Number 
0.05% Trypsin-EDTA Life Technologies 25300-054 
0.2 µm syringe filter Sartorius Stedim 16534 
0.2 ml PCR tubes Alta Biosciences LW2330AS 
1.5 ml microcentrifuge 
tubes 
Fisher Scientific T331-10B 
100 mm Sterilin plates VWR 391-2016 
100bp ladder NEW ENGLAND 
BIOLABS 
N3231L 
1-200 µl filter tip VWR 7320541 
13 mm coverslips VWR 631-0149 
15 ml centrifuge tube VWR 734-1813 
1kb ladder NEW ENGLAND 
BIOLABS 
N3232L 
24 well plate Fisher Scientific TKT-190-0104 
2A antibody Millipore ABS31 
2-Mercaptoethanol Sigma-Aldrich M3148 
2-propanol Sigma-Aldrich I9516 
30% Acrylamide Biorad 161-0158 
50ml Centrifuge tubes VWR 7341827 
50x TAE MP Bio 11TAE50X01 
6 well plates Fisher Scientific TKT190050T 
96 well plate Fisher Scientific TKT-180-070U 
99% Glycerol Sigma-Aldrich G5516 
Acetic acid glacial Fisher Scientific A/0360/PB17 
Advanced DMEM/F12 Life Technologies 12634010 
Agarose Melford MB1200 
Albumin from chick egg 
white 
Sigma-Aldrich A5378 
Alexa Fluor 350 goat α mouse 
IgG (H&L) 
Life Technologies A11045 
Alexa Fluor 350 goat α rat IgG 
(H&L) 
Life Technologies A21093 
Alexa Fluor 488 Donkey α 
goat IgG (H&L) 
Life Technologies A11055 
Alexa Fluor 488 goat α 
chicken IgY (H&L) 
Abcam ab150169 
Alexa Fluor 488 goat α mouse 
IgG (H&L) 
Life Technologies A11001 
Alexa Fluor 488 goat α rabbit 
IgG (H&L) 
Life Technologies A11008 
Alexa Fluor 488 goat α rat IgG 
(H&L) 
Life Technologies A11006 
Alexa Fluor 594 goat α mouse Life Technologies A11005 
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IgG (H&L) 
Alexa Fluor 594 goat α rabbit 
IgG (H&L) 
Life Technologies A11012 
Alexa Fluor® Goat α rabbit 
IgG 594 
Life Technologies A11012 
Ammonium acetate Fisher Scientific A/3440/50 
Ammonium persulfate Fisons A/6160/53 
Ampicillin sodium salt Sigma-Aldrich A9518 
Ascorbic Acid Sigma-Aldrich A4544 
BaCl2   
BamHI-HF NEW ENGLAND 
BIOLABS 
R3136S 
BDNF Miltenyi 130-096-286 
BglII NEW ENGLAND 
BIOLABS 
R0144S 
Blotting paper Sigma-Aldrich Z74759-100 
Bond breaker TCEP Solution 
neutral pH 
Thermo Scientific 77720 
Boric acid Sigma-Aldrich B6768 
Bovine serum albumin Sigma-Aldrich A7906 
CaCl2 Sigma-Aldrich 499609 
Calbindin Swant CB38a 
Cell scraper VWR 734-1527 
CHIR 99021 CHDI CHDI-00401952-0000 
Complete mini EDTA-free 
protease inhibitor cocktail 
tablets 
Roche 11873580001 
Cryostor CS10 Stem cell technologies 7930 
CsCl   
CTIP2 antibody Abcam ab18456 
DAPT CHDI CHDI-00396736-0000 
DARPP32 antibody Abcam ab40801 
DCX antibody Santa Cruz sc8066 
DEPC treated DNAse free 
H2O 
Life Technologies 46-2224 
Dimethyl formamide Sigma-Aldrich D8654 
Dispase 1mg/ml Stem cell technologies 7923 
Distilled water Life Technologies 15230-188 
DMEM:F12 Life Technologies 21331-020 
DMSO Sigma-Aldrich D2650 
Donkey α rabbit IgG HRP GE NA934V 
Ebf1 antibody Abcam Ab126135 
EcoRI-HF NEW ENGLAND 
BIOLABS 
R3101S 
EDTA Sigma-Aldrich E5134 
EGTA   
Endo-free Maxi prep kit Qiagen 12362 
Ethanol Sigma-Aldrich E7023 
Fetal Bovine Serum Life Technologies 10437-028 
Fluoromount-G® Southern Biotech 0100-01 
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Forskolin CHDI CHDI-00000087-0000 
FOXP1 (Mouse) antibody Abcam ab32010 
FoxP1 (Rabbit) antibody Abcam Ab16645 
GABA Tocris 0344 
GeneClean® Kit MP Bio 111001200 
Geneticin® 50 mg/ml 
solution 
Life Technologies 10131-035 
GFAP antibody Sigma-Aldrich G3893 
GFP antibody Abcam ab13970 
Glucose BDH 101174Y 
Glutamax™ Life Technologies 35050-061 
Glycine Sigma-Aldrich G8790 
Goat serum Life Technologies 16210-064 
Guanosine Sigma-Aldrich G6264 
HBSS Life Technologies 14170-120 
HEPES VWR  
HiSpeed Plasmid Midi prep 
kit 
Qiagen 12643 
Hoechst 33342 Thermo Scientific 62249 
IPTG Melford Biosciences MB1008 
Islet1 antibody Abcam Ab109517 
IWR1 CHDI CHDI-00476979-0000 
Kanamycin sulphate Life Technologies 11815-032 
KCl   
Knockout DMEM Life Technologies  10829-018 
LB Agar Life Technologies 22700-025 
LB Broth Base Life Technologies 12780-052 
LDN 193189 Sigma-Aldrich SML0559 
LDN 193189 CHDI CHDI-00396388-0000 
Leupeptin   
L-Glutamine Life Technologies 25030-024 
Lipofectamine LTX Life Technologies 15338030 
Lipofectamine RNAiMAX Life Technologies 13778030 
Lumi-film 
chemiluminescent 
detection film 
Roche 11666916001 
MACS Neurobrew 21 Miltenyi 130-093-566 
MACS Neurobrew 21 
without vitamin A 
Miltenyi 130-097-263 
MAP2 (Mouse) antibody Sigma-Aldrich M1406 
MAP2 (Rabbit) antibody  Abcam ab32454 
Marvel powdered skimmed 
milk 
- - 
Matrigel hESC qualified VWR 734-1440  
Menzel Gläser Superfrost 
plus slides 
VWR 631-9483 
Methanol Sigma-Aldrich 32213 
MgCl2   
MicroAmp 96 well plate Life Technologies 4314320 
Mouse neural stem cell Lonza VPG-1004 
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nucleofector solution 
mTESR1 complete medium Stem cell technologies 5879 
Na.ATP   
Na.GTP   
NaCl   
NcoI-HF NEW ENGLAND 
BIOLABS 
R3193S 
Neurobasal A Life Technologies 10888-022 
NheI-HF NEW ENGLAND 
BIOLABS 
R3131S 
Nitric acid Sigma-Aldrich 438073 
Nitrocellulose membrane Amersham RPN203D 
NMDA   
Normal goat serum DAKO X0907 
NotI-HF NEW ENGLAND 
BIOLABS 
R3189S 
Novex® Protein ladder Life Technologies LC5800 
Nucleofector solution Cell 
line V 
Lonza VCA-1003 
Nunc 60mm dishes VWR 734-2040 
Oct6 antibody Abcam Ab31766 
One Shot® TOP10 
Chemically competent E. 
coli 
Life Technologies C404003 
OptiMEM reduced serum 
medium 
Life Technologies 31985-062 
Paraformaldehyde Sigma-Aldrich 158127 
PBS pH 7.4 Life Technologies 10010-056 
PD0332991 CHDI CHDI-00482855-0001 
Penicillin-streptomycin 
5000 U/ml 
Life Technologies 15070-063 
Petri dish with lid 
borosilicate glass   
Fisher 11313704  
pGEM® T easy vector Promega A1360 
Phenol:Chloroform:Isoamyl 
alcohol 25:24:1 
Sigma-Aldrich P3803 
Pierce BCA assay Thermo Scientific 23225 
Platinum® Taq Polymerase Life Technologies 11304-011 
Poly-D-Lysine 
hydrobromide 
Sigma-Aldrich P6407 
Potassium acetate Sigma-Aldrich P1190 
PSD-95 Abcam ab18258 
Random primers Life Technologies 48190-011 
Rat IgG2a kappa 
monoclonal isotype control 
Abcam ab18450 
Ribonuclease A from 
bovine pancreas 
Sigma-Aldrich R4642 
RIPA lysis buffer Sigma-Aldrich R0278 
RNA Clean and Concentrator-
5 
Cambridge Biosciences R1015 
RNA Clean and Cam Bio R1015 
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Concentrator-5 (50) 
RNaseOUT™ Recombinant 
Ribonuclease Inhibitor 
Life Technologies 10777019 
RNeasy mini kit QIAGEN 74104 
S100β Sigma-Aldrich S2532 
Safeview Nucleic Acid 
Stain 
NBS Bio NBS-SV1 
SalI-HF NEW ENGLAND 
BIOLABS 
R3138S 
Sample buffer Laemmli 2x Sigma-Aldrich S3401 
SB431542 CHDI CHDI-00447536-0000 
Set of dATP, dCTP, dGTP, 
dTTP 
Promega U1240 
Sheep α mouse IgG HRP GE NA931V 
SmaI NEW ENGLAND 
BIOLABS 
R0141S 
SOC medium Life Technologies 15544-034 
Sodium Azide Sigma-Aldrich S8032 
Sodium Dodecyl Sulphate Sigma-Aldrich L3771 
Sodium hydroxide Sigma-Aldrich S5881 
Sodium tetraborate Sigma-Aldrich 221732 
Stempro Accutase Life Technologies A1110501 
Streptolysin-O Sigma-Aldrich S0149-25ku 
Subcloning efficiency 
DH5α 
Life Technologies 18265-017 
Superscript II® Life Technologies 18064-014 
SuperSignal West Dura 
chemiluminescent 
substrate 
Thermo Scientific 34075 
SuperSignal West Pico 
chemiluminescent 
substrate 
Thermo Scientific 34077 
SYBR green Thermo Scientific F100L 
Synaptophysin Abcam ab8049 
SYTO16 green fluorescent 
nucleic acid stain 
Life Technologies S7578 
T25 flask BD Falcon 353108 
T4 DNA ligase NEW ENGLAND 
BIOLABS 
M0202S 
TEMED Sigma-Aldrich T9281 
Thermo Scientificsensitive 
alkaline phosphatase 
Promega M9910 
Total RNA - Human Fetal 
Normal Tissue: Brain: 
Frontal Lobe 
Amsbio R1244051-50 
Tris Roche 10708976001 
Tris HCl Sigma-Aldrich T5941 
Triton X-100 Sigma-Aldrich T8787 
Trypan blue Sigma-Aldrich T8154 
Tween 20 Sigma-Aldrich P1379 
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Vectashield Vector laboratories H-1400 
XbaI NEW ENGLAND 
BIOLABS 
R0145S 
Xgal Melford Biosciences MB1001 
Y27632 dihydrochloride Abcam AB120129 
β-actin antibody Sigma-Aldrich A2228 
 
